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Abstract
Ras monomeric GTPases are key molecules in the signalling pathway of renal 
fibrogenesis and exist in three isoforms (Kirsten, Harvey and Neural). The aim of this 
thesis was to determine whether inhibition of Ki-Ras expression by ASOs could 
ameliorate the process of renal fibrosis. 
All isoforms of Ras were expressed in rat renal fibroblasts (primary culture and cell 
line (NRK-49F)) and in a rat epithelial cell line (NRK-52E). In vitro administration of 
Ki-Ras ASOs resulted in a specific knockdown of the isoform mRNA in all cells. An 
associated rise in Ha-Ras mRNA was noted in fibroblast cells but absent in epithelial 
cells.  
ASOs administration in non-diseased male Wistar rats resulted in specific renal Ki-
Ras mRNA knockdown and an associated decrease in Ras protein expression. Oligo 
accumulation was seen in the renal proximal tubular cells with extra-renal deposition 
seen in the liver, heart and wound-tissue. Significant hepatic Ki-Ras mRNA 
knockdown and inflammation was also demonstrated in ASO treated subjects.  
In a rat model of unilateral ureteric obstruction (UUO) a significant rise in both Ki-
Ras and N-Ras mRNA expression in the obstructed kidneys compared to non-
obstructed kidney samples was demonstrated. 
Ki-Ras ASOs administration to models of UUO significantly reduced the isoform 
mRNA expression, when compared to vehicle-only and scrambled-oligos (SO), and 
resulted in a significant decrease in renal fibrosis scores, based on trichrome and 
picrosirius red staining, and interstitial collagen I and !-SMA expression, based on 
immunohistological staining and western blotting.  
ASO administration resulted in an increase in interstitial cell expression of FSP-1, Ki-
67 and ED-1. These findings were absent in vehicle-only and control oligo groups.  
In summary, administration of ASOs specifically and significantly reduce Ki-Ras 
mRNA expression and ameliorate fibrosis in a rat model of renal fibrosis in the 
presence of increased interstitial cell proliferation and inflammation. !
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Chapter 1: Introduction 
1.1 Chronic kidney disease and end-stage renal failure 
Renal failure is a growing worldwide problem. The expanding rates of diabetes, 
hypertension and obesity in the western world coupled with a longer life expectancy 
has seen the prevalence of chronic kidney disease (CKD) increase in developed 
nations. A systematic review of 26 studies revealed a prevalence of CKD in patients 
of over 30 years of 7.2% and of 23-36% in those over 64 years of age (Zhang and 
Rothenbacher 2008).  Though studies suggest that less than 2% of the CKD 
population progresses to end-stage renal failure (ESRF) requiring renal replacement 
therapy (RRT) (Coresh, Selvin et al. 2007), this still represents significant numbers.  
Data from the 13th annual UK Renal Registry in December 2010 
(http://www.renalreg.com/Reports/2010.html) showed the prevalence of renal 
replacement therapy (RRT) within the adult population at the end of 2009 was 794 
pmp compared to 694pmp at the end of 2005. This represents a 3.2% annual increase 
from 2008 and though this is a more modest measure than the 7% global annual 
increase predicted by Moeller in the early part of the decade (Moeller, Gioberge et al. 
2002) it still reflects the lack of development in the field of prevention of CKD 
progression to ESRF. The registry also reported an improvement of age-adjusted 
(adjusted to age 60) one-year survival rate of 85% in 2000 to 89% in 2008 for those 
on RRT. Though this is an improvement, these figures still represent an age-
standardized mortality rate at the age of 30-34 years for those on RRT of 19 times 
greater than the general population. To put this into perspective this translates to a 
median life expectancy of 20 years for a 25-29 year old on RRT and 4 years for those 
over 70 years old on RRT compared to the national average of 79.8 years at birth and 
18.9 years at age 65 (Office of National Statistics 2010). The 5-year survival of a 
dialysis patient of 60 years is about 45% and is comparable to that of patient with 
colonic or ovarian cancer, with the risk of cardiovascular death estimated at about 100 
times higher in ESRF patients on haemodialysis (Bleyer, Russell et al. 1999). Thus a 
40 year-old dialysis patient has the same risk of a cardiovascular event as an 80 year-
old without renal disease (Foley, Parfrey et al. 1998).  
Apart from the medical aspects of CKD and ESRF, there is also a significant socio-
economic impact of CKD. Data from the United States Renal Data System (USRDS) 
show that though CKD patients make up less than 10% of the total Medicare over-65 
! ##!
years population, they account for up to 28% of total Medicare expenditure. For the 
UK, at present an expenditure of 2% of the total NHS budget is required for the 
0.05% of the population with chronic renal failure. Based on values in 2003 and a 
predicted doubling of the renal failure population, the National Kidney Federation 
predicted that 4% of the NHS budget would be required for renal treatment by 2013. 
 
1.2 Progression of Chronic Kidney Disease 
Irrespective of the initial aetiology of renal insult the progression of widespread 
destruction of the renal parenchyma by scarring leads to chronic kidney disease 
(CKD) and ultimately to ESRF. Studies have shown that the natural progression of 
CKD towards ESRF occurs at a steady rate even if the initial “insult” to the kidney 
has been removed (Mitch, Walser et al. 1976; Rutherford, Blondin et al. 1977). ESRF 
is characterized by both tubulointerstitial fibrosis and glomerulosclerosis resulting in 
renal fibrosis or “scarring” (Figure 1.1). It has long been established that the decline 
in renal function best correlates to the degree of tubulointerstitial fibrosis as opposed 
to glomerulosclerosis. (Mackensen-Haen, Bohle et al. 1992; Nath 1992; Bohle, 
Wehrmann et al. 1994; Muller, Zeisberg et al. 2000). Considering the major impact 
that ESRF has upon society much work has been undertaken to understanding the 





Figure 1.1: Histological difference between normal and fibrosed kidney. 




1.3 Tubulointerstitial fibrosis and fibrogenesis 
The process of renal fibrosis or ‘scarring’ begins with an initial insult to the kidney, 
which may be from a variety of causes (Figure 1.2). This initial injury results in the 
release of numerous growth factors, cytokines and chemokines, which initiate 
inflammation and subsequent fibrogenesis. Fibrogenesis is a complex process 
involving several steps: (i) the infiltration of inflammatory cells, (ii) increased 
proliferation and activation of fibroblasts, (iii) tubular epithelial cell apoptosis and 
subsequent tubular atrophy, (iv) capillary loss and (v) production and deposition of 
excessive extracellular matrix (ECM) (Fine, Ong et al. 1993; Norman and Fine 1999). 
The phenomenon of epithelial-to-mesenchymal transition (EMT) has been described 
which is believed by many to be fundamental in the process of renal fibrogenesis 




Figure 1.2: Schematic of the process of renal fibrosis depicting postulated 
cellular mechanisms (Adapted from Iwano, Plieth et al. 2002). 
The current model of renal fibrogenesis reflects an inappropriate wound healing 
response to injury (Kuncio, Neilson et al. 1991; Eddy 2000; Wynn 2008). After an 
initial insult, tissue attempts to repair and recover from the damage. These recovery 
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processes involve production of pro-inflammatory cytokines and activation of resident 
cells. In acute inflammatory reactions subsequent vascular changes and inflammatory 
infiltration rapidly resolve but persistent chronic inflammation leads to fibrosis.  The 
innate repair process is thought to be composed of two phases: a regenerative phase 
where injured cells are replaced by viable ones with no obvious lasting sequelae of 
damage and a “fibroplasia” phase in which connective tissue replaces normal 
parenchymal tissue. Following tissue injury both epithelial and endothelial cells may 
release inflammatory mediators which initiate recruitment and activation of 
inflammatory cells. The secretion of pro-fibrotic cytokines by infiltrating leukocytes 
stimulates an increase in the myofibroblast population, the cell responsible for matrix 
deposition, and initiates the process that allows for wound contraction and repair. 
Subsequently, collagen fibres become organised, angiogenesis takes place, scar tissue 
is eliminated by matrix metalloproteinases (MMPs) and viable epithelial/endothelial 
cells proliferate and migrate across the wound to regenerate damaged tissue. Whilst 
initially this repair process is beneficial, the problem arises in the presence of a 
continuing and persistent insult where there is loss of control of fibrogensis and 
excess matrix deposition occurs in areas of normal tissue resulting in permanent 
scarring (Wynn 2007).  
In her review (Eddy 2000), Eddy divided the process of renal fibrogenesis into four 
arbitrary phases which is a helpful and logical way to approach the complex 
pathophysiology of fibrosis and has been adapted for this thesis: 
(i) Cellular injury, activation and inflammation 
(ii) Fibrogenic signalling  
(iii) The Fibroblast and Epithelial Mesenchymal Transition 
(iv) Parenchymal destruction 
 
1.3.1 Cellular injury, activation and inflammation 
It is postulated that bioactive molecules of the plasma not normally filtered by the 
glomerulus appear in the ultrafiltrate in chronic renal disease (Wang, Lapage et al. 
1999; Zoja, Benigni et al. 1999; Hirschberg and Wang 2005). Exposure of tubular 
cells to these molecules such as albumin, transforming growth factor-" (TGF-") and 
hepatocyte growth factor (HGF), in the “proteinuria of disease” results in tubular cell 
activation and the subsequent release of injurious molecules that may facilitate 
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inflammation or themselves directly contribute to fibrogenesis (Burton and Walls 
1994; Burton and Harris 1996; Abbate, Zoja et al. 2006). In vitro studies have shown 
that many of these proteins may induce “tubular cell activity” and overexpression of 
pro-inflammatory molecules. These molecules include monocyte chemoattractant 
protein-1 (MCP-1) (Wang, Chen et al. 1997; Donadelli, Abbate et al. 2000), RANTES 
(Zoja, Donadelli et al. 1998) and IL-8 (Tang, Leung et al. 2003). Furthermore there is 
evidence of generation of hydrogen peroxide (Morigi, Macconi et al. 2002; Tang, 
Leung et al. 2003), which leads to upregulation of chemokine expression by a 
signalling pathway thought to involve mitogen-activated protein kinase/ extracellular 
signal regulated kinase 1 and 2 [MAPK/ERK 1/2] (Dixon and Brunskill 1999; Dixon 
and Brunskill 2000; Donadelli, Zanchi et al. 2003). In vivo studies have also 
confirmed the role of proteinuria in inducing inflammation via upregulation of various 
chemokines and transcription factors including NF-#B and MCP-1(Eddy and 
Giachelli 1995; Gomez-Garre, Largo et al. 2001; Eardley, Zehnder et al. 2006). 
There is also evidence that renal tubular cells can synthesize factors of the 
complement cascade (Zhou, Marsh et al. 2001) and PTECs themselves have been 
found to be able to activate serum complement via the alternative pathway (Biancone, 
David et al. 1994) resulting in pro-inflammatory activity including production of 
hydrogen peroxide and cytokines (David, Biancone et al. 1997). Complement is an 
important mediator of interstitial inflammation and fibrogenesis as can be seen from 
the significant attenuation of injury in a C3-deficient mouse model (Abbate, Zoja et 
al. 2008). Epithelial cells have also been demonstrated to be a source of macrophage 
colony stimulating factor (M-CSF). There is now evidence that this growth factor may 
be vital for tubular cell survival and regeneration following injury (Menke, Iwata et 
al. 2009). However M-CSF-1 remains an important macrophage mitogen (Lan, 
Nikolic-Paterson et al. 1995; Isbel, Hill et al. 2001) and induces macrophage 
interstitial infiltration. 
This release of inflammatory mediators by the tubular epithelial cells results in 
infiltration by mononuclear cells including macrophages, lymphocytes, eosinophils 
and plasma cells. Traditionally it has been well accepted that macrophage infiltration 
as part of the inflammatory process was detrimental in the process of fibrogenesis and 
may induce renal cell death both directly, by inducing apoptosis of tubular cells 
(Tesch, Schwarting et al. 1999; Duffield, Erwig et al. 2000; Kipari, Cailhier et al. 
2006), or indirectly via the release of cytokines that suppress VEGF expression 
! #'!
(Kang, Joly et al. 2001) that leads to diminished peritubular capillary cell proliferation 
and subsequent epithelial cell ischemia and hypoxia (Khan, Cleveland et al. 1999). 
Much of the evidence for this theory was derived from animal models of macrophage 
depletion or knockout of macrophage recruitment proteins (Holdsworth, Neale et al. 
1981; Tesch, Maifert et al. 1999; Tesch, Schwarting et al. 1999; Lange-Sperandio, 
Cachat et al. 2002). Although macrophage infiltration as part of assumed acute 
inflammation usually precedes development of, and is believed to contribute to 
fibrosis, a variety of studies have shown that this is not always the case and that the 
two processes may actually be distinct mechanisms. In fact it is now thought that 
inflammation may, under certain circumstances, be beneficial depending on the 
phenotype of inflammatory cell. Nishida et al. found that wild-type mice reconstituted 
with angiotensin II type I receptor (Agtr1)-negative bone marrow possessed reduced 
numbers of peripheral-blood monocytes/macrophage progenitors in bone marrow and 
had decreased renal interstitial macrophage numbers but exhibited more severe 
fibrosis following unilateral ureteric obstruction when compared to Agtr1(+/+) 
controls (Nishida, Okumura et al. 2005). They postulate that the benefits of active 
macrophage infiltration are derived from their ability to phagocytose dead cells and 
debris which may be pro-fibrotic. One study employing pharmacological inhibition of 
the CSF-1 receptor c-fms (Ma, Liu et al. 2009) found that treated groups had 
significantly attenuated accumulation of the macrophage population following 
obstruction but there was no difference in either the early or late renal fibrosis score 
when compared to controls. In addition macrophages have now also been shown to be 
a source of hepatocyte growth factor (HGF) (Chen, DeFrances et al. 1996), a 
molecule which is thought to have a role in the inhibition of EMT (Mizuno, 
Matsumoto et al. 2001; Yang and Liu 2002; Mizui, Isaka et al. 2004), as well as Wnt 
ligand Wnt7b, which has been shown to promotes tubular cell regeneration following 
ischemia-reperfusion injury . 
Interstitial fibrosis is characterized by tubular destruction that may in part be due to 
tubular ischemia from matrix-associated loss of interstitial capillary network. It is well 
recognized that hypoxia induces macrophages recruitment and release of angiogenic 
factors (Kuwabara, Ogawa et al. 1995; Murdoch, Giannoudis et al. 2004; Murdoch, 
Muthana et al. 2005; Elbarghati, Murdoch et al. 2008) and as a result these cells may 
be influential in maintaining or regenerating capillaries in the face of renal fibrosis. 
These paradoxical roles for the macrophage in fibrosis has now led to another theory: 
! #(!
it is not just the absolute degree of macrophage infiltration within tissue that is 
associated with severity and progression of fibrosis but actually the “phenotype” and 
“degree of activation” of the macrophage which is involved and also the time phase of 
injury, acute or recovery (Lange-Sperandio, Cachat et al. 2002; Duffield 2003). It is 
now recognized that circulating monocytes have a high degree of cellular plasticity 
and following recruitment to site of injury may differentiate into specific subsets of 
macrophages with differing functions depending on cytokines and cell signals of the 
microenvironment (Geissmann, Auffray et al. 2008; Ricardo, van Goor et al. 2008). 
Broadly speaking there are two recognized definitive macrophage subsets: classically 
activated (M1) and alternatively activated (M2). Classical activation results in a pro-
inflammatory phenotype M1, whereas the M2 phenotype is recognized as being anti-
inflammatory and may secrete trophic factors involved in angiogenesis and wound 
healing by matrix remodeling (Mosser and Edwards 2008). However though the M2 
phenotype is associated with wound resolution, it is also associated with promotion of 
fibrosis in chronic disease states. Lin et al. demonstrated that following UUO, initially 
high Ly6C expressing monocytes were recruited to the kidney which subsequently 
divided into low, intermediate or high expressing Ly6C phenotypes (Lin, Castano et 
al. 2009) and that the high Ly6C expressing M2 macrophages assumed a pro-fibrotic 
expressing-profile compared to the other phenotypes.  Anders et al. employed 
RANTES antagonists in a murine model of glomerulonephritis and found that despite 
decreased macrophage infiltration there was a significant increase in glomerular 
injury.  They noted that the RANTES analogs reduced macrophage infiltration but 
increased activation state as characterized by morphology and inducible nitric oxide 
(NO) synthetase expression (Anders, Frink et al. 2003).  The importance of timing of 
infiltration in the process of fibrosis was illustrated by Duffield et al. Using a carbon 
tetrachloride murine model of liver fibrosis, which has distinct injury and recovery 
phases, they developed a transgenic mouse that allowed selective depletion of 
macrophages. They discovered that macrophage depletion in advanced liver fibrosis 
resulted in reduced scarring but depletion during recovery led to a failure of matrix 
degradation (Duffield, Forbes et al. 2005). A study depleting macrophages using 
cyclophosphamide in models of UUO showed no effect on early fibrosis but increased 
degree of fibrosis at later time points suggesting a role for macrophages with regards 
to repair at a later stage of injury (Nishida, Okumura et al. 2005). These studies 
suggest functionally distinct subpopulations of macrophages may play critical roles in 
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both the injury and recovery phases of inflammatory scarring and that the “degree” of 
macrophage infiltration alone may not provide the whole answer. Furthermore M1 
and M2 states do not appear to be terminally committed and they may actually revert 
between these phenotypes based on the microenvironment (Duffield 2003; Arnold, 
Henry et al. 2007). These findings are supported by work by Lee et al. demonstrating 
that macrophages may switch phenotype in vivo following renal ischemic-reperfusion 
(I/R) injury (Lee, Huen et al. 2011). The group also demonstrated that the timing and 
subclass of macrophage recruited dictated both the degree of initial renal injury as 
well as the subsequent degree of renal repair following I/R injury.  
Thus distinct processes of inflammation and fibrosis are now being increasingly 
recognized (Wynn 2004; Ricardo, van Goor et al. 2008) and may also explain the lack 
of efficacy of non-specific anti-inflammatory therapy in preventing the progression of 
fibrosis. In fact complete macrophage depletion may be detrimental and selective 
depletion may be far more beneficial (Ricardo, van Goor et al. 2008). 
Furthermore there is now evidence that bone marrow derived cells normally 
reconstitute renal mesangial and interstitial cells as part of normal cellular turnover 
(Imasawa, Utsunomiya et al. 2001; Li, Truong et al. 2007) and though the majority of 
renal regeneration is from intra-renal cells (Lin, Moran et al. 2005), these bone 
marrow derived cells are thought to contribute to tubular epithelial cell regeneration 
by a process of cell fusion (Li, Truong et al. 2007; Lin 2008). The haematopoietic cell 
type involved has been elusive but there is now increasing focus, at least in liver 
repair, on macrophages (Willenbring, Bailey et al. 2004; Thorgeirsson and Grisham 
2006). This is supported by the facts that fetal macrophages play a trophic role in 
kidney development (Rae, Woods et al. 2007), macrophages have the ability to 
undergo cell fusion with self or other cell types in response to inflammation 
(Ovchinnikov 2008) and have been shown to transform in to vascular elements 
including endothelial and smooth muscle cells (Zhao, Glesne et al. 2003; Bailey, 
Willenbring et al. 2006). Thus macrophages may play a significant role in organ 
regeneration and not just in injury. 
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1.3.2 Fibrogenic signalling 
Injured epithelial cells and activated leukocytes secrete a host of pro-fibrotic 
mediators that contribute to the process of fibrogenesis. In addition, several have both 
proliferative and apoptotic effects depending on cell type and model of injury. To go 
into detail about each of these elements is beyond the realms of this thesis, however 
Table 1.1 aims to provide a summary of mediators of fibrogenesis that have been 
more widely studied. The single cytokine that is widely accepted to be the most potent 
pro-fibrogenic stimulus is transforming growth factor "1 (TGF"1) which will be 
discussed later in more detail. 
Mediator Role & mechanism of 
action 
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role in fibrosis 
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Table 1.1: Mediators of fibrosis 
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Transforming Growth Factor-"  (TGF") 
Transforming growth factor " (TGF") is the best studied of all pro-fibrotic growth 
factors and it is widely recognised to be vital in the process of fibrosis in many organs 
including the kidney. TGF" is a founding member of the TGF" superfamily which 
consists of nearly 30 mammalian proteins that regulate a diverse range of 
physiological processes which include wound healing, cell cycle control, chemotaxis 
and development. Other family members include activins, inhibins and BMPs. TGF" 
itself is a 25kD dimeric protein which has three isoforms in mammals (TGF"1-3). All 
three isoforms share significant sequence homology and appear to be functionally 
similar. TGF" is initially secreted as a latent precursor bound to a latency-associated 
peptide (LAP) (Annes, Munger et al. 2003) that inhibits binding to the TGF" receptor. 
This complex is then bound to Latent TGF" binding protein (LTBP1-3). The 
importance of the latent complex in development of renal fibrosis has been 
demonstrated (Huang, Chung et al. 2008). Following proteolytic cleavage TGF" 
becomes active and may bind to its heteromeric receptor complex consisting of TGF" 
type I/type II receptors (Nunes, Munger et al. 1998) that possess serin-threonine 
kinase activity. The TGF"-activators responsible for LTBP cleavage and release 
include plasmin, proteases MMP-2 and MMP–9 and thrombospondin-1 (Border and 
Noble 1993; Daniel, Wiede et al. 2004).  Furthermore a non-proteolytic mechanism of 
TGF"-LAP inactivation has been recognized involving integrins. !v"6 integrin and 
it’s role in fibrogenesis was first identified in the process of lung fibrosis (Munger et 
al. 1999). Expressed at low levels in normal alveolar epithelial cells, there was up-
regulation of expression in disease models such as the lung fibrosis induced by 
bleomycin (Munger et al. 1999). However it is now been demonstrated that !v"6 
integrin is also overexpressed in human kidney epithelium in disease states such as 
IgA nephropathy and membranous glomerulonephritis (Trevillian et al. 2004). !v"6 
integrin acts as a receptor for RGD (argining-glycine-aspartate) sites in components 
of fibrosis such as fibronectin and vitronectin but also for TGF"-LAP 1 and 3. The 
binding of !v"6 is thought to induce a conformational change in TGF"-LAP thus 
allowing TGF" to bind to its receptors (Annes 2004). Moreover the knockout of this 
integrin appeared to protect against both bleomycin-induced pulmonary fibrosis and 
renal fibrosis induced by obstruction (Munger et al. 1999, Ma et al. 2003). In addition 
administration of monoclonal antibodies against this integrin were found to attenuate 
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fibrosis in a mouse model (Col4A3-/-) of Alport’s syndrome and the mechanism of 
protection correlatated with decreased TGF" activity and expression (Hahm et al. 
2007). Thus !v"6 integrin appears to be a have a role in in the initiation of fibrosis 
and is a potential therapeutic target in this process. Interestingly these proteins that 
appear to be involved in liberating TGF" from it’s binding protein are also 
fundamentally involved in the processes of wound healing and fibrosis. The best-
recognised intracellular pathway of TGF" signalling involves the ‘small mothers 
against decapentaplegic’ (Smad) family of transcriptional activators (Massague 1998). 
The final steps of this pathway involves the nuclear translocation of a Smad 2/3-Smad 
4 complex and subsequent binding to the Smad-binding element of the target gene to 
alter transcription. However it is now clear that TGF" biological activity involves 
several Smad-independent pathways including the MAPK/Erk, p38 and Jun-kinase 
and integrin-linked kinase cascades (Li, 2009; Siegel, 2003). Furthermore following 
secretion by both resident renal cells and infiltrating leukocytes, TGF" may also auto-
induce its own expression. TGF" expression has been found to increase through the 
course of chronic kidney injury and activation of the latent protein is enhanced in 
pathological conditions (Bissell, Roulot et al. 2001; Daniel, Wiede et al. 2004).  The 
pro-fibrotic effects of TGF" were first realised in the 1980s with in vitro work 
showing an association of TGF" levels and increased matrix synthesis, decreased 
matrix degradation and modulation of receptors mediating matrix deposition (Ignotz 
and Massague 1986; Edwards, Murphy et al. 1987; Ignotz and Massague 1987; Laiho, 
Saksela et al. 1987; Heino, Ignotz et al. 1989). TGF" is thought to trigger fibrogenic 
processes including: EMT, chemotaxis of fibroblasts, activation of fibroblasts to 
myofibroblasts, transcription of matrix encoding gene and matrix binding integrins. In 
addition TGF" may also activate inhibitors of matrix metalloprotinases (MMPs) such 
as tissue inhibitor of metalloprotinases (TIMP) (Ma and Chegini 1999) or 
plasminogen activator inhibitor (PAI) (Overall, Wrana et al. 1989; Rerolle, Hertig et 
al. 2000) leading to reduced matrix degradation.  
The central role of TGF" in fibrosis is supported by several in vivo experiments 
demonstrating exogenous TGF"-promoted wound closure and scarring (Mustoe, 
Pierce et al. 1987; Lin, Sullivan et al. 1995; Sullivan, Lorenz et al. 1995) while 
inhibition of TGF" signalling pathways suppressed extracellular matrix synthesis and 
scarring (Shah, Foreman et al. 1995; Cordeiro, Mead et al. 2003) in animal models of 
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renal fibrosis such as subtotal nephrectomy, diabetic and obstructive nephropathy 
(Wu, Cox et al. 1997; Shihab, Bennett et al. 2002; Lan, Mu et al. 2003; Russo, del Re 
et al. 2007; Huang, Chung et al. 2008). Thus TGF" remains an important and viable 
target for the treatment of progressive renal fibrosis. 
 
1.3.3 The Fibroblast & the Myofibroblast 
The fibroblast is central to the process of fibrosis. Though first described in the 19th 
century, the most recent accepted definition of an interstitial fibroblast is a “non-
vascular, non-epithelial, non-inflammatory cell of the connective tissue and is its 
principal cell component” that possesses a “fusiform or spindle –like shape in profile” 
with “a stellate nucleus and abundant rough endoplasmic reticulum, collagen 
secreting granules and actin filaments”(Kalluri and Zeisberg 2006). The persistence of 
ambiguity in defining this cell type is due to the lack of reliable specific cell markers. 
Though there are now several well accepted and established indicators of fibroblast 
phenotype-such as vimentin and fibroblast specific protein-1 (Strutz, Okada et al. 
1995), these are in no way specific to the fibroblast nor are they present in all 
fibroblasts, with expression possibly varying with degree of fibroblast maturity. 
Matters are further complicated as it has now been shown that fibroblasts in mammals 
are highly heterogenous and fibroblasts isolated from different anatomical sites show 
highly divergent gene-expression patterns (Chang, Chi et al. 2002; Sorrell and Caplan 
2009). Furthermore the environment in which the fibroblast exists also has a major 
impact upon its activity: fibroblasts from fibrotic kidneys exhibiting a much higher 
capacity for proliferation and matrix production when compared to their counterparts 
from normal non-fibrotic kidneys (Muller and Rodemann 1991; Strutz, Zeisberg et al. 
2000).  
The main functions of fibroblasts are 1) the deposition of extracellular matrix 
including the synthesis of the major components such as Collagen I and III and 
fibronectin, 2) regulation of epithelial differentiation, 3) regulation of inflammation 
and 4) involvement in wound healing (Tomasek, Gabbiani et al. 2002). It is widely 
accepted that to perform many of these functions the quiescent fibroblast must adopt 
an “active” fibroblast phenotype deemed the “myofibroblast”. This phenotype 
describes the fibroblast that possesses contractile properties (Tomasek, Gabbiani et al. 
2002) and was originally identified as the cell responsible for wound contraction 
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(Gabbiani, Hirschel et al. 1972). Visualized under electron microscopy they are 
characterized by bundles of actin microfilaments associated with contractile proteins 
and the presence of a well-developed rough endoplasmic reticulum (Gabbiani 1992; 
Ina, Kitamura et al. 2002; Qi, Chen et al. 2006). !SMA is a major component of this 
contractile apparatus (Darby, Skalli et al. 1990), is up regulated during wound healing 
(Desmouliere, Geinoz et al. 1993) and is now widely used as a marker of the 
myofibroblast to differentiate it from the relatively more “quiescent” fibroblast 
phenotype. However !SMA expression is not exclusive to myofibroblasts nor is it 
expressed by all myofibroblasts (Hinz, 2010). With regards to renal fibrosis the 
myofibroblast is believed to be the phenotype of the cell responsible for ECM 
deposition and fibrosis within the tubulointerstitium (Qi, Chen et al. 2006) and their 
presence directly correlates to the subsequent progression of renal failure (Zeisberg, 
Strutz et al. 2000). In the setting of tubulointerstitial fibrosis, fibroblasts appear to 
maintain their active phenotype despite the removal of the initial stimulus, a situation 
that mirrors the clinical phenomenon of progressive renal failure in patients despite 
treatment/removal of initial cause (Strutz and Muller 1995). How the maintenance of 
this active state is achieved remains unclear.  
 
1.3.4 Origin of the myofibroblast and Epithelial-
Mesenchymal Transition 
Though it is now generally accepted that fibroblasts/myofibroblasts are responsible 
for renal fibrosis the origin of fibroblasts in the kidney, especially in the diseased 
state, is far more controversial. In the 1800s Cohnheim stated that these “contractile 
cellular elements” were direct descendents of migrating leukocytes. This theory was 
largely disregarded when Ross et al. showed that fibroblasts were mainly of local 
origin and not derived from blood-borne cells (Ross, Everett et al. 1970).  The 
conclusion from this set of experiments using radioactive labelling was supported by a 
series of subsequent studies demonstrating that adult fibroblasts localized to sites of 
embryonic mesenchymal cells and arise locally during embryogenesis from 
mesenchymal progenitor cells via a process of differentiation (Ekblom and Weller 
1991; Lang and Fekete 2001). However this issue has become more complicated as 
not only is the original theory that some fibroblasts are of bone marrow lineage being 
revisited (Poulsom, Forbes et al. 2001; Forbes, Poulsom et al. 2002) but other possible 
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sources are being implicated including periadventitial/pericytes (Wiggins, Goyal et al. 
1993; Lin, Kisseleva et al. 2008) and tubular epithelial cells via the phenomenon of 
epithelial-mesenchymal transition (EMT) (Strutz, Okada et al. 1995; Iwano, Plieth et 
al. 2002). With regards to bone marrow derived precursors of renal cells more recent 
studies have confirmed that transition of bone marrow derived cells to tubular 
epithelial cells may exist and could contribute a small but significant part of 
parenchymal regeneration following injury (Fang, Alison et al. 2005; Yen, Alison et 
al. 2007). The role that bone marrow derived cells, fibrocytes, play in the process of 
renal fibrogenesis is more controversial. Grimm et al. examined biopsies of chronic 
allograft rejection from patients who had received grafts from opposite sex donors 
(Grimm, Nickerson et al. 2001). Using immunohistological techniques and in situ 
hybridization they suggested that upto 30% of interstitial mesenchymal cells were of 
bone marrow origin. However this was disputed by Iwano and Neilson using genetic 
tagging techniques who concluded that only 12% of the interstitial population derived 
from the bone marrow, 36% derived from EMT and the remaining 52% from a variety 
of sources including resident interstitial cell proliferation (Iwano, Plieth et al. 2002). 
However a distinction between the origin of the fibroblast and the activity of the 
fibroblast has been made by Roufosse et al (Roufosse, Bou-Gharios et al. 2006). 
Using bone marrow transplantation from transgenic mice in a model of fibrosis they 
concluded that though 8.6% of !SMA-positive interstitial cells were of bone marrow 
origin, none of these cells were collagen producing. The true significance of 
contribution to fibrosis by bone marrow-derived fibroblasts remains unclear.  
Epithelial-mesenchymal transition (EMT) was first described by Greenburg and Hay 
during their observation of epithelial cells from anterior lens suspended in collagen 
gels (Greenburg and Hay 1982). They found that “…Elongated cells derived from the 
apical surface develop pseudopodia and filopodia characteristic of migratory cells and 
acquire a morphology and ultrastructure virtually indistinguishable from that of 
mesenchymal cells in vivo.” and concluded that the collagen gel can “…promote 
dissociation, migration, and acquisition of secretory organelles by differentiated 
epithelial cells, and can abolish the apical-basal cell polarity characteristic of the 
original epithelium.” The phenomenon of EMT is a dynamic process by which 
terminally differentiated epithelial cells undergo a conversion to adopt a mesenchymal 
phenotype. This process involves the loss and gain of several cellular markers and 
characteristics, which are summarised in Table 1.2 and in Figure 1.3. To date there are 
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now three accepted variations of EMT. Type 1 is classified as developmental EMT as 
seen in biological circumstances, type 2 refers to adult epithelial and endothelial cells 
transition to fibroblasts and type 3 involves metastases associated with cancer. 
 
Table 1.2: Cellular changes associated with EMT 
Loss of Gain of 
1) Expression of E-Cadherin 
2) Expression of ZO-1 
3) Epithelial cell adhesion 
4) Integrity of basement membrane 
5) Cell polarity 
1) Expression of !SMA 
2) Expression of FSP-1 
3) Expression of vimentin 
4) Enhanced migratory activity 
!
Figure 1.3: Schematic illustrating the key events of the process of EMT (Adapted 
from Liu 2004) 
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EMT has been observed to occur in cells from different organs including hepatic, lung 
and skin (Chaudhuri, Zhou et al. 2007; Ikegami, Zhang et al. 2007; Jain, Shaul et al. 
2007; Zeisberg, Yang et al. 2007; Kim, Wei et al. 2009). In addition the process has 
been of particular interest to the oncology field since EMT is believed to be 
fundamental for the metastases of malignant cells in cancer (Thiery 2003; Tse and 
Kalluri 2007; Yilmaz and Christofori 2009). With regards to the kidney and its 
embryonic development, EMT should not be a completely surprising phenomenon. 
The mammalian kidney develops from two embryonic tissues: the ureteric bud and 
the metanephric mesenchyme, which form the collecting system and the nephrons and 
interstitial cells respectively (Herzlinger, Abramson et al. 1993; Herzlinger 2002). 
During this differentiation multipotent nephron progenitors of the metanephric 
mesenchyme develop into glomerular and tubular epithelial cells (Herzlinger, 
Abramson et al. 1993; Oliver, Barasch et al. 2002), representing mesenchymal to 
epithelial transdifferentiation (MET). It now appears feasible that in pathological 
conditions there is a “reverse embryogenesis” reflecting renal cell plasticity.  There is 
compelling evidence that EMT occurs in disease states of the kidney.  Strutz et al. 
first demonstrated the existence of EMT within the kidney by demonstrating the 
expression of FSP-1 by tubular epithelial cells in a murine model of renal fibrosis 
(Strutz, Okada et al. 1995). The presence of EMT has now also been shown in models 
of renal fibrosis including remnant kidney post 5/6 nephrectomy (Ng, Huang et al. 
1998) and unilateral ureteric obstruction (Yang and Liu 2001) with the latter study 
able to show co-expression of both mesenchymal and epithelial cell markers within a 
high proportion of cells. Other renal disease models in which EMT appears to play a 
major role include diabetic nephropathy, anti-glomerular basement membrane disease 
and nephrotoxic nephritis (Ng, Fan et al. 1999; Oldfield, Bach et al. 2001; Li, Yang et 
al. 2003).  Iwano et al. used an elegant genetic technique to demonstrate EMT in a 
model of UUO. Using transgenic mice that expressed LacZ in tubular cells they were 
able to demonstrate that these LacZ cells adopted a different morphology and were 
able to migrate to the interstitium under conditions of ureteric obstruction. 
Furthermore they reported that these same cells expressed FSP-1 and HSP47, a stress-
induced collagen chaperone protein, indicating that interstitial mesenchymal collagen 
producing cells can derive from tubular epithelial cells (Iwano, Plieth et al. 2002). 
EMT has also been observed in human renal tissue. Using techniques of 
immunohistochemistry and in situ hybridization these studies support the theory that 
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EMT occurs in clinical renal disease and is associated with deteriorating renal 
function (Jinde, Nikolic-Paterson et al. 2001; Rastaldi, Ferrario et al. 2002). Further 
evidence for EMT contributing to renal fibrogenesis comes from studying potential 
anti-fibrotic molecules. Both BMP-7 and hepatocyte growth factor have been shown 
to prevent or even reverse renal fibrosis and in both cases their effects appear to 
involve inhibition of EMT (Yang and Liu 2002; Klahr 2003; Zeisberg, Hanai et al. 
2003). 
However various factors regarding the demonstration of EMT have recently called 
into question the true role of EMT and even its existence in renal fibrosis. Firstly, 
though EMT has been demonstrated in vitro, evidence of in vivo existence has being 
less convincing. Histological demonstration of EMT has relied on catching an 
‘intermediate transitional’ state showing co-localization of both epithelial and 
myofibroblastic cell markers in addition to expression of transcriptional signals of 
EMT (Snail, Twist) and possibly use of lineage tags. Many of the cell markers such as 
FSP-1 and !SMA are non-specific for fibroblasts and may be expressed by other cell 
types including macrophages, as can the expression of the EMT markers. Though 
Iwano et al used lineage tagging to demonstrate existence of EMT in vivo (Iwano, 
Plieth et al. 2002), there has been a lack of reproducibility of these results using 
similar methods in other models of renal injury (Humphreys, Lin et al. 2010; 
Koesters, Kaissling et al. 2010; Li, Zepeda-Orozco et al. 2010). Interestingly one of 
these genetic lineage studies though unable to demonstrate EMT in vivo did show that 
epithelial cells readily underwent EMT in vitro as primary cultures (Humphreys, Lin 
et al.2010). However it must be remembered that these fate-mapping studies are all 
completed in murine models and the lack of lineage tags within human epithelial cells 
means that advanced stages of EMT cannot be detected in humans. Finally the 
presence and degree of EMT does not necessarily correlate with myofibroblastic 
activity, thus the clinical significance of EMT is called into doubt. The failure of a 
number of studies to confirm the tubular epithelial origin of myofibroblasts has led to 
increasing emphasis upon other cells as being the source of myofibroblasts. Using 
methods including fate-tracing other cells that have been considered to be the source 
of the myofibroblastic population include perivascular cells (pericytes) (Humphreys, 
Lin et al. 2010; Faulkner, Szcykalski et al. 2005; Lin, Kisseleva et al. 2008), 
circulating fibroblast precursors (fibrocytes) (Sakai, Furuichi et al. 2010; Wada, Sakai 
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et al. 2007) and endothelial cells (Wiggins, Goyal et al. 1993; Zeisberg, Potenta et al. 
2008). Though many of these studies admit to not being able to completely 
distinguish between infiltration by circulating fibrocytes and true perivascular 
pericytes as a source of fibroblasts they do dispute the significance of the role of 
EMT.  
Though EMT has now been widely perceived to exist in vitro, the debate regarding its 
existence and clinical significance in the process of renal fibrogenesis continues. 
Conceptually the idea of reversal of embryonic pathway at sites of injury is attractive. 
Furthermore many of the transcriptional pathways of EMT are also anti-apoptotic 
(Snail, Twist) for tubular epithelial cells thus may drive this process. However the 
lack of specific markers of fibroblasts and EMT has meant that its existence in vivo in 
humans cannot be conclusively proven. In addition the lack of real-time technology to 
demonstrate true cell transition and the absence of true human epithelial cell lineage 
tags means current methodology relies on demonstrating cells co-expressing epithelial 
and mesenchymal markers at static time points which may rely upon luck as much as 
ability and may explain the numerous conflicting studies. Advocates of EMT and its 
contribution to renal fibrosis add that EMT represents a dynamic spectrum of change 
and that the transition of the epithelial cell does not necessarily need be completed. 
Thus not all epithelial cells will become fibroblasts and not all cells undergoing EMT 
will co-express all markers of epithelial/mesenchymal cells in transitional state at one 
time, making not only timing of tissue analysis critical but also selection of markers 
vital. Furthermore, though not all epithelial cells may transition to fibroblasts, those 
that do complete EMT may further proliferate. Thus, in the absence of lineage tags, in 
theory, a significant number of fibroblasts in the human fibrotic kidney may have 
been derived from a few fibroblasts of EMT origin. Despite the controversy there 
remains much focus upon epithelial-mesenchymal transition in renal fibrosis. 
Though the true origin of the myofibroblast is in dispute, the cell signalling pathways 
involved in regulating EMT appear to be more clearly delineated. At present the main 
protagonists are TGF", Smad-dependent and independent pathways, integrin-linked 
kinase signalling and Wnt/"-catenin signalling. TGF" Smad-dependent pathways 
have previously been discussed but non-Smad signalling of TGF" is also thought to 
regulate EMT via Rho (Masszi, Di Ciano et al. 2003), MAPK (Janda, Lehmann et al. 
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2002; Erdogan, Pozzi et al. 2007) and phosphatidylinositol-3-kinase/Akt (Docherty, 
O'Sullivan et al. 2006; Zeng, Yao et al. 2008) cascades.  
Integrin-linked kinase (ILK) is an intracellular kinase that interacts with cell matrix 
integrins and phosphorylates intracellular proteins such as Akt and glycogen synthase 
kinase 3" (GSK-3"). This allows for stabilisation of "-catenin and expression of 
genes required for EMT (Hannigan, Troussard et al. 2005). Studies have 
demonstrated both the importance of ILK and the benefits of inhibiting this molecule 
in renal fibrosis (Li, Yang et al. 2003; Li, Tan et al. 2009). Furthermore many 
members of the ILK-signalling pathway (including ILK and PINCH-1 itself) are up 
regulated by TGF" in a Smad-dependent manner (Li, Dai et al. 2007).  
Wnt/"-catenin signalling is well recognised in regulating EMT at least in 
organogenesis and metastasis (Huber, Kraut et al. 2005; Pulkkinen, Murugan et al. 
2008). However there is now evidence that this pathway plays a significant role in 
EMT in renal disease. Interacting via Frizzled receptors, Wnt protein binding results 
in dephosphorylation of "-catenin thus allowing escape from ubiquitin-mediated 
degradation. Subsequent accumulation of "-catenin leads to translocation to the nuclei 
where it binds to T cell factor/lymphoid enhancer binding factor-1 (LEF1) to induce 
transcription of target genes involved in EMT, including Twist, c-myc, Snail and 
fibronectin (Surendran, Schiavi et al. 2005; He, Dai et al. 2009). Data is now 
emerging that inhibition of this cascade may also ameliorate renal disease (Hwang, 
Seo et al. 2009). 
 
1.3.5 Parenchymal destruction and dysfunction of matrix 
degradation 
Fibrosis occurs as a result of excessive matrix accumulation but also an 
accompanying decrease in degradation. The matrix “scar” is made up of normal 
interstitial proteins such as collagen (I, III, V, VII and XV) and fibronectin. However 
it is now believed that the excessive matrix produced in the development of interstitial 
fibrosis is not a mere passive end-product but actually actively contributes to the 
process of fibrosis and cell survival (Eckes, Kessler et al. 1999; Marastoni, Ligresti et 
al. 2008). These constituents of matrix include proteoglycans, polysaccharides and 
glycoproteins. For example thrombospondin accumulation has been seen to predict 
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the development of interstitial fibrosis (Hugo, Shankland et al. 1998; Hugo, Kang et 
al. 2002), which may in part be due to the protein’s observed ability to activate TGF" 
both in vitro and in vivo (Crawford, Stellmach et al. 1998). Interstitial fibrosis has 
been viewed as a dynamic process where initially the ‘scaffold’ is thought to be 
unstable and susceptible to degradation perhaps as part of the healing process. 
However with time a persistent fibrogenic process results in the formation of non-
reversible interstitial scarring due to enzymic modification by glycoslylation, 
oxidation or transglutamination (Johnson, Skill et al. 1999) leading to formation of 
cross bridges that conveys both stability and a resistance to proteases. Studies have 
shown that inhibition of these processes (Johnson, Fisher et al. 2007) may also reduce 
fibrosis and protect renal function. The ongoing fibrotic process also leads to changes 
in the composition of matrix such as the increase in the ratio of collagen I to collagen 
III that may also add to the stability of the “scar”.  The process of pathological 
fibrosis not only depends on the increase in matrix production and stability in disease 
but also on a decrease in the ability to degrade and remodel matrix. The normal 
kidney produces several proteases with the potential to degrade ECM. Of these, the 
two groups that have been best studied are the matrix metalloproteinase [MMP] and 
serine protease family. MMPs are zinc-containing endopeptidases that have a role in 
renal development (Lelongt, Trugnan et al. 1997) and homeostasis and are now 
widely implicated in renal pathophysiology. Regulation of MMPs is by a series of 
tissue inhibitors of metalloprotinases (TIMP), endogenous specific inhibitors that bind 
to the active catalytic domain of the MMP. Many non-ECM proteins also act as 
substrates for MMPs and these include cell adhesion molecules (such as cadherins 
and integrins) and growth factors (TGF" and FGF) and their receptors (Yu and 
Stamenkovic 2000; Nagase, Visse et al. 2006). MMPs are classified into six groups: 
collagenases, gelatinases, stromolysins, matrilysins, membrane-type MMPs and other 
MMPs while four TIMPs have been identified in vertebrates. Within the kidney 
expression of both MMPs and TIMPs appear to vary both spatially and temporally 
and between species (McMillan, Riordan et al. 1996; Suzuki, Miyazaki et al. 1997; 
Eddy, Kim et al. 2000; Ogbureke and Fisher 2005). The most abundant and the best-
studied MMPs in the kidney are MMP-2 and MMP-9 from the gelatinase group. 
Originally these gelatinases have been seen as protective molecules but more recent 
studies have forced this view to be re-addressed. In the unilateral ureteric obstruction 
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model an early rise in MMP-2 expression with a decrease in both MMP-1 and MMP-
9 activity (Gonzalez-Avila, Iturria et al. 1998; Iimura, Takahashi et al. 2004) has been 
demonstrated. This was accompanied by an increase in TIMP expression (especially 
TIMP-1) (Duymelinck, Dauwe et al. 2000). It is now recognised that TIMPs may 
have cellular effects outside of inhibition of MMPs that include inhibition of 
apoptosis, growth promotion, induction of changes in cell morphology and 
inflammation (Gomez, Alonso et al. 1997; Cai, Zhang et al. 2008). The development 
of a transgenic mouse that overexpresses MMP-2 which progresses to chronic renal 
disease with associated histological changes of glomerulosclerosis and 
tubulointerstitial fibrosis further highlights the role of MMP-2 in CKD (Cheng, 
Pollock et al. 2006). MMP-2 is required for TGF"-driven EMT possibly by its ability 
to cleave LAP of TGF" (Cheng and Lovett 2003). However, whereas overexpression 
of MMP-2 appears to accentuate fibrosis, an increase in MMP-9 levels appears to 
attenuate both glomerular and interstitial scarring (Dworkin, Gong et al. 2004; Uchio-
Yamada, Manabe et al. 2005; Bauvois, Mothu et al. 2007; Hultstrom, Leh et al. 2008). 
The difference in effects of MMP-2 and MMP-9 expression may be less to do with 
degradation of ECM proteins than with activation/degradation of non-ECM pro-
fibrogenic molecules (Lelongt, Bengatta et al. 2001; Catania, Chen et al. 2007). As 
yet the role of the various MMPs in fibrogenesis has to be clearly delineated. The 
other major family of proteinases is the serine proteinases that include plasmin and 
cathepsin G.  Plasmin not only may degrade some elements of matrix such as 
fibronectin but also has a role in activating collagenase precursors (Hu, Yang et al. 
2006). In turn active plasmin is a result of proteolytic activation of latent plasminogen 
by either tissue-type or urokinase-type plasminogen activator [tPA or uPA]. Both tPA 
and uPA are inhibited by Plasminogen Activator Inhibitors (PAI). Not normally 
expressed by the kidney, PAI-1 levels are induced by numerous cytokines and growth 
factors released in a variety of renal diseases (Tomooka, Border et al. 1992; Eddy and 
Giachelli 1995; Tang, Friess et al. 1998; Duymelinck, Dauwe et al. 2000). PAI-1-
inducing elements include pro-fibrotic interleukin-1", TNF-!, angiotensin II and 
TGF" (Wilson, Reid et al. 1995; Wilson, Haites et al. 1996; Kanalas and Hopfer 
1997; Nakamura, Nakamura et al. 2000). In vivo studies demonstrate a protective 
outcome in models of obstructive and protein overload nephropathy using PAI-1 null 
mice (Oda, Jung et al. 2001) while PAI-1 overexpression leads to worse fibrosis 
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(Matsuo, Lopez-Guisa et al. 2005). A further interesting observation in these studies 
was a significant delay in interstitial macrophage recruitment in PAI-1 deficient mice 
(Oda, Jung et al. 2001). Hence the fibrosis protective effects of PAI-1 deficiency may 
lie not only in the increase in ECM turnover by plasmin activation (and subsequently 
activated MMPs) but perhaps also in the blunting of the acute inflammatory response 
in these disease models (Ha, Oh et al. 2009). Though it is predicted plasmin should 
enhance MMP activity and ECM degradation, it is also recognised that plasmin may 
activate TGF" and promote EMT (Zhang, Kernan et al. 2007) and in fact a deficiency 
of plasminogen activation may be protective (Yang, Shultz et al. 2002). These studies 
suggest that PAI-1 inhibition of plasmin induction could be beneficial and the 
protective effects of PAI-1 deficiency may involve mechanisms independent of 
plasmin formation (Hu, Lin et al. 2008). 
The accumulation of matrix and expansion of interstitial space results in parenchymal 
destruction of the kidney and tubular atrophy. The renal tubules comprise up to 80% 
of the total kidney volume and subsequent loss leads to “atubular” glomeruli and 
subsequent renal failure. Tubular cell loss occurs mainly by apoptosis and possibly 
autophagy and EMT (Yang, Johnson et al. 2001). The circumstances as to whether a 
tubule regenerates or degenerates are unclear though the duration and extent of insult 
must be an important factor. Though fibrosis has been assumed to “cause” tubular 
atrophy this has yet to be conclusively proven and at present the most accurate 
conclusion is that fibrosis correlates with tubular loss. The most widely accepted link 
is that of hypoxia. (Norman, Orphanides et al. 1999; Nangaku 2006; Fine and Norman 
2008). Tubular cells are highly metabolically active and have a fragile blood supply. 
Progressive fibrosis leads to progressive capillary loss, microvascular rarefaction and 
resulting oxidant stress and generation of ROS may lead to both tubular damage and 
promote further interstitial fibrosis (Orphanides, Fine et al. 1997). The lack of 
angiogenesis in such conditions has yet to be explained.  
In summary the process of renal fibrogenesis is complex and its progression is 
dependent upon the balance and expression of a whole plethora of cytokines and 





1.4 Ras monomeric GTPases 
The discovery of Ras dates back to 1964 when Jennifer Harvey identified that a 
preparation of a murine leukaemia virus from a leukaemic rat induced sarcomas in 
newborn rodents (Harvey 1964). In 1967, in the laboratory of Werner Kirsten, the 
Kirsten isoform of the murine sarcoma virus was discovered (Kirsten and Mayer 
1967). The ras gene was identified as the transforming element in the respective 
Harvey and Kirsten rat sarcoma viruses (Scolnick, Rands et al. 1973). Ha-ras and Ki-
ras are mammalian counterparts of the viral Harvey and Kirsten genes. In 1983 a third 
member of the ras gene family was discovered, Neural ras (N-ras), derived from a 
human neuroblastoma cell line (Hall, Marshall et al. 1983; Shimizu, Goldfarb et al. 
1983). Furthermore splice variants of Ki-ras are now recognised: Kirsten ras 4A (Ki-
ras 4A) and Kirsten ras 4B(Ki-ras 4B) which differ in their terminal fourth exon. Ki-
Ras 4B is the predominant Ki-Ras variant in mammals (Chen, Otto et al. 2000). The 
Ha-ras gene is on the short arm of chromosome 11(11p15.1-15.5), Ki-ras on the short 
arm of chromosome 12 (12p12.1-pter) and N-ras on the short arm of chromosome 1 
(1p22-p32).  
Ras monomeric GTPases became of particular interest in the early 1980s when the 
laboratories of Weinberg, Cooper, Barbacid and Aaronson showed that mutations of 
ras were the dominant oncogene in various forms of cancers (Der, Krontiris et al. 
1982; Parada, Tabin et al. 1982; Shimizu, Goldfarb et al. 1983) and they play a vital 
role in the control of cell proliferation (Barbacid 1987). Their importance as a 
regulator of cell proliferation is reflected by the fact that mutations of ras are found in 
20-30% of all human cancers (Bos 1989). 
The Ras proteins are however only the initial members of a larger “Ras superfamily” 
of closely related monomeric GTPases. This family is comprised of over 150 
GTPases which include Rho, Rac and Rab proteins. All these small G proteins are 
monomeric molecules ranging from 20 to 40 kDa and all possess a structurally 
conserved GTP binding domain capable of hydrolytic activity (Bourne, Sanders et al. 
1991). The Rho sub-family consists of about 20 members including Rho, Rac and 
Cdc42 and share 30% homology with Ras proteins and 80-90% homology between 
each other. Whereas Ras has been identified as being involved in the process of cell 
proliferation it appears that Rho proteins are involved in formation of the cell 
cytoskeleton, cell-cell interaction and cellular motility (Hall 1992; Ridley 1995; 
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Mackay and Hall 1998). While Rho appears to regulate contractile actin-myosin 
filament formation, Cdc42 induces filopodia formation, a process involving finger-
like extensions consisting of actin bundles and probably associated with 
recognition/regulation of the microenvironment. Rac regulates lamellipodia formation 
and membrane extension during phagocytosis (Heasman and Ridley 2008). 


















Figure 1.4: Molecular structure of Ras-GTP (Kim, S.-H., Prive, G. G. and Milburn, 
M. V. (1993) Handb. Exp. Pharmacol. 108). 
 
The Ras proteins are 188-189 amino acids in length and have a molecular weight of 
21 kilodaltons (Figure 1.4). There is a high degree of homology within the first 165 
amino acids between the isoforms and this region contains the major effector and 
GTP binding regions. However the remaining 24 amino acids are highly dissimilar 
between the isoforms of the proteins and are termed the “hypervariable region” 




Figure 1.5: The ‘Hypervariable region’ of human Ras isoforms (Figure taken 
from (Shields, Pruitt et al. 2000)). Ras molecules demonstrate 85% homology in the 
amino-terminal residues but significant divergence in the final 24 carboxy-terminal 
residues, the hypervariable region. 
Ras is a central cellular component in the signalling pathway of numerous cell surface 
receptors and acts as a convergent point for a variety of effector molecules. The 
protein can be seen as a molecular switch that allows transduction of upstream signals 
to downstream effector molecules resulting in end cell response (Figure 1.6) 






























Figure 1.6 : Upstream cell activation of Ras pathways. 
 
Regulation of Ras protein activity is by binding with guanine nucleotides 
(Wittinghofer 1998), the nature of which, whether triphosphate (GTP) or diphosphate 
(GDP), determine the ability of Ras to interact with downstream proteins. In the 
“dormant” form Ras is highly bound to GDP. Activation of Ras results in the release 
of the GDP molecule and binding of GTP (Figure 1.7). This results in a 
conformational change in the Ras molecule allowing it to interact with downstream 
effectors. Due to high affinity of Ras to GDP, molecules known as Guanine 
Nucleotide Exchange factors (GNEFs) are required to accelerate GDP disassociation. 
One of the most vital Ras GNEFs is son-of-sevenless (SOS) which interacts with Ras 
via the adapter molecule Grb2. Activation of cell surface tyrosine receptors depends 












homology-2 (SH2) and phosphotyrosyl domains. These are common binding domains 
which are well preserved in nature (Campbell 1998). The formation of this adapter 
molecule complex allows translocation of cytosolic SOS to the plasma membrane 
where the GNEF can interact with Ras. The disassociation of GDP and subsequent 
binding of GTP allows Ras to interact with downstream effector molecules 
(Sundaram 2006; McKay and Morrison 2007).  
Figure 1.7: Ras GTPase molecule activation & deactivation-a ‘molecular on/off 
switch’. GNEF, guanine nucleotide exchange factor, GAP, GTPase activating protein. 
 
Initially Ras was found to be a signalling component downstream of a variety of 
tyrosine kinase receptors (a family of receptors for agonists that include EGF, FGF 
and PDGF) (Buday and Downward 1993; van der Geer, Hunter et al. 1994; Howe and 
Juliano 1998) but it has now been demonstrated that Ras can also act downstream 
from other cell surface receptors. G-protein coupled receptors, including those for 
Angiotensin II and Endothelin-1, possess seven membrane-spanning domains and 
were originally thought to signal via Ras–independent pathways. However it is now 
known that theses receptors may involve Ras GTPases via two mechanisms (Luttrell, 
Daaka et al. 1997). The first involves interaction of the activated receptor with a 
docking protein, either focal adhesion kinase (FAK) or SHC (Src homology 2 domain 
containing) transforming protein 1 (Della Rocca, van Biesen et al. 1997). Following 
phosphorylation this then binds to the Grb2/SOS complex bringing the GNEF to the 
plasma membrane to interact with Ras. Alternatively a non-receptor proto-oncogenic 
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tyrosine kinase, Src, may be activated by G-Protein receptor with subsequent binding 
of the Grb2/SOS complex in the membrane (Luttrell and Luttrell 2003; Luttrell 2003). 
Cell-cell and cell-matrix interactions via the integrin family of proteins may also 
activate the Ras pathway (Schlaepfer, Hanks et al. 1994). The signalling pathway is 
similar to that of Ras activation by G-Proteins which involves activated integrins 
utilizing FAK to recruit the Grb2/SOS to the membrane (Ramos 2008; Yee, Weaver 
et al. 2008). There is also evidence now that Ras may be involved in TGF" signalling 
in fibroblasts (Axmann, Seidel et al. 1998; Janda, Lehmann et al. 2002; Zavadil 
2009). The relationship between TGF" and Ras is complex, not fully understood and 
will be discussed later. From current evidence it can be appreciated that Ras is a 
downstream convergent point for many cell surface receptors and their ligands, acting 
as an “on/off switch” to allow transduction of upstream signals to an array of 
downstream effectors. Hence targeting Ras may circumvent the relative redundancy 
in the multitude of signalling events involved in the process of fibrogenesis. 
 
1.4.2 Ras activation and molecular conformational change 
Upon exchange of GDP for GTP, there are two highly mobile regions of the Ras 
molecule that change conformation termed Switch I (residues 30-38) and Switch II 
(residues 60-76) (Polakis and McCormick 1993). Residues 32-40 of the molecule 
have been identified as the effector binding and transforming element (Sigal, Gibbs et 
al. 1986; Marshall, Davis et al. 1991) and this region overlaps with Switch I and alters 
conformation of GTP binding. In addition it has now been shown that residues 
surrounding this region are also vital for effector binding though do not undergo 
conformational change. This region has been termed the ‘activator’ or ‘constitutive 
effector’ region (Marshall 1993; Fujita-Yoshigaki, Shirouzu et al. 1995; Nassar, Horn 
et al. 1995) and may be important for the binding of GTPase-activating proteins 
(GAP) (Schaber, Garsky et al. 1989). The switch II region has also been shown to be 
vital to Ras function and blocking this region abolished Ras transforming capabilities 
(Milburn, Tong et al. 1990). Subsequently it has been discovered that this region was 
required for direct interaction with GNEFs such as SOS (Quilliam, Hisaka et al. 
1996). SOS has also been shown to exert its effect via the switch I domain in addition 
to switch II. There are distinct functional roles to switch I and switch II: switch II 
mediates the anchoring of Ras to SOS, whereas the interaction with switch I leads to 
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disruption of the nucleotide-binding site and GDP dissociation via a catalytic 
mechanism (Hall, Yang et al. 2001). The displacement of GDP and subsequent 
binding of GTP catalysed by GNEFs such as SOS leads to a conformational change of 













Figure 1.8: Ras-effector regions (Figure taken from Campbell et al., Oncogene (17) 
1998). Effector interaction residues of Ras molecule occur within the highly 
homologous region of the molecule. CAAX motif required for post-translational 
modification (C, cysteine, A, aliphatic amino acid, X, serine or methionine). 
 
1.4.3 Ras deactivation 
Activated Ras (bound to GTP) is “turned off” by its own innate ability as a GTPase to 
hydrolyse GTP to GDP. However this process of GTP-hydrolysis is intrinsically slow 
and requires another group of proteins, known as GTPase-activating proteins or 
GAPs, to accelerate the reaction (Cales, Hancock et al. 1988). These proteins include 
RASAL1, neurofibromin (NF1) and p120 GAP (Garrett, Self et al. 1989; Martin, 
Viskochil et al. 1990) and have been found to share conserved residues with which 
they interact with Ras (Miao, Eichelberger et al. 1996; Scheffzek, Lautwein et al. 
1996). The binding of GAPs to Ras allows the stabilization of the transition state of 
the GTPase reaction and increases the reaction rate by more than one thousand-fold 
(Ahmadian, Stege et al. 1997; Scheffzek, Ahmadian et al. 1997).  
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Ras mutations are the single most common abnormality of human proto-oncogenes 
and occur in 30% of all human cancers and up to 90% in specific tumour types. (Bos 
1989). The most common mutation found is at residue 12 where there is a substitution 
of glycine for valine resulting in reduced binding of and response to GAPs (Trahey 
and McCormick 1987; Hall 1992; Wittinghofer, Scheffzek et al. 1997) and 
constitutively active Ras. 
 
Figure 1.9: Schematic of Ras molecule illustrating residue sequences involved in 
Ras function. (C, cysteine, A, aliphatic amino acid, X, serine or methionine). 
 
1.5 Posttranslational processing of Ras 
It was well-recognized for some time that the activity of Ras is critically dependant 
upon correct localization to the inner surface of the plasma membrane (Willumsen, 
Christensen et al. 1984; Magee, Gutierrez et al. 1989) despite the fact that Ras 
proteins per se do not themselves possess any hydrophobic sequences which could 
mediate this (Barbacid 1987). It is thought that differential localization of the Ras 
isoforms allows for specific signalling and function by bringing respective isoforms 
into contact with distinct pools of effectors and activators (Prior and Hancock 2001). 
The effect of differential microdomain localization was only first noted in 1999 in 
studies that disrupted the integrity of the lipid raft microdomain of the plasma 
membrane which resulted in inhibition of Ha-Ras activation of Raf but not that of 
Ki(B)-Ras (Roy, Luetterforst et al. 1999). The ability of Ras to be membrane-
associated is achieved via a complex series of posttranslational modifications 
resulting in the prenylation of the protein. Despite a high degree of homology 
between the isoforms there is a significant difference in the C-terminal hypervariable 
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region (HVR) of 23-24 amino acids. However in all Ras HVR there is a highly 
conserved CAAX motif (C being cysteine, A any aliphatic amino acid and X any 
amino acid) (Hancock, Cadwallader et al. 1991). The initial step involves prenylation 
of the cysteine residue by farnesyl protein transferase to generate S-farnesyl cysteine 
thioester, allowing for binding to the endoplasmic reticulum (ER) and golgi apparatus 
(Zhang and Casey 1996; Choy, Chiu et al. 1999). Subsequently at the ER, the AAX 
motif is cleaved off by the endopeptidase Ras converting enzyme Rce1 (Otto, Kim et 
al. 1999) and the farnyslated cysteine is methylated by isoprenyl cysteine 
carboxymethyl transferase (ICMT) (Gutierrez, Magee et al. 1989; Wright and Philips 
2006). Both Rce1 and ICMT are ER-localized proteins that have been shown to be 
vital for development with knockout of either enzyme leading to late embryonic 
lethality in mice at between 10.5 to 15.5 days (Kim, Ambroziak et al. 1999; Bergo, 
Leung et al. 2001). There is now increasing focus on these enzymes as potential 
therapeutic targets to Ras activation (Svensson, Casey et al. 2006). The inability of 
Ras to be activated in the absence of farnesylation also led to the promotion of 
farnesyl transferase inhibitors (FTI) as potential anti-Ras therapies. However the use 
of the FTIs have not been as effective as predicted and led to the discovery that both 
Ki(B)-Ras and N-Ras could be alternatively prenylated by geranylgeranyl transferase 
in the absence of farnesylation (Whyte, Kirschmeier et al. 1997). Though this farnesyl 
group is essential, farnesylation itself provides only a weak membrane binding 
affinity and stabilization of association is obtained by a second motif signal that 
allows for correct trafficking and microlocalisation of each isoform (Hancock, 
Paterson et al. 1990). For Ha-Ras, N-Ras and the splice variant Ki(A)-Ras this 
involves palmitoylation of cysteine residues adjacent to the farnesylated cysteine 
residue. The cysteine residues that undergo palmitoylation are C181 and C184 in Ha-
Ras, C181 in N-Ras and C180 in Ki(A)-Ras and augment localization to the plasma 
membrane (Smotrys and Linder 2004; Magee and Seabra 2005). Ki(B)-Ras however 
does not undergo palmitoylation but instead a polybasic chain of six lysine residues 
(K175-K180) that provides a net positive charge to the HVR domain and allows it to 
interact electrostatically with the negatively charged phospholipids of the internal 
membrane leaflet (Figure 1.11) (Hancock, Magee et al. 1989; Hancock, Paterson et al. 
1990).   
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Figure 1.10: Hypervariable regions of Ras isoforms demonstrating combinations 
of posttranslational lipid modifications and membrane interacting polybasic 
motifs (Figure taken from (Henis, Hancock et al. 2009)). [The terminal four 
residues represent the CAAX motif, C being Cysteine, A any aliphatic aminio acid 
and X, serine or methionine. K,  lysine.] 
The essential nature of these posttranslational modifications became evident with 
mutagenic studies that rendered Ras-GTP cytosolic thus inhibiting membrane 
interaction and activation of downstream effectors (Hancock, Paterson et al. 1990; 
Jackson, Cochrane et al. 1990). The enzyme responsible for palmitoylation is also 
thought to be ER bound though as yet has not been fully characterized (Apolloni, 
Prior et al. 2000). Non-palmitoylated Ha-/N-Ras mutants and Ki-Ras mutants lacking 
the polybasic sequence highlight the importance of the second signalling motif. In 
both cases the mutants accumulated in the ER suggesting these sequences and 
modifications were vital for Ras protein trafficking from the ER to the plasma 
membrane. It is now recognised that the palmitoylated isoforms of Ras access the 
plasma membrane by vesicular trafficking through the classical exocytic pathway via 
the Golgi body whereas polybasic Ki-Ras appears to be excluded from this pathway 
and is transported to the membrane via an uncharacterized Golgi-independent route 
(Choy, Chiu et al. 1999; Apolloni, Prior et al. 2000). Data now indicates that the 
vesicular form of transportation of palmitoylated Ras may not be the sole pathway 
(Zheng, McKay et al. 2007). With regards to Ki-Ras, transportation has been thought 
to involve association with microtubules (Thissen, Gross et al. 1997). This hypothesis 
is supported by the finding that the polybasic domain of Ki-Ras mediates microtubule 
binding (Chen, Otto et al. 2000). However subsequent electron microscopic and 
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immunofluorescent analysis has failed to find a close relationship between Ki-Ras and 
microtubules though an accumulation in endosomes has been observed (Apolloni, 
Prior et al. 2000; Lu, Tebar et al. 2009). The high affinity electrostatic interaction 
between Ki-Ras and the membrane has led others to postulate that there may be no 
specific transport mechanism but Ki-Ras reaches the membrane by simple passive 
diffusion. In fact it has been shown that mutations to the polybasic domain of Ki-Ras 
to allow for the same overall net charge and amphiphilic character to be retained, do 
not prevent the protein associating with the plasma membrane (Jackson, Li et al. 
1994; Roy, Leventis et al. 2000). At present the pathway of Ki-Ras trafficking to the 
plasma membrane has yet to be fully identified.  
 
Figure 1.11: Post-translational modification and trafficking of Ras. ER, 
endoplasmic reticulum. FTase, Farnesyl transferase. GGTase, 
Geranylgeranyltransferase. C-(X)y-C indicates two cysteine residues separated by an 
amino acid sequence. 
 
A difference in microlocalizations within the plasma membrane may provide a basis 
for their different roles and interactions with downstream effectors. The lipid raft of 
the membrane is a liquid-ordered structure consisting of sphingolipids and 
glycosphingolipids packed with cholesterol where proteins are anchored via long, 
saturated acyl chains. Proteins with only farnesylated or geranylgeranylated groups 
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and lacking fatty acid chains are excluded from this region. Ki-Ras, lacking in a 
palmitoylated chain, has been shown to reside in the disordered non-raft plasma 
domain while Ha-Ras has been shown to target both the caveolae and non-caveolar 
lipid rafts (Prior and Hancock 2001). Furthermore the Ha-Ras microlocalization is 
more complex than previously thought. In GDP-bound form Ha-Ras has been shown 
to be equally distributed between the lipid raft and cholesterol-independent domain 
but the binding of GTP leads to majority translocation to the non-raft domains (Prior, 
Harding et al. 2001; Prior, Muncke et al. 2003). It appears that this translocation is 
critically dependent on the hypervariable “linker region” of Ha-Ras: the sequence of 
amino acids of the hypervariable region of Ras which is not involved in farnesylation 
or palmitoylation (Jaumot, Yan et al. 2002; Rotblat, Prior et al. 2004). Differential 
localization of the isoforms clearly has important consequences for downstream 
effector interactions. This is supported by the observation that Raf, though recruited 
equally well to lipid raft or non-raft domains of the plasma membrane, is much less 
efficiently activated in the former localization (Prior and Hancock 2001). Apart from 
the plasma membrane there is now increasing interest in other intracellular platforms 
for Ras activation. Effectors and facilitators of Ras signalling have been localized to 
the ER, the Golgi apparatus and endosomes (Chiu, Bivona et al. 2002; Arozarena, 
Matallanas et al. 2004; Mitin, Ramocki et al. 2004). However many of these studies 
involve Ras-overexpression and the significance of these findings in untransformed 
cells is unclear. 
 
1.6 Ras Effectors 
Effectors of Ras may be defined as molecules that can bind preferentially to the GTP-
bound state of Ras as opposed to the GDP-bound state. Over the last decade there has 
been much evidence to show that multiple signalling pathways are activated by Ras. 
However the individual cellular response resulting from Ras activation may differ 
considerably between different cell types and different environmental contexts despite 
the identical effector protein downstream of Ras being activated (Cowley, Paterson et 
al. 1994). The first identified effector protein was Raf and it is through the 
examination of the Ras-Raf interaction that the subsequent binding regions between 
the molecules were discovered. Mutational analysis revealed that the effector-binding 
region of Ras consisted of residues 32-40, crossing over with switch I domain (Sigal, 
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Gibbs et al. 1986; Marshall, Davis et al. 1991; Shirouzu, Koide et al. 1994).  Switch II 
was not seen to be directly involved in binding of Raf but appeared to contribute to 
selectivity of binding (Nassar, Horn et al. 1995). The effector binding region of Ras, 
termed the Raf-Binding Domain (RBD), residues 51-131, interacts with the Raf 
molecule via a mechanism involving formation of antiparallel " sheets (Scheffler, 
Waugh et al. 1994; Herrmann, Martin et al. 1995; Nassar, Horn et al. 1995). Affinity 
studies show that the affinity of the RBD of Raf to GTP-bound Ras is 1000 fold 
higher than to GDP-bound Ras (Herrmann, Martin et al. 1995) and allows 
translocation of the normally cytoplasmic Raf to the plasma membrane where 
phosphorylation possibly by non-receptor kinases, such as src, takes place. In this way 
GTP-bound Ras acts as a membrane-anchor for Raf (Leevers, Paterson et al. 1994; 
Stokoe, Macdonald et al. 1994). However the process of Raf activation is more 
complex and may involve several other proteins, in particular 14-3-3 protein which 
also regulates Raf activity (Li, Janosch et al. 1995; Luo, Zhang et al. 1995). The 
process of Raf activation is now thought to involve both dephosphorylation and 
phosphorylation of target residues. Active Ras displaces 14-3-3 from its binding site, 
via dephosphorylation of a phosphoserine residue by protein phospahatase 2A, to 
allow membrane localization (Jaumot and Hancock 2001; Kubicek, Pacher et al. 
2002). Accumulation of Raf to the plasma membrane and subsequent phosphorylation 
leads to a marked increase in the molecule’s own kinase properties with the major 
phosphorylation sites identified forming a high affinity MEK-binding epitope 
(Marais, Light et al. 1995; King, Sun et al. 1998; Xiang, Zang et al. 2002). The 
activation of Raf following Ras-GTP binding is the first step of the well-recognized 
mitogen-activated protein kinase (MAPK) signalling cascade (Figure 1.10). Once 
activated, Raf (or MAPK kinase kinase) phosphorylates two downstream MAPK 
kinases (also called MAP/Erk Kinase: MEK1 and MEK2) that subsequently 
phosphorylate tandem threonine and tyrosine residues in two downstream MAPK, 
also known as extracellular signal related kinases, Erk1 and Erk2 (Avruch, Zhang et 
al. 1994; Robinson and Cobb 1997). Activated ERK1/2 translocate to the cell nucleus 
where they phosphorylate and activate the family of E-twenty six (ETS) transcription 
factors including Elk-1 to induce gene expression (Deng and Karin 1994; Gille, 
Kortenjann et al. 1995; Janknecht, Ernst et al. 1995). Elk-1 is a ternary complex factor 
protein. Activation of Elk-1 and formation of a complex with the serum response 
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factor (SRF) at the serum response DNA element domain of many promoters of gene 
expression leads to induction of expression of immediate early genes such as c-fos. In 
addition ERK also phosphorylates c-Jun leading to activation of the AP1 transcription 
factor made up of fos-jun heterodimers (Yordy and Muise-Helmericks 2000). These 
pathways mediate such diverse functions as cell growth, proliferation, survival and 
differentiation, though the end cell response appears to depend not only on the cell 
type and the cellular context/environment but also on the intensity and duration of 
ERK activity (Weber, Raben et al. 1997; Woods, Parry et al. 1997; Kerkhoff and 
Rapp 1998; Xue, Murray et al. 2000).  
Though the MAPK pathway is the best characterized of signalling pathways 
downstream to Ras, there are now an increasing number of other candidate effectors. 
These alternative signalling networks first became apparent when it was noted that 
certain point mutations of Ras within the effector domain led to an inability to bind 
Raf but were still able to exert biological effects within cells (Campbell, Khosravi-Far 
et al. 1998) and appear to have a far more complex relationship to Ras as compared to 
Raf/MEK/ERK pathway. 
Phosphatidylinositol 3-kinase (PI3-K) is an important regulatory protein in cell 
signalling and has a vital role in the processes of cell growth, apoptosis and malignant 
transformation (Krasilnikov 2000). The enzyme consists of a regulatory p85 subunit 
and a catalytic p110 subunit. Upon stimulation the p85 subunit is recruited to the 
membrane while the p110 mediates phosphorylation of phosphoinositides at position 
three of the inositol ring (Kapeller and Cantley 1994).  Ras has been shown to interact 
with the p110 subunit leading to an increase in PI3-kinase activity (Kodaki, 
Woscholski et al. 1994; Rodriguez-Viciana, Warne et al. 1994). This rise in PI3-
kinase activity has been linked to protection from apoptosis via a protein kinase B/Akt 
(PKB/Akt) mechanism in epithelial cells (Khwaja, Rodriguez-Viciana et al. 1997). 
However the relationship between Ras and PI3-kinase is more complicated than a 
simple linear signaling pathway. Firstly there is data that shows that PI3-kinase may 
actually be responsible for activation of small GTP-binding proteins such as Rho and 
Rac, two members of the Ras GTPase superfamily (Reif, Nobes et al. 1996). 
Furthermore a subsequent study has indicated that PI3-kinase itself may be an 
activator of Ras (Hu, Klippel et al. 1995). The Ras-PI3-kinase relationship has yet to 
be clearly delineated.  
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On the basis that effector proteins are those that bind to Ras in a GTP-dependant 
manner, several other candidate proteins have been identified. These include Ral–
Guanine nucleotide dissociation simulator (Ral-GDS), which acts as a guanine 
nucleotide exchange factor for the Ras-related GTPases RalA and RalB (Kikuchi, 
Demo et al. 1994). The exact functions of Ral GTPases have been elusive but they 
appear to be components of Src-mediated activation of phospholipase D (PLD) and 
subsequent lipid second messengers including diacylglycerol (Jiang, Luo et al. 1995). 
Furthermore there appears to be an association between Ral GTPases and the Rho 
network, which is involved in cytoskeleton regulation (Jullien-Flores, Dorseuil et al. 
1995). In this way Ras binding of Ral-GDS may be the initial step in bridging Ras 
activation to Rho signalling via Ral GTPase and PLD. Ral may be involved in c-fos 
promoter regulation and contribute to regulation of cyclin D1 through activation of 
NF-#B and so be involved in mitogenesis and survival signalling (Murai, Ikeda et al. 
1997; Henry, Moskalenko et al. 2000). Mitogen-activated protein kinase kinase kinase 
1 (MEKK1) is a serine-threonine kinase that regulates the kinase pathway involving 
stress-activated protein kinase Jun-N-terminal kinase (JNK) and has been found to 
directly interact with Ras-GTP (Derijard, Hibi et al. 1994; Russell, Lange-Carter et al. 
1995). JNK activation occurs in stressful environmental conditions such as UV 
radiation and heat and may also be activated in response to cytokines such as nerve 
growth factor and epidermal growth factor in a Ras-dependant manner (Minden, Lin 
et al. 1994). JNK cascade activation leads to phosphorylation and activation of c-jun 
transcription factor and is implicated in apoptosis, oncogenic transformation and 




Figure 1.12: Ras effector pathways. Solid lines are activating and dashed are 
inhibiting actions. Members of the Ras superfamily are represented in red. Degree of 
activation of each phosphorylation cascade and the degree of cross-talk is dependent 
on initial stimulus. 
 
1.7 Ras isoforms and differential cellular function 
There is now increasing evidence that Ras isoforms may have distinct roles within the 
cell and the hypervariable region may be vital to this function. Firstly there is 
significant variation in the levels of expression of isoforms not only between tissues 
types but also at different time points of development in mice. Ha-ras transcripts are 
most highly expressed in the brain, muscle and skin while Ki-ras levels are highest in 
the gut, lung and thymus of mice (Leon, Guerrero et al. 1987). Furthermore during 
murine pre-natal development there is differential expression with time points: N-ras 
transcripts being highest at day 10 and Ki-ras lowest towards the end of gestation 
(Muller, Slamon et al. 1983). Though these findings suggest that the isoforms possess 
distinct cellular functions, at least in development, the fact that all three isoforms are 
! '"!
concurrently expressed in most murine and human tissues and share high degree of 
homology suggests that there may be a degree of functional overlap and potentially 
compensatory alterations in expression (Chesa, Rettig et al. 1987; Furth, Aldrich et al. 
1987). Following the analysis of various human tumours it was found that 80% of 
pancreatic adenocarcinomas harboured a mutated Ki-ras gene while in acute myeloid 
leukaemia, N-ras was the most frequently mutated (Bos 1989). In addition it was 
found that different oncogenic isoforms of Ras resulted in different effects. In a 
mouse model of colon cancer Ki-Ras overexpression resulted in hyperproliferation of 
colonic epithelium. Though this was not observed with N-Ras overexpression, a 
resistance to apoptosis was demonstrated (Haigis, Kendall et al. 2008).  More 
compelling evidence comes from the use of knockout mice. Knockout of N-Ras, Ha-
Ras or the splice variant Ki(A)-Ras produced phenotypically normal mice (Umanoff, 
Edelmann et al. 1995; Esteban, Vicario-Abejon et al. 2001; Plowman, Williamson et 
al. 2003). However the absence of Ki-Ras, in particular Ki(B)-Ras variant, led to 
embryonic lethality with defects of haematopoeisis, myocardial cell proliferation and 
neuronal cell survival (Johnson, Greenbaum et al. 1997; Koera, Nakamura et al. 
1997). However the relationship between Ras isoforms and development is more 
complex than this. Potenza et al. generated genetic mice in which Ki-Ras was 
replaced by Ha-Ras so that neither splice variant of the Ki-Ras protein was expressed. 
Unlike previous experiments involving null-Ki-Ras models, these mice reached 
adulthood with normal development during embryogenesis but did develop 
cardiomyopathy (Potenza, Vecchione et al. 2005). This study suggests that during 
embryogenesis there is a degree of redundancy in the roles of the isoforms yet 
specific Ras isoform functions are required for certain aspects of normal 
developmental homeostasis. Further support for specific roles of each isoform comes 
from the observation that Ha-Ras and Ki-Ras localize to distinct microdomains within 
the plasma membrane (Roy, Luetterforst et al. 1999). Ki-Ras is localized 
predominantly to the disordered plasma membrane, whereas Ha-Ras localizes mainly 
to the cholesterol-rich lipid rafts (Prior and Hancock 2001; Hancock 2003). 
Subsequently it has been shown that the different platforms within the plasma 
membrane in which the different isoforms of Ras reside may provide novel spatial 
and dynamic differences that Ras may utilize for differing signal transduction 
(Hancock and Parton 2005). In addition it was discovered that Ha-Ras and Ki-Ras 
signalling are differently dependent on the process of endocytosis (Roy, Wyse et al. 
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2002) with Ha-Ras, but not Ki-Ras, signalling through the Raf/MEK/MAPK cascade 
requiring endocytosis and endocytic recycling. Carozzi et al. also showed that a 
natural mutant of caveolin-3, C71W, specifically inhibited activated Ha-Ras 
signalling but not that by Ki-Ras thus indicating that different isoforms localizing to 
different microdomains provide different cell signals (Carozzi, Roy et al. 2002). 
Knockdown of Ha-Ras using antisense oligonucleotides (ASO) in mouse mesangial 
cells resulted in an increase in apoptosis not observed in ASOs to control, Ki-Ras or 
N-Ras. However in human mesangial cells, ASOs to both Ha-Ras and Ki-Ras but not 
N-Ras reduced proliferation but not apoptosis. This suggests not just a distinct role of 
isoforms but also a distinct role between species (Hendry, Khwaja et al. 2006). Within 
the kidney Kocher et al. showed distinct cellular distribution of Ras isoforms in 
samples of normal and diseased human kidney tissue. Using isoform specific 
monoclonal antibodies, staining for Ha-Ras and Ki-Ras was widespread but was 
absent in podocytes whereas N-Ras staining appeared to be localized to the collecting 
duct cells in normal kidney(Kocher, Moorhead et al. 2003)and the expression and 
distribution of each isoform differed significantly in diseased samples. The same 
group also employed immunogold labeling and EM to study Ras isoform distribution 
in normal human kidney samples and demonstrated distinct subcellular localization 
within the kidney. The affinity of Ras isoform for downstream effectors also differs. 
Studies have shown that activation of Raf was most efficient by Ki-Ras followed by 
N-Ras then Ha-Ras (Hamilton and Wolfman 1998; Voice, Klemke et al. 1999). 
However with regards to PI3K activation Ha-Ras was found to be more potent (Yan, 
Roy et al. 1998). 
In conclusion Ras isoforms appear to have distinct subcellular distribution which may 
be related to the individual functional aspects of the isoform. The different isoforms 
appear to have distinct roles both in development and homeostasis that may also be 
related to this localization and the affinity of each isoform to downstream effectors. 
There appears to be a degree of redundancy or potential compensatory change 
between the three isoforms in certain circumstances but there is also a large body of 





1.8 Ras and TGF"  
Though Ras does not appear to be directly downstream of TGF" there is now 
increasing evidence of crosstalk and interaction between the two signalling cascades. 
Atfi et al. used a prostate cancer cell line to show signals, initiated by receptor of 
TGF", could downregulate Src family kinases resulting in an accumulation of its 
substrate, non-phosphorylated SHC (Atfi, Drobetsky et al. 1994). The group 
postulates the decreased affinity of binding to the Grb/SOS complex may inhibit Ras 
activation. Other studies have shown a less direct link, with Ras pathway influencing 
the Smad signalling cascade downstream of TGF". Mulder demonstrated, in 
proliferating TGF"-sensitive epithelial cells, that TGF" signalling involved rapid 
activation of the Ras pathway for growth inhibitory effects and autoinduction and 
these effects involved the Ras-mediated phosphorylation of Smad 1 (Mulder 2000). 
However the role of Ras in TGF" signalling appears to differ in transformed cells as 
well as in cell type. Overexpression of Ras in transformed lung epithelial cells 
conveyed a resistance to TGF" (Kretzschmar, Doody et al. 1999). The constitutively 
active Ras cascade results in inhibition of nuclear accumulation of Smad 2 and Smad 
3 and inhibition of transcriptional activation. This may explain the resistance to 
growth inhibitory response to TGF" in oncogenic cells. Paradoxically the 
overexpression of Ras in renal mesangial cells promotes Smad 3-dependent processes 
including collagen I synthesis (Hayashida, Decaestecker et al. 2003). The reason for 
the differing response of sustained Erk activation between the different cell types is 
unknown. 
In untransformed epithelial cells the administration of TGF" has been observed to 
result in a transient activation of the Ras/MEK/Erk pathway (Mulder and Morris 
1992). Crosstalk between the Ras and TGF" pathways has also been demonstrated in 
mesangial and fibroblastic cells. Some of the TGF" downstream effects in fibroblasts, 
including growth inhibition, have been shown to be Ras dependent (Hu, Shen et al. 
1999; Kivinen and Laiho 1999). Martinez-Salgado et al. were also able to 
demonstrate involvement of Ras isoforms in TGF"-induced proliferation and 
associated collagen and fibronectin synthesis using fibroblasts from double knockout 
(KO) Ha- and N-Ras mice (Martinez-Salgado, Fuentes-Calvo et al. 2006). Ras 
activity also appears to be involved in the expression of the TGF" downstream 
effector molecule connective tissue growth factor (CTGF). Chen et al. showed that 
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CTGF expression in cultured mesangial cells required synergy between Smad and 
Ras/MEK/ERK signalling (Chen, Blom et al. 2002) while Leask et al. were able to 
demonstrate that Ras activation is of equal importance in TGF"-induced CTGF 
expression in fibroblasts (Leask, Holmes et al. 2003). Leask’s group further 
demonstrated both in vitro and in vivo that prostacyclin derivatives prevent the 
fibrotic response to TGF" by inhibiting the Ras/MEK/ERK pathway. They further 
concluded that the Ras pathway did not directly affect Smad activity but may be of 
importance in a promoter-specific manner (Stratton, Rajkumar et al. 2002). Phanish et 
al. used antisense oligonucleotides to demonstrate that TGF"-induced expression of 
CTGF in human proximal tubular epithelial cells was N-Ras dependent. The group 
also observed that N-Ras inhibition diminished TGF"-autoinduction (Phanish, Wahab 
et al. 2005). 
The growing interest in EMT has also led to further investigation into TGF" 
activation of Ras especially in the field of cancer.  Janda et al. examined the role of 
hyperactive Ras/MAPK pathway on TGF"-induced EMT in a combined in vitro/in 
vivo carcinogenesis model of polarized Ha-Ras-transformed mammary epithelial cells 
(EpRas) (Janda, Lehmann et al. 2002). They concluded that a hyperactive Raf/MAPK 
pathway is required for ‘full’ EMT involving change in both phenotypic and cellular 
markers. In contrast TGF" alone induces “scattering”-a spindle-like cell phenotype 
which is fully reversible after factor withdrawal and does not involve sustained 
marker changes. This suggests that EMT seems to be a close in vitro correlate of 
metastasis and requires synergism between TGF" and Ras/Raf/MAPK signalling. The 
group also found that activation of phosphatidylinositol 3-kinase (PI3K) induces 
“scattering” and protects from TGF"-induced apoptosis. The expression of the 
transcription factor Snail is also induced by TGF" and subsequent overexpression 
represses E-cadherin expression and induces EMT (Peinado, Olmeda et al. 2007) 
while silencing of Snail, at least in tumour cells, reduces capacity for invasion by 
down regulating EMT (Olmeda, Jorda et al. 2007). Horiguchi et al. demonstrated that 
Snail is a key regulator of TGF"-induced EMT in pancreatic tumor cells (Horiguchi, 
Shirakihara et al. 2009) and that Snail induction by TGF" was highly dependent on 
co-operation with active Ras signals. Furthermore using Ki-Ras siRNA to silence Ki-
Ras activity they were able to abolish Snail induction by TGF" in pancreatic cancer 
Panc-1 cells. Safina et al. found that TGF" induces EMT but limits cell migration and 
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motility by increasing cell-matrix adhesions. Conversely Ras hyperactivation does not 
appear to cause EMT per se but enhances cell migration through matrigel via a 
method of high molecular weight-tropomyosins suppression (Safina, Varga et al. 
2009). Thus activated Ras alters the TGF" response, conferring a tumorgenic and 
invasive potential to cells, a major aspect of EMT in metastases. Though the majority 
of investigations regarding TGF" and Ras activation involve transformed cell lines 
there is now an increasing interest in this phenomenon outside the field of oncology. 
Xie et al. used both normal murine mammary gland (NMuMG) epithelial cells and 
mouse cortical tubule (MCT) epithelial cells to demonstrate increased gene expression 
of Ras, Raf, MEK1/2, and Erk1/2, as shown by microarray analysis and real-time 
polymerase chain reaction, in a model of TGF"-induced EMT (Xie, Law et al. 2004). 
In a TGF" 1-driven in vitro EMT model using primary human tubular epithelial cells 
(HUTEC), Campanaro et al. employed large-scale oligonucleotide microarrays, to 
show an excess of up-regulated proteins involved in biological processes, such as 
"morphogenesis", "cell fate determination" and "regulation of development" with the 
most up-regulated genes belonging to these categories. They found that Smad 
signalling was not the major effector for these genes but instead the RAS/MAPK 
signalling pathway seemed to be the main regulator involved in the cell cycle and 
proliferation/apoptosis (Campanaro, Picelli et al. 2007). Shimizu et al. have utilized 
siRNA against MAPK1 to demonstrate amelioration of glomerular disease in a 
murine model of lupus nephritis (Shimizu, Hori et al. 2010). As part of their studies 
they found that knockdown of MAPK1, a downstream effector molecule of Ras, 
significantly decreased TGF" expression. More recently, one group has demonstrated 
a direct link between Ras signalling pathway and EMT. Bozic et al. showed that the 
glutamate receptor, N-methyl-D-aspartate (NMDAR), present on proximal epithelial 
cells was critical in maintaining the normal epithelial phenotype and modulating 
TGF"-induced EMT in HK-2 cells (Bozic, de Rooij et al. 2011) and the mechanism of 
this antagonistic effect involves decreased activation of Ras-GTPase and subsequent 
inhibition of the Ras-MEK pathway. The group further demonstrated that 
administration of NMDA in UUO models significantly attenuated fibrosis. From these 
studies there appears to be increasing evidence for TGF" and Ras crosstalk in EMT 
and possibly subsequent fibrogenesis. 
 
! ''!
1.9 Ras and Renal disease 
There is a large body of evidence that supports a role for Ras and even individual 
isoforms of Ras in renal disease. Our group has previously employed ASOs to 
demonstrate that the pre-dominantly expressed isoform in human renal fibroblasts 
was Kirsten (95% of total Ras) (Sharpe, Dockrell et al. 1999) and that this Ras 
isoform played a pivotal role in EGF and serum-induced fibroblast proliferation. In 
addition, Ha-Ras, though expressed at a lower level than Ki-Ras, was also seen to 
contribute significantly towards fibroblast proliferation while N-Ras knockdown did 
not (Sharpe, Dockrell et al. 2000). Mesangial cell proliferation and subsequent matrix 
deposition has also been shown to be Ras dependant. An increase in membrane 
associated Ras was observed in the presence of mesangial cell proliferation induced 
by high glucose (Danesh, Sadeghi et al. 2002) while Chen et al. also found that in 
mesangial cells CTGF induction required Smad and Ras/MEK/ERK synergy (Chen, 
Blom et al. 2002). Furthermore there appears to be distinct roles for Ras isoforms in 
the homeostasis of mesangial cells (Hendry, Khwaja et al. 2006). 
Further evidence for the role of Ras in renal disease is provided by studies inhibiting 
Ras and its downstream effectors. Farnesylthiosalicylic acid (FTS) is a compound that 
displaces prenylated Ras from its site of action at the plasma membrane. Khwaja et al. 
showed that FTS reduced PDGF-driven human mesangial cell proliferation but had no 
effect on serum induced proliferation despite both Ras and phospho-MAPK activation 
being inhibited in both conditions (Khwaja, Sharpe et al. 2005). Furthermore PDGF-
stimulated activation of the survival protein Akt was inhibited by FTS while serum-
stimulated activation of Akt was unaffected by FTS resulting in increased HMC 
apoptosis in the former condition. In vivo effects of FTS on the kidney have also been 
observed. In a rat model of Thy-1 nephritis an increase in glomerular expression of 
Ki-Ras and N-Ras isoforms was observed and was almost fully prevented by FTS. 
Intraperitoneal administration of FTS resulted in both a reduction of glomerular 
cellular proliferation and inflammation as well as a decrease in proteinuria by day 10 
(Clarke, Kocher et al. 2003). These results indicate that this model of cytokine-driven 
glomerular cell proliferation and invasion is likely to involve Ras signalling pathways 
and Ras inactivation by FTS ameliorates this damage. Masterson et al used 
farnesyltransferase and geranylgeranyltransferase inhibitors (FTI and GGTI 
respectively) to target the post-translational process of prenylation of Ras. The group 
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reported a significant decrease in rat renal fibroblast proliferation and CTGF 
expression with both agents. However there was a far more significant decrease in 
collagen production with FTI while GGTI administration alone resulted in a decrease 
in collagen lattice contraction (Masterson, Kelynack et al. 2006). It is now recognized 
that Ras proteins (or at least the Kirsten and Neural isoforms) are preferentially 
farnyslated though, like Rho proteins, may be alternatively geranylgeranylated. This 
study indicates the distinct roles between these two members of the Ras superfamily.  
Statins have also been used to target the prenylation pathway (Fried 2008). Inhibition 
of HMG-CoA reductase inhibits the first step of prenyl group formation and in this 
way reduces the degree of achievable Ras prenylation. These agents are known to be 
safe in humans and in various models of renal disease studies report an attenuation of 
progression of renal disease though the majority used doses of statin far greater than 
that administered in the clinical environment (Vrtovsnik, Couette et al. 1997; Yokota, 
O'Donnell et al. 2003; Li, Yang et al. 2004; Sabbatini, Pisani et al. 2004). Though the 
above studies all demonstrate an important role for Ras in renal disease progression 
the treatments are non-specific and have a generalized effect on all members of the 
Ras ‘superfamily’ of GTPases so one cannot delineate the actual role of the Ras 
proteins in disease. Furthermore they do not and cannot differentiate between the Ras 
isoforms, which are now thought to have distinct cellular roles. 
Several studies have focused on the downstream effectors of the Ras superfamily and 
demonstrated a role for the Ras signalling pathway in renal disease. Choudhury et al. 
demonstrated the importance of both the MAPK and PI3K pathway in PDGF-driven 
mesangial cell proliferation (Choudhury, Karamitsos et al. 1997) while Xu et al. 
observed that the co-activation of Ki-Ras and Erk by advanced glycation end products 
in mesangial cells was PI3K-dependant (Xu and Kyriakis 2003). Rodriguez-Pena et 
al. reported an increased ratio of activated Ras and increased levels of phosphorylated 
ERK 1/2 and Akt/PKB in a model of unilateral ureteric obstruction (Rodriguez-Pena, 
Grande et al. 2008) Inhibition of these downstream effectors resulted in a decrease of 
myofibroblastic phenotype, fibroblast proliferation and matrix deposition indicating a 
role for Ras in tubulointerstitial fibrosis. 
However only in 2010, a direct link between Ras activation and renal fibrogenesis has 
been conclusively demonstrated by a seminal paper from the group of Michael 
Zeisberg (Bechtel, McGoohan et al., 2010). The group elegantly demonstrated that 
hypermethylation of RASAL1 gene, resulting in the decreased expression of the Ras  
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GAP RASAL1, correlated with Ras hyperactivity and a subsequent increase in 
fibrosis in a number of murine models of renal fibrosis. They also demonstrated that 
the administration of FTS significantly reduced fibrosis when compared to control 
groups though this was thought to be by a RASAL1 hypermethylation-independent 
mechanism. The group concludes that “hyperactive Ras contributes to fibroblast 
activation and fibrosis” and “that the antifibrotic capacity of Ras inhibitors should be 
further explored.” 
 
1.10 RNA interference and Gene silencing 
The term gene therapy was conceived in the 1980s and originally referred to the 
insertion of a ‘normal’ functioning gene into a cell that possessed a defective form of 
the gene. However more recently a subset of gene therapy has developed which 
involves the inactivation of specific genes that are involved in disease process. This 
strategy has been termed ‘Gene Silencing’. Now the human genome has been mapped 
this technique offers huge potential for research into elucidating gene function and 
pathways of cellular signalling. The two methods of gene silencing that have been 
most widely used are: Antisense oligodeoxynucleotides (ASO) and short-interfering 
RNA (siRNA) also known as RNA interference (RNAi). The mechanism of action of 
siRNA was determined by Fire & Mello in 1998 (Fire, Xu et al. 1998). It involves the 
initial cleavage of double stranded RNA by the enzyme Dicer into short RNA 
duplexes which are incorporated into a ribonucleoprotein-endonuclease complex 
termed ‘RNA Induced Silencing Complex’ (RISC). Once incorporated into RISC, the 
antisense strand of unwound siRNA binds to the specific endogenous RNA target 
sequence. The target RNA transcript is then bound and degraded by endonulease 
activity of RISC. The precise mechanism of target RNA recognition and degradation 
by RISC remains unclear. However the use of siRNA has been shown to be over ten 
times more potent than either sense or antisense RNA use alone and has been proved 
to be a powerful tool for target mRNA knockdown in vitro. The major problems 
associated with the use of this technology have been related to short half-life, 
efficiency of transfection and side effects, especially involving interferon mediated 
systemic inflammatory responses, their use in vivo has been restricted though it 
appears only a matter of time before these obstacles are overcome (Fire 2007; Wang, 
Hendry et al. 2008). 
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Zamecnick and Stephenson were the first to recognize the potential of ASO in 1978 
when studying inhibition of Rous sarcoma virus replication (Stephenson and 
Zamecnik 1978). Since then antisense technology has developed into a powerful 
research tool and has begun to make its mark in the world of clinical therapy.  
ASO consist of a single strand of 12 to 22 oligodeoxynucleotides which are 
complementary to the target mRNA sequence (Loke, Stein et al. 1989). Binding of the 
ASO to target mRNA transcript via Watson-Crick hybridization results in steric 
inhibition of translation by the ribosomal complex but more importantly the induction 
of RNase H, which cleaves the 3'-O-P-bond of the RNA molecule (Figure 1.13). This 
mechanism of action theoretically provides 100% specificity for the target gene; an 
unachievable goal for most conventional pharmacological agents. 
Since the 1970s ASO have been used widely as research tools used to investigate 
mechanisms of disease pathogenesis in vitro, particularly in the field of nephrology. 
The use of ASO to target the kidney in vivo has been both challenging and highly 
rewarding. Unmodified, single-stranded oligonucleotides are rapidly broken down in 
serum by endogenous nucleases greatly limiting cellular uptake. To overcome this, 
ASO have a modification of the phosphate backbone whereby non-bridging oxygen 
molecules are replaced by sulphur molecules, greatly enhancing resistance to nuclease 
activity. These phosphorothioate ASO have a half-life in serum in the region of 10 
hours (in comparison to 30-60 minutes of unmodified forms) and, following 
parenteral administration, have a systemic bioavailability as high as 90% (Crooke and 
Bennett 1996). Further modifications of the sugar-phosphate backbone of the 
oligonucleotides can be made to increase their stability and RNA affinity without 
compromising binding selectivity. Unfortunately, complete 2’-O-modification of the 
molecule results in the loss of its ability to activate RNAase H. This has led to the 
development of chimeric oligonucleotides or ‘Gapmers’ that are formed by 
combining 2’-O-modified oligonucleotides with regions of 2’-deoxy 
phosphorothioates. The resulting second generation ASO supports both RNAase H 
activity and demonstrates enhanced nuclease resistance and RNA affinity. Following 
parenteral administration, these ASO distribute to all peripheral tissues with the 
highest accumulation being in the liver and kidneys, which have a concentration ratio 
to plasma of 20:1 and 80:1 respectively after 2 hr (Sands, Gorey-Feret et al. 1994). 
Within the kidney ASO are filtered freely by the glomerulus and reabsorbed by 
proximal tubule epithelial cells (Rappaport, Hanss et al. 1995) making antisense 
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technology a very attractive tool for the investigation and possibly treatment of renal 
disease. 
Although some animal studies have shown that ASO infusions may lead to 
complement cascade activation (Levin 1999; Farman and Kornbrust 2003), these 
effects appear to be both dose-dependent and related to rate of administration. 
Subsequent clinical studies using lower doses of ASO have reported minimal toxic 
effects. Furthermore subsequent generations of ASO have lower toxicity profiles 
(Jason, Koropatnick et al. 2004). There has therefore been much interest in pushing 
forward ASO for clinical therapy. Although currently there is only one ASO licensed 
for clinical use, Formivirsen (Vitravene®) for AIDS-related CMV retinitis, numerous 
others are in Phase 2 of clinical development such as ASO to ApoB-100 for the 
treatment of hypercholesterolaemia, ASO to ICAM-1 in ulcerative colitis and many 
others. With the publication by Tillman et al demonstrating efficacy of oral delivery 
of ASO in man (Tillman, Geary et al. 2008), comes the potential that this form of 
gene therapy becoming part of the normal repertoire of therapeutic options open to the 




Figure 1.13: Mechanisms of action of siRNA and antisense oligonucleotides 
(ASO). (Figure from Wang, 2008). Targeted RNA silencing by siRNA is via 
incorporation into RNA Induced Silencing Complex (RISC) and antisense via RNAse 
H degradation to target-ASO duplex molecule. 
 
For the purpose of this project and its translational aspect, ASOs have several 
advantages over siRNA. They have a much longer half-life, are being used at present 
in a clinical setting and have been proven to be both safe and efficient in vivo.  
Furthermore with regards to renal disease ASOs concentrate in the PTECs of the 







1.11 Aims of project 
The potential importance of Ras in renal fibrosis has been described above. Our group 
has previously demonstrated that Ki-Ras is pivotal to renal fibroblast proliferation in 
vitro. Targeting this isoform may ameliorate renal fibrosis. This project aims to 
further this work by studying the effects of Ki-Ras inhibition with antisense 
oligonucleotides in a rat model of renal fibrosis induced by unilateral ureteric 
obstruction.  
The specific aims of this project are: 
1) To validate the efficacy and specificity of Ki-Ras antisense oligonucleotides in 
vitro in both rat renal fibroblasts and tubular epithelial cells. 
2) To develop a model of renal interstitial fibrosis secondary to unilateral ureteric 
obstruction. 
3) To characterise Ras isoform expression within the normal rat kidney and in a 
rat model of unilateral ureteric obstruction. 
4) To determine the effects both in renal and extra-renal tissue of Ki-Ras 
inhibition by antisense oligonucleotides in a rat model of renal fibrosis. 
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Chapter 2: Methods and Materials 
2.1 Cell culture & passage 
Cells were plated and grown in 75cm2 flasks containing DMEM medium (Gibco) 
supplemented with penicillin (100IU/ml), streptomycin (100µg/ml), amphotericin 
(2.5µg/ml) and fetal calf serum (FCS) (Sigma) to give a final concentration of 5-10% 
FCS by volume. Flasks were incubated in Techne incubators set at 37ºC with 95% O2 
and 5% CO2. Primary cultures and commercial cell lines were grown in separate 
incubators. For the purposes of passaging, cells were grown to 70% confluence and 
washed twice in phosphate-buffered saline (PBS) prior to incubation at 37ºC for five 
minutes with 1ml of 1x Trypsin-EDTA (Life-Technologies, Paisley, UK).  Trypsin 
was neutralised by re-suspending released cells in 10% FCS/DMEM. For 
experiments, cells were sub-cultured into either 35mm or 100mm diameter dishes. 
Only cells of at least three passages were used in experiments. 
 
2.2 Primary culture of adult rat fibroblasts 
Kidneys harvested from PVG (Piebald Virol Glaxo) rats were kindly donated by Dr 
Greta Sawyer, King’s College London. PVG rats are inbred to provide a genetic 
background for production of congenic resistance to autoimmune thyroiditis and 
allergic encephalitis. The technique of retrieval and culturing of fibroblasts was 
adapted from a previously published protocol (Johnson, Saunders et al. 1998) and has 
been previously used in our laboratories. The freshly harvested rat kidneys were 
placed in a 100mm dish of sterile ice-cold Hank’s Balanced Salt solution (HBSS) and 
decapsulated using forceps. The cortex was removed using scissors and the medulla 
disposed of. The shaven cortex was further ‘minced’ under sterile conditions and 
washed in HBSS to remove any remaining blood. Excess HBSS was removed and the 
kidney cortex ‘mince’ was re-suspended in 50-100ml Collagenase XI solution 
(0.5mg/ml made up in HBSS). The suspension was placed in a water bath at 37ºC for 
30-40 minutes and a magnetic sterile stirrer was used to aid enzymatic digestion. The 
digestion process was terminated by the addition of an equal volume of ice-cold 2% 
FCS/HBSS solution. The suspension was decanted into a sterile 50ml falcon tube, 
with any residual cortex discarded, then centrifuged at 1000G at 4ºC for 5 minutes. 
The supernatant was discarded and the pellet re-suspended in 50ml ice-cold 2% 
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FCS/HBSS and re-spun at 1000G at 4ºC for 5minutes. The supernatant was disposed 
of and pellet retained. The pellet was then re-suspended in 30ml sterile 50% Percoll 
solution (50% Percoll/50% HBSS containing mannitol (0.82g in 30ml Percoll/HBSS 
solution pH7) and centrifuged at 30,000G at 4ºC for 30 minutes to create a density 
gradient. In an accompanying falcon tube density beads in an identical 50% Percoll 
solution were used as a reference for density distribution. Following centrifugation, 
the cellular layer in the sample correlating to the top band (F1) layer of density beads 
were harvested and re-suspended in a new sterile falcon tube in 50ml of 
DMEM/10%FCS medium and centrifuged at 1000G at 4ºC for 5 minutes. The 
supernatant was removed and pellet re-suspended again in medium and again 
centrifuged at 1000G at 4ºC for 5minutes. The supernatant was disposed off and the 
remaining pellet weighed. The pellet was then once again re-suspended in medium in 
a volume sufficient to allow plating of 100mg of cellular material per 100mm dish. 
These initial plated cells were allowed to attach for 2 days before medium was 
changed. After 10 days growth, cells were trypsinized and replated. Following two 
passages, cultures of cells were phenotypically fibroblastic in 95% of cases. 
 
2.3 Commercial cell lines 
Normal adult rat fibroblast (NRK-49F) and epithelial (NRK-52E) cells were obtained 
from the European Collection of Cell Cultures (ECACC no: 86101301 and 87012902 
respectively). Cells were resuscitated according to accepted guidelines and sub-
cultured 1:10-1:20 when grown to 70-80% confluence. Only cells that had undergone 
at least three passages were utilized in experiments. These cells were employed in this 
project as they were seen to as closely mimic as possible ‘normal’ rat renal cells 
physiologically and with regards to response to treatment. 
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2.4 Antisense Oligonucleotides 
 Antisense oligonucleotides (ASOs) were supplied by ISIS Pharmaceuticals, Carlsbad, 
California. In total, six different oligonucleotides were used throughout the duration 
of this project: two targeting Ki-Ras in the rat (ASO 1 and ASO 2) and four as 
control. Two of the controls (CO 1 and CO 2) have no recognised target in the rat, 
while the other two are scrambled oligos of ASO 1 and ASO 2, named SO 1 and SO 2 
respectively. All were 20-mer second generation gapmers consisting of a ten 
nucleotide phosphorothioate backbone with the addition of five 2’-methoxyethyl 
modified nucleotides at either end. These alterations provide resistance against 
degradation and decreased toxicity while maintaining a high target binding affinity in 
comparison to non-modified oligos. Table 2.1 summarises the properties of each oligo 
including the NIH accession number of the target gene when base sequence is 
interrogated. 
 






































































2.5 In vitro transfection of oligonucleotides 
Methods of cell transfection with oligonucleotides varied depending on cell type used. 
Initially oligonucleotides were diluted with OptiMEM (Gibco BRL, Life 
Technologies Paisley, UK) to form a 10µM stock. 
Primary cell cultures and NRK-49F cell lines:  Cells were grown in 100mm dishes 
to a confluence of 50-70% and washed with PBS prior to transfection. Oligos were 
transfected into cells using a cationic liposomal system, either Lipofectin or 
Oligofectamine  (Invitrogen).  
For Lipofectin, 1.25µl of Lipofectin per 100nM oligo per 100µl final transfection 
volume was used as advised by ISIS and as for previous published protocol (Sharpe, 
Dockrell et al. 1999). The final volume for a 100mm dish was 2ml with a final oligo 
concentration of 200nM. To ensure maximum transfection efficiency an initial 
solution of Lipofectin in five-times its volume of Opti-MEM transfection medium 
was vortexed and incubated at room temperature for 45 minutes.  The appropriate 
amount of oligo was then added to this solution and left at room temperature for a 
further 15 minutes before being made up to its final volume with Opti-MEM and 
added to the cells for transfection. In later experiments Oligofectamine liposomal 
transfection system (Invitrogen) was used as a result of literature stating higher 
efficiency of oligo transfection. For each 1ml of a final transfection volume, 4µl 
Oligofectamine was diluted in 15µl Opti-MEM and rota-mixed and allow to stand at 
room temperature for 10 minutes. Specific oligo was then added as required to 
achieve a final transfection concentration of 200nM-400nM. The solution was gently 
mixed and allowed to stand for 20 minutes at room temperature. Opti-MEM was then 
added to make a final transfection volume of 2 ml per 100mm dish.  
Cells were incubated in transfection medium at 37ºC for 6-18 hours followed by 
immediate RNA extraction. For protein retrieval, cells were incubated in transfection 
medium at 37ºC for 18-20 hours followed by addition of 2% FCS/DMEM medium 
and allowed to grow for further 48 hours prior to lysis.  
NRK-52E cell line: The normal rat renal epithelial cell line obtained from ECACC 
proved to be difficult to transfect using the standard protocol above. As a result an 
adaptation of the technique of “reverse transfection” using Lipofectamine LTX 
reagent (Invitrogen) was employed. Initially developed as a method of high-output 
analysis of genetic function in cells using microarray, it appears that cells may be 
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more receptive to transfection via the reverse as opposed to standard protocol (Erfle, 
Neumann et al. 2007). The basis of the process involves detachment of target cells 
that are then subsequently re-plated at higher cell density into a dish containing pre-
prepared transfection complexes. The combination of increased cell:complex ratio 
and the cell detachment may increase efficiency of transfection. In summary, cells 
were grown to 80-90% confluence, washed twice in sterile PBS and 1ml of trypsin 
added and incubated at 37°C for 3-5mins with intermediate shaking to detach cells. 
They were then transferred and resuspended in 4mls 10% FCS/DMEM medium and 
centrifuged at room temperature for 5mins at 13000rpm. The supernatant was 
discarded and the cells were resuspended in 500µl of Opti-MEM. Transfection 
medium was made up using 6.25µl of Lipofectamine LTX for every 500µl Opti-
MEM. Specific Oligo was added at a dose so that final transfection medium 
concentration would be 200nM. This solution was vortexed and stood at room 
temperature for 30min before being transferred to cell plate. The cell suspension was 
subsequently added to the transfection medium. For higher cell density, amalgamation 
of two dishes post-trypsin treatment was used. Final volume in our studies was 2ml in 
100mm dish with a final oligo concentration of 200nM. 
As for standard protocol, cells were incubated at 37ºC for 6-18 hours followed by 
immediate RNA extraction. 
 
2.6 LDH Cytotoxicity assay 
CytoTox 96 non-radioactive cytotoxicity assay (Promega) was used to assess the 
presence of cytotoxicity secondary to oligonucleotide transfection at varying 
concentrations. CO 1, ASO 1 and ASO 2 were used at concentrations of 50nM, 
100nM, 200nM, 500nM and 1000nM. The protocol used was as according to 
manufacturer’s instructions outlined as follows: for test samples, each well contained 
50µl of approximately 5000 NRK-49F cells, 100µl of medium (10% FCS DMEM) 
and 50µl of Control Oligo/ASO in OptiMem (at 4x target concentration to allow for 
dilutional effect).  
Baseline control wells were as follows: 
a) Baseline: Culture Medium Only control (150µl Medium + 50µl OptiMem)  
b) Baseline LDH Cell Release: Positive control (100µl Medium + 50µl OptiMem + 
50µl of approximately 5000 NRK-49F cells) 
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c) Target Cell Volume Correction Control: (100µl Medium + 50µl OptiMem+ 50µl 
Lysis Buffer) 
d) Target Cell Maximum LDH Release Positive control: (50µl Medium + 50µl 
OptiMem + 50µl Lysis Buffer +50µl of approximately 5000 NRK-49F cells).  
 
Both control and test samples were run in quadruplet per plate. Once samples were 
plated they were incubated overnight at 37°C. Subsequently 45mins prior to 
harvesting supernatant 10µl of lysis solution (10x) was added per 100µl well volume 
to test samples, Target Cell Volume Correction Control samples and Target Cell 
Maximum LDH Release Positive Control samples. The plate was further incubated 
for 60mins then 50µl aliquots of supernatant from each well were transferred to a 
fresh 96 well plate. 50µl of activated substrate mix was added to each well. The plate 
was covered with foil to prevent light exposure and left at room temperature for 30 
mins. 50µl of ‘Stop Solution” was then added to each well to terminate enzymatic 
reactions. Any large bubbles in individual wells were popped with a sterile needle and 
the absorbance recorded at 492nm.All values were normalized for Baseline culture 
medium only control. 
Absorbance for Maximum LDH release = (Target Cell Maximum LDH Release 
Positive Control -Target Cell Volume Correction Control). 
Percentage cytotoxicity for each sample compared to non-treated cells was calculated 
as follows: 
% Cytotoxicity = Abs (sample) – Abs (Baseline LDH Cell Release) x100                                               
Abs (Maximum LDH release) 









2.7 Total RNA isolation 
All solutions were made up using water pre-treated with 0.1% diethyl pyrocarbonate 
(DEPC) (See Appendix I). All materials used in this section were either purchased 
pre-treated to be RNAse free or treated to be RNAse free using the following 
protocol: 
a) Soak in 0.1M Sodium Hydroxide solution (made up with 0.1% DEPC 
water) for 60mins then, 
b) Soak in 1mM EDTA solution (made up with 0.1% DEPC water) for 
60mins then,  
c) Soaked and rinsed in 0.1% DEPC water overnight 
 
Bench surfaces were treated with RNAse-free spray (Qiagen) pre-procedure. 
RNA isolation and purification was performed using a Qiagen RNeasy Mini kit. The 
principle involves initial lysis and homogenization of biological samples in the 
presence of highly denaturing chaotropic agent guanidine isothiocyanate (GITC) 
containing buffer that also inactivates RNases. Addition of ethanol provides optimal 
conditions for RNA to bind to the silica membrane of columns to allow for efficient 
removal of contaminants. Pure RNA can subsequently be eluted from the membrane 
using RNase free water. The process isolates RNA molecules longer than 200 
nucleotides and excludes most RNA below this length (such as 5S RNA and tRNA), 
thus also providing enrichment of target mRNA. 
From cell cultures: Cells grown on a monolayer were washed in PBS and total RNA 
extracted using the Qiagen RNeasy mini-kit® (Qiagen Ltd) using the manufacturer’s 
protocol. This process involved direct lysis of cells by addition of 600µl of GITC 
lysis buffer to each 100mm cell dish followed by disruption of cell membranes by 
traumatic needle lysis. The cell lysates were then homogenized by passing through a 
QIAshredder® sitting in a 2ml-collection tube that was subsequently centrifuged at 
15,000 rpm for 2 minutes.  Equal volumes of 70% ethanol was added to the lysates 
and mixed by pipetting. Samples (upto 700µl) were then transferred to RNeasy spin 
columns for adsorption of RNA to RNA-binding MinElute membrane. Contaminants 
were removed by sequential spin washes in wash buffers and mRNA was eluted with 
30-50"l of RNAse-free water per sample.  RNA was stored at –80oC. 
! )+!
For tissue samples: 30mg of sample was initially homogenized in 600µl lysis buffer 
using a Potter homogenizer. This suspension was then transferred to a QIAshredder 
and above protocol subsequently followed. Glassware and homogenizer were initially 
made RNase free by above protocol.  
Quantification of the isolated RNA was achieved using a spectrophotometer. An 
absorbance of 1 unit at a wavelength of 260nm corresponds to 40"g of RNA per ml 
and all calculations were based on this. To determine purity, absorbance was also 
measured at 280nm. The A260:A280 ratio provides an estimate of purity with pure 
RNA having a ratio of 2. All samples used in this study had a ratio of 1.8-2.3. RNAse-
free water was used for all dilutions of RNA samples for quantification. For later 
samples a Nanodrop 2000 spectrophotometer (Thermo Scientific) was used for RNA 
quantification. The principle of measurement is identical but far less volume of 
sample is used and the automated process reduces both operator and processing error 
while being technically easier. 
 
2.8 Protein extraction 
From cell cultures: Cell were washed twice in ice-cold PBS and then lysed by the 
addition of ice-cold PBSTDS lysis buffer containing protease inhibitors (1x PBS, 1% 
Triton-X 100, 0.5% sodium deoxycholate, 0.1% SDS, leupeptin 0.5"g/ml, pepstatin 
1.0"g/ml, EDTA 1.0mM, PMSF 0.2mM). 1ml of PBSTDS lysis buffer was used per 
100mm dish and 250µl per 35mm dish. Cells were left in lysis buffer on ice for 10 
minutes then scraped off dish surface and transferred to an eppendorf tube on ice. 
Further traumatic cell lysis was achieved by pipetting cell suspension in eppendorf via 
a 22G needle and syringe. The lysate was left on ice for 30-40minutes prior to 
centrifugation at 13,000G for 20 minutes at 4oC. The resulting cellular precipitate was 
discarded and the supernatant collected and stored at - 80oC. 
From tissue: This protocol was adapted from a published protocol (Yang and Liu 
2002). 100-200mg of tissue was placed in a thick-bottomed glass tube containing 1ml 
PBSTDS lysis solution and homogenized using a potter homogenizer on ice for 30 
seconds or until a homogenous suspension was obtained. The suspension was then 
transferred to an eppendorf on ice and further traumatic cell lysis was achieved via a 
22G needle and syringe. Subsequent steps were identical to that of protein extraction 
from cell cultures as described above. 
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The concentration of protein was determined by a colorimetric protein assay (BCA 
Protein Assay kit, Pierce) based on the reactions: 
1) Peptide + Cu2+$ Tetradentate- Cu1+ complex 
2) Cu1+ + 2 Bicinchoninic Acid (BCA) $BCA-Cu1+ complex (purple) 
Concentration of protein was read at a wavelength of 540nm at an absorbance of A562. 
A standard curve for analysis was made using serial dilutions of Bovine Serum 
Albumin. 
 
2.9 Semi-quantative PCR Primer design 
Semi-quantative polymerase chain reaction (SQ-PCR) primer pairs targeting the 
isoforms of Ras in the rat were designed initially by studying the cDNA sequences 
provided by the National Center for Biotechnology Information GenBank using the 
Basic Local Alignment Search Tool (BLAST). Using these as source sequences for 
the ‘Primer 3’ web based design program (Massachusetts Institute of Technology) 
optimum primer pair sequences were suggested. Selected primer sequences were 17-
20 base pairs in length, at least 50% G-C rich, were non-palindromic and had similar 
melting temperature to it’s opposite pair. The selected sequences were then re-
analysed using BLAST to confirm specificity of primer to target product. Primers 













Table 2.2: SQ-PCR primer pair sequences 
 
2.10 Semi-Quantative [Standard] PCR (SQ-PCR) 
The single step system Promega’s Access SQ-PCR kit (Promega, Southampton, UK) 
was used for semi-quantative PCR analysis of sample RNA. This allows both reverse 
transcription and DNA amplification to occur in a single test tube and so minimizes 
pippetting errors and contamination. The kit uses thermosensitive AMV reverse 
transcriptase (AMV-RT) from Avian Myeloblastosis Virus for first strand DNA 
synthesis, and the thermostable Tfl DNA Polymerase from Thermus flavus for second 
strand cDNA synthesis and amplification. The Access SQ-PCR System buffer permits 
activity of both polymerases therefore negating the need for buffer additions between 
the reverse transcription and PCR amplification steps. AMV reverse transcriptase 
works at 48°C which minimizes problems encountered with secondary structures in 































In all SQ-PCR reactions 0.5"g of total RNA and 50pmol of each primer was used. 
The number of nanograms of primer in 50pmol was derived from the following 
formula: 50pmol=16.3ng x b (where b= number of bases in the primer). 
Each tube contains a final volume of 50µl reaction mixture consisting of:  
10µl  AMV/Tfl 5x reaction buffer 
2µl  Magnesium Sulphate (25mM) 
1µl AMV RT 
1µl Tfl DNA polymerase 
1µl dNTP mix (10mM each dNTP) 
1µl Upstream Ras primer (50µM) 
1µl Downstream Ras primer (50µM) 
1µl Upstream "-actin primer (50µM) 
1µl Downstream "-actin primer (50µM) 
10µl Total RNA sample (1pg-1µg total RNA) 
21µl Nuclease free water 
 
Magnesium is required as a co-factor for both AMV transcriptase and Tfl DNA 
polymerase. "-actin was used as an internal control. 
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The reaction protocol is outlined below: 
First strand cDNA synthesis 
1 cycle  48°C for 45mins Reverse transcription 
 
 
 1 cycle  94°C for 2mins AMV RT inactivation 
      RNA/cDNA/Primer denaturation 
 
Second strand cDNA synthesis and PCR amplification  
27-40 cycles  94°C for 30sec Denaturation 
    56-59°C for 1min Annealing 
    68°C for 2mins Extension 
 
1 cycle  68°C for 7mins Final extension 
 
 
1 cycle  4°C    Soak 
 
Figure 2.1: Semi-quantative PCR reaction protocol. 
 
The annealing temperature for each reaction was calculated at 4-5oC below the 
melting temperature of each primer and averaged between the forward and reverse 
primer. For initial detection of Ras isoform mRNA, maximum amplification using 40 
cycles of PCR was used. However, in order to assess the effects of the ASOs on 
mRNA levels a semi-quantitative approach was needed.  To achieve this, the 
exponential phase of the amplification reaction was determined by varying the cycle 
number from 20 to 35. Cycle numbers 22 to 30 were demonstrated to be in the 
exponential phase for Ras products. To minimize pipetting error and allow 
quantification by comparison, an internal standard was used in the form of "-actin 
mRNA.  This form of RNA is relatively stable in cells regardless of experimental 
conditions. 20% of the final reaction product volumes were analysed on a 1.5% 
agarose gel containing 1"l/100ml ethidium bromide. TAE buffer containing 
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1"l/100ml ethidium bromide was used for electrophoresis. A 50bp DNA Step ladder 
(Promega, G452A) was used as a product size marker. The gel was subsequently 
viewed in a UV light box. 
 
2.11 Real-Time (Quantitative)-Polymerase chain reaction 
(QPCR) 
There are several advantages of QPCR compared to traditional SQ-PCR. The process 
of PCR consists of three main phases: Exponential, Linear and Plateau. During the 
exponential phase PCR is efficient, specific and precise and slows through linear 
phase before stopping in plateau phase. Ideally samples should be analysed in the 
exponential phase of PCR where differences between samples are amplified 
compared as opposed to plateau phase. Furthermore end-point results for SQ-PCR are 
obtained from running samples on an agrose gel with ethidium bromide. Gel 
resolution may be poor thus making it difficult to differentiate changes below 5-10 
fold. The use of a loading control is required to normalize the starting copy number of 
each target in each sample but may further add operator and interpretation error. 
Furthermore the use of ethidium bromide does not provide a quantative, numerical 
result. As opposed to SQ-PCR, QPCR allows for the monitoring of PCR as it occurs 
so reactions are characterized by the point during cycling when amplification of target 
is first detected rather than the amount of target that has accumulated after a set 
number of cycles thus ensuring PCR is analysed in exponential phase. Compared to 
SQ-PCR, QPCR is far less time consuming, has fewer practical techniques thus 
reducing operator error, is highly sensitive as analyses samples in exponential phase 
and allows detection of a two-fold change and provides a numerical interpretable 
result. QPCR in this project employed TaqMan chemistry (Applied Biosystems). 
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TaqMan chemistry: The TaqMan sequence detection system developed by Applied 
Biosystems utilizes a fluorgenic probe and the 5’ nuclease activity of Taq DNA 
polymerase. The system allows the detection of a specific PCR product as it 


















Figure 2.2: Summary of the Taqman sequence detection system (from “Essentials 
of Real Time PCR”, Applied Biosystems). R, reporter dye, Q, quencher dye. 
Quantitation assay: Quantitation of target in QPCR using TaqMan chemistry relies 
on the increase of fluorescence with each cycle of PCR. Initially there is little change 
in fluorescent signal and this defines the baseline for the amplification plot. An 
increase above this baseline implies detection of accumulation of target. A fixed 
fluorescent threshold may be set above baseline. The fractional cycle number for 




Figure 2.3: Amplification plot obtained by QPCR. Red line represents threshold 
from which Ct can be deduced. 
 
Quantitation may be absolute or relative. The former involves determining values by 
use of a standard curve. Relative quantitation is used for analyzing changes in target 
expression between a given sample and a control sample and was utilized in this 
project using the comparative Ct method. The comparative Ct method of relative 
quatitation requires the measurement of an endogenous control gene in addition to 
target gene. One can standardize the amount of target gene to endogenous control 
gene for any given sample. Thereafter by comparing standardized values a relative 
quantitation of target between samples may be derived. The comparative Ct method 
has the benefit of eliminating need for a standard curve however it is necessary to 
assess the validity of the endogenous control. For this method to be valid the control 
gene must not significantly alter in experimental conditions and both target and 






The arithmetic formula that is derived to give the amount of target, normalized to an 
endogenous control, in a sample and relative to a calibrator sample is 
     2 –!!Ct 
where  !!Ct is the difference between the normalized values of target Ct between 
sample and calibrator sample. 
QPCR in this project was a two-step process involving initial reverse transcription 
and then subsequent measurement of target cDNA. 
 
Reverse Transcription step 
Reverse transcription of total RNA was performed using Omniscript kit (Qiagen) 
following product protocol. Oligo-dT (Qiagen, 82840865) was not included in the kit. 
Omniscript Reverse Transcriptase is a recombinant heterodimeric enzyme expressed 
in E. coli. An outline of the protocol per tube is below: 
2 µl 10x Buffer RT  
2 µl  dNTP Mix (5 mM each dNTP)  
2 µl  Oligo-dT primer (10 µM)  
1 µl per 20 µl reaction Omniscript Reverse Transcriptase  
5µl RNA containing (50ng-2 µg RNA) 
RNase-free water added to make a final volume of 20µl 
The final 20µl reaction mixture was incubated at 37oC for 1 hour. Following 
incubation mixture was diluted to 75-100µl volume with RNase-free water and used 
in QPCR or stored at -80°C. 
 
QPCR Step 
QPCR was performed on an ABI Prism 7900HT using the Applied Biosystems 
Taqman chemistry system. The housekeeping gene GAPDH was used as an 
endogenous control. QPCR was performed on 96 well and 384 well plates. 
Measurement of target and endogenous control levels for each sample was performed 




Reagents 96 wells 
(Final volume of 
25µ l/well) 
384 well 
(Final volume of 
10µ l/well) 
(2x) Taqman Mastermix 12.5µl 5µl 
Taqman Gene 




Water 5.75µl 2.3µl 
RT Product 5µl 2µl 
 




Assay ID Product size 
(bp) 
Ki-Ras NM_031515 Rn00580460_m1 125 
N-Ras NM_080766 Rn00821645_g1 82 
H-Ras BC099130 Rn01479665_g1 106 
GAPDH NM_017008 Rn99999916_s1 87 
 
Table 2.4: Taqman gene expression assay identification. TaqMan gene expression 
assays and TaqMan mastermix were purchased from Applied Biosystems. The 
process of QPCR was performed with an ABI Prism 7900HT. The thermal cycling 











Figure 2.4: Taqman gene expression assay cycle 
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2.12 Validation of QPCR and reference control 
Quantitative PCR allows the monitoring of the progress of PCR as it occurs so that 
data is collected throughout the process instead of at the end, as in semi-quantitative 
SQ-PCR, and allows for detection of changes as small as two-fold. Two step SQ-PCR 
using Taqman chemistry and the comparative (Ct) method of relative quantitation 
were employed in this project. In order for this method to be employed a suitable 
reference control is required. 
Ideally when using the comparative (Ct) method of analysis, the Ct value for each 
gene target should be between 18 and 30 cycles, as this correlates to exponential 
phase of PCR, in addition to being of similar range with regards to Ct value of 
reference house-keeping or control gene. This avoids analysing samples that have 
either low abundance or supersaturation of target, both of which may lead to 
unreliable Ct values.  
In addition the reference control gene target must be stable in the model of UUO, that 
is that their mRNA levels should not alter as a result of experimental conditions. The 
two gene reference controls that were examined were "-actin and GAPDH.  Using 
kidney samples from three sham kidneys and five obstructed kidneys (12 days 
duration), the Ct value was compared for the two gene targets in samples standardized 













Figure 2.5: Ct values for "-actin and GAPDH in sham and obstructed samples 




From the above figure it appears that the Ct value of "-actin significantly falls, which 
translates to an increase in "-actin mRNA levels in the condition of experimental 
obstruction. GAPDH mRNA levels however appear to be stable in this setting when 
compared to sham. As a result GAPDH was used as the ‘housekeeping’ reference 
control gene target for QPCR. However it must be taken into consideration that the 
above validation of reference controls was completed in models of UUO at 12-days 
whereas majority of experimental groups were assessed at 16-days. 
For calculations to be valid, the efficiency of target and reference amplification during 
QPCR must be approximately equal. A sensitive method of assessing this is by a 
calibration curve & observing how %Ct varies with template dilution. 
Serial dilutions of rat renal RNA obtained from two samples of whole kidney tissue 
was analysed for Ki-Ras and GAPDH levels. 
 
Figure 2.6: Graph of log of serial dilution of RNA obtained from whole rat 
kidney against absolute Ct cycle numbers. Results from two separate experiments. 
Slope of line of best-fit are shown along each lone of best-fit. 
The above figure shows that the slope of corresponding Log RNA vs. Ct lines of 
regression of Ki Ras and GAPDH are near identical suggesting equivalent 
amplification.  
PCR percentage efficiency can be determined by the formula: 
   10-1/slope – 1 x 100 
From the above analysis, the mean PCR amplification efficiencies for Ki-Ras and 
GAPDH  are similar at 91% and 82% respectively 
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To further validate the use GAPDH as a housekeeping gene reference for Ki-Ras 
comparative QPCR, %Ct vs. Log RNA dilution was plotted (Figure 2.7). The slope in 
both cases is <0.1, which fulfils the required criteria for a pair of target and reference 
sequences to be used in comparative Ct method of QPCR. 
 
 
Figure 2.7: Plot of log input amount versus !Ct of serial dilution of rat kidney 
RNA.A summary of two separate experiments. 
 
2.13 Western Blotting [Polyacrylamide Gel Electrophoresis] 
Immunoprecipitation: Due to relatively low abundance of Ras within the cell, Ras 
was concentrated from crude protein lysates using immunoprecipitation. The total 
protein concentrations of cell lysates were assayed as previously described and equal 
amounts of total protein (0.5–1 mg) from each sample were used.  All volumes were 
normalised to 1ml with PBSTDS.  15"l of anti-Ras-agarose conjugate (anti-v-H-Ras 
rat monoclonal antibody (Y13-259) agarose conjugate (OPO1A), Calbiochem) was 
added per ml volume of lysate and all samples were left rotating at 4oC overnight. 
Samples were then centrifuged at 2,500G at 4oC for 3 minutes and the supernatant 
discarded.  The pellets were further re-suspended in 1ml of PBSTDS and centrifuged 
again as above before being washed in 1ml of PBS and again centrifuged as above. 
Following a further wash in 1ml of 50mM Tris solution (pH6.5) and centrifugation as 
above supernatant was discarded and the pellets were re-suspended in 40"l x3-4 
western sample buffer containing 5% 2-mercaptoethanol and heated to 100oC for 3 
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minutes.  The agarose beads were removed by pulse centrifugation for 15 sec and 30-
35 "l of final supernatant was used for both mini and large gel SDS electrophoresis. 
SDS polyacrylamide gel electrophoresis: For non-Ras proteins that are relatively 
abundant, immunoprecipitation was not required prior to western blotting. For these 
samples 10-20 "g of total protein was used per sample. A volume of 40"l x3-4 
western sample buffer containing 5% 2-mercaptoethanol was added and final volume 
made up to 50 "l with PBSTDS. Each sample was heated to 100oC for 3 minutes to 
fully denature the proteins.  30 "l of each sample was then loaded on to either a SDS 
polyacrylamide mini gel or loading gel. The gel concentrations used ranged from 8%, 
10%, 12% or 15%.  Both biotinylated and colour molecular weight markers were used 
as reference ladders.  Mini-gels were run at a constant voltage of 200v for a period of 
time according to desired weight band of colour marker (‘Colorburst’, Sigma). Large 
resolving gels were run at a constant current of 70-80mAmps at ph6.8 for a duration 
according to colour marker for desired weight band of target. 
Following electrophoresis, gels were blotted onto nitrocellulose membranes (Hybond-
C, Amersham Biopscience, RPN203G) at 100V for 45–60 minutes.  The membranes 
were then blocked and detected as below.   
Membrane Blocking and Immunodetection: Following blotting, nitrocellulose 
membranes were blocked for 1 hour at room temperature in either 5% dried skimmed 
milk/0.1% PBST for non-phospho-specific primary antibodies or in 5% bovine serum 
albumin/TBST for phospho-specific primary antibodies. The membrane was then 
incubated at 4oC overnight in a heat-sealed bag containing the primary antibody 
[diluted in blocking solution]. Primary antibodies and their dilutions are provided 
below.  
2.14.3 Immunodetection: Following incubation, the nitrocellulose membrane was 
washed three times for 10 mins each either in 0.1% PBST or, for phospho-specific 
antibodies, in 0.05% TBST. The membrane was then incubated in a heat sealed bag 
with secondary antibody conjugated with horseradish peroxidase for 30 mins. The 
membrane was then subsequently washed three times, for 10mins each, either in 0.1% 
PBST or, for phospho-specific antibodies, in 0.05% TBST. The membrane was then 
developed using a chemiluminescence ECL system (Pierce 32106) and exposed to X-
Ray film for 5 sec to 10 mins. Film was then fixed and washed. A biotinylated protein 
ladder detection system (New England Biolabs) was used to determine molecular 




Colour marker: ‘Colorburst’ electrophoresis marker (8-220 kDa) (Sigma C1992) 
Biotinylated protein ladder detection kit (Cell Signaling #7727S) 
Table 2.5: Primary Antibodies used in Western Blotting 
 
2.14 Model of unilateral ureteric obstruction 
Adult male Wistar male rats (mean initial weight 200 grams) were used for in vivo 
models of renal fibrosis. Pre-op all instruments (including ties) were cleaned 
thoroughly and autoclaved. 
Anaesthesia: Inhaled anaesthesia was preferred over the injected for several reasons. 
Induction is rapid and recovery post anaeasthesia is equally quick. One avoids the use 
of injections, which may result in tissue injury and furthermore as the dose of 
anaesthesia may be rapidly adjusted the dose per animal can be more tightly 
controlled. Each animal was placed in an induction chamber and exposed to 3-4% 
Isoflurane at an oxygen flow rate of 4 litres/minute. Induction was confirmed by 1) 
loss of righting reflex, 2) loss of both pinch and tail reflex and 3) a decrease in rate 
but increase in depth of respiration. The abdomen of each animal was shaved prior to 
transfer to a heated mat. Isoflurane delivery was maintained by a facemask and 
concentration was reduced 2-2.5% for maintenance and oxygen flow rate was reduced 







































1/2000 42 kDa 
Collagen I 
Mouse mAB 
1/100 Santa Cruz 
(sc-59772) 
1/1000 70-90 kDa (Mature) 
140-210 kDa (Precursor) 
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Procedure: Once maintenance of anaesthetization was reconfirmed, abdominal 
region was cleaned using chlorhexidine solution. A midline laparotomy incision was 
made using aseptic technique and the contents of intestinal cavity were wrapped in 
moist sterile gauze and gently removed to the side. The contents were periodically 
moistened with sterile saline. Using a magnifying lamp, the left kidney was exposed 
and the left ureter identified. The left ureter was isolated by blunt dissection and two 
6/0 silk ligatures were used as ties to cause obstruction. The ureter was NOT ligated. 
Abdominal contents were replaced and incision was re-sutured in two stages using a 
deep muscle layer continuous suture followed by a continuous skin suture. 
Buprenorphine was administered subcutaneously (s/c) at a dose of 30µg/kg. Any first 
dose of treatment (oligo or vehicle) was also administered subcutaneously at this 
point. Rats were placed in an incubator at 30°C to recover. 
For rats acting as controls, a sham operation was performed involving a laparotomy 
and manipulation and blunt dissection of the ureter only.  
Harvesting: Rats were sacrificed at various time points by a schedule one method. 
Some groups received an intraperitoneal injection of BrdU (25mg/kg) 1hour pre 
sacrifice. Both left obstructed kidneys and contralateral non-obstructed kidneys were 
cut in half longitudinally with one half placed in liquid nitrogen for storage at -80°C. 
The remaining half was placed in formalin for blocking in paraffin. Extra-renal tissue 
consisting of heart, liver and laparotomy wound tissue were also harvested and placed 
in liquid nitrogen before storage at -80°C. 
 
2.15 In vivo administration of oligonucleotides 
Oligonucleotides were administered by subcutaneous injection either in the nape of 
the neck or rear limbs as variation of injection points prevented tissue damage. 
Oligonucleotides were dissolved in sterile water and administered on alternate days at 
doses of 5mg/kg, 12.5mg/kg or 20mg/kg during this project. Time length of 






2.16 Histology:  
2.16.1 Paraffin embedded: 
Preparation of tissue: Tissue was fixed in 40% neutral buffered formalin solution for 
24-48 hours then subsequently embedded (“blocked”) in paraffin wax to enable 
sectioning. The process of blocking was an automated process performed in the 
Histopathology department, King’s College Hospital, London. Blocks were cut into 
4µm tissue sections using a microtome (Reichert Jung 2030). Sections were floated in 
a water-bath (Raymond A Lamb mounting water bath) containing distilled water at a 
temperature of 42-45°C. The sections were then lifted from water surface on glass or 
polysine slides and allowed to drip dry for 5mins. The slides were then placed on a 
heating block (Raymond A Lamb hotplate) at a temperature of 60-80°C for at least 5 
mins to allow wax melting and adherence of section to slide. Prior to staining, slides 
were required to be de-waxed and rehydrated as per protocol used below. Distilled 




















Mounting: Following staining of paraffin embedded tissue, section was again 
dehydrated and cleared before subsequent mounting in a synthetic medium (Mountex 
mounting medium, Cellpath)  
 
2.16.2 Cryosection: 
Preparation of tissue: Tissue for cryosectioning was placed in liquid nitrogen 
immediately on harvesting and was stored at -80°C until use. The tissue was not fixed 
in formalin. For sectioning, tissue was removed from storage and placed on a cryostat 
chuck and embedded in OCT, a tissue support medium. The medium and tissue were 
frozen immediately by placing chuck in a dish of liquid nitrogen allowing conductive 
freezing. The block was then transferred to a cryostat for sectioning. The cryostat 
chamber was set at -18 to -23°C with the blade temperature set at -18°C. Sections of 
5µm were cut employing an anti-roll plate and transferred on to a polysine slide. The 
sections may then be stored non-fixed or may be fixed in acetone. For the latter, 
sections were placed in acetone at room temperature for 10 mins then allowed to air 
dry. All cryosections were stored at -20°C. 
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2.17 Basic & special stains: 
Only paraffin embedded samples were used for basic and special stains. 
Positive control slides of human placental tissue were used for basic and special 
staining procedures.  
 
2.17.1 Haematoxylin & Eosin stain: In this project H&E staining was an 
automated process and allowed for viewing of general, non-specific tissue structure 
under light microscopy. Nuclei are stained by oxidized haematoxylin and tissue 
counterstained with eosin, which differentially stains cytoplasm and tissue 
constituents varying shades from red to pink. 
The outline of the automated procedure is as follows: 
  Dewax & rehydrate tissue as above. 
  Stain in Mayer’s haematoxylin   10mins 
  Rinse in running water 
  Differentiate in 1% acid-alcohol  2-4secs 
  Wash & blue sections in running water 
  Counterstain in 1% eosin   3 mins 
  Wash in running water 
  Dehydrate, clear & mount 
   
2.17.2 Picrosirius Red: This technique is a variation of one used for staining of 
amyloid fibres. Sirius red is a strong anionic dye and stains collagen by a reaction 
between the sulphonic acid groups of the dye with the basic groups of the collagen 
molecule. The dye molecules attach to the collagen fibres in such a way as to allow 
enhanced birefringence under cross-polarized light. Picrosirius red solution was made 
up as described in Appendix I. A concentration of 0.02% was used if sections were to 
be viewed under bright light, to remove background stain,  and 0.1% for viewing 
under cross-polarized light. 
 






Picrosirius red protocol:    
   Dewax & rehydrate tissue        
   Rinse in water     10 mins 
   Picrosirius Red solution   120 mins 
   Wash in 0.05% Acetic Acid (x 2)  2 mins per wash  
   Dehydrate, clear & mount 
 
Under bright field white light collagen fibres appears red on a yellow-red 
background. Under cross-polarized light larger collagen fibres appear yellow or 
orange while the thinner ones (including reticular fibres) appear green. 
 
2.17.3 Picro-Mallory Trichrome: Trichrome stains are widely used for the 
differential differentiation of connective tissues and there are several different 
variations of this technique. PMT staining, a variant of Masson’s trichrome 
staining, was used in this project. Due to acidic staining solutions, hematoxylin 
was unable to be used as a counterstain and a combination of Celestine blue-
hematoxylin was used instead: 
 
Picromallory trichrome protocol:    
   Dewax & rehydrate tissue 
   Celestine Blue-haemalum sequence 
   Wash and blue sections in running water 
   Rinse in 70% Industrial Methylated Spirit 
   Stain in Picro-Orange      10 mins 
   Rinse in distilled water 
   Stain with Ponceau fuchsin     2 mins  
        Differentiate in 1% Phosphomolybdic Acid   
   Rinse in distilled water 
   Counterstain in Aniline Blue     2 mins 
   Rinse in distilled water 
   Treat sections with 1% Acetic Acid as required 




Of note, the differentiation step is vital and requires microscopic examination of 
section while preventing dehydration. At this stage red blood cells should appear 
yellow but fibrin remain red. Cell nuclei appear blue-black, red blood cells 
yellow, muscle and fibrin red and collagen and reticulin blue. 
 
2.18 Immunohistological staining: 
Both paraffin embedded and cryosections were used for immunohistohemistry 
(IHC). Sections were mounted on polysine slides and baked overnight at 40-45°C 
prior to use. The process of IHC techniques fundamentally relies on whole or 
fragments of antibodies.  The use of antibodies allows for selective identification 
of target epitopes via antigen-antibody interaction. Both polyclonal and 
monoclonal antibodies were employed as part of this project. 
  
2.18.1 Antigen retrieval: In tissues that have been fixed in formalin, the 
formation of formaldehyde cross-links may result in the loss of immunoreactivity 
of certain antigens. To overcome this and to unmask the epitope for antibody 
binding several antigen retrieval techniques (see Appendix II) were trialled in this 
project and the optimal method was:  
    Pressure cook in citrate buffer (pH 6) 3mins 
        followed by Placement in distilled water   5mins 
This method of antigen retrieval gave the most homogenous and consistent 
results with regards to immunohistological staining. It was vital that tissue 
section drying was avoided at any point in this process.  In addition not all 
immunohistological staining required antigen retrieval. 
 
2.18.2 Immunodetection:  For the majority of IHC tissue analysis the 
indirect method of detection was employed. This involves the use of a labelled 
secondary antibody directed towards the primary antibody that also allows for the 
amplification of signal. Primary antibodies used are shown in Table 2.6. Instead 
of a secondary antibody, DAKO REAL Envision detection system (Dako, 
K5007) was used for signal generation. This synthetic dextran polymer system 
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allows for far more sensitive binding thus requires less incubation time and 
results in a decrease in non-specific antibody binding and improved amplification 
of signal and is a system which is now regularly used in clinical medicine. The 
secondary antibodies of the polymer were raised in goat and directed against both 
mouse and rabbit.  Signal detection used 3’,3’-diaminobenzidine (DAB) as a 
chromagen. Oxidation of DAB by peroxidase resulted in a brown end product. 
  
2.18.3 Peroxidase block: Peroxidase activity in tissue sections was blocked. 
by treating sections with 2% Hydrogen peroxide (30 parts) in methanol solution 
prior to incubation with primary antibody. 
 
2.18.4 Serum block: In order to reduce non-specific binding of secondary 
labeled antibody or polymer, sections were also serum blocked using serum from 
host of secondary antibody. As secondary antibody component of the Envision 
polymer system were raised in goat, goat serum (at a concentration of 1 in 10 
made up in wash solution) was used in the blocking step. This solution of serum 
block was also used to make up the primary antibody solution. 
 
2.18.5 Counterstain: For DAB substrate, counterstaining with haematoxylin 
was employed: 
 
   Hematoxylin    3mins 
   Rinse in running water 
   1% Acid alcohol    3 dips 
   Rinse in running water 
 
Paraffin embedded protocol: The protocol for each antibody was essentially 
similar. There are variations in incubation time and wash solutions which are 
noted in Table 2.6. Both positive and negative controls for each antibody were 
used to ensure optimum staining and to assess non-specific staining and 









      
      
 
   
 
        
        
 
 
       
      
       





      
 
       
 
 
     
Figure 2.8: Immunohistological staining protocol for paraffin embedded samples
      
       





Dewax & rehydrate 
tissue 




Incubate [Primary antibody] 
Variable time!
Envision polymer detection system 
30 mins!
Develop with chromagen 
DAB  5-10 mins!
Counterstain in hematoxylin 










Cryosection IHC: The protocol for frozen tissue staining differed from that of 











        
 
 



















If taken from -20°C, allow tissue sample to 
thaw at room temperature for 10-15mins!
Serum block 
60 mins!
Incubate [Primary antibody]: 1 hour at room temperature 
If overnight incubation: at 4°C with antibody diluted 1 in 10 !
Envision polymer detection system 
30 mins!
Develop with chromagen 
DAB  5-10 mins!
Counterstain in hematoxylin 
Dehydrate, clear & mount 










Primary Antibodies used in IHC: The table below gives the various parameters of 
antibodies used in IHC. All antibodies were made up in serum blocking solution. 










1/200 Sigma clone 
1A4 (A2547) 



















60 mins  
Room Temp 
PBS (HIER)  








PBS (HIER)  






60 mins  
Room temp 
PBS (HIER)  



























60 mins  
Room temp 






60 mins  
Room temp 
0.1% TBST (HIER)  







60 mins  
Room temp 
0.1% TBST (HIER)  
PC Citrate buffer 
pH6 
 
Table 2.6: Primary Antibodies used in IHC; HIER Heat induced epitope retrieval, 
PC: Pressure cook, 
Control samples for !SMA and Collagen I: Placental tissue 
Control samples for Ki-67 and ED1: Lymph node tissue 
Control samples for Ki-Ras and Pan Ras: Skin tissue 
Negative controls used for all staining. 
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2.20 Laser microdissection and pulsed capture (LMPC) 
The rationale behind PALM and subsequent RNA analysis was to attempt to localize 
mRNA knockdown to renal cellular compartments. Thus measurement of Ras mRNA 
within isolated cellular compartments in samples would indicate location of mRNA 
knockdown effect. The principle of laser microdissection involves restricted 
dissection of target area from tissue mounted on a special membrane slide. The 
process was performed using P.A.L.M. Microlaser Technologies that allows for 
microdissection and micro-manipulation systems using LMPC (Laser Microdissection 
and Pressure Catapulting). PALM microlaser technology consists of a robo-stage 
under the control of PALM microbeam software. Cutting is via a solid-state laser that 
is passed via the microscope and focused through the microscope and focused through 
an objective to a beam diameter of under 1µm. Following dissection the target region 
is “pulsed” upwards into the specialized adhesive cap of an RNAse free eppendorf 
container. This avoids any physical contact for tissue transfer and so reduces 
contamination risk. Following collection of several target regions, tissue could be 
lysed and RNA retrieved. In this project the protocol of tissue preparation, cell 
recognition and laser microdissection was adapted from a protocol kindly provided by 




Figure 2.10: Schematic of PALM depicting laser dissection and ‘pulsing’ of 




2.20.1 Tissue preparation for PALM: 
Frozen tissue sections were used for PALM microdissection. 10µm cryosection were 
cut using a Microm microtome cryostat cryo-star HM 560 MV. The chamber and 
blade were cleaned with RNAse Zap (Qiagen) prior to cryosectioning. Tissue was 
prepared as mentioned in histology section. Chamber was set at -20°C and the blade 
at -18°C. The section was then mounted on 1mm Polyethylene (PEN)-membrane 
covered slides (PALM microlaser technology, Cat 1440-1000). Sections were then 
stained to allow cellular identification and microdissection as follows: All solutions 
were made up with DEP-C treated water and all steps were performed at room 
temperature unless specified. The cryosections were dehydrated in ascending 
concentration of ice cold ethanol from 75%, 90 % and 100%-at 1 min in each. The 
sections were subsequently stained with ice-cold 1% Nissl stain for 90 seconds. The 
section was then washed in ascending concentrations of ice-cold ethanol (of 75%, 
90% and 100%) for 20 seconds in each then mounted on a PEN-membrane slide prior 
to loading on the robo-stage. A PALM adhesive cap RNAse-free eppendorf was 
loaded into the collection arm. Using PALM Microbeam HT software, one was able 
to navigate across the section under x10 to x60 magnification. The software allowed 
manual outlining of target regions or cells for microdissection. Microdissection was 
on performed at x20 to x40 magnification. The PALM microbeam laser would 
automatically cut sequential targeted regions. For the purpose of tubular cell 
microdissection, the settings were speed of 23, laser energy 68, laser focus 56, 
catapulting energy 90 and catapulting focus 68, all of arbitrary units. Microdissected 
regions were collected in RNase-free eppendorf containers and immediately 
underwent RNA retrieval. The whole process from tissue cryosection to initiation of 
RNA retrieval was to be restricted to a maximum of 30 minutes per section to reduce 
RNA degradation. The number of tubules collected on each sitting ranged from 30 to 







2.20.2 RNA retrieval of microdissected cells 
RNA retrieval from collected microdissected tissue was performed using the RNeasy 
Micro kit from Qiagen (Qiagen, 74004). This kit is designed to purify RNA 
(maximum of 45µg) from small amounts of tissue and even from single cells. The 
principle of the kit is similar to RNeasy Mini kit used for whole tissue RNA retrieval 
(see Section 2.7). Protocol was as for manufacturer’s instructions and summarized as 
follows:  Microdissected cells catapulted on to the adhesive cap were disrupted by 
addition of 75µl of lysis buffer RLT followed by vortex mixing. The lysate was 
transferred to a QIA-shredder for further homogenization by centrifuging at 2 mins at 
>10,000 rpm at room temperature. Further lysate disruption was achieved by needle 
lysis. An equal volume of 70% ethanol was added to the sample before transfer to an 
RNeasy MiniElute column. The tube was centrifuged for 15 seconds at >10,000 rpm 
and the flow through discarded. 350µl of Buffer RW1 (wash solution) was added to 
the sample and tube was centrifuged once again for 15 seconds at >10,000 rpm and 
the flow through discarded. 80µl of DNase I incubation mix was added to the sample 
and gently mixed by tube inversion and incubated at 20-30°C for 15 mins. The DNase 
mix allows for digestion of contaminating DNA in the RNA solutions prior to RNA 
clean up. Following digestion by DNase, 350µl of Buffer RW1 was added to the 
sample and tube was centrifuged once again for 15 seconds at >10,000 rpm and the 
flow through discarded. 500µl of Buffer RPE was then added to the sample and 
centrifuged once again for 15 seconds at >10,000 rpm and flow through discarded. 
500µl of 80% ethanol was then added and column was centrifuged for 2 minutes at 
>10,000 rpm and flow through discarded. The column was then further centrifuged at 
>10,000 rpm for 5 minutes and flow through discarded. The column was then 
transferred to a new collecting column and RNA eluted by addition of 10-14µl of 
RNase-free water and centrifuging for 1 minute. RNA quantitation was performed as 
previously described. In order to reduce tissue temperature related damage, the 
process from staining until completion of microdissection took no longer than 20 





2.21 In situ hybridization (ISH): 
ISH was performed on paraffin embedded tissue using a non-radioactive ISH 
Hybriprobe® Triseq kit purchased from Biognostik. All glassware and materials was 
made RNAse-free (See Appendix I). All solutions were made up with DEP-C treated 
water. Hybriprobes are fluorescein-isothio-cyanate (FITC) labeled single stranded 
phosphodiester DNA oligonucleotides. Each probe is double labeled with FITC 
groups at 5’ and 3’ end nucleotides. The Triseq kit provides three different probes 
directed at three different regions of the same target mRNA to enhance signal 
intensity and assay sensitivity and so is of benefit in targeting mRNA with low or 
normal expression. 5µm paraffin embedded sections were cut, mounted on polysine 
slides and oven baked overnight at 45°C. Protocol was as for manufacturer’s 
instructions: Sections were dewaxed and rehydrated then underwent Proteinase K 
digestion (freshly made, 20-50µg/ml) at 37°C for 15-20 mins in a humid chamber to 
increase accessibility of mRNA in formalin fixed tissue. Following a wash in PBS, 
sections were taken through a prehybridization step. This step allows equilibration 
with the hybridization buffer (Hybribuffer) and reduces background staining. 
Prehybridization was carried out in tightly sealed boxes containing humidifying box 
buffer (50% formamide/ 4 x SSC). Hybribuffer was activated by heating up to 95°C 
before cooling to 35°C and being added to sections. Sections were incubated in 
hybribuffer at 30°C for 2-4 hours. Subsequently prehybridization was drawn off and 
hybridization solution (activated hybribuffer containing each probe at a concentration 
of 60pmol/1000µl hybribuffer) added. Sections were incubated overnight at 30°C in 
humidified boxes. Sections were then washed twice for 30 seconds in 1 x SSC, 
followed by a wash in 1 x SSC for 5mins then a two 15 minutes (stringent) washes in 
0.1 x SSC at 40°C for prior to detection of hybriprobes.  Sections were washed in 
PBS then serum blocked for 30 mins in goat serum (1 in 10) prior to incubation with 
goat anti-FITC antibody conjugated to alkaline phosphatase (Vector MB-2100) at a 
dilution of 1/100 for 1 hour at room temperature. Visualization of signal was obtained 
by addition of NBT/BCIP substrate (Vector SK5400) to produce a blue stain. Section 
was then counterstained using neutral fast red (1 min) before rinsing in distilled water, 
dehydration and mounting. Poly-d(T) hybriprobes were used as a positive control. 
Hybriprobes for Ki-Ras were designed by Biognostik. The sequences for the 





CCTGCTGTGTCGAGAATATCCAAGAGACAG H11554 BC141051.1 
Mus musculus v-Ki-ras2 
CTAGGACCATAGGCACATCTTCAGAGTCCT H11555 BC126086.1 
Rattus norvegicus v-Ki-ras2 
ATGTATAGAAGGCATCGTCAACACCCTGTC H11556 BC126086.1 
Rattus norvegicus v-Ki-ras2 
 
Table 2.7: ISH hybriprobe sequences 
Several alterations to the above manufacturers protocol were performed and are 
documented in Appendix II. The basis of variation in steps originated from published 
literature, in particular that of Dr JH Pringle (Bailey et al. 1999), and current ISH 
protocol utilized for clinical samples by the Department of Histopathology, King’s 
College Hospital, London. 
 
2.22 TUNEL Assay: 
Detection of apoptosis in tissue sections was performed using a TACS TdT (terminal 
deoxynucleotidyl transferase) kit (R&D systems TA4625). The TACS kit detects 
DNA fragmentation resulting from apoptosis through a combination of enzymatic and 
immunohistological techniques. The incorporation of biotinylated nucleotides into the 
3’-OH ends of DNA fragments by terminal deoxynucleotidyl transferase (TdT) is 
subsequently followed by their detection using streptavidin-horseradish peroxidase 
conjugate and development of signal using DAB substrate. The enzyme reaction 
generates colour precipitate where DNA fragmentation has occurred. The sections are 
subsequently counterstained to allow for morphological identification. Paraffin 
sections of 4µm were used. Tissue was initially dewaxed and rehydrated. Following 
incubation in 1x PBS for 10 mins at room temp, tissue was permeabilized with 
Protinase K solution (15 mins at 21°C). Samples were washed twice in distilled water 
before endogenous peroxidase activity was quenched using 10% Hydrogen Peroxide 
solution (5 mins at room temp). Following a wash in PBS for 1 min, samples were 
incubated in TdT labeling buffer (5 mins at room temp) before transfer to TdT 
labeling reaction mix for 1 hr at 37°C. The reaction was terminated by addition of 
Stop buffer (5 mins at room temp). Samples were washed x 2 in 1xPBS for 2mins per 
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wash prior to incubation with Streptavidin HRP solution (10 mins at room temp). 
Colour preciptation with DAB (2-10 mins at room temperature) was completed 
following a further wash in distilled water. Finally samples were counterstained with 
hematoxylin. Positive controls were provided by incubation of samples with TACS 
nuclease solution provided. 
 
2.24 Summary of method of scoring system used for 
histological evaluation within this project 
 




Method of assessment (All blinded assessments) 
Picromallory Trichrome 
(PMT) 
Histological: Overall degree of fibrosis in renal cortex assessed 
by a consultant histopathologist under bright light. Degree of 
tubulointerstitial fibrosis was provided as a percentage. 
Picrosirius Red (PSR) Histological: Overall degree of fibrosis in renal cortex assessed 
by a consultant histopathologist under bright light. Degree of 
tubulointerstitial fibrosis was provided as a percentage. 
!-SMA Histological: Overall degree of expression in renal cortex 
assessed by a consultant histopathologist under bright light. 
Degree of expression was provided as a percentage. 
 
Immunoblotting: !-SMA & GAPDH expression in renal 
cortical samples were measured by densitometry. !-SMA 
expression (relative to GAPDH) for each treatment group was 
then normalised to sham-operated control group.   
Collagen I Histological: Overall degree of fibrosis in renal cortex assessed 
by a consultant histopathologist under bright light. Degree of 
tubulointerstitial fibrosis was provided as a percentage. 
FSP-1 Histotological: Mean number of FSP-1+ cells across ten random 
cortical views per section (at x40 magnification). FSP-1+ cells 
were divided into glomerular, tubular and interstitial 
compartments. 
Ki-67 Histotological: Mean number of Ki-67+ cells across ten random 
cortical views per section (at x40 magnification). Ki-67+ cells 
were divided into glomerular, tubular and interstitial 
compartments. 
ED-1 Histological: Overall degree of expression in renal cortex 
assessed by Nikon Elements BR software package. Mean score 
was derived by assessment across five random cortical views 
per section at x20 magnification. Degree of expression was 
provided as a percentage. 
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The table above summarises the methods used for assessment of fibrosis and markers 
of fibrosis and inflammation used in this project. Assessments made by a consultant 
histopathologist, would include interpretation of staining thought to be non-specific 
and oedema-related with views of the whole sample taken over magnifications 
ranging from x10 to x40 with assessment. Evaluationof FSP-1 and Ki-67 was less 
complex due to low non-specific background staining and the discrete nature of the 
stain. ED-1 staining was performed using TAR-/! U<353/10! QB! 0-61.423! 847R4I3!.9A79! 4<<-.0! 5340=2353/1! -6! 4234! 5340=23>! 23<41AV3! 1-! 0371A-/! 033/M! K<<!0458<30!.323!4003003>!.A19!-83241-20!E<A/>3>!1-!1234153/1!-6!0458<3M!!
2.25 Statistics 
Statistical analysis of data was performed using Prism 4 software package (Graphpad 
software). For pairs of data, an unpaired t-test was used. For group data, an ANOVA 
(Analysis of variance) was initially performed. Subsequently Bonferroni adjustment 
was used to correct for multiple testing in this case. A linear regression model was 
used for multiple variances in analysis of data of unbalanced design. 
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Chapter 3: Characterization of Ki-Ras antisense 
oligonucleotides in vitro and in vivo 
 
Previous screening work performed by our group, using primary culture rat renal 
fibroblasts, identified two antisense oligonucelotides out of a series of twenty Ki-Ras 
ASOs supplied by ISIS Pharmaceuticals that were deemed highly efficient when 
transfected in vitro (unpublished data). Preliminary data from administration of these 
two ASOs, ASO 1 & ASO 2, in rat models of UUO showed a decrease in !SMA 
expression and collagen IV deposition compared to a sham-treated control group 
(unpublished data). ISIS Oligo 15167 (CO 1), targeting the human HIV promoter 
sequence, was used as a control oligo in in vitro experiments unless otherwise 
specified. 
In vitro models employed in this project consisted of primary culture of adult PVG rat 
renal fibroblasts, obtained from freshly discarded kidneys at time of sacrifice, and 
commercial cell lines were obtained. NRK-49F fibroblasts and the equivalent tubular 
epithelial cell line, NRK-52E, were used. The cell lines represent fibroblastic and 
epitheloid clones isolated from a mixed cell growth of Normal Rat Kidney cells. Thus 
they best represent non-transformed rat cells and are expected to possess similar 
physiology and allow the undertaking of comparative studies between different cell 
types from the same species.  
 
3.1 Ras mRNA expression in rat renal fibroblasts following 
ASO transfection 
3.1.1 Primary cell cultures 
Following transfection with CO 1 and Ki-Ras ASOs, total RNA from cells was 
extracted and Ras mRNA expression compared using SQ-PCR. Subsequent SQ-PCR 
products were run on a DNA gels. Results are representative of duplicate 
experiments. There was an observable decrease in Ki-Ras mRNA expression with an 
accompanying increase in Ha-Ras expression following transfection with ASO 1 & 
ASO 2 compared to CO 1. Due to limited amounts of RNA extracted from primary 












Figure 3.1: SQ-PCR expression of Ki-ras & Ha-ras mRNA in primary cultures 
of rat renal fibroblasts following transfection by control and Ki-Ras antisense 
oligonucleotides.. Products of reactions completed in the linear phase of 
amplification using 27 cycles of PCR. Upper bands represent isoforms of Ras as 
indicated, the lower bands represent amplification product of "-actin.  















Figure 3.2: Densitometry analysis of Ki-Ras and Ha-Ras cDNA expression 
relative to "-actin in primary cultures of rat renal fibroblasts following 
transfection by control and Ki-Ras antisense oligonucleotides. (n=2 for Ki-Ras, 
















































3.1.2 Fibroblast cell line (NRK-49F)  
Following transfection with oligonucleotides and RNA extraction, SQ-PCR was 
initially employed to analyse expression of Ras. However despite using a low number 
of cycles of PCR, a significant difference in Ki-Ras expression was not observed. 
This may have been due to an issue of technique, a failure of transfection of NRK-
49F cells, a failure of knockdown of target mRNA or significantly higher Ras 
expression in NRK-49F cells as compared to primary cell cultures. The knockdown 
results observed in primary cell cultures suggested that the Ki-Ras ASOs were active 
and the absence of observable mRNA knock down in NRK-49F cells was thought to 
be due in part to the amplifying nature of semi-quantitative SQ-PCR and possible 
insensitive method of assessing any changes. Subsequently real time PCR (QPCR) 
was employed. QPCR is specific and sensitive, being able to detect differences as 
small as two-fold. However, more importantly, QPCR provided an objective 
quantitative end-point that was not available for semi-quantitative PCR. The QPCR 
comparative measurement of Ras mRNA (See Methods & Materials) from NRK-49F 
cells transfected with Ki-Ras ASOs and CO 1 were analysed for mRNA expression of 


















Figure 3.3: Quantitative PCR determination of expression of Ras mRNA 
isoforms in NRK-49F cells transfected with Ki-Ras ASO at 200nM. Following 
RNA retrieval samples were run on 96 well plates in triplicate and Ras mRNA 
expression relative to CO 1 group was calculated using the comparative method of 
analysis with GAPDH as an internal reference gene. Each graph is a representation of 
three separate QPCR analyses with samples run in triplicate on each analysis. 
[ *denotes p value <0.05, ** p < 0.01] 
 
The above figures show that both Ki-Ras ASOs reduced expression of Ki-Ras mRNA 
by 35% (ASO 1) and 70% (ASO 2) in comparison to CO 1 administration. In addition 
the knockdown effect of ASOs was specific for the Ki-Ras isoform, with no 
knockdown of either N- or Ha-Ras, though an up-regulation of the latter isoform was 




3.2 Ras mRNA expression in rat renal epithelial cell line 
(NRK-52E) 
It has been proposed that the increase in the population of fibroblasts in the process of 
renal fibrogenesis, is as a result of the phenomenon of epithelial-mesenchymal 
transition (EMT). Since oligonucleotides have been shown to be actively taken up by 
the tubular epithelial cells of the nephron, their effect in normal rat renal epithelial 
cells was investigated. Figure 3.3 show that there is no significant difference in 
mRNA expression of N- and Ha-Ras in NRK-52E cells following transfection with 
Ki-Ras ASOs when compared with either transfection with control oligos or vehicle-
only (OptiMem). There was a decrease in Ki-Ras mRNA expression in the ASO 1 
group by 32% and by 57% in the ASO 2 group in comparison to vehicle-only control. 
Though no significant statistical difference was seen between control and antisense 
oligo groups, a definite trend towards decreased Ki-Ras mRNA levels following ASO 
administration was observed. 
Figure 3.4: QPCR determination of 
expression of Ras mRNA isoforms in NRK-
52E cells following transfection with Ki-Ras 
ASO at 200nM. Expression is measured relative 
to vehicle-only group using the comparative 
method of analysis with GAPDH as an internal 
reference gene. [n=3 for Ki- & N-ras; n=2 for 
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3.3 ASOs and cytotoxicity  
CytoTox 96 (Promega) non-radioactive cytotoxicity assay from Promega was used to 
assess oligonucleotide toxicity. The assay is based on comparative analysis of lactate 
dehydrogenase release. Cytotoxicity of oligonucleotides was assessed at different 
concentrations of oligonucleotides ranging from x0.25 to x5 concentration of that 
used in in vitro experiments (200nM). From figure 3.4 it can be seen that none of the 
oligonucleotides had any significant cytotoxic effects on NRK-49F up to a dosage of 




Figure 3.5: Cytotoxicity in NRK-
49F cells following 
oligonucleotide transfection. 
A non-radioactive colourmetric 
LDH assay was employed to assess 
cytotoxcity. Results are depicted as 
a mean and spread of degree of 
cytoxicity in relation to vehicle –
only negative control and 
maximum cell lysis. (n=3 per dose-
group with samples run in 






































3.4 Assessment of ASO specificity and effects in non-
obstructed rats 
Though cell culture studies provide one with the opportunity to establish and 
investigate the role of certain molecules and mediators in specific cell types, when 
looking to translate potential therapies from benchside to bedside, this highly 
controlled environment is not representative of a whole biological organism where a 
multitude of different cells interact and respond to both local and distant cell signals.  
In order to achieve a better insight into this, animal models have been used to 
elucidate disease processes and evaluate potential therapies. Apart from considering 
the cross-talk of cells, in vivo models also allow for the examination of “proof of 
concept” and restrictions to potential therapies as well as providing information 
regarding toxicity and side effects. Oligonucleotides employed in this assessment 
include control oligo CO 2, antisense oligos ASO 1 and 2 and scramble oligos SO 1 
and 2. 
 
3.4.1 Ras mRNA and protein expression  
The specificity and efficiency of oligos in vivo were initially investigated in non-
obstructed male Wistar rats. By examining the effects of the oligonucleotides in non-
diseased models, changes in Ras expression induced by obstruction can be removed 
and the specific effects of each oligo both at a molecular and organism level may be 
analysed.  In figure 4.1, QPCR was used to demonstrate that there is a specific and 
significant knockdown of Ki-ras by ASO 2 compared to CO 2 of 66%. ASO 1 only 
reduced Ki-Ras expression by 12%. There is no significant Ras knockdown by CO 2 




































Figure 3.6: Expression of Ras isoform 
mRNA on administration of 
oligonucleotides in non-diseased rat 
models. Real time PCR was used to 
analyse mRNA expression of Ras 
isoforms Kirsten (A), Neural (B) and 
Harvey (C) in retrieved renal tissue. The 
results are a combination of two separate 
QPCR analyses, each analysis being 
composed of three replicates per animal. 
Thus each point is representative of the 
mean of six replicates from one single 
animal. Oligos were administered at a 
dose of 12.5mg/kg subcutaneously on 
alternate days over a 6-day period (Three 
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The above RNA analysis indicates that only Ki-Ras mRNA levels are specifically 
affected by Ki-Ras ASO administration in non-diseased models. Thus it is postulated 
that any change in pan-Ras protein expression is due to ASO effect on Ki-Ras protein 
levels and not those of Ha- or N-Ras. Subsequently an immunblot of pan-Ras protein 
expression and was normalised to GAPDH in solution from the immunoprecipitation 





















Figure 3.7: Western blot analysis for pan-Ras in oligo-treated non-diseased rat 
models. A Immunoblot for pan-Ras. GAPDH in the supernatant from Ras 
immunoprecipitation was used as a loading control. This blot is representative of three 
similar blots. B Densitometry of blot bands to quantify Ki-Ras protein expression 
relative to GAPDH. 
The above graph demonstrates that there is a knockdown of Ki-Ras protein by ASO 1 








3.4.2 Cell proliferation  
Ras is known to be a key molecule in the control of cell proliferation, therefore renal 
tissue was stained for the cell proliferation marker Ki-67 to investigate effects of ASO 




















Figure 3.8: Sections of non-diseased rat renal tissue stained for Ki-67 following 
treatment with saline or oligos (x10 and x40). Representative sections from 
treatment groups following indirect immunodetection using a Ki-67 monoclonal 
antibody and signal detection with HRP-DAB. 
The mean number of Ki-67 positive cells per section (magnification x20) were 
compartmentalized into glomeruli, tubules and interstitium. 10 views per section were 

























There was no significant difference in Ki-67 positive cells within the glomeruli or 
tubular cells between groups but a significant increase in positive cells in the 
interstitium in Ki-Ras ASO-treated groups compared to saline and control oligo 
treated groups.!
 
Figure 3.9: Distribution of Ki-67 
positive cells in glomeruli, tubular 
and interstitial compartments in 
ASO-treated rat kidneys. Each point 
represents a mean number of Ki-67 
positive cells counted over 10 views at 

































3.5 Tissue distribution of oligonucleotides following 
subcutaneous administration 
To our knowledge, this project is the first to utilize subcutaneous administration of 
antisense oligonucleotides in a renal fibrosis model. From published literature and 
information from ISIS, it is well recognized that paraenteral oligo administration 
results in active uptake of oligos by proximal tubular cells of the nephron. To 
investigate if this was also true of subcutaneous administration and to confirm that 
oligos would reach renal tissue at the dose (12.5mg/kg) that was administered, 
sections were stained using an antibody against oligonucleotides provided by ISIS 
Pharmaceuticals. Though the exact epitope target of the antibody was not provided, 
the fact that it was able to target all oligos suggests that the target epitope was part of 
the phosphorothioate spine. Antibodies against aquaporin-1 and aquaporin-2 were 
used to differentiate proximal and distal tubules/collecting ducts respectively and by 
staining sequential sections (‘zero sections’), renal cortical cells in which ASO 
accumulated could be identified. As part of this experiment the distribution of the 
antisense oligos both within the kidney and in non-renal tissue was investigated.  
Aquaporin 1 Aquaporin 2 ASO 1 
Figure 3.10a: Sequential   sections   from   a   single   rat   kidney immunostained for 
Aquaporin 1,  Aquaporin  2  and  oligonucleotide  deposits  following administration 
of ASO 1 (12.5mg/kg) (x10). The same proximal convoluted tubule (PT) and distal 











Figure 3.1b: Sequential   sections   from   a   single   rat   kidney immunostained 
for Aquaporin 1, Aquaporin 2  and  oligonucleotide  deposits  following 
administration of ASO 1 (12.5mg/kg) (x40). 
 
Immunostaining of sequential sections as demonstrated above revealed that oligos 
administered via subcutaneous injections were able to accumulate within the kidney. 
Furthermore oligos accumulated in proximal tubular cells (identified by expression of 
AQ-1) and the interstitium with virtually no oligo uptake being seen in distal tubular 
cells (as identified by AQ-2 expression). This suggests that oligonucleotides 
administered by subcutaneous injection are able to target the kidney, be freely filtered 
and then appear to be actively taken up by the proximal tubular cells with little 
reaching the distal nephron in the non-obstructed kidney.  
 
Aquaporin 1 Aquaporin 2 ASO 1 
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3.6 Distribution of oligo in non-renal tissues 
Non-renal tissues harvested included heart, liver and tissue circumventing the 
laparotomy scar. Tissues was stained for oligo deposition using the specific anti-oligo 





















The use of anti-oligo antibody confirmed that, following subcutaneous administration, 
there was a significant accumulation of oligo within both renal and hepatic tissue. 
However a high degree of deposition of oligo was also observed within both cardiac 
and muscle tissue. 
Figure 3.11: Oligonucleotide deposition within renal and non-renal tissue of non-
obstructed Wistar rats following subcutaneous administration of ASO 1 at a dose of 
12.5mg/kg subcutaneously on alternate days over a 6-day period (Three doses in total).  










3.7 Effects of oligonucleotide administration on non-renal 
tissues 
3.7.1 Hepatic tissue 
Hepatic tissue is recognized to have a high cellular turnover and has been shown to 
both actively and specifically take up oligos that are administered parenterally. 
Hepatic tissue from UUO models that were treated with oligos was retrieved and 














Figure 3.12: Ki-Ras mRNA expression in hepatic tissue of rat models of UUO 
following oligo administration. Oligos administered at 12.5mg/kg on alternate days 
over a six day period. Each point is the mean result of six replicates of a single 
sample. SO 1 and 2 are scrambles of ASO 1 and 2 respectively. 
 
In relation to vehicle-only treated UUO group, there is a significant rise in Ki-Ras 
expression seen in scrambled oligo groups. ASO 2 reduces Ki-Ras expression by 49% 
while ASO 1 has no significant effect compared to vehicle-only treated group. 
Subsequently, hepatic tissue was stained with hematoxylin and eoisin and analysed by 
a consultant liver histopathologist in a blinded fashion. Unfortunately hepatic tissue 
treated with scrambled oligos was lost during storage due to freezer malfunction and 




























Figure 3.13: Sections of hepatic tissue from UUO model treated with (A) ASO 1 
and (B) ASO 2 stained by H&E (x20). Note significant increase in peri-portal 
inflammation in ASO 2 treated section compared to ASO 1. 
 
Hepatic lobar inflammation was defined by necrosis of individual hepatocytes, 
mitosis of hepatocytes and increases in numbers of intralobular (intrasinusoidal) 
leucocytes. It was observed that inflammation was principally a portal-tract 
phenomenon, with dense cuffs of leucocytes around portal-tract structures.  These 
cuffs appear to be isolated and expand the portal tract itself rather than infiltrating the 
limiting plate or seeping into the lobule.  Ductular reaction was scant and focal and 
restricted to within the substance of the portal tract.  Architecture of the liver was not 
observed to be disordered with portal tracts and draining venules disposed regularly 
throughout. The degree of inflammation was given as an arbitrary score with regards 
to inflammation with 1 being minimal and 4 severe. Inflammation was separated into 























Figure 3.14: Inflammation score for hepatic tissue treated with Ki-Ras ASO. 
Sections were scored in a blinded fashion by a consultant hepatic histopathologist 
with an arbitrary score of 1-4 and inflammation divided into lobar and portal tract. 
Each point represents one animal. 
The degree of inflammation within liver tissue was found to be significantly higher in 
tissue retrieved from ASO 2 treated models as compared to vehicle-only and ASO 1 
treated tissue. Liver tissue retrieved from ASO 1 treated models had an inflammation 
























3.7.2 Cardiac tissue 
Following the observation of inflammatory effects in the liver subsequent to ASO 












Figure 3.15: ED-1 staining of cardiac tissue retrieved from non-obstructed 
Wistar rats following administration of vehicle-only or ASOs. Oligos 















Figure 3.16: Number of positive ED-1 cells per field of view in cardiac tissue 
retrieved from non-obstructed Wistar rats following administration of  
oligos. Oligos administered at 12.5mg/kg on alternate days over a 6-day period 
Each point represents one animal.  
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The above results demonstrate that, following administration of oligos, the degree of 
inflammation within the heart is comparable with that of the liver with regards to 
individual ASO effect. Both CO 2 and ASO 1 result in a doubling of ED-1 positive 
cells when compared to vehicle-only treated models but ASO 2 treated group results 
in a  near five-fold increase in ED-1 positive cells per view reflecting increased 
macrophage infiltration and possibly inflammation.  
 
3.8 Summary of results: 
1) Transfection of both primary culture fibroblasts and NRK-49F fibroblast 
cell line with Ki-Ras ASOs at 200nM demonstrated significant and 
specific knockdown of Ki-ras mRNA expression.  
2) Knock down of Ki-ras mRNA resulted in an observed compensatory rise 
in Ha-ras mRNA expression in primary culture of rat renal fibroblasts and 
in NRK-49F cell line. There were no observed changes in N-ras 
expression.  
3) Transfection of NRK-52E epithelial with Ki-Ras ASOs at 200nM reduced 
Ki-ras expression compared to vehicle-only control.   
4) Transfection of NRK-52E epithelial with Ki-Ras ASOs at 200nM did not 
alter either Ha-ras or N-ras mRNA expression when compared to vehicle-
only control 
5) Transfection of NRK-49F cells at a concentration of 200nM did not induce 
cytotoxicity based on an LDH assay. 
6) Administration of CO 2 in non-diseased Wistar rat models did not 
significantly alter mRNA levels for any of the isoforms of Ras when 
compared to vehicle-only group. 
7) Administration of Ki-Ras ASO 2 (12.5mg/kg) in non-diseased Wistar rat 
models resulted in both specific and significant knock down of Ki-Ras 
mRNA when compared to CO 2 group. These results were comparable to 
those obtained in vitro. 
8) Protein expression of pan-Ras was decreased by 60% and 45% on 
administration of Ki-Ras ASO 1 and ASO 2 respectively in comparison to 
CO 2. 
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9) Administration of Ki-Ras ASOs resulted in a significant increase in 
interstitial cells undergoing active proliferation as detected by Ki-67 
expression. There was no observed change in Ki-67 positive cell numbers 
in either glomerular or tubular compartments following ASO 
administration. 
10)  Following subcutaneous administration, accumulation of oligonucleotides 
within kidney is demonstrated. The proximal tubular cells are the main site 
of oligo uptake and accumulation within the kidney with no deposition 
seen in distal tubule cells. 
11)  Following subcutaneous administration, oligos have a systemic deposition 
including within cardiac, hepatic and muscle tissue in addition to renal. 
12)  Both the scramble oligos, SO 1 and SO 2, increase Ki-Ras hepatic 
expression compared to UUO-VO. Administration of ASO 1 and ASO 2 
reduces Ki-Ras mRNA expression in the liver by 14% and 65% 
respectively compared to UUO-VO. 
13)  Administration of ASO 2 resulted in significant inflammatory changes in 
both the lobar and portal tract areas of the liver in comparison to vehicle-
only treated group. These changes were not observed on administration of 
ASO 1. 
14)  Administration of ASO 2 resulted in a significant increase in ED-1 
positive cells in cardiac tissue in comparison to vehicle-only, CO 2 and 
ASO 1 treated groups.  
 
 
3.9 Discussion  
The main aim of this project was to translate previous in vitro work undertaken by our 
group (Sharpe, Dockrell et al. 1999) to in vivo models. However, as the oligos being 
used for this project were targeted against a different species to those previously used, 
examination of oligo transfection in rat kidney cells in vitro allowed validation of 
oligo specificity and efficiency in organism-specific cells. The results of this series of 
experiments indicate that both the Ki-Ras ASOs are effective and specific in knocking 
down Ki-Ras mRNA expression in rat primary renal fibroblasts and NRK-49F cells. 
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This knockdown was associated with a possible compensatory up-regulation of Ha-
Ras isoform mRNA expression within these mesenchymal cells. 
The rat tubular epithelial cells (NRK-52E) cell line was found to be quite resistant to 
ASO transfection using the simple protocol employed for mesenchymal cells (both 
primary and NRK-49F). Successful transfection of the epithelial cell line required the 
technique of ‘reverse transfection’ which involves addition of detached epithelial cells 
onto a plate of pre-prepared transfection complexes. Following transfection, NRK-
52E cells demonstrated a lesser degree of Ki-Ras mRNA knockdown when compared 
to their sister NRK-49F cells. This decrease in efficiency may in part be due to 
difficulties in transfecting this cell line. However, whereas there appears to be a 
compensatory rise in H-ras expression on Ki-Ras ASO transfection in NRK-49F 
fibroblast cells, both expression of N- and Ha-Ras mRNA in NRK-52E epithelial cells 
remained unchanged when Ki-Ras mRNA was knocked down. This difference in 
‘compensatory’ response may indicate different roles for the isoforms of Ras in 
different cell types. 
Using a LDH-based cytotoxicity assay, it was demonstrated that the relative decrease 
in Ki-Ras mRNA following transfection with ASOs was not as a result of increased 
cell death from cell toxicity. In fact there was no significant difference in cytotoxicity 
at increasing concentrations of ASO. 
Analysis by QPCR for Ras mRNA expression in vivo from oligo treated non-diseased 
rat models reflected results obtained in vitro, demonstrating a significant knockdown 
of Ki-Ras mRNA expression by ASO 2 (67%), with minimal Ki-Ras mRNA 
knockdown (12%) by ASO 1. Both ASOs were specific to Ki-Ras with no significant 
affects on either N- or Ha-Ras levels. Since the ASO effects in non-obstructed 
kidneys were seen to be specific for Ki-Ras mRNA, in this context one can assume 
that the decrease in pan-Ras protein expression reflects mainly Ki-Ras protein 
knockdown. Immunoblot analysis revealed a significant decrease in pan-Ras protein 
following Ki-Ras ASO administration and moreover it was noted that despite low-
level Ki-Ras mRNA knock down by ASO 1, this antisense appeared to produce a 
greater degree of protein level knockdown overall. However there was significant 
variability in the immunoblot results and this is likely to represent inaccuracies with 
regards to immunoprecipitation and normalization to GAPDH of the residual 
supernatant following immunoprecipitation which may be highly variable and 
inaccurate. 
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There was no observable difference in the number of Ki-67 positive cells within the 
glomeruli or tubular compartments between groups. However there was a significant 
increase in Ki-67 positive cells in the interstitium of sections taken from both the 
active Ki-Ras ASO groups in comparison to vehicle and CO 2 treated groups. The 
lack of increase in Ki-67 cells in the CO 2 group indicates that this observation is due 
either to Ki-Ras knockdown per se or possible specific attributes of Ki-Ras antisense 
oligo. Since Ki-Ras is pivotal to cell proliferation the increase in interstitial 
proliferation is surprising, though the identity of the proliferating cells is unknown 
and may represent non-mesenchymal cells. 
Employing antibodies to oligonucleotides and aquaporin-1 and 2 allowed for 
identification of proximal tubular cells as the cells in which oligos were deposited 
within the renal cortex following subcutaneous administration. The lack of any 
correlation of oligo-positive cells with those expressing aquaporin-2 suggests that that 
following systemic administration, oligos are freely filtered at the glomerulus and 
actively reabsorbed at the proximal tubule. This appears to be an efficient process 
since minimal oligo appears to reach the distal nephron for reabsorption as reflected 
by lack of accumulation of oligo in distal tubular cells. 
Analysis of non-renal tissues also confirms that subcutaneous administration of ASO 
results in systemic distribution with evidence of oligo deposition in cardiac, hepatic 
and muscle tissue. 
As a site of significant oligo accumulation, the extra-renal effects of ASOs on hepatic 
tissue was investigated. QPCR of hepatic tissue revealed a significant increase in Ki-
Ras mRNA levels on administration of scrambled oligos compared to vehicle-only 
treatment. Though administration of ASO 1 did not significantly reduce hepatic Ki-
Ras mRNA levels, ASO 2 reduced expression by 49% compared to vehicle-only 
treated tissue. These results of mRNA knockdown reflect the ASO potency observed 
in renal tissue with more potent knockdown effects observed with administration of 
ASO 2. It is well recognized that oligonucleotides are actively taken up by liver cells, 
in particular the Kupffer cells, and these results confirm this. Histological analysis of 
liver samples was limited by the loss of tissue treated by scrambled oligos due to 
storage malfunction. However analysis of remaining samples revealed significant 
inflammation both in lobules and portal tracts of models treated by ASO 2 compared 
to vehicle-only. Inflammation with ASO 1 administration was minimal and on par 
with the vehicle-only group.  
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Cardiac tissue from oligo treated models was also investigated for inflammation by 
staining for ED-1 expression, a cell marker of macrophages. It was found that though 
there was an increase in ED-1 positive cells seen in ASO 1 and CO 2 treated samples 
a much greater increase in cell numbers was observed on administration of ASO 2. 
This demonstrates that subcutaneous administered oligos may be widely deposited 
throughout peripheral tissues. Furthermore that the oligos themselves may induce a 
inflammatory reaction within the tissue they are deposited in and that the make-up of 
individual oligos, perhaps in terms of which bases they are composed of or the 
binding site of target mRNA, may dictate the degree of inflammatory response. 
 
The above results demonstrate that subcutaneous administration of ASOs is able to 
target both the kidney and liver and that uptake of these molecules may potentially 
lead to significant knock down of both Ki-Ras mRNA and protein levels. The 
observed reduction in Ki-Ras expression was not associated with any decrease in cell 
proliferation within the kidney. The uptake of certain oligos may lead to increased 
inflammation within various tissues depending on the oligo make-up. This point was 
discussed with ISIS pharmaceuticals and it was confirmed that oligos had been 
recognised to induce inflammation but they are now able to design newer oligos that 
avoid this effect. 
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Chapter 4: Expression & characterization of 












Figure 4.1: Gross appearance of an obstructed kidney compared to a kidney 
from a sham-operated model following 12-days obstruction. 
 
As part of this project a model of renal fibrosis secondary to unilateral ureteric 
obstruction was set up (see Methods & Materials). An assessment of fibrosis and the 
process of fibrogenesis was made using both histological staining and molecular 
markers. The time periods for the length of obstruction examined were 5, 12 and 16 
days. Following assessment of fibrosis, made by a consultant renal histopathologist, at 
these various time points, it was concluded that the optimum time period for 
observing both a significant degree of interstitial fibrosis and a rise in fibrogenic 




4.1 Fibrosis in UUO kidney samples compared to sham at 




















Figure 4.2: H&E stained sections from sham and UUO kidneys Day 5, 12 & 16 
(x10). Note dilated tubules, flattened tubular cells, increased interstitial area and 
inflammatory infiltrate in obstructed samples. !
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Various stains, both special and immunohistological, were used to examine tissue for 
fibrosis and parameters of fibrogenesis: 
1) Fibrosis & matrix deposition: Picromallory trichrome (PMT) and Picrosirius 
Red 
2) Myofibroblastic activity: alpha smooth muscle actin (!SMA) & collagen I 
3) Fibroblast marker: Fibroblast specific protein 1 (FSP-1) 
 
















Figure 4.3: Picromallory trichrome (PMT) staining of kidney sections from 
Sham and UUO kidneys at day 12 (x20). Fibrin & muscle stain red, collagen & 
reticulin stain blue, nuclei stain blue/black & red blood cells stain yellow. The sham 
section demonstrates normal perivascular collagen staining. The UUO section 
demonstrates dilated tubules with flattened epithelial cells, expansion of interstitial 








Figure 4.4: Sections of sham and UUO kidney at day 16 stained using 0.1% picrosirius red 
(x20). (A) Bright light: collagen fibres appear red on yellow-rose background. Note normal 
perivascular  (arrow) staining in sham sample around an artery & increased interstitial staining 
(arrowheads) in UUO section. (B) Cross-polarized light: Larger collagen fibres (I & III) appear 
orange-yellow while thinner fibres appear green. Note normal perivascular collagen deposition in 
sham sample (arrow) and interstitial deposition within UUO samples (arrowheads) that are 


























Figure 4.5: !SMA staining of kidney sections from Sham and UUO at day 12 
(x10). Note normal perivascular staining for !SMA expression in sham section 
but lack of interstitial staining. There is widespread interstitial !SMA expression 
detected on UUO sample. 
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Figure 4.6: Collagen I staining of kidney sections from Sham and UUO at day 12 
(x10). Polyclonal antibody to collagen I shows widespread interstitial collagen 
expression  (arrowheads) detected on UUO sample that is absent in sham sample. !!
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The previous figures are representative of renal tissue from sham and UUO models. 
Sections from both groups were scored by a consultant renal histopathologist for 













Figure 4.7: Renal cortical tubulointerstitial fibrosis based on picromallory 















Figure 4.8: Cortical tubulointerstitial !SMA and collagen I expression in sham 



























Staining and scoring of FSP-1 in three sham-operated and nine obstructed kidney 
samples was performed with score based on the mean of ten views per section at a 











Figure 4.9: FSP-1 staining of kidney sections from two Sham and two UUO at 
day 16 (x40). Note scant staining in sham section but increased expression was 


















Staining for FSP-1 demonstrated an increase in tubular expression in obstructed 
kidneys when compared to sham. Though this difference was statistically significant, 
in absolute terms the mean difference was one positive cell.  However obstruction 
resulted in a mean five-fold increase in FSP-1 expression within the interstitium of 
obstructed kidneys when compared to sham-operated samples. 
Figure 4.10: FSP-1 positive cells 
per view (x 40) in day 16 sham-
operated and obstructed kidneys. 
Cell count compartmentalized in to 

























4.5 Ras isoform mRNA expression in a rat model of UUO 
4.5.1 Semi-quantative PCR 
Semi-quantative reverse transcriptase polymerase chain reaction (SQ-PCR) was used 
to examine mRNA expression. Primers were designed using published sequences for 
the different isoforms (see Methods & Materials). "-actin was used as reference gene. 
The figures below are representative examples of SQ-PCR results comparing Ras 








Figure 4.11: DNA gel of SQ-PCR of Ki-ras (159bp) from renal tissue of sham-
operated rats and the obstructed kidney of UUO 12 day models. The SQ-PCR 
reaction was carried out using 26 cycles of PCR. The figure is representative of 3 
separate SQ-PCR experiments using identical renal samples of UUO at 12 days. "-






! ddG! F945! "?471A/
!
Figure 4.12: DNA gel of semi-quantative SQ-PCR of N-ras (204bp) and Ha-ras 
(224bp) from renal tissue of sham-operated rats and the obstructed kidneys of 12 
day UUO models. The SQ-PCR reaction was carried out using 25 cycles of PCR. 
The figure is representative of 3 (Ha-Ras) and 4 (N-Ras) separate SQ-PCR 
experiments using identical renal samples. "-actin was used as a loading control. !
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When Ras isoform mRNA expression was normalised to "-actin expression there was 
found to be no significant difference between Ras isoform expression in sham as 
compared to obstructed kidney cortical tissue.  
Previous studies have observed a difference in both total and isoform Ras protein 
expression in both human and animal models of renal disease (Kocher, Moorhead et 
al. 2003; Grande, Fuentes-Calvo et al. 2009). It was thought that the lack of 
observation in difference in Ras mRNA expression may be in part due to lack of 
sensitivity secondary to high amplification of SQ-PCR and the relative inability to 
adequately discriminate between bands on gel electrophoresis. Furthermore, the 
potential of change in expression of "-actin mRNA levels in obstructed kidneys was 
also considered to be a possible factor in a result that was inconsistent compared to 
previous other studies. Subsequently real-time PCR (or QPCR) was employed. QPCR 
is highly sensitive and can detect differences as low as x2 to x10. In addition GAPDH 
mRNA levels were shown to be more stable in the context of UUO than "-actin levels 
(see Methods & Materials) and thus GAPDH was used as a reference gene. 
 
4.5.2 Real-time PCR 
** 
Figure 4.13: QPCR measurement of Ras 
isoform expression in sham-operated, 
contralateral non-obstructed and obstructed 
kidneys (day 12) [** p<0.01]. QPCR was 
performed using Taqman gene expression assay 
(Applied Biosystems). GAPDH was used as a 
reference gene and quantitation was relative to 
expression in sham group. !
** 
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Results from QPCR analysis of Ras isoforms show no difference in Ha-Ras mRNA 
expression between UUO and sham kidneys. However there was a significant 
increase in Ki-Ras mRNA expression of 71% and in N-Ras mRNA expression of 80% 
observed in UUO samples compared to sham (both p value <0.001). The rise in these 
isoforms of Ras mRNA expression is localised to the obstructed kidney alone with 
measurement of Ras isoform expression in the contralateral non-obstructed kidney 
being comparable to sham for all Ras isoforms. 
 
4.6 Ras isoform protein expression in a rat model of UUO  
Due to relatively low abundance in the cell, Ras protein isolation required overnight 
immunoprecipitation from protein lysates of kidney samples (See Methods & 
Materials). Western blotting for Ras isoforms as well as for Pan-Ras was performed. 
There was strong non-Ras band at 25-27kD of unknown origin that was constantly 
detected. This protein band was not further investigated in this project. Comparison of 
Ras protein expression was measured using area and densitometry. The following 







Figure 4.14: Western blot for Ki-Ras (A) and Pan-Ras (B) in Sham and UUO 
kidney (day 12). Note consistent heavy artefact 26kD band. Ras protein detected at 
21-22kD with high intra-group variability in band density. Immunoblots are 
representative of three experiments. 
 













Figure 4.15: Comparison of band density for Ki-Ras (A) and pan-Ras (B) for 
Sham and UUO kidneys (day 12).  
 
The results obtained from western blotting for Ras proteins were highly variable and 
lacked consistency despite using identical samples and materials, with band density 
for a single sample varying significantly between experiments. The mean 
measurement of band density/area  demonstrated an overall decrease in Ras protein in 
UUO samples when compared to sham. This contradicts both previous published 
studies and results obtained from analysis of mRNA levels using QPCR in this 
project.  
 
4.7 Ras immunohistochemistry  
Histological staining for Ras protein allows assessment of abundance and localization 
of Ras as a whole and its various isoforms both in sham and UUO kidney and how 
expression changes during the process of renal fibrosis secondary to obstruction.  
As mentioned in Methods & Materials the actual practical process of obtaining 
satisfactory immunohistological staining for Ras was difficult and required the trial of 
several antigen retrieval techniques (see Appendix I). Poor antibody specificity with 
high isoform crossover resulted in an inability to differentiate isoforms and a high 
non-specific background. The procedure of immunohistochemistry, though 
occasionally successful, was in by no means consistent, homogenous or reliable 




















Figure 4.16: Immunohistological staining for Ki-Ras (A) Section of UUO kidney 
[x20]. In both above figures, note once again occasional non-specific apical tubular 
epithelial stain (arrows) but lack of cytoplasmic or interstitial staining.  (B) Section of 
UUO kidney [x40]. Note increased staining of apical border of tubular cells and a 
degree of increase on interstitial staining (arrowhead). 
 
4.8 Localization of Ki-Ras mRNA expression 
Whole renal cortex tissue lysate is used for analysis of Ras expression thus there may 
actually be an underestimate of ASO knockdown effects on renal cells alone as there 
may be a contribution from infiltrating inflammatory cells to the overall Ras 
expression within the kidney sample. In addition, oligonucleotides have been shown 
to be actively taken up by proximal tubular cells with interstitial infiltration being 
more problematic. Though overall knockdown of Ki-ras mRNA expression in whole 
tissue lysate has been seen on administration of ASOs (see Chapter 3), the 
compartment which is affected, be it glomerular, tubular or interstitial, is not 
identified. We attempted to localize the cellular compartments in which Ki-Ras 
mRNA is expressed and assess how expression in these cells altered in UUO and by 








4.8.1 Laser microdissection and pulsed collection 
This technique allows for exclusive dissection of tubular cells and thus removes the  
possible confounding factor of target gene contribution from infiltrating inflammatory 
cells. The microdissection process was performed using P.A.L.M. Microlaser 
Technologies incorporating a micromanipulation systems using laser microdissection 
and pressure catapulting [LMPC] (see Methods & Materials). Laser microdissection 
has previously been used in mRNA analysis of renal tissue. Nagasawa et al. used 
LMPC to confirm upregulation of TGF" mRNA in glomeruli of an anti-Thy1.1 rat 
models (Nagasawa, Takenaka et al. 2000). Cohen et al. also used PALM 
microdissection technology from human renal transplant rejection biopsy tissue 
(Cohen, Grone et al. 2002) and were able to employ both paraffin embedded samples 
as well as cryosections.  
From my initial trials, dissection of 10 proximal tubules (each tubule consisting of a 
mean of 15-20 epithelial cells) from sham kidney samples only resulted in a mean 
RNA retrieval of 0.4 ng/"l. For adequate RNA reverse transcription a minimum of 
50ng of RNA was required. Subsequently up to 120 tubules were dissected from 
various tissue samples including UUO vehicle-treated tissue. RNA retrieval 
unfortunately only produced a maximum of 3.8ng/ "l RNA-still significantly too low 
for RNA RT by this method.  
Thus though LMPC isolation of Ki-Ras knockdown is still potentially possible, the 
process is restricted by time limits for each section, high number of cells required for 
adequate RNA retrieval and may be influenced by low Ras expression generally in 
cells. Furthermore adequate RNA retrieval from sham kidneys may not reflect UUO 
samples where tubules are distended and tubular cells are flattened and atrophic. 
Though this work focused mainly on tubular retrieval (since oligos have been shown 
to actively be taken up by these cells), future attempts should also consider 







4.8.2 In situ hybridization 
In situ hybridization (ISH) provides an ideal method for localizing mRNA expression 
within tissue samples. However it is a difficult technique and in the case of renal Ras 
expression there are the further complicating factors: 
1) Ras is expressed at low levels  
2) the fact that Ras mRNA is a relatively small molecule  
3) identification of Ras isoforms means probes are required to be 
directed to the nucleotides coding for the hypervariable region-
which is only 20% of the whole sequence of which not all may be 
spatially available for probe binding. 
A commercial non-radioactive ISH kit was used to attempt to localize Ki-Ras 
(Hybriprobe® Triseq kit purchased from Biognostik). This kit was designed for 
detecting RNA which has a low level of expression.  
Unfortunately the results from using this kit were highly variable and inconsistent. 
Though the positive control, Poly dT probes, was successful experiments employing 
probes for Ki-Ras were never successful despite over six attempts with variation in 
probe concentration and stringency of experiment. In part this is due to the points 
mentioned above. In addition of the three actual probes provided in the kit only two 
were directed towards rattus norvegius Ki-Ras and it is unclear from manufacturer’s 
data whether these probes have been designed with regards to spatial character of 
molecule. ISH is still of great potential in localizing Ki-Ras mRNA expression within 
tissue. However there must be particular aspects of the technique that must be 
addressed including design of probes, use of multiple probes to amplify detection and 









4.9 In vivo TUNEL staining for apoptosis 
Ras has a significant role in cell proliferation and survival. A TACS TdT (terminal 
deoxynucleotidyl transferase) kit (R&D systems TA4625) was used to detect 
apoptosis. 10 views per section were analysed for positive TUNEL staining at 








Figure 4.17: UUO vehicle only treated section stained with TUNEL assay. 
Positive TUNEL cells marked by arrows. 
 
Unfortunately the staining of tissue sections was not always consistent and several 
sections were not adequately stained for scoring. This process will require repeating 
to improve the number of samples for each condition. Another method to look at 
degree of in vivo apoptosis is to analyse expression of caspase-3 on SDS PAGE and 
immunoblotting though this does not have the advantage of localizing apoptotic cells. 
 
4.10 Summary of results of characterization of UUO model: 
1) A model of renal fibrosis based on unilateral ureteric obstruction over a 
12-16 day period was set up and characterized by using a histological 
fibrosis score based on PMT & PSR staining. 
2)  There is a significant increase of molecular markers of fibrogenesis 
including !SMA, FSP-1 and collagen 1 in the UUO model when 
compared to sham-operated kidneys. 
3) Both Ki-Ras and N-Ras mRNA expression was increased by 71% and 
80% respectively in obstructed kidneys compared to sham-operated 
kidneys. There was no change in Ha-Ras mRNA levels.  
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4) Changes in Ras isoform mRNA levels was localized to obstructed kidney 
and did not extend to the non-obstructed contralateral kidney of UUO 
models. 
5) Attempts at measurement of Ras protein expression by western blotting 
and immunohistological methods were inconsistent and severely restricted 
by poor antibody specificity and the lack of an appropriate loading control 
due to requirement for immunoprecipitation. 
6) Attempts at localisation of Ras isoform mRNA expression and up-
regulation employing laser microdissection and in situ hybridization were 
unsuccessful in this project 
The table below summarises changes observed in Ras expression and fibrosis markers 
in the rat kidney following ureteric obstruction when compared to a sham-operated 




Ras Isoforms mRNA 
expression measured by 
QPCR in obstructed 
kidneys in comparison to 
sham-operated kidney 
samples 
Fibrosis & fibrotic markers in obstructed kidneys in 




1) Kras upregulated by 
71%  
2) Nras upregulated by 
80% 
3) Hras expression 
equivalent to sham 
 
All Ras isoform expression 
in the contralateral kidney 
was equivalent to sham 
1) !SMA: Increased tubulointerstitial expression  x 6 
2) Collagen I: Increased tubulointerstitial expression 
by x 5 
16 days 
 
1) Kras  upregulated 
by 84%  
2) Nras  upregulated 
by 87% 
3) Hras upregulated by 
23% 
 
1) PMT: Increased tubulointerstitial expression x 10 
fold 
2) PSR: Increased tubulointerstitial expression x 7 
fold 
3) FSP-1:Interstitial: x 5 fold 
4) Collagen 1: Increased tubulointerstitial expression 
by x 5 fold 
5) !SMA: Increased by x 8 fold  
 
 




The development of an animal model of renal fibrosis was central to this project. The 
model of unilateral ureteric obstruction was chosen for several reasons. It is a model 
of tubulointerstitial fibrosis that is widely employed and provides significant 
quantifiable molecular and histological changes over a short time span. It is a robust 
model and so often used to evaluate potential therapies. Furthermore the contralateral 
non-obstructed kidney may provide an internal control to the disease process if so 
wished and the potential for reversal of obstruction can aid future studies into fibrosis 
recovery. The initial assessment of the model in this project revolved around 
determining the duration required to provide significant histological fibrosis with 
observable differences in the molecular parameters for quantifying fibrogenesis and 
the subsequent characterisation of Ras expression both at an RNA and protein level. It 
was found that a duration of obstruction of 12-16 days provided significant fibrosis on 
staining with PMT and picrosirius red (PSR). This time frame is consistent with other 
studies looking at Ras expression in murine models of renal fibrosis (Grande, Arevalo 
et al. 2009). In addition, immunostaining for collagen I and !-SMA expression were 
also significantly increased in UUO models at this time point. A significant increase 
in interstitial expression of FSP-1 was also observed in the obstructed renal tissue. 
This may represent an increase in fibroblast population as part of the fibrotic process 
induced by obstruction. However FSP-1 expression must be viewed with caution as 
there is now data showing that FSP-1 is expressed by active mononuclear cells and 
not exclusively by fibroblasts. Interestingly, there was also a statistically significant 
rise in tubular expression of FSP-1 following renal obstruction. However in absolute 
terms this difference was a mean of 1 cell/view only and was a reflection mainly of 
the complete absence of FSP-1 positive tubular cells in sham kidneys. However the 
presence of FSP-1 positive tubular cells may be argued to represent a phase of EMT, 
though the non-specificity of this cell marker and the fact that detection for co-
expression with cell markers of tubular cells was not undertaken must be taken into 
consideration. 
With regards to Ras RNA expression, use of SQ-PCR showed that all three isoforms 
are expressed in the kidney. However unlike cell culture studies (see Chapter 3), the 
use of this technique was unable to reliably discriminate between the levels of 
expression of isoforms of Ras in vivo. Furthermore, "-actin was used as a house-
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keeping gene but subsequent analysis demonstrated that this gene expression 
appeared upregulated in obstructed when compared to sham-operated kidney samples. 
Ras, though ubiquitous, is normally expressed at low levels in vivo, thus small 
increments in the level of Ras expression may have significant cellular effects but 
may be difficult to detect. Subsequently QPCR was employed and showed that there 
was a significant increase in Ki-Ras and N-Ras mRNA expression in obstructed 
kidney when compared to sham kidney samples (p<0.01). Furthermore the increase in 
both Ki-Ras and N-Ras expression appeared to be localised to the obstructed kidney 
while expression in the contralateral non-obstructed kidney was comparable sham. To 
investigate whether these changes in mRNA expression were translated to protein 
level SDS PAGE was employed. 
Western blotting for Ras protein from whole kidney lysate was technically difficult. 
Due to low abundance of Ras protein, immunoprecipitation of protein was required 
and so a loading control was unable to be employed. In addition the sensitivity of 
western blotting itself is very much dependent on the affinity of antibodies used and 
the antibodies for the Ras isoforms are recognized to have a high degree of cross-
reactivity. Thus results were highly variable and lacked consistency despite using 
identical samples and materials on repeated experiments. Apart from the technical 
difficulty of the process and the lack of antibody specificity, the inconsistent results 
obtained from western blotting may be due to a relative difficulty in the extraction of 
a low abundant target protein, such as Ras, from fibrotic kidneys compared to non-
fibrotic sham samples due to a combination of cell atrophy, matrix deposition and 
fibrosis. The fact that our experiments tend to demonstrate a decrease in Ras protein 
in UUO samples, which contradicts previous published studies and our results 
obtained from analysis of mRNA levels using QPCR, supports the idea that Ras 
isoform protein analysis was unreliable when employing current available antibodies 
to Ras isoforms and SDS PAGE techniques in this project. In addition there was the 
presence of a heavy slower running artefact band with a molecular weight of 28-30kD 
near that of Ras. The significance of this band with regards to Ras is unknown. With 
regards to the molecular weight of this molecule, it was not possible that the band 
represented dimers or polymers of Ras. A possibility may be the detection of heavy or 
light chains of the Raf-binding antibody of the agarose beads used for 
immunoprecipitation. These antibody components (generated in Sprague-Dawley 
rats) may have broken off to form aggregates which are subsequently bound to Ras. 
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The heavier complex is then detected in immunoblotting. Thus true quantification of 
Ras protein levels, and its isoforms, was not possible when the amount could not be 
reliably quantified especially in the absence of a reliable loading control. 
Immunohistochemical (IHC) methods were employed to assess protein expression. 
The benefit of such a technique would be not only to provide a quantifiable result but 
also localisation of Ras isoforms which would be of benefit later in the project when 
employing ASOs. However IHC for Ras also proved to be difficult and gave 
inconsistent results and non-homogenous staining. Much of the staining appeared to 
be non-specific uptake and harsh methods of antigen retrieval were required, which in 
turn may have denatured the target protein. Furthermore on contacting the technical 
departments of Calbiochem and Santa-Cruz, it was confirmed that the antibodies 
employed were not completely specific for the various isoforms of Ras and there was 
a crossover of upto 20-30% between ‘isoform-specific’ antibodies. The lack of 
specificity of antibodies against Ras isoforms meant that accurate localisation of 
specific isoform proteins in renal tissue was not possible and our attention turned to 
detection of mRNA isoforms of Ras. Initially in situ hybridization was attempted. 
Due to normally low abundance of Ras mRNA, a non-radioactive assay composed of 
three probes to allow for signal amplification was employed. Unfortunately, despite 
some success using the control poly-dT probe, no significant signal was successfully 
achieved either with the control !-Tubulin or Ki-Ras probes despite numerous 
variation in experimental conditions. In part this may be due to probe sequences: only 
two of the three were directed at rat (the other being mouse directed) and it was 
unclear if the target sequences of the probe were spatially available for binding. 
However since the control poly-dT probe did show some degree of success, the 
possibility arises that there was insufficient RNA preservation in the tissue or 
insufficient amplification of signal. In situ hybridization must still be considered a 
potential option for localizing Ras isoform expression, though the relative short 
sequence in base variability between isoforms would mean probe design would be 
difficult and a cocktail of several probes directed against the hypervariable region of 
individual isoforms and subsequent amplification would be required. It may be that 
the use of a radioactive probe may provide a more distinct picture by removal of 
background signal and the use of fresh frozen samples may remove potential issue of 
rapid RNA degradation. An alternative approach to localising Ras expression 
differences was by use of laser microdissection and subsequent QPCR. The 
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technology of PALM allows for single cells to be dissected out of tissue sections, 
collected and RNA retrieved. The rationale for use of this was to dissect out specific 
cortical regions or cells and analyse them for Ras isoform mRNA expression using 
QPCR in sham, UUO and ASO treated kidneys. Unfortunately, though this procedure 
was seen to work, insufficient amounts of RNA was retrieved to provide adequate 
reverse transcription and subsequent QPCR. This may be in part that the tissue used, 
though snap-frozen at retrieval, had been stored for a significant period of time before 
cryosection and freshly retrieved tissue should be used instead. Furthermore it was 
seen that a lower amount of RNA was retrievable from obstructed kidneys as opposed 
to sham-operated for a comparable number of cells dissected. It has been recognosed 
that more RNA can be retrieved from more active cells. In this way, possible 
decreased tubular activity in UUO may result in decreased retrievable RNA. This may 
mirror the results seen on western blotting for Ras protein in UUO samples where the 
apparent lower amounts of protein seen on immunoblots may reflect increasing 
difficulty in retrieving protein as opposed to ‘absolute’ low levels of protein. The 
same may apply for retrieval of RNA from individual cells by microdissection. 
Though neither in situ hybridization nor laser microdissection was successful within 
the scopes of this project, they still hold potential to be of success in localising Ras 





Chapter 5: Administration of Ki-Ras antisense 
oligonucleotides to a rat model of unilateral 
ureteric obstruction: ASO dose determination & 
Ras mRNA analysis  
 
5.1 Experiment I: Administration of low dose (5mg/kg) Ki-
ASO in a model of UUO  
Low dose Ki-Ras ASO 1 at 5mg/kg was administered on alternate days over a 12-day 
period to a rat model of UUO. This dose was initially selected on the advice of ISIS 
Pharmaceuticals and on the basis of preliminary experiments performed by Dr Helen 
Clarke (unpublished). Both ASO 2 and control oligo CO 2 were not used due to lack 
of stock at the time of experiment. Saline was used for the control group. There were 
seven animals in each group. 
 








Figure 5.1: DNA gel of semi-quantitative PCR (25 cycles) products from kidney 
tissue of saline and ASO 1 (5mg/kg) treated UUO rats at day 12. Gel is 
representative of four separate PCR runs.  
Semi-quantitative PCR using RNA retrieved from whole kidney tissue from both 
groups failed to show any significant knockdown of Ki-Ras mRNA following ASO 1 







(see Chapter 4) and it was believed that SQ-PCR in this setting was not sensitive 





















There was an 18% decrease in Ki-Ras mRNA expression in ASO 1 treated group as 
compared with saline treated controls that was statistically significant (p<0.01). There 
was no significant difference in H-Ras expression between groups but there was a 
significant rise in N-Ras mRNA expression by 176% in the ASO group (p<0.05) 







Figure 5.2: Ras isoform mRNA 
expression in saline and ASO 1 
(5mg/kg) treated UUO kidneys by 
QPCR analysis at day 12. Seven 
animals in each group. (A) Ki-Ras 
(n=2), (B) Ha-Ras (n=1), (C) N-Ras 
(n=2). Bars represent standard error of 
mean. [n = number of QPCR analyses 
undertaken with each sample run in 































5.1.2 Protein expression in low dose ASO administration  
Cortical kidney tissue lysed and western blotting performed to analyse Ras isoform 
protein expression. As previously described, due to relative paucity of Ras protein 
immunoprecipitation was required, thus there was a lack of a loading control, though 





























Figure 5.3: Representative immunoblots for (A) Ki-Ras, (B) N-Ras and 
(C) pan-Ras protein in saline and low-dose (5mg/kg) ASO 1 treated UUO 
kidneys following 12 days of treatment. 600µg of protein from each sample 
protein lysate was loaded for immunoprecipitation with 20µl of anti-Ras 




























QPCR had shown a decrease in Ki-Ras mRNA levels in ASO 1 group compared to 
saline-control but there was no significant difference at a protein level. Furthermore 
the significant near three-fold increase in mRNA expression in N-Ras actually 
appeared to translate to a decrease in N-Ras expression at a protein level. 
Immunoblotting of pan-Ras showed a decreased protein expression in the ASO 1 
group. Results obtained from Ras protein analysis demonstrated high intra-group 
variability and it is difficult to interpret the significance of these highly variable 
results, especially with the technical issues associated protein retrieval and 
immnuoblotting as previously mentioned (see Chapter 4).  
 
Figure 5.4: Comparison of band 
density on immunoblots for (A) Ki-
Ras, (B) N-Ras and (C) pan-Ras 
protein in saline and low-dose 
(5mg/kg) ASO 1 treated UUO 
kidneys following 12 days of 
treatment. Seven animal per group. 
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5.1.3 Fibrosis scores in low dose ASO administration  
Fibrosis was assessed by staining with PMT and Picrosirius Red. !SMA staining was 
used to assess myofibroblastic activity. Following staining the sections were scored in 























Figure 5.5: Sections of UUO kidneys from saline-control and low-dose (5mg/kg) 
ASO 1 treated rat models at day 12 stained for fibrosis with (A) PMT and (B) 











Figure 5.6: Renal fibrosis scores for saline-control and low-dose (5mg/kg) ASO 1 


















Analysis of tissue demonstrated no difference in fibrosis score by PMT staining on 
administration of ASO 1 compared to saline-controls but an increase in fibrosis score 
by 16% on picrosirius red staining in ASO 1 treated group was noted. Staining for 
!SMA expression by immunohistochemistry did not demonstrate any differences in 





Figure 5.7: (A) Sections of UUO 
kidneys from saline-control and 
low-dose (5mg/kg) ASO 1 
treated rat models at day 12 for 
!SMA expression [x10]. (B) 
!SMA expression scores for 







5.2 Experiment II: Administration of high-dose (12.5mg/kg) 
Ki-ASO in a model of UUO 
Following these preliminary results with low dose ASO (5mg/kg), high dose ASO 
(12.5mg/kg) was subsequently administered to rat models of UUO subcutaneously on 
alternate days over a 16-day period. Initially CO 2 (ISIS 141923), which has no 
known gene target within the specie of rattus norvegius, was administered as a 
control oligo. Sterile water was administered using an identical protocol for a baseline 
vehicle-only control group. 
Following these initial experiments, scramble oligos of ASO 1 (ISIS 104440) and 
ASO 2 (ISIS 104419) , SO 1 (ISIS 417230) and SO 2 (ISIS 417226) were used for 
control groups. Tissue retrieved at day 16 included: Obstructed kidney, contra-lateral 
non-obstructed kidney, heart, liver and wound (scar tissue from laparotomy) tissue. 
 
5.2.1 Oligo uptake within the obstructed kidney 
As part of this project, it has been demonstrated that subcutaneous administration of 
ASO is taken up by the proximal tubules of the kidney (see Chapter 3). To investigate 
if this was also true of subcutaneous administration in a model of obstructive 
nephropathy and to confirm that oligos would reach renal tissue at the high dose 
(12.5mg/kg) that was administered, our group stained sections using a polyclonal 
















The above sections demonstrate that, following UUO, there is an overall increase in 
oligo deposition seen in the renal cortex with oligo presence seen within the 
interstitial department that was largely absent in non-obstructed kidneys. This 
suggests the possibility of increased oligo concentration in UUO kidneys and affects 
on cells not targeted in the non-diseased model where deposition was restricted to the 
proximal tubules (see Chapter 3).  
 
Figure 5.8: Sections of cortex from (A) a non-obstructed and (B) a UUO 
models both following ASO-1 administration (12.5mg/kg) and subsequent 
staining for oligo deposition. Both demonstrate oligo deposition within the cortex 
with accumulation in proximal tubules. However oligo deposition within the in 
UUO section also includes the interstitium and appears to be of greater intensity 
compared to the sham sample. !
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Figure 5.9: Relative expression of  (A) 
Ki-Ras ( n=4), (B) N-Ras (n=3) and Ha-
Ras (n=3) in sham, vehicle-only (VO), 
Control Oligo (CO 2) and antisense 
(ASO) groups in obstructed kidneys 
(UUO) and contralateral non-obstructed 
(CL) kidneys at day 16. Each point 
represents one animal. [n number 
represents the number of QPCR analyses 
undertaken with each sample run in 





As seen with characterization of UUO model, there is a significant increase in Ki-Ras 
mRNA levels (by 84%) by day 16 in vehicle-only obstructed kidney (UUO VO) 
compared to sham which localised to the obstructed kidney with levels in the 
contralateral kidney (CL VO) being equivocal to sham. Administration of ASO 1 and 
2 significantly downregulated Ki-Ras mRNA expression in the obstructed kidney 
(UUO ASO 1 and UUO ASO 2) by 45% and 49% respectively to a level of Ki-Ras 
mRNA expression comparable to sham-operated kidneys. Again it was noted that 
ASO 1 has a much greater Ki-Ras knockdown affect in the obstructed kidney than has 
been predicted from experiments of administration to non-obstructed models. As 
noted previously, there was an increase in N-Ras mRNA expression by 87% in 
obstructed kidneys (UUO-VO) as compared to a sham-operated kidneys and this 
again was localized to the obstructed kidney. Administration of ASO 2 appeared to 
further increase N-Ras mRNA expression by 72% in the obstructed kidney and 60% 
in the contralateral group when compared to the respective vehicle-only groups. ASO 
1 administration did not result in any significant difference in N-Ras expression when 
compared to vehicle-only controls. Obstruction resulted in a 23% rise in Ha-Ras 
mRNA expression but administration of ASO 1 and 2 significantly reduced 
expression by 40% and 41% of this isoform. Furthermore within the contralateral 
kidney, administration of ASO 1 further reduced Ha-Ras mRNA levels by 32%. CO 2 
was used as a control oligo. This oligo has no known target within the rat and has 
previously been used in this capacity (see Chapter 3) in non-obstructed rat models. In 
this experiment, administration of CO 2 to UUO models led to significant pan-Ras 
mRNA knockdown in all obstructed kidney samples with a knockdown of Ki-Ras by 
43%, N-Ras by 49% and Ha-Ras by 61%. The effects of CO 2 were isolated to the 
obstructed kidney of UUO models and the levels of all Ras isoforms in the 




5.3 Experiment III: Administration of high-dose (12.5mg/kg) 
Scrambled Oligos in a model of UUO 
Results obtained from administration of CO 2 in UUO models led to a request for a 
new control oligo from ISIS Pharmaceuticals. Scrambled oligos of the active Ki-Ras 
ASO SO 1 (417230) and SO 2 (ISIS 417226) were subsequently employed as 
controls. Initially these oligos were interrogated in models of UUO to examine effects 
on Ras expression.  
Following administration of SO 1 and SO 2 subcutaneously on alternate days over a 
16 days time period, tissue was retrieved and analysed using QPCR in comparison to 
vehicle-only and sham-operated samples from previous experiments. There were ten 
animals in each SO group and the following results represent two separate QPCR 
analyses using sham-operated renal tissue as reference control with each sample run 
















Figure 5.10: Ras isoforms mRNA 
expression in UUO models treated with 
Scrambled Oligos 1 and 2 and vehicle-
only (VO) in comparison to sham 
operated non-obstructed kidney and 
vehicle-only treated UUO. Each point 
















QPCR analysis shows a 70% rise in Ki-Ras expression in obstructed kidneys which is 
consistent with previous findings. The administration of SO 1 and SO 2 led to an 
upregulation of Ki-Ras expression by 169% and 175% respectively compared to 
sham-operated kidneys. N-Ras expression rose by 95% secondary to obstruction alone 
but a further rise SO groups was observed with SO 1 causing a 170% and SO 2 a 
154% mean increase in N-Ras mRNA expression in relation to sham-operated 
kidneys. There was a trend to decrease in Ha-Ras expression in all UUO groups 
compared to sham-operated though none were significant. There was no difference in 




5.4 Experiment IV: Contemporaneous in vivo experiment 
employing scrambled oligos 
The results obtained above from the combination of QPCR analyses was supported by 
a subsequent contemporaneous in vivo experiment involving subcutaneous 
administration of vehicle only (UUO VO), SO 2 and ASOs 1 and 2 at a dose of 
12.5mg/kg on alternate days over 16-day time period. The lack of suitable amounts of 
SO 1 meant this group was omitted for this experiment. Tissue was subsequently 
harvested for Ras mRNA expression analysis. 
 
Figure 5.11: Relative Ras mRNA 
isoform expression in obstructed 
kidneys from models of UUO in a 
contemporaneous experiment 
following administration of Ki-ASOs 
























There was no significant difference in mRNA expression levels of any of the isoforms 
of Ras following administration of SO 2 in comparison to UUO VO kidneys. 
Administration of ASO 1 and ASO 2 led to Ki-Ras knockdown of 27% and 76% 
respectively when compared to SO 2. These results mirror those previously obtained 
in vitro both with mesenchymal and epithelial cell lines and in in vivo experiments in 
non-obstructed animal models (see Chapter 3).  
There were no observable knockdown effects in N-Ras or Ha-Ras mRNA expression 
though the administration of ASO 2 led to an increase of N-Ras expression by 22%. 
This was not statistically significant but is consistent with previous experiments and 
observations of N-Ras expression increase associated with ASO 2 administration.  
 
5.5: Combined data from in vivo experiments 
The results of the contemporaneous experiment (Experiment IV) revealed that Ki-Ras 
mRNA was specifically knocked down on administration of ASOs in comparison to 
SO 2. Since the process of comparative method of QPCR analysis involves 
measurement against a sample’s own internal ‘housekeeping’ gene, in order to assess 
effects in relation to SO 1 in addition to increasing numbers in both the vehicle-only 
and SO2 treated control groups, the raw data from the above contemporaneous in vivo 
experiment was combined with raw data from previous in vivo Experiment III 
involving UUO vehicle only, SO 1, SO 2 and ASO administration. Further support for 
the rationale for using pooled data was the fact that the experiments were performed 
by a single operator using identical reagents and species, age and sex of animal (male 
Wistar rats of 200g) under identical operative conditions. Thus experiments were 
performed under consistent and reproducible circumstances though at different time 
points. Though this method cannot be seen to be a substitute to a true 
contemporaneous experiment, since there may be variations in animal batches, animal 
feed, tissue fixation and processing and reagents, it was seen as the best possible 
process logistically to obtain a more comprehensive overview of effects of ASOs in 
comparison to SOs on the expression of Ras isoforms. All raw QPCR data was 
collated and reanalyzed relative to UUO VO group. This additional data from the 
groups vehicle-only, SO 1 and SO 2 in Experiment III was obtained from a mean of 
three separate QPCR analyses. In order to assess comparability of data from this 
contemporaneous experiment with those that had been performed previously, delta Ct 
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values for Ki-Ras analysis from the Vehicle-only and SO 2 groups in the both the 
contemporaneous experiment (Experiment IV) and from the previous Experiment III 
were compared. Figure (5.12) shows that the mean delta Ct values of Ki-Ras were not 
significantly different when either vehicle-only (p= 0.6) or SO 2 group (p= 0.09) from 



















In addition, statistical analysis via a linear regression model using Ki-Ras delta Ct as 
the dependent variable with ‘Treatment with SO 2’ and ‘Time of experiment’ as the 
two variable factors was performed using statistical package SPSS IX to see if there 
was any observable significant measurement differences between the two 
experimental environments. Tables 5.1 & 5.2 below are results from this analysis 
demonstrating that though there was a significant difference (p=0.012) observed in 
the data with relation to treatment (that is, given SO 2 or not), there was no difference 














Figure 5.12: Comparison of variation in delta Ct values for relative 
measurement of Ki-Ras expression in a contemporaneous experiment 
(Experiment IV) compared to previous experiments (Previous) for the groups 



















1 2 .344* .127 .012 .083 .605 
2 1 -.344* .127 .012 -.605 -.083 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
 
 
Table 5.1:Results obtained from comparison of Ki-Ras delta Ct results obtained 
from Experiment III and IV using a linear regression model with variation in 




















1 2 -.176 .127 .178 -.437 .086 
2 1 .176 .127 .178 -.086 .437 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
 
 
Table 5.2:Results obtained from comparison of Ki-Ras delta Ct results obtained 
from Experiment III and IV using a linear regression model with variation time 
point (1=Experiment 3, 2= Experiment 4) of experiments. 
 
Combining the data from both experiments meant an increase in ‘n’ numbers for the 
different groups. This resulted in an increase of number of animals in Vehicle-only 
group from eight to thirteen animals and SO 2 from ten to seventeen animals. Ten 
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animals from SO1 were added to analysis while both ASO group numbers remained 




Figure 5.13: Relative Ras isoform 
mRNA expression derived from 
QPCR analysis using pooled data 
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The preceding graphs show that there is no significant difference in Ki-Ras 
expression between UUO-VO group and either SO groups. However there is a 
significant knock-down of Ki-Ras mRNA expression by administration of ASO 1 and 
ASO 2 by 53% and 97% respectively compared to UUO-VO. ASO 1 decreased Ki-
Ras mRNA expression by 61% when compared to its scramble (SO 1) while ASO 2 
decreased expression by 97% compared to SO 2. With regards to N-Ras both 
scrambled oligos increased N-Ras mRNA expression compared to UUO-VO. SO 1 
increased N-Ras mRNA expression by 100% and SO 2 by 37% when compared to 
UUO-VO control. There was a no significant difference in N-Ras expression 
observed with ASO 1 and ASO 2 when compared to UUO-VO. Both SO 1 and SO 2 
administration increased Ha-Ras expression in comparison to UUO-VO by 55% and 
14% respectively. However, as previously seen in in vivo administration of ASOs (see 
Chapter 4) there was also a decrease in Ha-Ras mRNA levels of 37% (ASO 1) and 
48% (ASO 2) compared to UUO-VO group though this was not statistically 
significant. 
 
5.6 Summary of results of administration Ki-Ras ASO to 
model of UUO: RNA analysis 
1) Low dose (5mg/kg) administration of ASO 1 in a 12-day rat model of 
UUO resulted in a specific knockdown in Ki-Ras mRNA expression in the 
obstructed kidney, a significant increase in N-Ras mRNA expression and 
no change in Ha-Ras mRNA expression compared to saline-control group. 
2)  Low dose (5mg/kg) administration of ASO 1 in a 12-day rat model of 
UUO resulted in an increase in fibrosis score both on PMT and picrosirius 
red staining and a trend towards increased !SMA expression compared to 
saline-control group. 
3) Following unilateral ureteric obstruction in a 16-day rat model there was 
an increase in Ras mRNA expression localized to the obstructed kidney of 
84% in Ki-Ras, 72% in N-Ras expression and 23% in Ha-Ras compared to 
sham-operated controls.  
4) Oligo deposition was seen to be in the proximal tubules and the 
interstitium of the obstructed kidney following high dose (12.5mg/kg) 
administration of ASO in a 16-day rat model of UUO. 
! "(&!
5) High dose (12.5mg/kg) administration of ASO 1 or ASO 2 in a 16-day rat 
model of UUO resulted in a specific knockdown of Ki-Ras mRNA 
expression in the obstructed kidney to levels comparable to sham-operated 
controls. ASO 1 and ASO 2 administration also reduced Ki-Ras mRNA 
expression in the contralateral non-obstructed kidneys when compared to 
vehicle-only and control oligo, CO 2, groups.  
6) High dose (12.5mg/kg) administration of ASO 2 in a 16-day rat model of 
UUO resulted in a further increase of 72% in N-Ras mRNA expression 
above the increase seen in vehicle-only group. These observations were 
localized to obstructed kidney only.  
7) High dose (12.5mg/kg) administration of ASO 1 or ASO 2 in a 16-days rat 
model of UUO resulted in a reduction in Ha-Ras mRNA by 40% and 41% 
respectively when compared to vehicle-only treated group.  
8) High dose (12.5mg/kg) administration of CO 2 in a 16-day rat model of 
UUO resulted in pan-Ras mRNA knockdown. These changes were 
localized to the obstructed kidney only.  
9) High dose (12.5mg/kg) administration of SO 1 and SO 2 in a 16-day rat 
model of UUO resulted in an increase in both Ki- and N-Ras mRNA 
expression in obstructed kidneys in comparison to vehicle-only group. 
There was no difference in Ha-Ras mRNA expression.  
10) A contemporaneous in vivo experiment demonstrated significant 
knockdown of Ki-Ras mRNA in obstructed kidneys on administration of 
ASO 1 and ASO 2 compared to SO 2. There was no difference between 
these groups or with vehicle-only group with regards to N- or Ha-Ras 
mRNA expression.  
11) Analysis of pooled data from in vivo experiments demonstrated that 
administration of high dose (12.5mg/kg) administration of ASO 1 and 
ASO 2 in a 16-days rat model of UUO resulted in significant and specific 
knockdown of Ki-Ras mRNA in obstructed kidneys compared to both 
vehicle-only and sister scrambled oligo control groups. There was no 
significant difference in N-Ras expression upon ASO administration when 
compared to vehicle-only. ASO administration was associated with a 




Low dose (5mg/kg) administration of Ki-Ras ASO 
Initially low dose Ki-Ras ASO 1 was administered at 5mg/kg on alternate days 
subcutaneously over a 12-day period in models of UUO. The choice of this dose arose 
from discussions with ISIS Pharmaceuticals and from preliminary work performed by 
Dr Helen Clarke from our group (unpublished) as part of her doctorate thesis. Dr 
Clarke had administered a Ki-Ras ASO at a dose of 5mg/kg intravenously in a rat 
model of UUO and was able to demonstrate a decrease in parameters of fibrosis. For 
this experiment, Ki-Ras ASO 2, which appears more potent in in vitro studies, was 
omitted due to a lack of availability at the time of the experiment. Semi-quantitative 
PCR analysis failed to identify any significant difference in Ras isoform expression 
between ASO 1 and saline-control groups and this is believed to be due to reasons 
previously mentioned (see Chapter 4).  Subsequent QPCR showed that there was a 
significant decrease of 18% in Ki-Ras mRNA expression in the ASO 1 treated group 
and an associated rise in N-Ras mRNA expression of 290% when compared to saline-
control group. Due to a lack of a control oligo group, one cannot exclude the fact that 
administration of an oligo per se had caused the observed changes in Ras mRNA 
levels. Though the knock down effect on Ki-Ras mRNA expression at this dose was 
statistically significant, in absolute terms the reduction may be insufficient to have 
effects clinically. Indeed Ras protein analysis by western blotting showed no 
significant difference in Ki-Ras protein levels between ASO 1 and saline-control 
groups. In fact there was a trend towards a decrease in N-Ras and pan-Ras protein 
levels in the ASO 1 group. The results from SDS PAGE and protein analysis are 
paradoxical to those that would be expected from mRNA analysis from QPCR. The 
previously mentioned difficulties with Ras protein retrieval and analysis (see Chapter 
4) may explain the apparent incongruous results between QPCR and western blotting. 
It was decided at this stage that future western blotting for Ras isoforms would be 
difficult to interpret in the absence of highly specific antibodies and the focus of the 
project should be on mRNA expression and histological end-points. 
Fibrosis scores by PMT and picrosirius red staining demonstrated an increased degree 
of fibrosis in the ASO 1 group. However when the absolute values are looked at, it 
can be seen that there is only a difference in fibrosis of 3% by PMT staining and 16% 
by picrosirius red staining, neither of which may be clinically significant. Maximum 
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fibrosis by any method of staining was 40%, which is surprisingly lower than 
expected for the duration of experiment (12-days). Thus, though the differences in 
fibrosis scores between the ASO 1 and saline-control groups can be seen to be 
statistically significant, with regards to absolute fibrosis the differences may be 
viewed as ‘clinically’ insignificant. This idea is supported by the lack of difference in 
!SMA expression between groups. From previous experiments and literature one 
would expect a greater degree of fibrosis and myofibroblastic activity (as reflected by 
!SMA expression) at this time point of obstruction. From the results of this 
preliminary low-dose (5mg/kg) ASO experiment it was felt that the following changes 
should be made to subsequent in vivo experiments: 
1) A more active fibrotic model be employed by extending length of experiment 
time from 12 to 16 days and using a double tie for obstruction. 
2) Increasing the total dose of ASO to be administered from 30mg/kg to 
100mg/kg. This decision was made following discussions with ISIS 
Pharmaceuticals who suggested a three-fold increase in dosage.  
3) Using a control oligo to isolate effects of targeting Ki-Ras as opposed to those 
effects associated to the administration of an oligo per se. 
4) Employing additional histological analysis parameters including those of 
fibrosis, proliferation and inflammation. 
 
High dose (12.5mg/kg) administration of Ki-Ras ASO 
QPCR analysis of Ras isoform expression in this series of experiments confirmed that 
Ki-ras mRNA expression was upregulated by 84% within the obstructed kidney with 
levels within the non-obstructed contralateral kidney being equivalent to that of sham-
operated kidney. N-Ras mRNA expression was also noted to increase by 87% while 
Ha-Ras expression did not significantly alter from sham-operated kidneys. These 
results are consistent with those obtained in characterizing the model of UUO (see 
Chapter 4). 
In Experiment II, following administration of 12.5mg/kg Ki-Ras ASOs, using an anti-
oligo antibody provided by ISIS Pharmaceuticals, it was demonstrated that ASO 
clearly deposits within the renal cortex. Though there is significant accumulation 
within the proximal tubules, as is seen with non-obstructed kidneys (see Chapter 3) 
there also appears to be a significant degree of deposition within the interstitium of 
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the obstructed kidney when compared to the non-obstructed kidney. It is unclear 
whether this increased deposition within this renal compartment has arisen from trans- 
or paracelluar transport of the oligos following glomerular filtration or as a result of 
drug delivery via renal capillaries on the background of renal injury and 
inflammation. It is also not clear whether the deposition within the interstitium lies 
within the matrix only or if the oligos have been taken up by specific cell types, 
though the likelihood is that both has occurred. However there appears to be overall a 
much higher degree of ASO accumulation within the obstructed kidney compared to 
the non-obstructed. It may be that in the obstructed kidney, the active tubular cell 
uptake and decreased clearance of oligos results in an increase in oligo deposition 
within the cortex. Administration of both ASO 1 and 2 resulted in knockdown of Ki-
Ras mRNA expression within the obstructed kidneys from the UUO upregulated state 
to a level comparable with normal sham-operated kidneys. Previous in vitro and in 
vivo experiments have revealed poor knock down effect by ASO 1 (see Chapter 3) 
but in this model of UUO, ASO 1 had a knockdown efficiency comparable to ASO 2. 
This may reflect the increased deposition and accumulation of ASO 1 within the 
obstructed kidney by aforementioned processes that leads to a greater degree of RNA 
hybridization and inhibitory effect. Ki-Ras mRNA expression was observed to be 
down-regulated in the contralateral non-obstructed kidneys of ASO treated models of 
UUO. The degree of knockdown is in keeping with previous results obtained with 
knockdown of Ki-Ras mRNA (12% by ASO 1, 66% by ASO 2) observed in non-
obstructed kidneys (see Chapter 3) and reflects true systemic effects of Ki-Ras ASOs 
following subcutaneous administration. There was a significant increase in N-Ras 
mRNA expression in obstructed kidneys following administration of ASO 2 that was 
absent on treatment with ASO 1. This difference was localized to the obstructed 
kidneys of ASO 2 group, with no significant difference in the expression of N-Ras 
mRNA within contralateral kidneys of all UUO groups. It was postulated whether the 
change in N-Ras expression was associated with Ki-Ras knockdown, either as a 
compensatory upregulation in presence of Ki-Ras knockdown or possibly 
representing a mechanism by which Ki-Ras induced suppression of N-Ras expression 
is removed. Another explanation may be that the compensatory rise in N-Ras 
observed with administration of ASO 1 and 2 may actually be involved in a protective 
cell-signaling pathway in a response to profibrotic process of obstruction. However 
when examining data, it appears unlikely that the change in N-Ras expression is 
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directly linked to Ki-Ras expression. Firstly when low-dose (5mg/kg) results are 
reviewed one can observe a significant increase in N-Ras expression (176%) in the 
absence of a significant Ki-Ras knockdown (only 18%). In this experiment, 
Experiment II, the degree of Ki-Ras knock down in ASO 1 group was comparable to 
that seen in ASO 2 but there was an absence of an increase in N-Ras mRNA 
expression in the former. Furthermore the experiments validating scrambled oligos 
SO 1 and SO 2 (Experiment III) demonstrated both a significant rise in Ki-ras mRNA 
expression upon administration of scrambled oligos with an associated rise in N-Ras 
mRNA expression.  This suggests that the rise in N-Ras is independent of Ki-Ras 
mRNA knockdown, either as a compensatory or non-suppressed response. From the 
characterization of the UUO model, a rise in N-Ras was noted which may represent 
an inflammatory infiltration with cells that predominantly express N-Ras. The 
subsequent further increase in this isoform upon administration of ASO 2 is likely to 
represent further increase in inflammatory infiltration and may represent a pro-
inflammatory nature of ASO 2. 
Ha-Ras mRNA expression was also decreased upon administration of both ASO 1 
and ASO 2 by 40% and 41% respectively. Again these changes are mainly localized 
to the obstructed kidney and are inconsistent with previous experiments. In vitro 
experiments employing cell lines demonstrated a rise in Ha-Ras expression (NRK-
49F) or no significant difference (NRK-52E) following ASO transfection when 
compared to vehicle-only group (see Chapter 3). In vivo experiments involving ASO 
administration in both non-obstructed (see Chapter 3) and obstructed (5mg/kg) 
models also both failed to demonstrate a difference in Ha-Ras mRNA expression on 
administration of ASOs when compared to vehicle-only groups. In addition, the 
contemporaneous experiment involving SO 2 and ASOs in this chapter (Experiment 
IV) also failed to demonstrate a significant difference in Ha-Ras mRNA expression. 
Previous validation of the Ki-Ras ASOs has shown that there is high specificity and 
effect of action with no obvious, significant direct targeting of other isoforms of Ras.  
From the above-mentioned experimental results and the fact that 20mer oligos, which 
are highly specific, were employed and the lack of Ha-Ras reduction in contralateral 
kidneys of ASO groups, it can be assumed that Ki-Ras ASOs do not target Ha-Ras via 
an antisense mechanism, be it full or partial complementary. This issue highlights the 
limitations of in vitro experiments compared to in vivo. In the latter situation there are 
a multitude of cells involved organ maintenance and function and the administration 
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of oligos in such an environment may stimulate changes (such as inflammation, cell 
infiltration or EMT) within both a non-diseased and a diseased model. This may result 
in a relative lower level of Ha-Ras mRNA expression within the total kidney samples 
analysed. Another possibility is that the observed knockdown of Ha-Ras may 
represent non-hybridization effects in association with increasing ASO levels in an 
environment of poor ASO clearance, in a way that ASO 1 has increased potency in 
UUO. There is now good evidence that oligos may interact with proteins themselves 
and affect their expression directly via an aptameric effect [Bennett et al. 2010]. From 
this series of experiments it is not possible to say if the observed result of Ha-Ras 
reduction in this case reflects the accumulation of ASO in an obstructed kidney or is 
an artefact, nor what the clinical significance of this observation is. 
The results of Ras expression in the CO 2 group were highly inconsistent with 
previous experiments. In this experiment, CO 2 administration resulted in a reduction 
of all Ras isoforms. This observation was localized to the obstructed kidney only with 
Ras mRNA expression in the contralateral kidney of CO 2 treated models being 
comparable to sham. Previous interrogation of the CO 2 oligo sequence did not reveal 
any recognized target within the rat. Furthermore, this oligo has previously been used 
as a control in both in vitro experiments employing renal epithelial cells (NRK-52E) 
and in vivo in non-obstructed rat models (see Chapter 3). In both cases there was no 
observable knockdown or up-regulation in any of the Ras isoforms on administration 
of CO 2. The generalized, non-specific Ras knockdown effects seen in this group 
suggests that the results are not particular to the ‘oligo sequence’ but may reflect a 
cellular response to CO 2 per se. Whereas obstruction appeared to increase ASO 1 
potency to enable Ki-Ras mRNA knock down of 4-fold greater than that observed in 
non-obstructed models, it may be that the same mechanism has resulted in CO 2 
becoming cell toxic. It is possible that CO 2, on the background of increased levels, 
may suppress mRNA expression of a number of proteins including Ras, but only Ras 
was examined in this project. In this way CO 2 may also have significant aptameric 
effects at high concentration. The argument that CO 2 does not cause a ‘true’ specific 
Ras knockdown is further supported by the absence of Ras knockdown in the 
contralateral kidneys of CO 2 group compared to UUO-VO thus excluding a systemic 
antisense effect that is demonstrated by Ki-Ras ASO administration. In summary it is 
postulated that the pan-Ras knockdown resulting from CO 2 administration reflects 
accumulation of the oligo in an environment of decreased clearance secondary to 
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obstruction leading to non-specific effects by a non-antisense mechanism of action on 
Ras (and possibly other proteins) related to the base constituency of CO 2. 
In order to dissect the effects of Ki-Ras ASOs administration from the effects of oligo 
administration per se two new oligos were requested from ISIS Pharmaceuticals. To 
allow for more specific examination of Ki-Ras knockdown effects of ASOs, theses 
new control oligos were ‘scrambles’ of the active ASO’s: SO 1 being a scramble of 
ASO 1 and SO 2 a scramble of ASO 2. Being scrambles of the ASOs, these oligos are 
made up of identical base composition with an aim to remove the artefactual/ toxic 
effects observed with CO 2 administration and effects that may result from different 
base sequence binding. The scrambled oligos have no known target in the rat and 
were subsequently used as controls in two separate in vivo experiments: 1) the 
contemporaneous administration of SO 1 and SO 2 into UUO models for validation of 
these oligos as controls (Experiment III) and 2) a contemporaneous experiment of 
administration of vehicle, SO 2, ASO 1 and ASO 2 in UUO models (Experiment IV). 
Due to a lack of sufficient amounts of SO 1, this oligo was omitted from the latter 
experiment. Administration of scrambled controls in a model UUO led to an observed 
rise in both Ki- and N-Ras mRNA expression in the obstructed kidneys when 
compared to vehicle-only samples. There was no difference in Ha-Ras mRNA levels 
between vehicle-only and scrambled oligo groups. The rise in the expression of N-Ras 
in the presence of a concurrent rise in Ki-Ras mRNA upon administration of an oligo 
suggests that the increase in N-Ras is secondary to oligo presence per se and not a 
result of effects of Ki-Ras expression. An increase in N-Ras mRNA following Ki-Ras 
ASO administration has been previously observed both in vitro and in vivo (see 
Chapter 3). 
 
Analysis of tissue from Experiment IV showed that there was no knockdown of any 
Ras isoform following administration of SO 2 when compared to UUO-VO, while 
administration of ASO 1 and 2 led to specific knock down of Ki-Ras mRNA 
expression consistent with results obtained both in vitro and in vivo in non-obstructed 
animal models (Chapter 3).  
Ideally to obtain a true picture of effect of ASO and scrambled oligos, a 
contemporaneous ‘master’ experiment consisting of groups of at least eight animals 
treated as follows- sham, UUO vehicle-only, CO 2, SO 1, SO 2, ASO 1 and ASO 2- 
would need to be undertaken. Due to the logistics of such a large experiment, lack of 
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reagents, time constraints and respect for 3R’s of animal experimentation this 
‘master’ experiment was not possible in this project. However since all experimental 
conditions were consistent (apart from oligos administered) with operations and tissue 
analysis performed by a single operator using data that consisted of internal controls, 
it was felt that the pooling of data from experiments performed at different time 
points to obtain an overall picture of the effects of oligo was justified. Raw QPCR 
data obtained from the above contemporaneous experiment was combined with raw 
QPCR data from previous individual experiments involving administration of SO 1 
and SO 2 in addition to vehicle-only and ASO administration experiments. To assess 
if the mean data from these different time points were statistically different the delta 
Ct values for Ki-Ras from vehicle-only and SO 2 groups from Experiment IV were 
compared to those obtained from previous vehicle-only and SO 2 experiments. T-tests 
between paired results showed that there was no significant difference between the 
mean delta Ct values for the identical experiments performed at different time points. 
From this combined data, there was no difference in mRNA expression in any of the 
isoforms of Ras was seen following administration of either SO 1 or SO 2. Treatment 
with ASO 1 and ASO 2 significantly reduced Ki-Ras mRNA expression with the 
latter reducing expression by 97%. Though a rise in N-Ras in ASO groups had 
previously been noted, on this combined analysis there was no statistically significant 
change in either N- or Ha-Ras mRNA levels in either of the ASO groups compared to 
vehicle-only. This may reflect the removal of the effect of outliers by including a far 
higher number of analyses in each group by pooling of data. In summary, from this 
pooled data, the administration of scrambled oligos did not result in any reduction in 
mRNA of any isoform of Ras while administration of ASO 1 and 2 both specifically 
and significantly reduced Ki-Ras mRNA expression in comparison to both vehicle-
only and scrambled oligo control groups. 
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Chapter 6: Administration of Ki-Ras antisense 
oligonucleotides to a rat model of unilateral 
ureteric obstruction: Assessment of fibrosis & 
molecular biomarkers 
 
6.1 Effects of Ki-Ras antisense oligonucleotides 
administration in vivo on weight gain 
Ras is a significant molecule in the signaling pathway for cell proliferation, thus there 
was concern that inhibition of this molecule may be associated with systemic effects. 
The higher dose of ASO (12.5 mg/kg) did not obviously affect animals phenotypically 
or with regards to gross behaviour. Models in the ASO groups gained weight in a 










The effects of Ki-Ras knockdown upon renal fibrogenesis was investigated by 1) the 
analysis of tissue samples stained by special stains and 2) immunohistological 
techniques for fibrosis and 3) markers of fibrogenesis and inflammation including 
!SMA, FSP-1 and CD68 (ED1). Although experiments providing tissue were not 
completed at identical time points, all staining was contemporaneous.  These sections 











Figure 6.1: Weight chart for control and ASO groups over 16-days duration 
of Experiment IV. !
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using a computer imaging software package (Nikon Elements BR package). All slides 
were scored in a blinded fashion. 
 
6.2 Effects of Ki-Ras antisense oligonucleotides 
administration in vivo on renal fibrosis  
Despite accurate assessment of parenchymal fibrosis being one of the most important 
parameters of evaluation of chronic kidney injury, definitions and methods of 
assessment of fibrosis in the clinical setting vary considerably and consistency 
between assessors is often difficult to achieve. The main stains used for analysis of 
degree of fibrosis in this project were picromallory trichrome (PMT) and picrosirius 
red (PSR). For PMT, areas of fibrosis would stain blue, while in picrosirius red 
collagen fibres would appear red. In addition, for PSR staining, under cross-polarized 
light, areas of fibrosis (characterized by excessive collagen type I and III deposition) 
would appear orange or red. However formal scoring for PSR slides undertaken by a 
consultant histopathologist was completed under bright-light to avoid inconsistencies 
with inadequate settings for cross-polarized light. 
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Figure 6.2: Representative sections of obstructed kidneys treated with control 
oligos (CO 2 & SO 2) and ASO 2 stained by PMT. Areas of fibrosis appear blue. 
(Sham and SO 2 x10, CO 2 and ASO x 20). Note interstitial inflammatory infiltration 
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Figure 6.3: Representative sections of obstructed kidneys treated with CO 2, SO 
2 and ASO 2 stained by picrosirius red viewed under cross-polarized light [x20]. 
Collagen type III and I appear orange. Fibronectin appears green. Note normal 






















Figure 6.4: Fibrosis score of renal cortex based on (A) PMT and (B) picrosirius 
red staining (both assessed under bright-light). 
 
Staining by both PMT and PSR showed a significant increase in fibrosis score from a 
background of 4% in sham kidneys to 57% on UUO-VO sections by PMT and 62% 
by picrosirius red. Fibrosis scores in CO 2 treated group were comparable to UUO-
VO treated group with scores of 78% and 52% based on PMT and PSR respectively. 
Treatment with ASO 1 and 2 significantly reduced the amount of fibrosis present on 
PMT staining to 13% and 15% and on picrosirius red to 21% and 26% respectively. 
Thus administration of Ki-Ras antisense reduced fibrosis scores to levels near 
comparable with sham-operated kidneys. However PMT and PSR staining of tissue 
from SO groups produced incongruous results depending on stain used. 
Administration of SO 2 appeared to reduce fibrosis score on PMT staining to 21%, 
but on PSR staining there was a fibrosis score in this group comparable to UUO-VO. 
In contrast, fibrosis score on PMT following administration of SO 1 was comparable 
to UUO-VO treated group, but on assessment by PSR staining appeared to reduce 
fibrosis score to 35%. In summary, there appears to be discrepancies in fibrosis score 
following administration of scrambled oligos depending on staining methods 
employed and validates our use of two staining methods for assessment of overall 
fibrosis. Despite these inconsistencies in fibrosis scores seen with scrambled oligos, 
















































































fibrosis on both methods of histological fibrosis assessment. However in order to 
obtain an overall view of effects of oligo administration on fibrosis, the data obtained 
from both PMT and PSR scoring was combined for each sample and the mean value 














Figure 6.5: Combined fibrosis score of renal cortex based on mean of PMT and 
picrosirius staining scores. Both ASOs significantly reduced fibrosis in comparison 
to sister scrambled oligo administration in models of UUO. Each point represents one 
animal. 
 
Combined PMT and PSR scores demonstrated an increase in fibrosis score of over 
ten-fold following ureteric obstruction (UUO-VO) compared to sham (62% vs. 6%). 
Administration of CO 2 did not significantly change the fibrosis score (67%) 
compared to UUO-VO. However administration of SO 1 and 2 resulted in a 
significant reduction of fibrosis score to 40% and 37% respectively when compared to 
UUO-VO treated group. These scrambled oligos have previously been shown to have 
no active target in the rat or to target any of the Ras isoforms (see Chapter 5). Despite 
this observed reduction in fibrosis score following administration of SOs, the 
administration of ASO 1 and 2 consistently resulted in a significant further reduction 
in the combined fibrosis score when compared to scrambled oligo groups with ASO 1 
further reducing fibrosis score by 56% in relation to SO 1 (p<0.01) and ASO 2 















































6.3 Effects of Ki-Ras antisense oligonucleotides 
administration in vivo on collagen deposition  
Collagen type I has been shown to be the collagen isoform which has the greatest 




Figure 6.6: Representative sections of obstructed kidneys treated with control 
oligo and ASO 2 immunohistologically stained for Collagen I. Interstitial collagen 
I expression is represented by DAB-peroxidase staining which appears brown. 














Collagen I expression in the interstitium increased from a background of 9% in sham-
operated kidneys to 50% in UUO-VO kidneys. Administration of CO 2 did not 
significantly alter expression (40%) compared to UUO vehicle-only group. Collagen I 
expression was seen to decrease by up to 58% in ASO treated groups in comparison 
to CO 2 group to 18% (ASO 1) and 17% (ASO 2).  
 
6.4 Effects of Ki-Ras antisense oligonucleotides 
administration in vivo on FSP-1 expression  
To assess the effects of Ki-Ras knockdown on fibroblast expression, renal tissue was 
stained for fibroblast specific protein-1 (FSP-1 or S100A4 protein). Cells labeled by 
the FSP-1 antibody display nuclear, cytoplasmic and membrane staining and in 
normal tissues the cells positively labeled by the antibody include fibroblasts, T-
lymphocytes, plasma cells, macrophages and Kupffer cells (DAKO A5114 
datasheet)(Le Hir, Hegyi et al. 2005). Following staining, sections were scored for 
FSP-1 expression. Due to discrete nature of cellular staining, assessment could be 
divided into glomerular, tubular and interstitial compartments. The results are the 
mean of 10 views per section at a magnification of x 40. 
Figure 6.7: Collagen I 
expression score of renal 
cortex based on intensity & 
percentage area of staining 
of section in sham, vehicle-


































Figure 6.8: FSP-1 staining of kidney tissue from sham and UUO models treated 
by vehicle-only, scrambled oligos and ASOs. FSP-1 positive cells appear brown. 


















The administration of oligonucleotides, either scrambled or antisense, did not affect 
FSP-1 glomerular or tubular cell expression in comparison to vehicle-only treated 
renal samples. There were very few positive FSP-1 cells in the interstitium of sham 
samples as expected. Obstruction led to a seven-fold increase in interstitial FSP-1 
expression compared to sham-operated kidneys and there was no change in 
expression following administration of SO 1 or 2. However administration of ASO 1 
and 2 resulted in a trend towards increased FSP-1 interstitial expression in 
comparison to SO treated groups, though this was only statistically significant in ASO 
1 treated group when compared to scrambled oligos where numbers of FSP-1 positive 
cells doubled. 
 
Figure 6.9: FSP-1 positive cells 
counts compartmentalized into 























































































































6.5 Effects of Ki-Ras antisense oligonucleotides 




























Figure 6.10: Representative sections of obstructed kidneys treated with CO 2, 
scrambled oligos and ASO 2 and stained for !SMA expression [x10]. Note peri-
vascular staining in ASO 2 section comparable to sham but complete absence of 
interstitial expression. 



















Figure 6.11: !SMA expression score of renal cortex based on intensity & 
percentage area of staining of section relative to sham kidneys. 
!-smooth muscle actin is widely accepted to be a marker of myofibroblastic activity 
and expression is seen to correlate to degree of matrix deposition. Renal sections were 
stained for this protein (Figure 6.10). 
 
Staining for !SMA showed an eight-fold increase in expression in UUO-VO 
compared to sham-operated kidneys. Administration of CO 2 doubled interstitial 
expression of !SMA. Scrambled oligo groups demonstrated a degree of !SMA 
expression comparable to UUO-VO with !SMA expression being nine-fold higher in 
SO 1 group and eight-fold higher in SO 2 group compared to sham-operated kidneys. 
Administration of ASOs led to a significant decrease in !SMA expression in 
comparison to both vehicle-only, control and scrambled oligo (CO 2, SO 1, SO 2) 
groups with ASO 2 reducing expression by three-fold compared to UUO-VO and 
ASO 1 reducing !SMA expression within obstructed kidneys to a level comparable 
with sham-operated kidneys. Samples were also examined for !SMA protein 
expression by western blotting using GAPDH as a loading control. The following 
blots are representative of at least three separate experiments using three samples 
from both sham-operated and UUO vehicle-only treated groups and five samples from 
































































Figure 6.12: Western blots demonstrating !SMA and GAPDH expression for 
various oligo treated UUO groups. Note significant decrease in band density for 
















































































Western blotting demonstrated that UUO-VO samples have a five-fold increase in 
!SMA expression relative to sham-operated kidneys. The administration of 
scrambled oligos does not reduce !SMA expression relative to UUO-VO group. 
However the administration of ASO 1 and ASO 2 reduced !SMA expression by 43% 
and 83% relative to their sister scrambled oligos. The administration of ASO 2 
reduced protein expression of !SMA in obstructed kidneys to a level comparable with 
sham-operated kidneys. 
 
6.6 Effects of Ki-Ras antisense oligonucleotides 
administration in vivo on Ki-67 expression 
Ras monomeric GTPase is a well-recognized pivotal molecule involved in the process 
of cellular proliferation, therefore it was postulated that the use of ASOs to down-
regulate Ras mRNA expression may potentially affect proliferation. Ki-67 is a cell 
proliferation marker that is expressed in the nucleus by cells in the active phases of 
the cell cycle (G1, S, G2 and M phases) but is absent in resting cells (G0). Renal 
sections were stained for Ki-67 and expression was subsequently compartmentalized 
into glomerular, tubular and interstitial areas. 10 views per section were scored to 






Figure 6.14: Ki-67 expression in renal cortex in Sham and Control Oligo, 
Scramble Oligo and ASO treated UUO kidney (x 20 and inset x 40) 
Sham UUO 
VO 
CO 2 SO 1 





























Following kidney obstruction there was no significant change in Ki-67 expression 
within the glomeruli but there was a significant increase in tubular and interstitial 
expression when compared to sham-operated groups. Administration of either CO 2, 
scrambled oligos did not alter glomeruli expression compared to UUO-VO group but 
ASOs administration resulted in an increase in expression within this compartment, 
though in absolute terms this was an increase of only 1 cell/view. Administration of 
an oligo per se (CO 2, scrambled or antisense) did result in decreased tubular cell 
Figure 6.15: Ki-67 expression 
compartmentalised into 
glomerular, tubular and 































































































































































expression by a mean of 42% compared to UUO-VO. Administration of CO 2 did not 
affect interstitial Ki-67 expression compared to vehicle-only treated group, but the 
administration of either scrambled or antisense oligos resulted in an increase of 
expression of interstitial Ki-67 by about 3-fold when compared to UUO-VO or CO 2. 
 
6.7 Effects of Ki-Ras antisense oligonucleotides 
administration in vivo on monocyte infiltration 
On analysis of sections for fibrosis it was noted that some sections, in particular those 
from ASO treated groups, had significantly more pronounced inflammatory 
infiltration of the interstitium. 
 
 
Figure 6.16: PMT staining of obstructed kidneys showing decreased fibrosis in 
ASO treated section but also increased interstitial inflammatory cell infiltration. 
 
Following this observation, sections were subsequently stained for CD 68, recognised 
by ED-1 antibody. ED-1 antigen is expressed by the majority of tissue macrophages 
and weakly by peripheral blood granulocytes. Positive staining by ED-1 antibody was 
scored using Nikon Elements BR software package on x20 magnification based on 5 















Figure 6.17: Representative 
sections sham and obstructed 
kidneys from vehicle-only and 
























Figure 6.18: Interstitial ED-1 staining of sham and obstructed kidneys from non-
treated and oligo treated models.  
 
Staining for tissue macrophages showed they were in scarce number (1%) in sham-
operated, non-obstructed kidneys. Numbers doubled to 2.4% on obstruction. 
Administration of CO 2 led to further increase in expression to 5.5%. However the 
administration of either scrambled or antisense oligonucleotides resulted in a 
significant increase in macrophage tissue infiltration peaking in the ASO 2 treated 














































6.8 Summary of results of administration Ki-Ras ASO in a 
model of UUO: Endpoint analysis 
 
1) Administration of oligos did not appear to grossly affect either behaviour 
or weight gain of animal models compared to vehicle-only treated group. 
2) Ureteric obstruction resulted in an increase of combined mean fibrosis 
score by 62% which is consistent with previous results.  
3) There was no significant difference in combined mean fibrosis score on 
administration of CO 2 when compared to UUO-VO (67% v 62%). 
4) Administration of SO 1 and SO 2 reduced combined mean fibrosis score 
by 35% and 40% respectively compared to UUO-VO. 
5) Administration of ASO 1 and ASO 2 reduced combined mean fibrosis 
score by 73% and 68% compared to UUO-VO. 
6) Administration of ASO 1 and ASO 2 reduced combined mean fibrosis 
score by 56% and 46% compared to sister scrambled oligo groups SO 1 
and SO 2 respectively. 
7) Administration of ASO 1 and ASO 2 significantly reduced Collagen I 
expression by 58% compared to CO 2 group.  
8) There was no significant difference in glomerular or tubular FSP-1 
expression between UUO-VO, scrambled oligos or ASO groups.  
9) There was an increase in interstitial FSP-1 expression in UUO-VO group 
compared to sham-operated kidney group but no difference between SO 
treated groups compared to UUO-VO.  
10) Administration of ASOs resulted in a trend towards increase in interstitial 
FSP-1 expression compared to scrambled oligo treated groups. 
11)  Ureteric obstruction led to an increase in !SMA expression in UUO-VO 
compared to sham-operated group based on immunohistology. There was 
no significant difference in expression on administration of SO 1 or SO 2 
compared to UUO-VO.  
12)  Administration of ASO 1 and ASO 2 significantly reduced !SMA cortical 
expression compared to UUO-VO and sister SO treated groups based on 
immunohistology. ASO 1 group reduced renal cortical !SMA expression 
score to a level comparable to sham-operated group. 
! #+$!
13)  Ureteric obstruction resulted in a significant increase in !SMA protein 
expression compared to sham-operated group based on western blotting. 
There was no significant difference in !SMA expression between UUO-
VO and SO 1 and SO 2 groups.  
14)  Administration of ASO 1 and ASO 2 reduced !SMA protein expression 
compared to sister SO groups based on western blotting. ASO 2 reduced 
!SMA expression to levels comparable with sham-operated kidneys. 
15)  There was no significant difference in Ki-67 glomerular expression 
between sham-operated, UUO-VO and scrambled oligo treated groups. 
Administration of ASO 1 and ASO 2 resulted in an increase in glomerular 
Ki-67 expression when compared to their sister scrambled oligo treated.  
16)  Ureteric obstruction led to a significant increase in tubular Ki-67 
expression. There was a decrease in Ki-67 tubular expression in all oligo 
(CO 2, SOs or ASOs) treated groups when compared to UUO-VO.  
17)  There was an increase in interstitial Ki-67 expression following ureteric 
obstruction. Though administration of CO 2 did not alter interstitial 
expression compared to UUO-VO, administration of SO 1, SO 2, ASO 1 
or ASO 2 resulted in a significant increase in interstitial Ki-67 expression. 
18)  There was no significant difference in ED-1 staining score between UUO-
VO or CO 2 groups. There was a significant increase in ED-1 staining on 






Ras is a ubiquitous cell molecule and plays a central role in cell proliferation, thus it 
was of a concern that the systemic administration of an ASO targeting Ki-Ras may 
result in significant decrease in cellular proliferation and significant clinical side 
effects. However following administration of oligos, animals gained weight at an 
identical rate and were of an identical endpoint mass compared to vehicle-only treated 
models. There were no observable significant differences either in macroscopic 
appearance or general behaviour in oligo treated models though neither parameter was 
formally assessed. The stains chosen for assessment for interstitial fibrosis were 
picromallory trichrome and picrosirius red. Trichrome staining is a widely used 
staining method in clinical medicine especially in the assessment of degree of fibrosis 
in renal biopsies in the clinical setting mainly due to the distinctive degree of staining 
of fibrotic areas. Picrosirius red was employed for the stains targeting of collagen 
fibres in particular collagen type I and III. A further advantage was the unique 
red/orange appearance of stained fibres under cross-polarized light allowing for better 
differentiation of collagen from background. One publication (Farris, Adams et al. 
2011) compared different staining methods and techniques with regards to assessment 
of renal fibrosis and concluded that, when considering efficiency, reproducibility and  
best correlation with estimated GFR the best current techniques include visual 
assessment of trichrome-stained slides and morphometric assessment of unpolarized 
picrosirius red stains. In comparison to sham-operated models there was a significant 
increase in fibrosis score following ureteric obstruction as measured both on PMT and 
PSR staining and these results were comparable to those previously seen (see Chapter 
4). Administration of CO 2 did not result in any significant change in fibrosis score as 
compared to vehicle-only treated group despite pan-Ras mRNA knockdown. 
Administration of scrambled oligos resulted in a significant discrepancy in fibrosis 
score depending on staining method, that is either PMT or picrosirius red, used to 
assess fibrosis. For fibrosis score based on PMT, there was no significant difference 
for SO 1 treated group when compared to UUO-VO but there appeared a significant 
reduction in fibrosis on administration of SO 2. However, when picrosirius red 
staining was used to assess fibrosis, the reverse was seen with SO 1 administration 
significantly reducing degree of fibrosis compared to UUO-VO whereas fibrosis score 
in SO 2 group was comparable to vehicle-only treated group. This observed 
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inconsistency in scoring based upon staining method is thought to be due to different 
degrees of oedema within the tissue and uptake of stains thus highlighting the degree 
to which tissue response to different oligos, timing of retrieval and treatment post-
harvesting may affect degree of staining. Other factors include animal batch, antigen 
retrieval, fixation time and stain penetration. Since quantification of fibrosis is not 
standardized and there is no widely accepted method of assessment, in order to 
overcome variables such as oedema, it is preferable to have an objective assessment 
by a single expert observer rather than a software-based model of measurement. This 
allows assessment of staining based on intensity, area and distribution allowing for 
more accurate exclusion of non-specific staining as opposed to assessment on colour 
difference alone. The inconsistency seen with the fibrosis scores in this project 
validates the decision to use two different methods to assess the degree of fibrosis 
within tissue samples. In order to obtain a more robust reflection of degree of fibrosis 
between treated groups, the fibrosis scores achieved by PMT and PSR were combined 
to provide an overall ‘combined mean fibrosis score’. Results showed that there was a 
significant increase in fibrosis score following ureteric obstruction from 6% (sham) to 
62% (UUO-VO) and that CO 2 administration did not significantly change this score. 
Administration of both SO 1 and SO 2 appeared to reduce fibrosis scores by about 
20% though it is uncertain how true this knockdown in fibrosis score really is in the 
absence of a true contemporaneous experiment. Ideally to remove all confounders, a 
‘master’ experiment would need to be performed using identical animal batches with 
all ureteric obstruction and treatments performed at exactly the same time points and 
identical harvest and fixation times with same-day sectioning and staining. This was 
logistically impossible in the scope of this project. There was an insufficient amount 
of reagents, the limit of time constraints and only a single operator. Additionally a 
large repeated experiment could not be justified with respect to the 3 ‘R’s 
(replacement, reduction and refinement) of in vivo work. Thus groups compared were 
from different time points and may have varied to a degree with regards to animal 
batch and tissue treatment and staining post-harvest that may lead to a degree of 
discrepancies in results as seen in SO groups, however all experiments were 
performed by a single operator using an identical protocol with scoring performed as 
much as possible by a single assessor for each parameter with an aim to ensure results 
were as consistent and reproducible as possible. 
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Despite the discrepancy between stains observed with administration of scrambled 
oligos, it was demonstrated that administration of either ASO 1 or 2 consistently 
halved the fibrosis score when compared to either SO group on both PMT and PSR 
staining. The consistent reduction in fibrosis score on administration of Ki-Ras ASO 
in comparison to scrambled oligo groups independent of staining method implies that 
active Ki-Ras knockdown, not just oligo per se, administration, contributes to 
decreased end-point fibrosis scores. 
Interstitial collagen I expression was also seen to increase following ureteric 
obstruction as expected. CO 2 administration did not significantly alter the 
expression. Administration of ASO 1 or ASO 2 both significantly reduced collagen I 
expression.  Again this suggests the active knockdown of Ki-Ras mRNA expression 
and not the presence of an oligo per se has an active role in reducing collagen 
deposition within the interstitium in a model of UUO. The attempts to stain samples 
from the scrambled oligo groups using our protocol employing a collagen I polyclonal 
antibody proved to be more inconsistent and less successful and may in part reflect 
the difference in the nature of the renal tissue that has been eluded to in the above 
discussion regarding PMT and picrosirius red staining. 
To determine if the ASOs had an effect on fibroblast numbers, sections were stained 
for FSP-1 and compartmentalized into glomerular, tubular and interstitial expression. 
Ureteric obstruction led to an increase in both interstitial and tubular expression of 
FSP-1, though in the case of the latter, in terms of absolute numbers this was an 
increase of only 1 cell/view. Though the expression of interstitial FSP-1 was similar 
in SO 1 and SO 2 compared to UUO-VO, there was a trend to increased FSP-1 
expression in the interstitium of ASO treated models which was statistically 
significantly following administration of ASO 1. As an expression of the fibroblast 
population, this is unexpected especially in the light of decreased fibrosis and 
collagen I scores in the ASO treated groups compared to both UUO-VO and SO 
groups. Furthermore, previous data from our group had demonstrated that Ki-Ras 
knockdown reduced stimulated fibroblast proliferation in vitro. However it must be 
considered that there is debate regarding the degree to which FSP-1 is fibroblast 
specific and expression of this protein has also been demonstrated to be present in 
other cell types including T-lymphocytes, macrophages, Kupffer cells and plasma 
cells (Le Hir, Hegyi et al. 2005). Thus the increase observed in interstitial FSP-1 
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expression in ASO treated groups may not solely represent a fibroblast population but 
also an inflammatory one. 
Immunohistological staining for !SMA demonstrated a significant increase in 
interstitial expression following obstruction that may represent increased 
myofibroblastic activity. Administration of either CO 2 or scrambled oligos did not 
alter expression compared to UUO-VO but both ASO 1 and ASO 2 treatment resulted 
in significantly reduced !SMA expression compared to sister scrambled oligos with 
ASO 1 treated group reducing immunohistological expression of !SMA to a level 
comparable to sham-operated kidneys. The expression of !SMA protein was also 
analysed using SDS PAGE. Densitometry analysis of immunoblots revealed that there 
was a 5-fold increase in !SMA expression following ureteric obstruction. Neither 
administration of SO 1 or SO 2 resulted in a significant difference but both ASOs 
reduced !SMA expression compared to UUO-VO on western blotting with ASO 2 
administration resulting in complete knockdown of !SMA protein expression to a 
level comparable to sham-operated kidneys. Thus using two differing techniques of 
!SMA expression anaylsis, it has been demonstrated that administration of Ki-Ras 
ASO results in decreased !SMA expression in obstructed kidneys compared to both 
vehicle-only and scrambled oligo treated samples and may reflect a downregulation in 
myofibroblastic activity. Why ASO 1 should appear more potent on 
immunohistological assessment but ASO 2 more potent on western blotting is 
unknown, but may be associated with the degree of ease of either staining or 
extraction of protein from the individual ASO treated group.  Furthermore the 
presence of one outlier within the ASO 1 group following SDS PAGE may also have 
led to a higher than expected mean protein expression of !SMA than expected. If one 
takes into context the decrease in !SMA expression on the background of increased 
FSP-1 expression in ASO treated groups, it could be postulated that Ki-Ras inhibition 
does not reduce fibroblast population but does reduce myofibroblastic activation thus 
resulting in decreased matrix deposition and scarring despite increased fibroblast 
numbers. However since both !SMA and FSP-1 are not cell specific, in the absence 
of identification of !SMA/FSP-1 positive cells, this cannot be confirmed from this 
work.  
The effects of Ki-Ras inhibition on the proliferation of fibroblasts in vitro (Sharpe, 
Dockrell et al. 1999) suggests a potential mechanism for decreased fibrosis in ASO 
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treated groups in vivo. Tissue was stained for the cell nuclear proliferation marker Ki-
67 with expression compartmentalized into glomerular, tubular and interstitial areas. 
There was no significant difference in glomerular expression between sham, UUO-
VO, CO 2 or SO. However administration of Ki-Ras ASOs led to a trend towards 
upregulation of glomerular expression. The nature of these proliferating cells was 
undetermined. Ureteric obstruction alone (UUO-VO) led to a significant increase in 
tubular expression of Ki-67 and this observation may reflect an attempt at ‘healing’ of 
damaged tubules following obstruction. However administration of an oligo (either 
CO 2, scrambled or ASO) led to a decrease in tubular Ki-67 expression compared to 
UUO-VO. As this phenomenon was observed in all oligo groups, it can be assumed 
that this may be a result of oligo uptake by tubular cells per se and is not specific to 
the oligo sequences or antisense targeting effects. The recognized preferential uptake 
of and concentration of oligos within tubular epithelial cells (see Introduction) may 
affect tubular cell proliferation in a non-specific manner. Within the interstitium there 
is a sixteen-fold increase in Ki-67 expression upon obstruction compared to sham-
operated kidneys. Administration of CO 2 did not alter this level of expression. 
However there was a subsequent four-fold increase in interstitial Ki-67 expression 
upon administration of either ASOs or scrambled oligos compared to UUO-VO and 
CO 2 treated groups. Thus this observed difference in interstitial Ki-67 expression 
appears to be related to the base make up of the oligo (not the sequence) and is 
unlikely to be related to Ki-Ras inhibition. It is unclear at present which cells are 
actively undergoing proliferation.  
Despite decreased fibrosis scores, some sections from ASO treated groups appeared 
to have a noticeable increase in inflammation. To assess this more accurately, ED-1 
antibody against CD68, a cell surface antigen expressed by mononuclear cells, was 
used to stain sections. ED-1 staining showed that as expected there was an increase in 
monocyte presence in obstructed kidney sections as compared to sham-operated ones. 
Administration of CO 2 resulted in increased ED-1 staining that may reflect the 
administration and uptake of a foreign molecule by renal tubular cells. However the 
administration of both SOs and ASOs resulted in a further significant increase in ED-
1 staining over and above that seen with CO 2 treatment. Again, as for interstitial Ki-
67 expression, the degree of monocyte infiltration and inflammation appears to be 
related to base representation of the oligo and not the sequence. In addition a greater 
degree of inflammation was seen with ASO 2 administration and this appears to be 
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consistent with previous results (see Chapter 3). Previously assessment of ASOs 
found that ASO 2 appeared to be a more potent for Ki-Ras mRNA knockdown (see 
Chapter 3). However, in a model of UUO, the measurement of the endpoints of 
fibrosis showed that there was no significant difference between groups treated with 
ASO 1 or ASO 2. It may be that, in the case of UUO, ASO 1 may ameliorate fibrosis 
to the same degree as ASO 2 but with fewer systemic inflammatory effects. 
Following discussions with ISIS Pharmaceuticals we were informed that 
inflammation was a recognized effect of this generation of oligos, though new oligos 
that caused minimal inflammatory response were now in development. The 
correlation in the degree of interstitial Ki-67 expression and ED-1 staining between 
SOs and ASO groups suggest that the interstitial proliferating cells may in fact be 
inflammatory cells and not mesenchymal. However of particular interest is the fact 
that although there is a similar degree of inflammation between SOs and ASOs there 
remains a significant difference in end-point parameters of fibrosis and fibrogenic 
activity in the presence of a significant difference in Ki-Ras mRNA knockdown.  
These results suggest that there may be a dissection between the processes of 
inflammation and fibrosis.  It can also be postulated that there may be different sub-
populations of inflammatory cell infiltration in SO and ASO groups. Different 
subpopulations of macrophages (M1 and M2) are now recognized with differing 
properties. This may explain why equal degree of inflammation may be pro-fibrotic in 
one condition (scrambled oligos) and anti-fibrotic in another (ASOs). As both SOs 
and ASOs are identical with regards to length and base representation, the difference 
in inflammation and fibrotic response is postulated to be related to the effect of Ki-
Ras knockdown. 
 
In conclusion these results suggest that antisense inhibition of Kirsten-Ras 
ameliorates interstitial fibrosis in a rat model of unilateral ureteric obstruction despite 
increased inflammation and interstitial proliferation. In addition it is possible that Ki-
Ras may have a role with regards to inflammatory infiltration and also suggests that 
the degree of inflammation per se may not directly correlate to the degree of fibrosis. 
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Chapter 7: Discussion 
7.1 Summary of findings 
The work presented in this thesis combined both in vitro and in vivo experiments to 
demonstrate that specific Kirsten-Ras mRNA knockdown by antisense 
oligonucleotides ameliorates interstitial fibrosis in a rat model of unilateral ureteric 
obstruction. 
Transfection of primary rat renal fibroblasts and normal rat kidney fibroblastic and 
epithelial cell lines with Ki-Ras ASOs employing a cationic liposomal transfection 
system resulted in specific  knockdown of Ki-Ras mRNA expression. The efficiency 
of knockdown was seen to be far greater with ASO 2 transfection than ASO 1. A 
‘compensatory’ rise in Ha-Ras mRNA was associated with Ki-Ras knockdown within 
fibroblasts but this observation was absent in epithelial cells following administration 
of ASOs. None of the oligos were demonstrated to cause significant cytotoxicity in 
NRK-49F cells when compared to vehicle-only controls. 
Administration of these Ki-Ras ASOs in wild-type, non-diseased Wistar rats 
demonstrated uptake and concentration of oligos within the proximal convoluted 
tubules of the kidney with no uptake within the interstitium or distal tubules and 
collecting ducts. Oligo was also seen to be deposited in cardiac, liver and muscle 
tissue following subcutaneous administration. Within the kidneys, ASO 
administration resulted in specific knockdown of Ki-Ras mRNA to a degree 
comparable to that seen in vitro. Though ASO 2 again appeared more potent than 
ASO 1 with regards to mRNA knockdown of Ki-Ras, subsequent analysis of total Ras 
protein expression demonstrated a comparable decrease in protein levels by both Ki-
Ras ASOs when compared to CO 2. The administration of Ki-Ras ASOs was 
associated with a significant increase in interstitial expression of the cellular 
proliferation marker Ki-67 when compared to CO 2 group. This observation was 
absent in glomerular and tubular cell compartments. Analysis of liver tissue revealed 
that hepatic Ras expression following ASO administration reflected trend of results 
achieved in the kidney with comparable efficiency of knockdown by ASO 1 and ASO 
2. Examination of both cardiac and liver tissue revealed significant increase in 




A rat model of unilateral ureteric obstruction was set-up and characterized with 
regards to fibrosis and Ras expression as part of this project. With regards to 
histological fibrosis score and expression of fibrogenic markers, an optimal 
experimental time-period of 16 days was employed. A significant rise in both Ki-Ras 
and N-Ras mRNA was noted in the obstructed kidney compared to sham-operated 
kidneys. This observation was localized to the obstructed kidney only and not the 
contra-lateral non-obstructed kidney. No significant difference in Ha-Ras mRNA 
levels was observed. Protein analysis was limited by the lack of specific Ras isoform 
antibodies, a limitation observed by other groups (Fuentes-Calvo, Blazquez-Medela et 
al. 2010).  
Low dose (5mg/kg) administration of ASO 1 in UUO models over a 12-day period 
did not significantly decrease Ki-Ras mRNA expression or affect fibrosis parameters 
but a rise in N-Ras mRNA was noted in comparison to a saline-only treated group.  
 
Administration of high dose (12.5mg/kg) Ki-Ras ASO to models of UUO over a 16-
day period resulted in increased deposition within the proximal tubules when 
compared to non-obstructed models. In addition there was deposition of oligo in the 
interstitium of obstructed kidneys that is absent in non-obstructed kidneys. Following 
administration of ASOs a decrease of Ki-Ras mRNA from up-regulated levels seen 
with vehicle-only treated UUO models to a level comparable with sham-operated 
kidneys within the obstructed kidney was noted. A decrease in Ki-Ras mRNA 
expression within the contralateral kidney was also noted. In UUO models the 
potency of ASO 1 was found to be comparable to ASO 2 with regards to Ki-Ras 
mRNA knockdown. N-Ras mRNA expression within ASO treated groups was also 
found to increase while Ha-Ras mRNA expression decreased. Administration of CO 2 
in UUO models led to pan-Ras isoform knockdown effect that was isolated to the 
obstructed kidney. This was not previously seen following CO 2 administration in 
non-obstructed models and was thought to be an artefact related to accumulation of 
CO 2 on the background of obstruction. Analysis of end-point data demonstrated both 
a significant increase in fibrosis scores and expression of !SMA and collagen I 
following ureteric obstruction comparable or greater than that observed in vehicle-
only. Administration of both ASO 1 and ASO 2 resulted in a significant decrease in 
histological fibrosis score, !SMA and collagen I expression compared to CO 2 
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treated groups. There were no obvious gross adverse effects on animal growth or 
behaviour following oligo administration. 
 
Validation experiments showed that administration of scrambled oligos (SO 1 and SO 
2) in UUO models did not result in knock down of any isoform of Ras when 
compared to UUO-VO group and this data was supported by a contemporaneous 
experiment. These results suggest that Ki-Ras mRNA knockdown was specific to Ki-
Ras ASO administration and not due to oligo administration per se. However 
administration of SO 1 and SO 2 resulted in inconsistencies in fibrosis scores 
dependent on stain used to assess fibrosis. It is postulated that these discrepancies are 
the result of dissimilarities in tissue treatment and reaction. However the 
administration of either ASO 1 or ASO 2 resulted in further reduction in fibrosis score 
when compared to SOs treated groups suggesting an anti-fibrotic effect associated 
with antisense Ki-Ras knockdown. Both ASO 1 and ASO 2 administration resulted in 
a significant decrease in !SMA expression in the obstructed kidney, assessed by both 
immunohistological and western blotting analysis, to a level comparable with sham-
operated kidneys when compared with SOs groups.  
  
FSP-1 expression was increased following obstruction as expected. Though 
expression was the same between UUO-VO and SO groups in the interstitium, there 
was a trend to increased interstitial FSP-1 expression in ASO treated groups. Ureteric 
obstruction also led to a significant increase in tubular Ki-67 expression but the 
administration of any oligo (control, scrambled or antisense) led to a significant 
decrease in Ki-67 expression in this compartment compared to UUO-VO. Both the 
administration of either scrambled oligos or ASOs resulted in a significant increase in 
interstitial Ki-67 expression when compared to UUO-VO and CO 2 treated groups. 
Staining for CD 68 (using ED-1 antibody), a macrophage marker, also demonstrated a 
significant increase in expression within renal tissue of SO and ASO treated groups 
when compared to UUO-VO and CO 2 groups. The parallel results obtained from Ki-
67 and ED-1 staining suggests that these differences may be determined by the 
specific nucleotides representation (not the actual sequence) of the scramble and 
antisense oligo make up. 
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However, despite a heavy degree of inflammatory infiltrate there was a significant 
decrease in fibrosis score and expression of molecular markers of fibrogenesis in 
ASO treated groups compared to SO treated groups. This is surprising as it is widely 
accepted that the degree of interstitial inflammation correlates with the degree of 
fibrosis, yet findings in this project appear to contradict this idea.  
 
In summary the work presented in this thesis has shown that subcutaneous 
administration of Ki-Ras antisense oligonucleotides in a rat model of renal fibrosis 
significantly reduces the degree of interstitial fibrosis both on a histological and 
molecular level. The amelioration of fibrosis by Ki-Ras ASOs appears to be 
independent of the degree of interstitial cellular proliferation and inflammatory cell 
infiltration. 
 
7.2 Choice of cell models 
The aim of this project was to examine the effect of inhibition of wild type Ras in the 
process of renal fibrosis. To this end, in order to best extrapolate a cell model to that 
of a living organism, the former must be as closely related to the latter as possible. 
We initially used primary cell lines derived directly from rat renal tissue. Though this 
has the benefit of being a cell model that most closely correlates to the organism 
being studied, there are several restrictions. Retrieval is time consuming, primary 
cells are less robust and they have a shorter life span and are usually unable to 
undergo multiple passages compared to cell lines. Due to the method of retrieval, the 
‘purity’ of cells may also be limited and there may be several different cell types in 
each retrieval batch and these cells may also change phenotype after only a few 
passages. Both these effects will result in inconsistent results. Immortal cell lines do 
not possess these issues. They have the advantage of availability, reproducibility and 
they retain their phenotype through multiple passages. Their robustness allows for 
increased survival following various treatments and possibly a decreased vulnerability 
to infection. However in attaining these attributes, certain physiological changes may 
take place and this transformation can significantly alter cell characteristics and their 
response when compared to cells of true wild-type parentage, though these changes 
may not always be immediately obvious. Thus there is a risk that observations in 
these cell lines may not be truly reflective of response in wild-type scenario. 
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Furthermore it must be remembered that cells are grown and treated in non-
physiological buffers and reagents that may induce a different response from that 
which is deemed normal in man. 
For our purposes of validating ASO characteristics, we employed both a fibroblast 
and epithelial cell line in addition to primary cell cultures. NRK-49F is a fibroblast 
cell line derived from a mixed normal rat kidney cell culture and exhibits contact-
inhibition and possesses a mesenchymal cell morphology. The lack in specific 
fibroblast markers makes differentiation from other cell types difficult but they have 
been observed to have distinctly different characteristics to their sister epithelial cell 
line. NRK-52E is an epithelial cell line cloned from the same mixed culture of normal 
rat kidney cells as NRK-49F, but has epithelial-like morphology. These epithelial 
cells have distinct growth and transforming characteristics distinct from NRK-49F 
cells. Both cell lines are robust and retain their phenotype following multiple passages 
but may transform spontaneously especially if not maintained in a sub-confluent state. 
 
7.3 Choice of in vivo models 
It is well established that the degree of renal dysfunction best correlates to the degree 
of tubulointerstitial fibrosis (Bohle, Strutz et al. 1994). There are several models of 
renal tubulointerstitial fibrosis including diabetic nephropathy, cyclosporine-induced 
and hypertensive. However these models will also have concurrent glomerular 
changes and involve either administration of disease inducing compounds or genetic 
mutations with specific end-points occurring only after a relatively long time period. 
One of the most widely accepted experimental models of renal tubulointerstitial injury 
and fibrosis is that of obstructive nephropathy. This model was created by Hinman 
and Morion in 1926 and has several advantages compared to the aforementioned ones. 
Firstly a wild-type animal may be used and so no additional compounds or genetic 
manipulation is required which may better reflect the “real” state and is of added 
value when assessing new therapeutic compounds. Secondly the rate at which fibrosis 
occurs is far more rapid than other methods. Thirdly the model provides both 
histological changes (essentially in the tubulointerstitium) and quantifiable molecular 
changes that have been shown to reflect fibrogenesis. This includes increased 
capillary permeability, inflammatory cell infiltration, de novo myofibroblasts 
production and increased matrix production with progressive tubular loss. Finally 
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unilateral ureteric obstruction (UUO) allows for the use of the contralateral non-
obstructed kidney as a control if appropriate. Unfortunately in the classical UUO 
model, functional data is not available. This model has not previously been used in 
our laboratory and part of this project was the development and characterization of 
this model of renal fibrosis.  
Despite the benefits of animal models in studying disease and potential therapies, one 
must be very aware of the shortfalls in results obtained. Firstly it is highly unlikely 
that any one model will adequately represent the true entity of ‘renal fibrosis’ and 
data obtained from one experiment may not be wholly applicable to another model. 
Thus a therapy deemed successful in one model of fibrosis must always be evaluated 
in at least one other.  In addition in various models, especially those models of 
toxicity or secondary cause (adriamycin, cisplatin, Thy-1), it is difficult to distinguish 
treatment effects on fibrogenesis as opposed to amelioration or removal of underlying 
cause or stimulating factor and natural organ recovery. The timing of treatment is also 
important. Majority of experimental treatment is provided early, whereas in the 
human clinical scenario interventions are usually at medium to late stage of fibrosis 
progression when disease is clinically apparent. Early administration also implies that 
treatment results are focused on fibrosis development as opposed to fibrosis 
modulation or reversal. Furthermore in the clinical setting patients tend to be on 
multiple medications (such as ACE inhibitors) that are absent in the animal model. 
The lack of a good molecular marker of fibrosis means that results are not 
standardized, with fibrosis being assessed by different techniques and parameters, 
thus quantification of fibrosis may vary considerably in different hands. Finally one 
must be aware that there may be considerable variability in outcomes for even well 
defined models in part due to animal strain variability but also in regards to their diet 
and care. More importantly the translation of therapeutic interventions in animal 
models must be translated to humans with the utmost care as they may potentially be 
ineffective or worse, harmful. 
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7.4 Targeting Ras signaling 
 
 
Figure 7.1: Potential targets of the Ras signaling pathway. PM, Plasma membrane. 
FTS, farnesylthiosalicylic acid.  FTI, Farnesyltransferase inhibitor. GGTI, 
Geranylgeranyl transferase inhibitor. mAB, neutralizing monoclonal antibody. ASO, 
Antisense oligonucleotide. siRNA, short-interfering RNA. 
 
The above figure summarizes the potential targets along the Ras signaling pathway 
which may be of therapeutic value in renal disease. Since Ras appears to be a 
convergent point for a plethora of cytokines and growth factors, the use of 
monoclonal antibodies or agents to any single one of these upstream molecules may 
be redundant with regards to inhibition of Ras activation (Stadler 2005; Gagliardini 
and Benigni 2006). Inhibitors of prenylation in the form of statins and prenylation 
inhibitors, such as farnesyl- and geranylgeranyl transferase inhibitors (FTI and 
GGTI), have shown more promise. However these agents are not specific for Ras 
proteins and may affect other members of the Ras GTPase superfamily such as Rho 
and Rac. In addition one must consider that at least Ki-Ras and N-Ras can be 
alternatively geranylgeranylated so possibly in order for a significant therapeutic 
Statin 
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effect both FTI and GGTI may be required to achieve significant clinical effect and of 
the subsequent complete inhibition of prenylation of Ras (or other molecules) may be 
toxic. Statins have been widely used in clinical medicine and have been shown to be 
promising in animal models of renal disease. However statins are also non-specific 
with regards to their actions on Ras signaling and, though statins have been shown to 
be safe and are now widely used for their benefits in cardiovascular disease, the dose 
at which they have been employed with regards to Ras inhibition in animal studies 
have tended to be extremely high (30-40mg/kg) and likely to cause side effects such, 
as myopathy, if translated into humans (Laezza, Mazziotti et al. 2006; Trebicka, 
Hennenberg et al. 2007). Furthermore, since 40% of all human cancers are associated 
with a mutation in Ras, clinical trials utilizing statins to inhibit Ras activity have been 
undertaken mainly within the oncology community and have not as yet proved 
beneficial (Jakobisiak and Golab 2003), though this may in part be due to the 
background oncogenic nature of Ras in these settings.  
S-trans, trans-farnesylthiosalicylic acid (FTS) is a synthetic prenyl derivative of a 
rigid carboxylic acid which structurally resembles the carboxy-terminal 
farnesylcysteine group common to all Ras proteins (Marciano, Ben-Baruch et al. 
1995).  FTS has been shown to interfere with the anchoring process of the Ras protein 
to the plasma membrane which is vital to the molecule’s function. Dislodgement of 
Ras from its plasma membrane domains both removes it from proximity to 
downstream effectors and facilitates its degradation and has been shown to be 
effective both in vitro and in vivo (Gana-Weisz, Haklai et al. 1997; Reif, Weis et al. 
1999; Clarke, Kocher et al. 2003; Khwaja, Sharpe et al. 2005; da Silva Morais, Saliez 
et al. 2008). FTS was administered daily via intra-peritoneal route in these studies 
though now an oral compound of FTS, Salirasib, has been developed (Haklai, Elad-
Sfadia et al. 2008). However recent results from a phase II trial of Salirasib in patients 
with lung adenocarcinomas with Ki-Ras mutations have been disappointing (Riely, 
Johnson et al. 2011). It is uncertain if these poor results are due to the dose of 
Salisirab employed, resistance to therapy of mutated Ki-Ras or whether it is related to 
the mechanism of FTS action and its non-specific effects on the Ras GTPase family 
of molecules. Many of the studies in which FTS inhibition of prenylated Ras have 
shown promise have involved transformed/malignant cells but in non-transformed 
cells there is now evidence that prenylation may not be essential for Ras activation 
(Khwaja, Dockrell et al. 2006). This suggests that the benefits of FTS in non-
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oncogenic circumstances may involve a mechanism of action other than simple Ras 
membrane dislocation.   
An alternative approach to inhibiting Ras activity has been to target the downstream 
effectors of the Ras pathway. The majority of these studies have been undertaken in 
the field of cancer and have employed monoclonal antibodies, small-molecule kinase 
inhibitors (such as BAY 43-9006 against Raf and PD98059 and PD184352 against 
MEK) and antisense oligonucleotides against kinases of the Ras pathway (Monia 
1997; Lyons, Wilhelm et al. 2001; Arslan, Kutuk et al. 2006). Though they have 
shown promise in cell and animal models, clinical trial have been of variable success 
(Stevenson, Yao et al. 1999; Lorusso, Adjei et al. 2005; Strumberg, Richly et al. 
2005). The degree to which these results can be translated to renal disease in the 
context of non-malignant cells has yet to be answered. However the importance of 
Ras in renal disease, and in particular in the process of fibrogenesis, has recently been 
highlighted by a seminal paper (Bechtel, McGoohan et al. 2010) which reported that 
the removal of inhibition of Ras activity by hypermethylation of Ras inhibitor 
RASAL 1 resulted in the perpetuation of fibrogensis in murine fibrosis induced by 
folate injections. Ras activation results in the activation of numerous downstream 
effector pathways, not just the pro-proliferative Raf/MEK/Erk cascade and several, 
such as the anti-apoptotic PI3K pathway, are potentially of equal importance in the 
process of progressive renal fibrosis. Furthermore, as well as the majority of previous 
studies being conducted on the background of transformed cells or states, the 
compounds employed to inhibit Ras function have not been isoform specific. In view 
that distinct roles of isoforms of Ras are now recognized, this now appears to be a 
very crude approach and numerous laboratories are now studying the targeting of 
individual Ras isoforms. One group has examined the role of Ras isoforms in H- and 
N-Ras knockout mice and concluded that there was no significant role for either 
isoform in early renal damage by UUO (3 days) (Grande, Arevalo et al. 2009). 
However they found that after 15 days of obstruction there was significantly lower 
degree of fibrosis and expression of inducers of EMT in H-Ras knockout mice 
compared to wild-type (Grande, Fuentes-Calvo et al. 2009). These studies reveal a 
significant role for Ras in progressive fibrosis induced by UUO and also imply that 
isoforms of Ras may have different roles in the process of fibrogenesis at different 
time points. However the use of knockout mice, which may have a different Ras 
mediated developmental profile than wild type, and the non-viability of Ki-Ras 
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knockout mice coupled with a degree of functional cross-over of isoforms of Ras 
means that the role of Ras isoforms in non-genetically modified conditions remains 
unclear.  
Though other groups have previously employed RNAi in animal models of renal 
disease, none have targeted Ras isoforms and their success has been limited by 
delivery of drug to target sites within the kidney, which have required techniques that 
would be difficult to translate to a clinical setting. From our knowledge, this project is 
the first to utilize systemic subcutaneous delivery of antisense oligonucleotides to a 
specific isoform of Ras in a model of interstitial renal fibrosis. 
 
7.5 Antisense oligodeoxynucleotides 
Zamecnick and Stephenson first recognised the potential of ASOs in 1978 when 
studying the inhibition of Rous sarcoma virus replication (Stephenson and Zamecnik 
1978). Since then antisense technology has developed into a powerful research tool 
and has begun to make it’s mark in the world of clinical therapy.  ASOs consist of a 
single strand of 20 to 22mer oligodeoxynucleotides which are complementary to the 
target mRNA sequence. The binding of the ASO to its target mRNA induces RNase 
H, a non-specific [endo-]ribonuclease, that cleaves the 3'-O-P-bond of RNA in the 
DNA/RNA duplex to produce 3'-hydroxyl and 5'-phosphate terminated products and 
results in target mRNA hydrolysis and ‘gene silencing’. For specific knock down 
effect appropriate choice of mRNA target sequence must be made. By considering 
potential folding patterns and inter-chain hybridization within any given RNA 
sequence single stretches which are most accessible to ASO may be chosen. 
Sequences of 20-22mers are used as 20 or more nucleotides occur only once in the 
human genome, thus decreasing non-specificity effects, and cellular uptake decreases 
with sequences over 25 bases (Loke, Stein et al. 1989). 
However more recently the knowledge regarding mechanism of oligo action has 
expanded. There is now evidence that oligos that do not induce RNase H may still 
affect gene expression via non-cleavage mechanisms. These include translational 
arrest where the oligo may inhibit mRNA translation by hybridizing to target mRNA 
and blocking binding and scanning by ribosomes but does not initiate RNase H 
degradation [Baker et al. 1997]. This mechanism has also been developed to target 
microRNA (miRNA) function [Davis et al. 2009]. Thus a single oligo may affect 
! ##+!
numerous gene expression targets by inhibiting miRNA activity. ASOs have also 
been developed that are complementary to telomere sequences of RNA in telomerase. 
By binding to these sequences and inhibiting telomerase activity, these ASOs can 
promote telomere shortening and cell proliferation [Hochreiter et al. 2006]. ASOs 
may also intefere with RNA intermediary metabolism by binding to pre-mRNA and 
modulating the splicing of the molecule by masking splicing enhancer and repressor 
sequences. This ‘splice-switching’ may realign the translational reading frame which 
may be of benefit in conditions such as Duchenne muscular dystrophy and "-
thalassaemia [Dominski et al. 1993; Roberts et al. 2006]. Oligos have also been 
shown to disrupt secondary and tertiary structures of RNA molecules upon binding 
that may affect the activity of the transcript [Ivanova et al. 2007]. Finally, there is 
now evidence that ASOs may also target promoter sequences of gene expression. This 
may result in either promotion or inhibition of gene transcription and is thought to 
involve targeting of short RNA transcripts at the promoter sites of the gene. It may be 
that these short RNA transcripts control gene expression by affecting histone 
methylation patterns [Schwartz et al. 2008; Janowski et al. 2005].  
 
7.5.1 ASOs: In vitro  
Within the realms of renal medicine antisense technology has been a useful research 
tool in determining gene function in vitro and over the last few years has become 
increasingly prolific in in vivo experiments. Our group has previously employed 
ASOs targeting Ras isoforms (Sharpe, Dockrell et al. 2000) to demonstrate that 
growth factor induced proliferation of HRF and Vero cells was dependent on Kirsten 
and, to a lesser extent, Harvey isoforms. Zhang et al. used an ASO targeting 
connective tissue growth factor (CTGF) (Zhang, Meng et al. 2004) in an in vitro 
model of EMT to demonstrate that CTGF could promote transdifferentiation while 
Okado et al. demonstrated that Smad 7 has a role in TGF" induced apoptosis in 
mesangial cells via activation of caspase-3 using antisense technology (Okado, Terada 
et al. 2002). Though the use of ASO has been taken up enthusiastically within the 
renal community, there has been great variability in the doses employed and the 
methods of cell transfection. Concentrations of ASO used have varied from 200nM to 
3µM with duration of transfection time varying from 6hrs to 24hrs. This variation in 
dose and transfection protocols may in part be a result of the variation in the ease of 
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transfection of various renal cell types. Cellular uptake of ASOs involves a 
combination of pinocytosis, absorptive and possibly receptor-mediated endocytosis 
(Akhtar and Juliano 1992). Naked ASOs have been shown to be inefficient and results 
in a low yield of internalization and methods employed to increase cellular uptake 
include the use of cationic liposomes, electroporation and microinjection techniques. 
(Regnier, Tahiri et al. 2000), (Williams and Buzby 2000). Despite these technical 
differences overall the use of ASO in vitro can be seen as successful. 
In this project, transfection of ASOs into cells also appeared to require different 
protocols depending on cell type. For primary rat fibroblastic cell cultures and 
fibroblast cell lines (NRK-49F) using a simple liposomal cationic system for 
transfection was sufficient, but transfection of epithelial cell line (NRK-52E) proved 
resistant to this protocol and reverse-transfection technique was required. Though 
transfection of Ki-Ras ASOs resulted in specific Ki-Ras knockdown in both 
fibroblastic and epithelial cell lines, there appeared to be a compensatory rise in Ha-
Ras in fibroblasts that was absent following treatment of epithelial cells. Previous 
work in primary human fibroblast cell cultures by our group have suggested that Ha-
Ras may have a role in stimulated fibroblast proliferation (Sharpe, Dockrell et al. 
2000) thus the observed rise in Ha-Ras on administration of Ki-Ras ASOs may reflect 
a compensatory response to maintain fibroblastic cell proliferation. It may be that 
whereas Ha-Ras has a role in proliferation in fibroblasts, this may not hold true for 
epithelial cells thus further supporting different roles for Ras isoforms in different cell 
types. Previous studies have demonstrated different roles of Ras isoforms in different 
cells. In vitro cell culture studies using renal mesenchymal cells have not 
demonstrated a role for N-Ras in fibroblast proliferation (Sharpe, Dockrell et al. 
2000), however those employing PTEC’s suggest a role in downstream signaling 
upon TGF" stimulation (Phanish, Wahab et al. 2005; Dockrell, Phanish et al. 
2009).Furthermore these discrepancies also indicate that investigation of the role of 
Ras in cell cultures alone may not be sufficient and use of animal models where 
multitudes of cell types interact is vital to further understanding of the role of 
physiological Ras in renal fibrosis. 
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7.5.2 ASOs: In vivo 
In general, administration of ASOs in in vivo models has been more challenging than 
that of in vitro and therapeutic development has been hindered by non-specific 
toxicity, short biological half-life of ASOs and heterogeneous distribution and poor 
targeted cell uptake on systemic administration. Side effects arising from antisense 
oligonucleotide administration can be divided into hybridization-dependent and 
hybridization-independent effects. Hybridization effects include exaggerated 
pharmacologiocal effects upon binding of oligo to target RNA which can be 
addressed by altering dose of administration and carful characterization of 
pharmacology. More pertinent is the hybridization of oligo to non-target RNA or ‘off-
target’ effects. This describes hybridization of the ASO to and RNA strand that may 
differ in sequence from the target by a few base-mismatches. Though 20mer 
oligonucleotides will demonstrate a 100% complementality match to the targeted 
RNA, it may exhibit partial complementality to several other genes. Both siRNA and 
miRNA will demonstrate more off-target effects than those seen by ASOs due to 
shorter sequences and the intergration of RISC which allows for fewer nucleotides to 
induce activity and numerous off-target effects.  
The observed H-ras knockdown in UUO models by Ki-Ras ASOs could be 
explained by off-target effects except that previous interrogation of the validity and 
specificity of both ASO 1 and 2 both in vitro and in vivo (in non-obstructed models) 
did not demonstrate any H- or N-ras knockdown when ASOs where administered. 
Furthermore H-ras knockdown was not demonstrated in contemporaneous experiment 
IV. This would suggest that the H-ras knockdown seen in UUO models in the prior 
experiments was not via a mechanism of hybridization-dependent mechanism. 
Off target hybridization-dependent effects can be minimized by performing careful 
analysis of oligo and potential targets with up to three mismatches. Analysis of only 
up to three mismatches has been chosen as further mismatches have been seen to be 
associated with loss of activity (Monia et al. 1995). 
Hybridization-independent effects are believed to be due to interaction of oligos with 
various proteins. These ‘aptameric’ effects may be sequence-dependent or 
independent. Sequence-dependent effects are initiated via interaction with Toll-like 
receptors (Krieg et al. 2006) that may result in inflammation, complement activation 
and development of constitutional symptoms such as fevers, chills and headaches. 
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Non-sequence specific effects may depend on the chemistry of the oligo in question 
and the proteins with which they interact and can cause thrombocytopenia, 
prolongation of APTT, liver transaminitis and injection site reactions. Second 
generation ASOs appear to be better tolerated than first though clinical effects are 
hard to predict for each specific oligo. Previous studies in animal models have shown 
that infusions of ASO may lead to complement cascade activation resulting in 
haemodynamic instability, neutropenia, prolonged activated partial thromboplastin 
times and a rise in hepatic transaminases (Farman and Kornbrust 2003)(Levin 1999). 
These effects appeared to be both dose dependent and related to rate of 
administration. 
The anti-cancer drug Oblimersen targeting the anti-apoptotic gene B-cell Lymphoma-
2 (bcl2) underwent numerous clinical trials since it’s development. However a study 
looking at Oblimersen’s effect in melanoma cells demonstrated non-specific 
downregulation of several proteins including cancer markers involved in apoptotic 
resistance and endoplasmatic reticulum (ER) stress such as the 78 kDa glucose 
regulated protein (GRP 78), protein disulfide isomerase A3 (PDIA3, GRP 58), 
calumenin, and galectin-1, as well as the glycolytic enzymes triose phosphate 
isomerase, glyceraldehyde phosphodehydrogenase, and phosphoglycerate mutase 
(Winkler et al. 2010). This was believed to be a result of the oligonucleotide’s 
aptemeric effect. 
The pan-Ras and H-Ras knockdown in UUO models noted on administration of CO 2 
and ASOs respectively in this project may be a result of such hybridization-
independent effects from increased oligo levels on the background of obstruction and 
decreased oligo clearance.  
Subsequent clinical studies involving various other antisense oligos have shown that 
non-specific side effects do occur with increasing dose but the majority of trials now 
use lower doses of ASO and report minimal toxic effects. In addition recent 
developments in antisense technology has resulted in subsequent generations of ASO 
with lower toxicity profiles (Jason, Koropatnick et al. 2004). 
Though ASOs are not degraded by RNAse H activity, they are, in unaltered form, 
rapidly degraded by endogenous nucleases. The modification of the phosphate 
backbone whereby one oxygen molecule is substituted for a sulphur molecule greatly 
enhances resistance to nuclease activity. These first generation phosphorothioate 
ASOs have a half-life in humans in the region of 10 hours in comparison to 30-60 
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minutes of the original unmodified phosphodiester agents (Crooke and Bennett 1996). 
However these phosphorothioate ASOs are comparably more toxic and have lower 
affinity to complementary RNA target. Second generation ASOs contain nucleotides 
with alkyl modifications, most commonly the addition of 2’-O-methyl group. These 
ASOs are less toxic and have higher affinity to RNA target. However they cannot 
induce RNAse (Kurreck 2003). This has led to the development of chimeric ASOs 
(‘gapmers’ ) consisting of phosphorothioate oligodeoxynuclotides backbone with 2’-

















Figure 7.2: (A) Structure of oligonucleotide. b = base [adenine, guanine, cytosine, 
or thymine]. When x= O, a phosphodiester oligmer is formed. When x=S, a 
phosphorothioate oligomer is formed. (B) Structure of second-generation 
phosphorothioate oligonucleotide with 2’-O-methoxy-ethyl (MOE) cap, b = base 
[adenine, guanine, cytosine, or thymine].  
 
Further numerous modifications of nucleotides have led to a third generation of 
ASOs. These molecules include peptide nucleic acids, addition of phosphoroamidate 
groups and intranucleotide bridging to decrease toxicity, enhance affinity and increase 
stability (Kurreck 2003)(Hughes, Hussain et al. 2001). Though these modifications 
A B 
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appear to affect the oligos RNAse H inducution ability, these modified molecules are 
now thought to affect RNA metabolism via non-cleavage mechanisms as mentioned 
above. Studies into systemic administration via parenteral routes other than 
intravenous show that phosphorothioate ASOs are rapidly and extensively absorbed, 
with a systemic bioavailability as high as 90% (Crooke and Bennett 1996). They 
distribute to all peripheral tissues with sites of highest accumulation being in the liver 
and kidney resulting in concentration ratios to plasma of up to 20:1 and 80:1 
respectively after 2 hours (Sands, Gorey-Feret et al. 1994). Clearance is via a 
mechanism of slow metabolism mediated by exo- and endonucleases. Within the 
kidney autoradiographic assays have shown labelled ASOs within cells of Bowman's 
capsule and the proximal tubule after systemic administration (Rappaport, Hanss et al. 
1995). The size and structure of phosphorothioate ASOs allows for free filtration at 
the glomerulus yet only a small percentage of ASO are excreted in the urine in non-
metabolised form, hence the accumulation in PTECs can be explained in part by high 
reabsorption rate by tubular cells.  
This project utilized antibodies to oligonucleotides and aquaporin channels to 
demonstrate uptake of oligos by proximal tubular cells with no accumulation within 
glomeruli or distal tubules or collecting ducts of the nephron following subcutaneous 
administration in non-obstructed Wistar rats. These results are compatible with the 
above literature and demonstrate that oligos of this size are freely filtered and actively 
taken up and concentrated within the PTEC, with little reaching the distal nephron. 
The high concentration of oligo within the kidney has made antisense technology an 
attractive potential therapy for renal disease. Deposition of oligo to a lesser extent was 
also seen within cardiac, liver and muscle tissue reflecting the true systemic 
distribution of oligonucleotides following subcutaneous administration. 
 
There has been much interest in pushing forward ASO for clinical therapy especially 
in the field of infection and oncology. However results of clinical trials have been 
variable and currently there is still only one ASO licensed for clinical use, 
Formivirsen for AIDS related CMV retinitis.  However there are several other ASOs 
at phases II and III of clinical trials. Mipomersen is an ASO to apolipoprotein B 
(apoB) administered subcutaneously on a weekly basis and has been shown to reduce 
LDL-C in patients with high cholesterol and cardiovascular risk. Phase III clinical 
trials in patients with familial hypercholesterolaemia in 2009 have so far been 
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positive. The advanced stage of Mipomersen development demonstrates that ASOs 
are effective when administered systemically at a relatively low frequency. Other 
ASOs in clinical trials at present include Alicaforsen, targeting ICAM-1, for the 
treatment of ulcerative colitis and LY2181308 targeting the protein survivin in 
patients with relapsed/refractory acute myeloid leukemia and hormone refractory 
prostate cancer [www.isispharm.com]. Furthermore the development and successful 
administration of an oral compound of ASO further enhances the translational 
potential of this therapy (Tillman, Geary et al. 2008).  
 
7.6 Model of unilateral ureteric obstruction 
Unilateral ureteric obstruction (UUO) is a well-accepted model of interstitial fibrosis. 
It is now clear that obstructive nephropathy is not a simple result of mechanical 
impairment to urine flow but a complex process resulting in alterations of both 
glomerular heamodynamics and tubular function caused by the interaction of a variety 
of vasoactive factors and cytokines that are activated in response to obstruction. These 
cytokines include PDGF and TGF", the mRNA levels of which have been shown to 
parallel the increasing tubulointerstitial damage seen with obstruction (Walton, 
Buttyan et al. 1992; Liapis, Nag et al. 1994). Experimental hydronephrosis appears to 
reflect the changes observed on obstruction in human kidneys where TGF" has also 
been seen to be upregulated (Kaneto, Ohtani et al. 1999).  Following urinary tract 
obstruction and tubular dilatation, there is an upregulation of the intrarenal renin-
angiotensin system, tubular apoptosis and macrophage infiltration of the interstitium 
leading to destruction of renal parenchyma and fibrosis that correlates with length of 
time of obstruction (Himmelstein, Coffman et al. 1990). Acute ureteric obstruction 
leads to an initial increase in interstitial volume of the renal cortex while prolonged 
obstruction eventually leads to tissue loss, tubular atrophy and fibrosis. Within a the 
obstructed kidney of a rat, the change in renal function occurs within 24 hours, with 
GFR falling to 52% at 4 hours, 23% at 12 hours and 4% at 24 hours (Harris and Gill 
1981; Capelouto and Saltzman 1993). Within this project it was concluded that the 
time point which provided the optimum endpoint results for fibrosis, both from a 
histological and molecular viewpoint, was 16-days. This time length of obstruction in 
our studies was comparable to previous studies of Ras in murine models of UUO 
(Grande, Fuentes-Calvo et al. 2009). 
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QPCR, a technique that is currently used in the clinical setting for detection of Ki-Ras 
mutations as a predictive factor for metastatic colorectal cancer (Santini, Galluzzo et 
al. 2011), was employed and demonstrated that all three isoforms of Ras are 
expressed in the obstructed kidney. From previous in vitro studies from our group an 
increase in Ki-Ras expression in the presence of fibrogenesis was expected, as a 
potential reflection of increased fibroblast proliferation, and this was observed to be 
true within this model of UUO with a rise of 71% compared to sham-operated 
kidneys. The role of Ha-Ras in stimulated fibroblast proliferation suggested that this 
isoform may also be up regulated in this context but this was not the case. However a 
significant increase in N-Ras mRNA expression (80%) in obstructed kidneys was 
observed when compared to sham-operated samples. The spectrum of Ras isoform 
expression demonstrated in this project using rat UUO models is significantly 
different from data published by Grande et al. showing an increase in all Ras isoforms 
in kidneys from mice that had undergone UUO (Grande, Arevalo et al. 2009). This 
may reflect species variation. However the group did use an antibody mediated 
ELISA assay to measure Ras expression and from our experience antibodies against 
specific Ras isoforms have had high-crossover binding and were unreliable in 
differentiating between isoforms. Both Ki- and N-Ras up-regulation in our model of 
UUO was localised to the obstructed kidney while expression in the contralateral non-
obstructed kidney was comparable to sham-operated samples. N-Ras is known to be 
expressed in inflammatory conditions and to play a role in suppressing T-regulatory 
cell numbers and function (Mor, Keren et al. 2008) as well as potentially having a role 
in both granulocyte and macrophage proliferation (Skorski, Szczylik et al. 1992). 
More recently it has also been shown that N-Ras is required for expression of TGF" 
induced messenger CTGF in human tubular epithelial cells (Dockrell, Phanish et al. 
2009). Thus in an environment of fibrogenesis with significant inflammation, N-Ras 
mRNA expression can be expected to be upregulated and the observed rise seen in 
obstructed kidneys may reflect the degree of tissue inflammatory cell infiltration or 
increased TGF" induced CTGF activation. These findings support the idea that 
different Ras isoforms may have different distribution and function within different 
cell types. The results obtained also reflect the differences between in vitro and in 
vivo studies. The role of Ha-Ras observed in fibroblast cell cultures may hold true for 
fibroblasts in the in vivo setting, but the multitudes of other cells present in renal 
! ##)!
tissue and the use of whole kidney cortex for analysis may result in the dilution of any 
changes in the mRNA levels of this isoform. In order to localize the cellular 
compartments in which Ki-and N-Ras were up-regulated several techniques were 
employed. Unfortunately results obtained from both immunohistochemistry and SDS 
PAGE were restricted by conditions and reagents previously mentioned (see Chapter 
4).  
Other methods used to attempt to localize Ras isoform expression include in situ 
hybridization and laser microdissection. In principle the use of ISH would be ideal for 
exactly localizing Ras mRNA knockdown but it is a difficult technique and in the 
context of localizing isoform specific Ras mRNA there are further challenges. The 
difficulty lies in discriminating between the isoforms of Ras and being able to amplify 
the detection and probe design. Ras isoforms share 80% homology with the remaining 
24 amino acids being within the hypervariable region. Thus in designing probes to be 
isoform specific there is only a sequence of about 72 bases that can be targeted. Not 
all bases of the sequence may be available for probe hybridization when the 
molecule’s tertiary spatial structure is taken into account. In addition Ras is expressed 
at low levels in renal tissue and detection would require signal amplification. Probe 
construction is restricted by several factors and a balance between hybrid stability, 
specificity and tissue penetration must be met. Following a discussion with Dr James 
Howard Pringle (Department of Cancer Studies and Molecular Medicine, University 
of Leicester) and taking into account the above factors, a cocktail of Ki-Ras probes 
would need to be designed and fully assessed prior to utilization. Furthermore the 
harsh retrieval techniques may need significant refinement to optimize antigen 
exposure and limit RNA damage or destruction. It was felt that this work would be 
beyond the scope and time scale within this project but does however remain a 
possibility for the future. Focus was then moved towards utilizing the success 
obtained with QPCR by employing the pulsed microdissection (Hudkins, Gilbertson 
et al.) and microcapture system that allows for even individual cells to be analysed 
with regards to mRNA expression. The hypothesis was that by dissecting out specific 
areas of renal cortex from samples (such as tubular cells and glomeruli), one could 
localize the cells in which Ras mRNA expression had changed using QPCR and thus 
localize Ras isoform up- or down regulation to specific cells. The process required 
strict working conditions and a time constraint in order to preserve RNA and restrict 
degradation and contamination. The technique was seen to be successful in isolating 
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renal tubular epithelial cells but the amount of RNA retrieved from obstructed tissue 
samples was insufficient for analysis. It may be that in the UUO model where tubular 
cells appear flattened with altered morphology, RNA retrieval from atrophic tubules 
on the background of obstruction is difficult and limited and a higher number of 
tubules may be required for resection as compared to sham-operated samples. This 
poor return may also be due to other factors including the use of stored frozen tissue 
as opposed to freshly harvested, poor technique by operator or requirement of 
refinement of parameters of procedure. Though this technique did not yield any 
interpretable results in this project, it remains one with the most potential in terms of 
isolating Ki-Ras ASO effect. Thus though both ISH and pulsed microdissection 
techniques were unsuccessful during this project, both still have great potential and 
could be revisited in the future.  
 
7.7 Renal targeting by antisense oligonucleotides 
The fact that PTECs actively take up oligonucleotides administered systemically, 
makes ASO therapy attractive for targeting kidney disease. However though PTECs 
readily take up ASOs following systemic administration, delivery to mesangial and 
interstitial cells has proved far more difficult. Several groups have looked at the 
potential of antisense therapy in animal models of renal disease using a variety of 
delivery methods. Cheng et al. administered ASO to Intracellular Adhesion Molecule 
1 (ICAM-1) intravenously via the tail vein in a mouse model of unilateral ureteric 
obstruction (UUO) and found decreased inflammatory infiltration and extracellular 
matrix accumulation compared to control ASO. (Cheng, Chen et al. 2000).  Isaka et al 
also used the UUO model of tubulointerstitial fibrosis and targeted interstitial cells 
with a TGF" ASO using an artificial viral envelope (AVE) of hemagglutinating virus 
of Japan (HVJ) (Isaka, Tsujie et al. 2000). Using retrograde ureteric administration of 
the AVE /ASO liposome, the group successfully targeted interstitial fibroblasts and 
showed treated models expressed less collagen I and !-smooth muscle actin as well 
as decreased fibrosis area on trichrome staining. Yokoi et al (Yokoi, Mukoyama et al. 
2002) administered naked CTGF ASO to the kidney by way of a hydrodynamics-
based technique to target the interstitium. The technique involves clamping off both 
the renal vein and artery while ASO is injected under high pressure via the renal vein 
with the kidney being reperfused within 2 seconds (Yazawa, Murakami et al. 2006). 
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The group reported that CTGF ASO administration using the hydrodynamic method 
reduced interstitial fibrotic areas in UUO. Antisense has also proved effective in other 
models of renal disease. Akagi et al. also used the HVJ liposome method to introduce 
TGF" ASO in rat anti-Thy 1.1 antibody models of mesangial proliferation (Akagi, 
Isaka et al. 1996) and demonstrated a role for TGF" suppression in the treatment of 
progressive glomerulosclerosis. In a model of anti-GBM, Yamada et al used ASOs to 
examine the role of CK2 (casein kinase II) in disease progression (Yamada, Katsuma 
et al. 2005). Using a cationic liposome transfection reagent the ASO was 
subsequently infused by osmotic pump into the peritoneum. They reported that by day 
14 the ASO treated group had significantly less proteinuria and lower blood urea 
nitrogen levels. From these studies one can appreciate that there is a potential role for 
ASO therapy in renal disease. However there are multiple techniques involved in 
delivery ranging from use of naked ASO to HVJ-complexed liposomes and in 
administration (from simple iv injection to use of electroporation) in order to target 
specific renal cells. Some methods of administration, such as the hydrodynamic 
model, may itself induce cytokine release and damage the kidney and the use of 
liposomal delivery systems are themselves toxic (Rudin, Marshall et al. 2004). 
Therefore though many of the techniques appear successful it is difficult to see how 
they will be directly translated to a human clinical setting. 
In this project Ki-Ras ASOs were administered by alternate day subcutaneous 
injection of naked ASO to a model of renal fibrosis. Immunohistological results from 
this project demonstrated that the ASOs were deposited within the PTECs of both 
obstructed and non-obstructed kidneys at day 16. In addition, there was evidence of 
accumulation of oligos within the interstitium of obstructed kidney samples that was 
absent in their non-obstructed counterparts. The mechanism of interstitial deposition 
in a model of UUO following subcutaneous injection is unknown and may involve 
either transcellular or paracellular routes. However in view that oligos are normally 
filtered prior to uptake by PTEC, within the obstructed model where GFR rapidly 
drops off, another route of uptake must exist. In this model oligos may possibly reach 
the interstitium via the increased vascular permeability associated with inflammation 
as part of the model. 
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The oligos appeared non-toxic and safe for the dose and time interval used for this 
experiment with no group demonstrating any difference in weight gain, endpoint mass 
or gross behaviour. 
 
7.8 ASO targeting of renal Ki-Ras in a model of UUO  
7.8.1 Ras expression 
Initial administration of ASOs (12.5mg/kg) in non-obstructed Wistar rats 
demonstrated a specific knockdown of Ki-Ras mRNA levels in correlation with 
results achieved in vitro, with ASO 2 having a potency of five-fold greater than ASO 
1. At a protein level, administration of ASOs translated to a significant decrease in 
pan-Ras expression by up to 90%. In view that the ASOs appeared specific in 
targeting Ki-Ras, it was assumed this total Ras knock-down at a protein level 
reflected decrease in the Kirsten isoform. The discrepancy in results between mRNA 
and protein Ras assessment in the ASO 1 group is most likely explained by the 
logistical challenges of western blotting leading to result inconsistencies as mentioned 
previously.  
Following administration of ASO 1 at a low dose  (total experimental dose of 
30mg/kg), discussions were held with ISIS Pharmaceuticals and a higher dose of 
ASOs (total experimental dose of 100mg/kg) was administered over a longer time 
period of obstruction in the presence of a control oligo (CO 2) group. High dose 
administration resulted in efficient knockdown of Ki-Ras mRNA by 80% compared to 
UUO-VO group by both ASO 1 and 2 to levels comparable with sham-operated 
kidneys. The observed equivalent potency of ASO 1 to ASO 2 in UUO models 
contradicts previous in vitro and in vivo experiments in non-obstructed models. This 
can be explained if one considers the accumulation of oligo in the PTECs and 
interstitium of obstructed renal sections and is compatible with the known 
pharmacodynamics of oligo distribution and clearance. The reduction of ASO 1 
clearance on the background of UUO has potentially led to accumulation within the 
obstructed kidney and increased therapeutic knockdown effect on Ki-Ras expression. 
Ki-Ras expression was also decreased to a lesser degree within the contralateral 
kidneys following administration of ASOs which suggests that subcutaneous 
injections of ASOs results in systemic distribution and effects which may be outside 
of target organ. The distribution and deposition of oligos in extra-renal tissue has been 
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demonstrated by immunohistology and the analysis of hepatic tissue from animals 
treated with antisense demonstrated knockdown of Ki-Ras on par with that seen 
within the non-obstructed kidney. These results provide evidence that these ASOs, 
when administered subcutaneously may have true systemic effects. Cardiac and 
muscle tissue has not as yet been analysed and it is uncertain whether the hepatic Ki-
Ras knockdown effects of ASOs would be replicated in these tissues at this dose of 
ASO or whether the hepatic effects are a response to the accumulation of oligo within 
this organ that is absent in cardiac or muscle. Ureteric obstruction results in the 
increase of N-Ras mRNA expression within the obstructed kidney, however the 
administration of ASO 2 further increased these levels when compared to UUO-VO 
and ASO 1. In addition there was an observable increase in N-Ras in the contralateral 
kidney of ASO 2 group suggesting that the rise in this isoform expression is a 
systemic response and associated with the administration of ASO 2 per se. Prior to 
use, both ASO 1 and ASO 2 had both been validated with regards to their specificity 
and efficacy in knocking down Ki-Ras mRNA both in vitro and in vivo, so it was 
unexpected to observe that ASO administration in UUO models resulted in a decrease 
in Ha-Ras expression. This observation was localized to the obstructed kidney only, 
thus suggesting this is not a true systemic antisense or off-target effect on Ha-Ras 
mRNA by ASOs but associated with oligo accumulation. The observed reduction in 
Ha-Ras expression is likely to be due to non-specific effects of the ASOs, perhaps by 
inducing a change in the cell population. By stimulating inflammatory cell infiltration, 
the level of total Ha-Ras within the whole cortex may be ‘diluted’ and thus expression 
appears to be decreased in comparison to UUO-VO samples where cell influx or 
turnover may be less prominent. CO 2 administration resulted in a knock down of 
pan-isoforms of Ras in a model of UUO again with knock down effects being 
localized to the obstructed kidney. This control oligo had also been previously tested 
and demonstrated no Ras targeting effects. It is postulated that the decreased 
clearance of CO 2 in the obstructed kidney resulted in accumulation to a level that 
caused non-specific cellular effects that include a decrease in Ras expression. One 
could argue that administration of CO 2 in obstructive nephropathy may affect other 
cell signaling molecules, but these were not measured in this project. However the 
precise nature of CO 2 effects on Ras mRNA expression and downstream effects in 
UUO remain unknown and were not further investigated in this project but it is 
postulated that this may involve a non-hybridization effect. 
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Following further discussions with ISIS Pharmaceuticals, two new controls oligos 
were provided. These were scrambled oligos of ASO 1 and 2, thus they had the 
advantage of being made up of the same respective bases, contained the equal number 
of hydrogen and covalent bonds and were of the same length and generation of 
oligodeoxynucleotides as the active Ki-Ras ASOs though the secondary or tertiary 
structure may differ. These scrambled oligos were initially validated in separate 
experiments against five sham-operated and five UUO-VO models to demonstrate 
that neither targeted any of the isoforms of Ras. A subsequent contemporaneous 
experiment confirmed that SO 2 did not have any knockdown effect on Ras isoforms 
while confirming the specific knockdown potency of both the ASOs. Ideally a master 
contemporaneous experiment should be performed to compare SOs and ASOs effect 
but for reasons previously outlined (see Chapter 5) this was not deemed possible or 
appropriate. Subsequently data from this experiment was pooled with data from the 
previous validation experiments of the scrambled oligos and vehicle-only groups 
(Experiment III). This was to increase ‘n’ numbers for VO and SO 2 groups as well as 
allowing for incorporation of analysis of SO 1, which was lacking from the 
contemporaneous experiment due to insufficient amounts at the time of the 
experiment. The rationale for pooling of the data was that all QPCR results were 
derived from experiments performed by a single operator in circumstances employing 
reagents, substrates and animal models that were as identical as possible, though they 
were performed at different time points. Furthermore data obtained for each animal 
was based on an internal control (that is, relative to GAPDH) thus results were 
relatively comparable. This idea was supported by the examination of the delta Ct 
levels for Ki-Ras between the contemporaneous and validation experiments for UUO-
VO and SO 2 groups which showed no significant difference in dCt values between 
identical groups at different time points. Pooled data confirmed that both SOs 
appeared inert with regards to Ki-Ras knockdown but both ASO 1 and 2 







7.8.2 Cell proliferation and inflammation 
Previous evidence demonstrating a role for Ki-Ras in stimulated fibroblast 
proliferation gave rise to the hypothesis that inhibition of this isoform may reduce 
fibroblast population expansion in a model of fibrosis. However administration of 
ASOs even in non-obstructed models resulted in a significant increase in interstitial 
expression of the cell proliferation marker Ki-67. This increase was further amplified 
in UUO models. Administration of SO 1 and 2 in UUO models gave a response equal 
to that of ASOs that was absent in UUO-VO and CO 2 groups. This suggests that the 
increase in interstitial Ki-67 expression is related to the base make up of the oligo in 
question and not due to the presence of any oligo per se. Since the cells expressing 
Ki-67 have not been characterized it is not possible to comment on the effects of 
ASOs on interstitial fibroblasts themselves, the proliferation of which may still be 
suppressed in the presence of proliferation of other interstitial cell types. 
There was also significant increase staining using the ED-1 antibody in both SOs and 
ASOs treated group over and above that observed in UUO-VO and CO 2 treated. This 
suggests that inflammatory infiltration within tissue samples, like Ki-67 expression, 
relys very much on the base make up of the oligo in question. Administration of ASO 
2 resulted in the most significant rise in ED-1 expression and this correlates to results 
in extra-renal tissues. Examination and scoring of cardiac tissue for ED-1 staining 
demonstrated that ASO 2 administration resulted in the highest score in this tissue 
also. Furthermore H&E staining of hepatic tissue demonstrated significant lobar and 
peri-portal tract inflammation in the ASO 2 group that was absent in UUO-VO and 
ASO 1 treated groups. Taking into account that ASO 2 administration also results in a 
significant rise in N-Ras mRNA expression, it is postulated that ASO 2 is highly pro-
inflammatory and the high N-Ras and interstitial Ki-67 expression along with the high 
interstitial ED-1 scores reflect significant inflammatory cell infiltration and 
proliferation in response to ASO 2 interstitial deposition. On discussion with ISIS 
Pharmaceuticals, they stated that the pro-inflammatory nature of ASOs has been well-
recognised and less inflammatory ASOs are currently in development. Of interest, 
ASO 1 appears to have Ki-Ras knockdown effects equal to ASO 2 in a model of UUO 
but not such potent pro-inflammatory effects. This property of ASO 1 could be taken 
advantage of in a clinical setting. 
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7.8.3 Fibrosis and fibrogenic markers 
Though in vivo experiments were performed at different time points, the actual 
staining of sections was performed contemporaneously and, where possible, to 
maintain comparative consistency, each staining run was comprised of sections from 
different treated groups for a single experiment.  
Employing PMT and picrosirius red staining, it was demonstrated that administration 
of ASO 1 and ASO 2 (12.5mg/kg) reduced fibrosis scores on obstructed kidneys to a 
level comparable with sham-operated samples. Despite the pan-Ras knockdown 
observed with CO 2 administration, there was no difference seen in fibrosis scores 
between this group and vehicle-only. This result supports the belief that mRNA 
knockdown effects seen with CO 2 are not truly Ras specific and are a due to non-
specific effects associated with the accumulation of the oligo per se. The 
discrepancies in fibrosis scores seen in SO 1 and SO 2 groups were thought to be due 
to tissue response to treatment, method of staining and tissue oedema. However the 
significant further decrease in fibrosis scores in ASO groups when compared to their 
scrambled oligo counterparts suggest that Ki-Ras mRNA knockdown has a role in 
fibrosis inhibition. The inhibitory role of Ki-Ras mRNA knockdown in fibrosis is 
further supported by the decrease in !SMA expression and collagen I interstitial 
deposition following ASO administration compared to control and scrambled oligos. 
From previous work by our group demonstrating in vitro inhibition of fibroblast 
proliferation upon Ki-Ras knockdown, it was though that this mechanism could 
explain fibrosis inhibition in vivo. However staining for FSP-1 expression showed an 
increase in the interstitial expression of this cell marker following administration of 
ASOs when compared to control and scrambled oligos. However FSP-1 expression 
has been shown not to be exclusive to fibroblasts (Lin, Kisseleva et al. 2008) and has 
been demonstrated to co-localize with macrophage markers (Inoue, Plieth et al. 2005) 
in addition to lymphocytes, plasma cells and Kupffer cells. Hence up-regulation of 
FSP-1 seen in the interstitium in this case may represent mononuclear cells in 
presence of heavy inflammation as opposed to fibroblasts and thus the true effect of 
the Ki-Ras ASOs upon fibroblast cell proliferation in vivo is masked.  
However despite equivocal interstitial inflammation between scrambled and antisense 
oligo treated samples, the significant decrease in fibrosis and fibrogenic markers in 
Ki-Ras ASO treated groups compared to SO treated groups suggests that the degree of 
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inflammation per se may not directly correlate to degree of fibrogenesis and this 
finding of reduced fibrosis in the presence of significant monocyte infiltration is of 
interest. Traditionally renal interstitial disease is characterized by inflammation, 
macrophage accumulation and subsequent promotion of fibrogenesis. However there 
is now a growing belief that a sustained macrophage presence may not be a 
detrimental condition and may actually be a beneficial process with regards to 
phagocytosis of dead cells and removal of foreign bodies (Ricardo, van Goor et al. 
2008). This theory is supported by studies demonstrating distinct macrophage 
subpopulations that may be distinguished by differential expression of cell surface 
antigens and proteins (Sunderkotter, Nikolic et al. 2004). These macrophage sub-
populations have been termed M1 (pro-inflammatory) and M2 (pro-fibrotic) 
(Martinez, Sica et al. 2008). Whereas the M1 population appears to be pro-
inflammatory, a higher expression of the M2 population is associated with a 
predominant anti-inflammatory response (Sunderkotter, Nikolic et al. 2004) thought 
to be associated with endocytic clearance, expression of trophic factors and decreased 
production of pro-inflammatory cytokine release compared to M1 (Kluth 2007; 
Wang, Wang et al. 2007). The expression of IL-1 receptor antagonist and arginase 1 
(an inhibitor of NO) are also thought to contribute to the anti-inflammatory actions of 
M2 (Wilson, Walbaum et al. 2004). However, though the M2 phenotype is recognized 
to be anti-inflammatory and associated with wound healing, in pathological 
circumstances it is thought to be profibrotic. Interestingly the same cytokines (IL-4 
and IL-13) appear to drive monocyte differentiation to a M2 phenotype as drive 
fibrocytes to become fibroblasts in vitro ( Shao et al. 2008). Though the macrophage 
is widely believed to be terminally differentiated and non-proliferative, there is 
evidence of a M1/M2 phenotypic switch, which may be dictated by the cellular 
microenvironment (Duffield 2003). Furthermore, there is now increasing interest in 
the role of macrophages in promoting tissue healing. Macrophages are now thought to 
have an ability to fuse or transdifferentiate into epithelial and mesenchymal cells 
including myofibroblasts (Havemann, Pujol et al. 2003; Zhao, Glesne et al. 2003; 
Vignery 2005). Once again this process and end-point result may be prompted by the 
surrounding microenvironment and various as yet unidentified cell signals.  
Within the kidney, two groups of such macrophage markers that have been studied 
include the S100 proteins (myeloid related protein MRP8 and MRP14) and cell 
surface marker Ly6c (lymphocyte antigen 6 complex) (Frosch, Vogl et al. 2004; Lin, 
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Castano et al. 2009). Frosch et al. demonstrated that MRP8/MRP14 complex 
expressing monocytes prevailed in glomerulonephritides (GN) associated with a high 
degree of cellular proliferation such as systemic lupus erythematosus GN while in 
chronic types of inflammatory reaction the majority of macrophages in the renal 
interstitium expressed MRP8 and MRP14 without concomitant formation of their 
complex. They conclude that distinct macrophage subpopulations prevail in the 
different forms of GN and reflect differences in the inflammatory mechanisms 
underlying the various forms of GN (Frosch, Vogl et al. 2004). More pertinent to our 
model of renal fibrosis are the recent findings from Lin et al. Their group used a 
model of UUO to identify three subset populations of macrophages/monocytes 
differentiated by the expression of Ly6c-high, medium and low. Using mRNA 
transcription profiling, they found that these subpopulations had differential 
functional roles in kidney injury. Furthermore the low Ly6c expressing macrophage 
subpopulation was associated with transcribing genes consistent with profibrotic 
function. In addition they demonstrated that native kidney macrophages, contrary to 
popular belief, had the ability to proliferate and make up to 40% of the final 
inflammatory macrophage population though they did not appear to contribute to the 
process of fibrosis (Lin, Castano et al. 2009).  
It may be that in this project, though both scrambled and antisense oligos induce a 
quantitatively equal degree of tissue inflammation, the qualitative nature of the 
infiltrate may be significantly different between macrophage subpopulations resulting 
in different endpoints of fibrosis & potential cell transdifferentiation. These studies 
show that there is a clear distinction between inflammation and 
monocyte/macrophage infiltration and subsequent fibrogenesis. 
From data presented in this thesis, a postulated mechanism of action for Ki-Ras 
inhibition in fibrogenesis is as follows: An initial insult to the kidney results in an 
inflammatory response. Monocyte infiltration with either a macrophage M1 or M2 
sub-population majority occurs depending on the microenvironment. Ki-Ras 
inhibition may skew macrophage sub-population towards pro-inflammatory M1 
phenotype thus explaining significant inflammatory infiltration on administration of 
ASOs. The relative decrease in M2 phenotype allows for adequate wound healing but 
decreased pro-fibrotic signalling with subsequent inhibition of myofibroblastic 
activity as reflected by decreased !SMA expression. There may also be reduced 
fibroblast proliferation in this setting. In combination this leads to a reduced fibrosis 
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endpoint. The increased Ki-67 expression within the interstitium may be associated 
with inflammatory cell proliferation as a response to M1 phenotype or perhaps cell 
regeneration via macrophage repair mechanisms.  
 
 
Figure 7.3: Postulated role of Ki-Ras in renal fibrogenesis  
 
Thus the results presented in this thesis show that antisense inhibition of Kirsten-Ras 
ameliorates interstitial fibrosis in a rat model of unilateral ureteric obstruction despite 
increased interstitial inflammation and cell proliferation. The process by which Ki-
Ras inhibition prevents fibrosis may involve decreased fibroblast population 
expansion and myofibroblastic activation and different sub-populations of 




7.9 Future studies 
Work in this thesis has shown that Ki-Ras antisense oligonucleotides are both specific 
and efficient in knocking down the Kirsten isoform of Ras mRNA and their 
administration in a rat model of UUO ameliorates fibrosis despite increased interstitial 
inflammation and proliferation. However there are also many questions raised by this 
project.  
 
One is the location of Ki-Ras knockdown. Whole cortical tissue was used for analysis 
and thus Ki-Ras knockdown may be underestimated since there is a contribution of 
Ki-Ras mRNA by inflammatory infiltrative cell population that may not be targeted 
by ASOs and in fact may be induced by the presence of ASOs. By optimizing 
techniques of PALM or in situ hybridization a more accurate measure of degree of 
effect, as well as localization, of the knockdown effects of ASOs may be determined. 
 
The cellular location of Ki-Ras knockdown is a step towards investigating the 
mechanism of anti-fibrotic effect. EMT is an attractive process to examine with 
regards to antisense technology, as it is believed to play a significant role in renal 
fibrogenesis and tubular epithelial cells are specific targets for oligo uptake following 
systemic administration. From cancer studies there appears to be an increasing 
interest in Ras and TGF" crosstalk especially concerning the downstream pro-EMT 
transcription factor Snail (Horiguchi, Shirakihara et al. 2009). More recently, there is 
convincing evidence that the Ras signaling pathway is involved in TGF" induced 
EMT in renal cells. Bozic et al. demonstrated that the N-methyl-D-aspartate receptor 
(NMDAR) present on proximal tubular epithelial cells is critical in maintaining 
normal epithelial phenotype and modulating TGF" induced EMT in HK-2 cells 
(Bozic, de Rooij et al. 2011) and that the mechanism of TGF" antagonism involved 
the inhibition of the Ras-MEK pathway and decreased activation of Ras GTPase. The 
perceived role of EMT in renal fibrosis, the fact that ASOs uptake in the kidney is 
primarily by tubular cells and recent literature suggests that further studies into the 
role of Ki-Ras in this phenomenon should be considered and downstream biomarkers 
and transcription factors of EMT (such as E-Cadherin, "-catenin and Snail) be 
examined both in vitro and in vivo following treatment with Ki-Ras ASOs.  
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Though this thesis has demonstrated that knockdown of Ki-Ras mRNA expression 
ameliorates fibrosis in a model of UUO, the actual mechanism and signalling 
pathways that play a part in this remain unclear. The pivotal role of Ras GTPase in 
cell signalling with regards to proliferation, apoptosis and differentiation requires that 
these pathways and their molecular components be examined in the presence of Ki-
Ras ASO administration in vivo. TUNEL staining was undertaken as part of this 
project but was unsuccessful. The subject of apoptosis and Ki-Ras mRNA knockdown 
requires revisiting and examination of apoptotic cell signals such as caspase 3 
expression may be of help. 
 
This body of work also supports the fact that different isoforms of Ras may have 
different expression in different cell types as well as different functions. The observed 
increase in N-Ras expression following oligo administration in vivo in this project is 
thought to be as a result of high inflammatory cell infiltrate. However the findings 
that N-Ras is involved in CTGF expression downstream from TGF" stimulation also 
raises the question that N-Ras increased expression in the presence of Ki-Ras 
knockdown may be associated with increased CTGF production. If this is true then 
there is increased N-Ras and CTGF production in Ki-Ras ASO treated kidneys but a 
significant decrease in TGF"-induced CTGF endpoints including fibroblast up-
regulation and induction of matrix production. This would suggest a signalling 
feedback mechanism of some degree from cells active in fibrogenesis to cells 
expressing CTGF and possibly other fibrogenic cytokines. Could this feedback 
mechanism involve the active myofibroblast? Does additional knockdown of other 
Ras isoforms have additional effect to Ki-Ras knockdown alone or would this lead to 
adverse effects?  Future experiments could involve measurement of CTGF in ASO 
treated and non-treated samples in vitro and in vivo and possible double knock out of 
both Ki- and N-Ras expression.  
 
Historically, increased inflammation on human biopsies is seen as detrimental and 
assumed to be a precursor to increased fibrosis. An important result in this thesis was 
the paradoxical finding of increased inflammation in ASO treated samples in the 
presence of decreased fibrosis. Subpopulations of macrophages/monocytes (M1 and 
M2) are now recognized and some of these are now thought to be wound healing. It 
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may be that the inflammation seen on ASO and control oligo groups may represent 
different sub-populations of macrophages and qualifying these sub-populations of 
macrophages by cell markers such as Ly6c or arginase-1 expression may shed light 
upon the role of Ki-Ras in inflammation and subsequent fibrosis.  
 
Interstitial Ki-67 expression was also increased in ASO and scrambled oligo treated 
groups and though it is postulated that this reflects inflammatory cell proliferation, the 
actual nature of these cells are unknown. Double staining for Ki67 and inflammatory 
cell markers such as CD3, CD20 or CD68 may identify the proliferating cell 
population. Unfortunately a true fibroblast specific marker remains elusive.  
 
Though ASO administration demonstrated decreased fibrosis, the in vivo experiments 
were artificial in that treatment was commenced at time of insult. It would be of 
interest to see if there was differential expression of Ras isoforms at different time 
points of fibrogensis (early vs. late) and whether administration of Ki-Ras ASOs in 
the late phase of disease (which is most similar to clinical presentation) has similar 
anti-fibrotic effects as found in this project. By establishing UUO prior to 
administration of ASOs with subsequent reversal of ureteric obstruction, effects of 
Ki-Ras knockdown with regards to regeneration and protection against irreversible 
renal fibrosis may also be examined.  
 
Though the UUO is a robust model for molecular and histological assessment of 
potential therapies, it cannot provide adequate data on functional outcome. Employing 
other models of interstitial fibrosis such as diabetic nephropathy, folic acid, 
hypertensive nephropathy or chronic allograft nephropathy one may be able to assess 
the functional benefits of Ki-Ras ASO administration. This would be of particular 
interest as there is already literature describing different Ras isoform patterns in 
human glomerulonephritidies (Kocher, Moorhead et al. 2003). Furthermore, though 
interstitial penetration by oligonucleotides appears difficult from previous literature, 
the findings presented in this project employing models of UUO demonstrated oligo 
deposition within the interstitium following simple subcutaneous administration. 
Whether this finding is isolated to obstructive nephropathy models or is shared 
between models of progressive fibrotic disease involving tubular injury and atrophy 
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and whether similar results are obtained on administration of Ki-Ras ASOs is 
unknown.  
 
Finally the focus of this project has been the kidney. However Ki-Ras ASO systemic 
administration may affect all organs. From this project there is evidence of hepatic 
effects from oligonucleotides. Other tissue sources such as cardiac and wound tissue 
(where there is high cell turnover) need also to be interrogated for a more 
comprehensive analysis of systemic effects of Ki-Ras knockdown. 
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Appendix I: Buffers & Solutions 
 
A1.1: Cell culture medium 
All culture media were obtained from Gibco BRL, Life Technologies (Paisley, UK).  
Foetal calf serum (FCS) and goat serum were obtained from Sigma (Poole, Dorset, 
UK) but dialysed FCS was supplied by Gibco BRL, Life Technologies.   
 
A1.2: Buffers and solutions 
DEPC water: 
Add 0.1ml DEPC (diethyl pyrocarbonate) to every 100ml water. Incubate for 
overnight at room temperature. Autoclave for 15 mins prior to use. 
 
1.5% DNA gel: 
Add 1.5g agarose to 100ml 1x Tris-acetate-EDTA (TAE) buffer. Microwave at 
medium power for 2 mins or until agarose melts. Cool to 60°C in a waterbath. Add 
1µl ethidium bromide (10µg/ml). Pour onto gel support and allow to set. Equilibrate 
in gel running buffer prior to use. 
 
HANKS’ balanced salts (HBSS):  
Obtained from Sigma. Calcium chloride 0.185g/l, magnesium sulphate 0.09767 g/l, 
potassium chloride 0.4 g/l, potassium phosphate monobasic 0.06 g/l, sodium chloride 
8 g/l, sodium phosphate dibasic 0.04788 g/l, D-glucose 1 g/l. 
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Gels for Tris-glycine SDS polyacrylamide gel electrophoresis: 
 
Resolving gel solution (20ml): 
Volume (ml) Resolving Gel 
Gel strength 10% 12% 15% 
Water 7.9 6.6 4.6 
30% acrylamide 
mix 
6.7 8.0 10.0 
1.5M Tris (pH 8.8) 5.0 5.0 5.0 
10% SDS 0.2 0.2 0.2 
10% ammonium 
persulfate 
0.2 0.2 0.2 
TEMED 0.008 0.008 0.008 
 
 
5% Stacking gel solution (10ml): 
Water    6.8ml 
30% acrylamide mix  1.7ml 
1M Tris (pH 6.8)  1.25ml 
10% SDS   0.1ml 
10% ammonium persulfate  0.1ml 
TEMED   0.01ml 
 
Phosphate buffered saline (PBS) x 10: 
80g sodium chloride, 2g potassium chloride, 14.4g disodium hydrogenphosphate, 
2.4g potassium dihydrogen phosphate. Titrate with 1M Hydrochloric acid to pH 7.4.  
 
PBST 0.1%: 
1x PBS, 0.1% Tween 20 (Bio-Rad Herts, UK),  
 
PBSTDS lysis buffer: 
1x PBS, 1% Triton-X 100, 0.5% sodium deoxycholate, 0.1% SDS, leupeptin 
0.5"g/ml, pepstatin 1.0"g/ml, EDTA 1.0mM, PMSF 0.2mM. 
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RNase-free protocol for glassware: 
Wash glassware thoroughly. Incubate in 0.1M Sodium Hydroxide solution for 1 hour 
at room temperature. Rinse in DEPC treated water. Incubate in 1mM EDTA solution 
for 1 hour at room temperature. Rinse in DEPC treated water. 
 
TAE (Tris-acetate EDTA ) Buffer (50 X) per 500ml: 
121g Tris base, 28.6ml glacial acetic acid, 14.6g EDTA. Make up with DEPC treated 
water. 
 
Towbin transfer buffer (1000ml): 
200ml methanol, 14.4g glycine, 3.03g Tris base. Make up with deionised water. 
 
Tris-buffered saline (TBS) 
50mM Tris-HCL pH 7.5, 150mM NaCl  
 
TBST 0.05% (1000ml): 
0.5ml Tween 20 in 1000ml 1xTBS 
 
Western gel running buffer: 
0.025M Tris, 0.192M glycine, 0.1% SDS. pH8.3. 
For 5000ml of 4x gel running buffer: 60.4g Tris, 288g glycine, 20g SDS. Make up to 
5000ml with deionised water. 
 
Western sample buffer (WSB) (6x concentrate): 
0.5M Tris pH 6.8, 0.35M SDS, 30% glycerol, 0.6M dithiothreitol, 0.175M 







A1.3: Standards and ladders 
 
Biotinylated protein ladder detection pack: 
For western blotting. Cell Signaling 7727S 
 
ColorBurst electrophoresis marker: 
For western blotting. Sigma C1992. 
 
50bp DNA ladder: 
For DNA gel. Promega G452A. 
 
A1.4: Histology solutions and sequences 
 
Acid-alcohol (100ml): 
70ml industrial methylated spirit, 30ml distilled water, 1 ml 1M Hydrochloric acid 
 
Acidified water: 
5ml acetic acid in 1000ml distilled water 
 
1% Aniline blue in 1% acetic acid: 
2g aniline blue, 2ml acetic acid, 200ml distilled water. 
 
Celestine blue haemalum sequence: 
Dewax and rehydrate sections. Stain in Celestine blue solution for 5 mins. Rinse I 
distilled water. Stain in Mayer’s alum haematoxylin for 5 mins. Differentiate and blue 
as required. Proceed with staining. 
 
Celestine blue solution: 
Dissolve 25g ferric ammonium sulphate in 500ml of distilled water. Add 2.5g 





Citrate buffer pH 6.0: 
Dissolve 2.1g citric acid monohydrate in 900ml distilled water. Add 26ml 1M sodium 
hydroxide. Adjust to pH 6 and make up to 1000ml with distilled water. 
 
Harris’ haematoxylin: 
Dissolve 4g haematoxylin in 40ml IMS. Dissolve 80g aluminum potassium sulphate 
in 800ml distilled water. Mix the two solutions and bring to boil. Remove from heat 
and place in fume cupboard and add 2g mercuric oxide. Cool rapidly, add 32ml acetic 
acid and filter solution. 
 
1% Nissl stain solution: 
2g Cresyl violet in 200ml RNase free water. 
 
Nuclear fast red: 
Dissolve 0.1g nuclear fast red in 10ml 5% aluminum sulphate solution. Warm 
solution to dissolve, cool and filter. 
 
Picro-orange solution: 
Dissolve 0.25g orange G dye in 100ml picric acid saturated in 80% propan-2-ol. 
 
Picrosirius red solution: 
0.1%: Dissolve 100mg Direct dye in 100ml saturated picric acid 
 
Ponceau-acid fuchsin: 
Mix equal parts of solutions A and B: 
Solution A: 0.5g Acid fuchsin, 1ml acetic acid, 100ml distilled water 
Solution B: 0.5g Ponceau de xylidine, 1ml acetic acid, 100ml distilled water. 
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Appendix II: Additional Methodology for 
histology and in situ hybridization 
A2.1 Ras Antigen retrieval 
Routine histology requires tissues to be fixed initially in formalin followed by 
subsequent processing and embedding in paraffin to allow ease of sectioning. This 
processing can lead to either masking or even destruction of target antigen. There are 
many antigen retrieval methods used to ‘unmask’ target epitopes in processed tissue. 
The most suitable method will vary widely according to epitope. 
Initially pre-treatment used was identical to that previously used in our laboratory 
(Kocher et al, 2005). Though from publications the pre-treatment appeared to provide 
specific and crisp Ras staining, in this project it was found that there was a very poor 
signal-to-background ratio using this method.  
As a result several antigen retrieval methods were used to optimize 
immunohistological staining for Ras which are listed below: 
 
1) Wash with saponin 0.05% for 30 mins and subsequent digestion with 0.1% 
pepsin (pH 2.3) at room temperature for 20 mins. [Original Method] 
2) Wash with saponin 0.05% for 30 mins and subsequent digestion with 0.1% 
pepsin (pH 1.8) at 37°C for 20 mins. 
3) Digestion with 0.1% pepsin (pH 1.8) at 37°C for 20 mins only 
4) Pressure cook in Tris EDTA (pH 9) for 3 mins 
5) Pressure cook in citrate buffer (pH 6) for 3 mins 
6) Microwave in citrate buffer (pH 6) for 20 mins and subsequent digestion with 
0.1% pepsin (pH 2.3) at room temperature for 20 mins. 
7) Microwave in citrate buffer (pH 6) for 20 mins and subsequent digestion with 
0.1% pepsin (pH 1.8) at 37°C for 20 mins. 
8) Digestion with 0.1% Trypsin (pH 7.8) at 37°C for 10 mins. 
9) Pressure cook in Tris EDTA (pH 9) for 3 mins and subsequent digestion with 
0.1% pepsin (pH 2.3) at room temperature for 20 mins. 
10)  Pressure cook in Tris EDTA (pH 9) for 3 mins subsequent digestion with 
0.1% pepsin (pH 1.8) at 37°C for 20 mins. 
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The antigen retrieval methods were repeated for both pan-Ras antibody and for 
isoform specific Ras. The reason for this is that the monoclonal antibody for pan-Ras 
is directed against a common epitope sequence in all Ras proteins but isoform specific 
antibodies will be directed against the terminal twenty amino acid sequence of each 
Ras isoform. Thus the pre-treatment method which may be optimal for pan-Ras may 
not necessary be the same for Ras isoforms.  
However from the above experiments is was found that the pre-treatment methods 
that provided optimum staining and signal-background ratio were: 
 
1) Pressure Cooking at in Tris EDTA buffer pH 9 for 3 mins 
2) Digestion with 0.1% Trypsin at 37°C for 10 mins. 
 
A2.2 Buffers & Solutions for Antigen retrieval 
10 x Tris EDTA buffer:  
12g Tris 
1g EDTA 
10ml 1N HCI 
500ml distilled water 
Dilute to x 1 and pH 9 prior to use. 
 
Trypsin solution 
0.1% Trypsin  




A2.3 Variations in in situ hybridization protocol H/!-2>32!1-!-81A5Af3!193!230=<10!479A3V3>!A/A1A4<<:!=0A/I!193!54/=6471=232g0!82-1-7-<!6-2!HFWh!40!-=1<A/3>!A/!0371A-/!#M#"h!03V324<!V42A41A-/0!.323!54>3!A/!193!82-7300!E403>!-/!published literature, in particular that of Dr JH Pringle (Bailey et 
al. 1999), and the current ISH protocol utilized for clinical samples by the Department 
of Histopathology, King’s College Hospital, London. These changes are highlighted 
below. It should be noted that the original manufacturer’s protocol was attempted 
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Antisense Knockdown of Kras Inhibits Fibrosis in a
Rat Model of Unilateral Ureteric Obstruction
Jia-Hui Wang,* Lucy J. Newbury,* A.S. Knisely,†
Brett Monia,‡ Bruce M. Hendry,* and
Claire C. Sharpe*
From the Department of Renal Medicine * and the Institute of
Liver Studies,† King’s College Hospital, London, United Kingdom;
and ISIS Pharmaceuticals,‡ Carlsbad, California
Tubulointerstitial fibrosis is the hallmark of chronic
kidney disease and is characterized by an increase in
the number and activity of interstitial fibroblasts and
by excessive matrix deposition. Ras is an intracellular
signaling molecule involved in cell proliferation and
differentiation. It has recently been implicated in the
pathogenesis of renal fibrosis. Of the three different
isoforms of Ras (Kirsten, Harvey, and Neural), we
previously demonstrated that the Kirsten isoform is
key in the control of renal fibroblast proliferation in
vitro. In this study, we used gene therapy in the form
of antisense oligonucleotides (ASOs) specifically to
silence Kras (alias Ki-ras) expression in a rat model
of renal fibrosis caused by unilateral ureteric obstruc-
tion. We demonstrate that renal Kras expression in-
creases by 70% in this model compared with sham-
operated animals and that treatment with ASOs can
reduce total renal Kras by >90% to levels well below
basal. This silencing is associated with a dramatic
inhibition of interstitial fibrosis, a fivefold reduction
in !-smooth muscle actin expression, and a 2.4-fold
reduction in collagen I deposition. This inhibition was
observed despite histologic evidence of marked intersti-
tial inflammation. These findings demonstrate that si-
lencing Kras expression can markedly inhibit renal fi-
brosis. This strategy should be considered as a new
potential therapeutic avenue. (Am J Pathol 2012, 180:
82–90; DOI: 10.1016/j.ajpath.2011.09.036)
Chronic kidney disease is a large and expanding prob-
lem worldwide. Whatever the initiating insult, the pres-
ence of progressive chronic kidney disease is associ-
ated with scarring of the tubulointerstitial compartment.
Interstitial myofibroblasts are responsible for the laying
down of extracellular matrix,1 and although sparse in
the normal kidney, after injury they increase in number
via several potential mechanisms, such as prolifera-
tion, pericyte and fibrocyte differentiation and migra-
tion, and epithelial to mesenchymal transition.2,3 Al-
though complex, the many fibrogenic cell signals and
phases of fibrosis are clearly described.4 Despite this
large body of knowledge, there is still no effective,
fibrosis-specific therapeutic agent that has been ad-
opted into clinical practice.
Ras monomeric GTPases are transduction mole-
cules in many extracellular signaling pathways that
regulate cell proliferation, survival, and differentiation.5
Although Ras family species are, to date, of particular
interest in oncology,6 we and others have accumulated
a substantial amount of evidence for a role for the Ras
monomeric GTPases in the pathogenesis of renal dis-
ease and in epithelial to mesenchymal transition. Ras
family members are downstream convergence points
for signal cascades mediated by many cell surface
receptors with ligands expressed in renal injury, such
as transforming growth factor !, platelet-derived
growth factor, angiotensin II, and epidermal growth
factor, allowing transduction of signal to downstream
profibrotic effectors. As such, they may be an impor-
tant potential target for treating the fibrosis of chronic
kidney disease.7–14
Recently, Bechtel et al15 demonstrated a direct link
between Ras activation and renal fibrogenesis. They
showed that hypermethylation of RASAL1 in fibrotic kid-
neys results in decreased expression of the Ras inhibitory
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protein RASAL1. This correlates with an increase in Ras
activity and a subsequent increase in fibrosis in several
murine models of renal fibrosis. The group concluded
that hyperactive Ras contributes to fibroblast activation
and fibrosis and that the antifibrotic capacity of Ras in-
hibitors should be further explored.
There are three separate isoforms of Ras: Kirsten
(Kras; alias Ki-Ras), Harvey (Hras; alias Ha-Ras), and
Neural (Nras; alias N-Ras). Although the isoforms are
85% homologous, they differ in their C-terminal 24 amino
acids, a “hypervariable region” of the molecule. This re-
gion confers on each isoform distinct characteristics with
respect to cell localization and function.16,17 Our group
previously demonstrated that Kras is the predominantly
expressed isoform in human renal fibroblasts and that
knockdown of this isoform by antisense oligonucleotides
(ASOs) results in significant inhibition of fibroblast prolif-
eration.18,19 In this study, we investigated whether silenc-
ing of Kras (alias Ki-ras) expression using ASOs is antifi-




ASOs were designed and produced by ISIS Pharmaceu-
ticals, Carlsbad, California. They are 20-nucleotide, fully
phosphorothioate “gapmers.” The five sugar residues on
each end are 2=-O-methoxy-ethyl modified. The central
10 sugars are deoxyribonucleotides. All pyrimidine bases
are 5-methyl substituted (T and me5-C). The oligonucle-
otide sequences were as follows: ASO 1, 5=-ATTCACAT-
GACTATACACCT-3=; ASO 2, 5=-CACACTTATTCCCTAC-
TAGG-3=; SO 1, 5=-ATTAACACGCCTACATACTT-3=; SO
2, 5=-CCCACTAAATCCGTTCTATG-3=; CO 1, 5=-TCAG-
TAATAGCCCCACATGG-3=; and CO 2, 5=-CCTTCCCT-
GAAGGTTCCTCC-3=. CO 1 was used for in vitro experi-
ments because this was the control used in a previous in
vitro study.18 CO 2 is a standard control oligonucleotide
used by ISIS Pharmaceuticals for in vivo work and was
used for the initial in vivo experiments. SO 1 and SO 2
were subsequently designed for this project and are
scrambles of ASO 1 and ASO 2, respectively.
Primary Culture and Cell Lines
Primary rat fibroblasts were cultured as previously de-
scribed.18 Briefly, rat kidneys were decapsulated in ster-
ile ice-cold HBSS. Cortices were removed and frag-
mented under sterile conditions. This tissue was digested
in a 1-mg/mL solution of collagenase type IV (Sigma-
Aldrich Co. Ltd., Dorset, UK) and incubated in a water
bath at 37°C for 30 minutes. The digestion process was
terminated by the addition of ice-cold 2% fetal calf serum
(Sigma-Aldrich Co. Ltd.)/HBSS solution. The digest was
then passed through a 100-!m sieve, and the filtrate was
centrifuged at 200 ! g for 5 minutes at 4°C to pellet
cellular material. This material was then washed in HBSS
and resuspended in 30 mL of a 50% Percoll solution (Sig-
ma-Aldrich Co. Ltd.) and centrifuged at 4°C at 30,000 ! g
for 30 minutes. The top band in the gradient obtained
contained the fibroblast fraction, which was harvested
and cultured in Dulbecco’s modified Eagle’s medium
Ham’s F-12 (Gibco BRL, Life Technologies, Paisley, UK)
supplemented with 10% fetal calf serum.
Normal adult rat fibroblast cells (NRK-49F) were ob-
tained from the European Collection of Cell Cultures
(6101301) and cultured in Dulbecco’s modified Eagle’s
medium supplemented with penicillin (100 IU/mL), strep-
tomycin (100 !g/mL), amphotericin (2.5 !g/mL), and
10% fetal calf serum.
Semiquantitative RT-PCR
Total cellular RNA was extracted using a Qiagen RNeasy
minikit (Qiagen, Crawley, UK). Promega’s Access RT-
PCR kit (Promega, Southampton, UK) was used for semi-
quantitative RT-PCR analysis of sample RNA. The primer
pairs targeting Kras and "-actin in the rat had the follow-
ing forward and reverse sequences, respectively: Kras,
5=-AGAGTGCCTTGACGATACAGC-3= and 5=-TCCCT-
CATTGCACTGTACTCC-3=; "-actin, 5=-CCCACACTGT-
GCCCATC-3= and 5=-TGATCCACATCTGCTGGA-3=. Sam-
ples were amplified for 22 cycles of PCR, and the products
were separated on a 1.5% agarose gel.
In Vitro Transfection of Oligonucleotides
Oligonucleotides were diluted with Opti-MEM (Gibco
BRL) to form a 10-!mol/L stock. Cells were grown to a
confluence of 50% to 70% and were washed with PBS
before transfection. Oligonucleotides were transfected
into cells using Lipofectin (Gibco BRL), a cationic lipo-
somal system. Lipofectin, 1.25 !L, was used per 100
nmol/L oligonucleotide per 100 !L of final transfection
volume. The final concentration of oligonucleotides used
for transfection was 200 nmol/L. Cells were transfected
for 6 to 12 hours before the transfection medium was
removed and replaced with normal culture medium.
UUO Model
All the experimental procedures were approved under
provisions of the Animals (Scientific Procedures) Act
1986 and were performed under license number PPL
70/6054. UUO was caused in adult male Wistar rats. After
a midline incision was made, the left ureter was isolated
and ligated with two 6/0 silk ties. The abdomen was
closed, and buprenorphine (30 !g/kg) was administered
subcutaneously. Any first dose of treatment (oligonucle-
otide or vehicle) was also administered subcutaneously
at this point. Animals undergoing the sham procedure
underwent a full laparotomy and manipulation of the ure-
ter without ligation. All the animals were sacrificed on day
16 after UUO.
Administration of Oligonucleotides in Vivo
ASOs and control oligonucleotides were administered by
subcutaneous injection in either the nape of the neck or a
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rear limb. Variation of injection points prevented cumula-
tive tissue damage. All oligonucleotides were dissolved
in sterile water and administered on alternate days at a
dose of 12.5 mg/kg.
RNA Retrieval from Tissue
RNA was retrieved from tissue using the Qiagen RNeasy
minikit. The sample (30 mg) was initially homogenized in
600 !L of guanidine-thiocyanate lysis buffer (supplied)
using a potter homogenizer. This suspension was then
transferred to a QIAshredder (Qiagen), and the manufac-
turer’s protocol was followed. Isolated RNA was quanti-
fied, and its purity was established using absorbance
spectroscopy.
Quantitative PCR
Reverse transcription of total RNA was performed using
the Omniscript reverse transcription kit (Qiagen) accord-
ing to the manufacturer’s protocol. The TaqMan se-
quence detection system (Applied Biosystems, Carls-
bad, CA) was used, and quantitative PCR (qPCR) was
performed using the ABI Prism 7900HT machine (Applied
Biosystems). Abundance of target-gene transcript was
quantified relative to the endogenous control glyceralde-
hyde-3-phosphate dehydrogenase. Target and endoge-
nous control levels for each sample were measured in
triplicate. TaqMan gene expression assays and TaqMan
master mix were purchased from Applied Biosystems.
Histologic Analysis
Tissue was fixed in buffered formalin for 24 hours, em-
bedded in paraffin, cut into 4-!m-thick sections, and
picked up onto glass slides (plain or polylysine coated).
Sections were stained with H&E.
Special Stains
Sections stained using the picro-Mallory trichrome (PMT)
and picrosirius red (PSR) techniques were used to as-
sess fibrosis. PSR-stained sections were viewed under
cross-polarized light and under bright light. The degree
of cortical fibrosis was scored by a consultant renal his-
topathologist in a randomized and blinded manner.
Immunostaining
Sections mounted on polylysine-coated slides were
deparaffinized after baking at 40°C overnight. Antigen
retrieval was performed by pressure cooking in citrate
buffer (pH 6) as required. Antibodies used were directed
against aquaporin 1 (AB2219; Millipore, Billerica, MA),
aquaporin 2 (AB3066; Millipore), modified oligonucleo-
tides (supplied by ISIS Pharmaceuticals, rabbit poly-
clonal), "-smooth muscle actin ("-SMA) (A2547; Sigma-
Aldrich Co. Ltd.), collagen I (AB755P; Millipore), Ki-67
(NCL-L-KI67-MM1; Novocastra, Newcastle on Tyne, UK),
ED-1 (MCA341R; Serotec, Kidlington, UK), and FSP-1
(S100A4) (A5114; Dako, Ely, UK). Detection was achieved
by a peroxidase substrate kit using a synthetic dextran
backbone polymer and diaminobenzidine [Dako EnVision
detection system (K5007), Dako]. Sections were assessed
after hematoxylin counterstaining. For "-SMA and ED-1,
slides were scored by measurement of staining intensity
and area using Nikon NIS-Elements (basic research) soft-
ware (Nikon, London, UK). Slides were scored in a
blinded manner based on five random cortical views per
section at !200 magnification. Staining for collagen 1
was scored by a consultant renal histopathologist in a
randomized and blinded manner. Staining for Ki-67 and
FSP-1 was scored in a blinded manner using light mi-
croscopy at !200 magnification. Ten random fields of
cortex were evaluated, with assignment of cells to glo-
merular, tubular, or interstitial compartments.
Western Blot Analysis
Western blot analysis was performed using antibodies
against "-SMA (A2547; Sigma-Aldrich Co. Ltd.) and pan-
Ras (OP40; Merck, Darmstadt, Germany). Glyceralde-
hyde-3-phosphate dehydrogenase (MAB374; Millipore)
was used as a loading control for "-SMA blots.
Immunoprecipitation
Due to a relatively low abundance of Ras within the cell,
Ras protein was concentrated from crude protein lysates
using immunoprecipitation; 0.5 mg of protein was used.
All the volumes were normalized to 1 mL with PBSTDS
[1! PBS, 1% Triton X-100 (Roche Diagnostics GmbH,
Mannheim, Germany), 0.5% sodium deoxycholate, 0.1%
SDS, 0.5 !g/mL of leupeptin, 1.0 !g/mL of pepstatin, 1.0
mmol/L EDTA, and phenylmethylsulfonyl fluoride 0.2
mmol/L]. Anti-Ras–agarose conjugate, 15 !L (OP01A;
Merck), was added per milliliter volume, and all the sam-
ples were incubated, under rotation, at 4°C overnight.
Samples were then washed and separated by SDS-
PAGE for analysis.
Statistical Analysis
Statistical analysis of data was performed using Graph-
Pad Prism version 4 software (GraphPad Software Inc.,
La Jolla, CA). When comparing two sets of data, an
unpaired Student’s t-test was used. For group data, anal-
ysis of variance testing was initially performed. Bonferroni
adjustment was then used to correct for multiple testing.
Results
ASOs Reduce Kras Expression in Vitro
ASOs consist of single strands of 20-22mer oligonucleo-
tides that are complementary to their target mRNA se-
quence. Binding of ASOs to target induces RNase H and
subsequent target mRNA hydrolysis, thereby effecting
“gene silencing.” Oligonucleotides administered system-
ically are filtered at the glomerulus and are rapidly taken
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up by tubular epithelial cells. Thus, they are an attractive
therapeutic option when considering potential therapies
for renal disease.20
Oligonucleotides ISIS 104440 (ASO 1) and ISIS
104419 (ASO 2) target the Kirsten isoform of Ras in the
rat. Four separate control oligonucleotides were used in
this study. All the oligonucleotides, control and antisense,
were 20-mer in length. Control oligonucleotide 15167
(CO 1) targets the HIV promoter sequence but has no
recognized target in the rat. Control oligonucleotide
141923 (CO 2) also has no recognized target in the rat.
Control oligonucleotides 417230 (SO 1) and 417226
(SO 2) are scrambled sequences of ASO 1 and ASO 2,
respectively.
Oligonucleotides were initially evaluated for specificity
and efficacy in vitro using primary rat renal fibroblasts in
culture. After transfection, RNA was extracted, and semi-
quantitative PCR was used to demonstrate knockdown of
Kras expression by transfection with ASO 1 and ASO 2
compared with CO 1 (Figure 1A). For further validation,
normal rat kidney cells [NRK-49F, European Collection of
Cell Cultures (86101301)] were transfected with ASO 1
and ASO 2. Both oligonucleotides significantly reduced
expression of Kras mRNA by 23% and 69%, respectively,
compared with CO 1 as assessed by RT-qPCR, with no
significant knockdown of either the Nras or Hras isoforms
(Figure 1, B–D). However, a nonsignificant trend toward
up-regulation of the latter isoform was noted, with an
increase in expression of 68% for ASO 1 and 44% for
ASO 2.
ASOs Reduce Kras Expression in Vivo
Oligonucleotides were administered subcutaneously to
adult male Wistar rats on alternate days at a dose of
12.5 mg/kg for 6 days. Sequential sections of renal
tissue were immunostained for aquaporin 1 to label
proximal convoluted tubules, for aquaporin 2 to label
distal convoluted tubules and collecting ducts, and
with an anti-oligonucleotide antibody to localize oligo-
nucleotide deposition. Figure 2A illustrates that oligo-
nucleotide is deposited in proximal convoluted tubules
only, with no staining apparent in either the glomeruli or
distal convoluted tubules and collecting ducts. RT-
qPCR analysis of renal tissue demonstrated oligonu-
cleotide effects reflecting those seen in vitro. No sig-
nificant difference was seen between CO 2– and
vehicle-only–treated groups regarding Kras expres-
sion. However, 12% and 66% knockdown of Kras
mRNA expression was seen in the ASO 1 and ASO 2
Figure 1. ASOs reduce Kras expression in vitro. A: Primary culture rat renal
fibroblasts were transfected with 200 nmol/L control oligonucleotide (CO 2)
or antisense oligonucleotides (ASO 1 and ASO 2). After 24 hours, the cells
were lysed, and extracted mRNA was subjected to semiquantitative RT-PCR
for Kras. !-actin primers were used to detect this housekeeping gene. B–D:
NRK-49F cells were transfected with 200 nmol/L control oligonucleotide (CO
2) or antisense oligonucleotides (ASO 1 and ASO 2). After 24 hours, the cells
were lysed, and extracted mRNA was subjected to RT-qPCR for Kras, Nras,
and Hras as indicated. n ! 3 separate experiments. Error bars are SEM. *P
" 0.05, **P " 0.001.
Figure 2. ASOs reduce Kras expression in vivo. Control or antisense oligo-
nucleotides were administered to Wistar rats subcutaneously on alternate
days at a dose of 12.5 mg/kg over 6 days (three doses). A: Sequential sections
were obtained from a single rat kidney and were immunostained for aqua-
porin 1, aquaporin 2, and oligonucleotide deposits as labeled. The corre-
sponding proximal convoluted tubule in each section is outlined in white,
and the corresponding distal convoluted tubule and collecting duct in each
section is outlined in black. mRNA and total protein were extracted from
whole renal tissue after sacrifice. B–D: mRNA was subjected to RT-qPCR for
Kras, Hras, and Nras as indicated (n ! 3 animals). E and F: Pan-Ras was
immunoprecipitated from a 0.5-mg aliquot of all protein extracted from
whole kidney tissue. The precipitate was then subjected to Western blot
analysis for total pan-Ras. To demonstrate equality of protein content among
samples studied, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) also
was quantitated, by Western blot analysis, in cell lysates after pan-Ras im-
munoprecipitation. The blot is representative of three similar experiments.
Error bars are SEM. *P " 0.001. VO, vehicle only.
ASOs to Kras Inhibit Renal Fibrosis 85
AJP January 2012, Vol. 180, No. 1
groups, respectively. No significant difference for any
group was seen regarding Hras and Nras expression
(Figure 2, B–D). Although modest effects were seen in
Kras mRNA expression after ASO treatment, these
were translated into decreases in total Ras protein
expression by 60% in the ASO 1– and 44% in the ASO
2–treated groups compared with the CO 2 control
group (Figure 2, E and F).
Kras and Nras Expression Is Increased in UUO
UUO was caused in male Wistar rats as described pre-
viously herein. Renal tissue from obstructed kidneys,
contralateral nonobstructed kidneys, and the kidneys of
sham-operated animals was analyzed for Ras mRNA lev-
els. This analysis demonstrated increases in Kras and
Nras expression by 70% and 80%, respectively, in ob-
structed kidneys compared with in the contralateral kid-
neys or kidneys from sham-operated rats (Figure 3). No
significant difference in Hras expression among groups
was found.
Kras ASOs Reduce Kras mRNA Expression
in UUO
Administration of Kras ASOs greatly reduced Kras ex-
pression in obstructed kidneys in a rat model of UUO
compared with renal tissue retrieved from UUO vehicle-
only and UUO control oligonucleotide–treated groups.
ASO 1 reduced Kras mRNA levels by 61% and 56%
compared with the scrambled oligonucleotides SO 1 and
SO 2, respectively, whereas ASO 2 reduced expression
by 97% compared with both these scrambled controls
(P ! 0.01). No statistically significant change in either N-
or Hras mRNA levels was found in either ASO group.
Administration of SO 1 or SO 2 resulted in a trend toward
increased expression of all isoforms of ras, but only the
rise in Nras in the SO 1–treated group was statistically
significant (P ! 0.01) (Figure 4). Administration of Kras
ASOs did not affect gross phenotypic appearance or
behavior of the animals or have a significant effect on
growth or weight gain (see Supplemental Figure S1 at
http://ajp.amjpathol.org).
Kras ASOs Inhibit Fibrosis in UUO
Sixteen days of UUO resulted in macroscopic, histologic,
and molecular evidence of obstructive nephropathy and
fibrosis. Compared with renal tissue from sham-operated
animals, obstructed kidneys had dilated tubules, flat-
tened tubular epithelial cells, greatly increased interstitial
volumes, and prominent inflammatory infiltrates. Fibrosis
was markedly increased, with evidence of substantial
myofibroblastic and macrophage activity as reflected by
an increase in !-SMA expression and ED-1–positive cells
(Figures 5 and 6). The degree of interstitial fibrosis was
determined by staining with PMT and PSR, and collagen
I deposition was stained directly using specific antibod-
ies (Figure 5A). ASOs were scored against CO 2 and SO
1 or SO 2 by a consultant histopathologist blinded to
treatment. Percentage fibrosis scores as derived from
PMT- and PSR-stained sections were averaged to pro-
vide an overall mean percentage fibrosis score (Figure
5B). This demonstrated an increase in the interstitial fi-
brosis score in vehicle-only–treated UUO models to
61.9% compared with the control sham-operated kidney
group baseline fibrosis score of 5.8%. No significant dif-
ference in fibrosis was observed after administration of
CO 2, with a mean observed fibrosis score of 67% in this
group. Although the administration of SO 1 and SO 2
reduced fibrosis scores to 40.1% and 36.6%, respec-
Figure 3. Kras expression is increased in UUO. UUO was caused in male
Wistar rats. mRNA was extracted from renal tissue from obstructed kid-
neys, contralateral kidneys (CL), nonobstructed kidneys, and kidneys
from sham-operated animals. Each sample (n " 5 to 10) underwent RT-
qPCR for Kras, Hras, and Nras. Expression of each gene was compared;
glyceraldehyde-3-phosphate dehydrogenase served as an internal con-
trol. *P ! 0.001.
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tively, the administration of active Kras ASOs additionally
reduced fibrosis, with ASO 1 reducing the fibrosis score
to 17% (P ! 0.001) and ASO 2 reducing it to 20.3% (P !
0.01).
Collagen I deposition was observed to increase from
9% in sham-operated kidneys to 50% in vehicle-treated
obstructed kidneys. Administration of CO 2 did not sig-
nificantly affect this finding (collagen I deposition score,
40%). However, administration of ASO 1 and ASO 2 re-
duced the collagen deposition score to 18.4% and 17%,
respectively (P ! 0.05 for both), compared with CO 2
(Figure 5C).
Kras ASOs Inhibit !-SMA Expression While
Increasing Inflammation in UUO
!-SMA is a well-recognized marker of myofibroblast ac-
tivity. Figure 6A shows tissue sections stained for !-SMA
from sham and UUO models, with quantified results
shown in Figure 6B. Expression of this protein rose from
1% to 44.5% of the total area after 16 days of UUO. This
was not significantly altered by the administration of CO 2
(53%) but was reduced to 21% and 32% by SO 1 and SO
2, respectively. Marked edema was also present. Admin-
istration of ASO 1 and ASO 2, however, further reduced
the expression of !-SMA to 3.9% and 20%, respectively,
in the presence of similar levels of edema. To quantify
!-SMA expression further, Western blot analysis for
!-SMA was performed on protein extracted from renal
tissue. This demonstrated a large up-regulation in protein
expression after UUO that was not affected by the ad-
ministration of control oligonucleotides (Figure 6, C and
D). However, ASO 1– and ASO 2–treated groups exhib-
ited a marked decrease in !-SMA expression that almost,
Figure 4. Kras ASOs reduce Kras mRNA levels in UUO. After 16 days of
UUO, mRNA was extracted from whole renal tissue from obstructed kidneys
and subjected to RT-qPCR for Kras (A), Nras (B), and Hras (C). n " 10 to 13
animals; each result is a mean of triplicate measures. *P ! 0.001. VO, vehicle
only.
Figure 5. Kras ASOs inhibit fibrosis in UUO. A: Tissue sections were fixed
and stained with PMT or PSR or were immunostained for collagen I as
indicated. UUO/control indicates SO 2 oligonucleotide for PMT and PSR and
CO 2 for collagen I. The PSR sections were viewed under cross-polarized
light. Images shown are representative. Original magnification, #100 for all
images. B: Each animal was assigned a mean fibrosis score by averaging the
percentage of fibrosis observed with PMT and the percentage of fibrosis
observed with PSR. This score is plotted against the treatment the animal
received as indicated. C: For each animal, the percentage of collagen depo-
sition was scored by a consultant histopathologist as described in Materials
and Methods and is plotted against the treatment the animal received as
indicated. n " 5 to 10 animals. *P ! 0.05. VO, vehicle only.
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in the latter group, reverted to basal levels (as expressed
in sham-operated animals).
Renal tissue from sham-operated and obstructed kid-
neys was also stained for FSP-1 expression (Figure 6A).
The discrete nature of staining allowed for stained cells to
be categorized as glomerular, tubular, or interstitial. As
expected, staining for FSP-1 was minimal in all compart-
ments in sham-operated kidneys. Obstruction led to a
nonsignificant rise in tubular expression of FSP-1 (data
not shown) and to an increase in interstitial expression
from 4 FSP-1–positive cells per view to 28 FSP-1–positive
cells per view (P ! 0.05) (Figure 7A). Administration of
oligonucleotides, either control or ASO, did not signifi-
cantly alter FSP-1 expression in either glomerular or tu-
bular compartments compared with the vehicle-only
group (data not shown). Although interstitial expression
of FSP-1 increased on administration of scrambled oligo-
nucleotides and Kras ASOs compared with administra-
tion of vehicle-only UUO, the increase was significant
only on administration of ASO 1 (P ! 0.001).
Measurement of intensity and area of ED-1 antibody
staining (against the macrophage marker CD 68) using
Nikon NIS-Elements (basic research) software clarified
the nature of the increased interstitial infiltrate (Figures 6
and 7B). Sham-operated samples revealed few macro-
phages per view (!1% of the total area). As expected,
Figure 6. Kras ASOs inhibit !-SMA expression despite increased interstitial
cell numbers in UUO. Oligonucleotides were administered subcutaneously
to adult male Wistar rats on alternate days at a dose of 12.5 mg/kg across 16
days after UUO or a sham operation. The animals were then sacrificed A:
Tissue sections were fixed and immunostained for !-SMA, FSP-1, ED-1, or
Ki-67 as indicated. Images shown are representative. Original magnification,
"100 for all images. B: Five random cortical views per section were scored
in a blinded manner by measuring staining intensity and area using Nikon
NIS-Elements (basic research) software. The results are plotted as percentage
of !-SMA tissue expression against the individual treatments as indicated. n
# 5 to 10 animals. C: Total protein was extracted from whole renal tissue and
underwent Western blot analysis for !-SMA. D: Densitometry was per-
formed, and !-SMA/glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
density ratios are plotted against each treatment as indicated. n # 3 to 5
animals. Error bars are SEM. *P ! 0.05, **P ! 0.001. VO, vehicle only.
Figure 7. ASOs increase inflammation in UUO. Tissue sections were immu-
nostained for FSP-1 (A), ED-1 (B), and Ki-67 (C). For ED-1 staining, five
random cortical views per section were scored in a blinded manner by
measurement of staining intensity and area using Nikon NIS-Elements (basic
research) software. The results are plotted as percentage of ED-1 tissue
expression. For Ki-67 and FSP-1 staining, cells that marked were counted by
two people in a blinded manner (light microscopy; original magnification,
"200) in 10 random fields of cortex. n # 5 to 10 animals. **P ! 0.001. VO,
vehicle only.
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obstruction resulted in an increase in ED-1 staining to
2.4%, reflecting the inflammatory infiltration associated
with UUO. The administration of CO 2 led to a doubling
of ED-1 staining (5.5%). However, ED-1 staining further
increased significantly with the administration of
scrambled and antisense oligonucleotides. SO 1 and
SO 2 administration increased ED-1 staining to 28%
and 32%, respectively (P ! 0.001). Administration of
ASO 1 increased ED-1 staining to 15%, but adminis-
tration of ASO 2 resulted in a more substantial increase
to 49% (P ! 0.001).
Ras is known to play a central role in cell proliferation.
Our previous work has demonstrated that Kras knock-
down reduces stimulated proliferation in renal fibro-
blasts.18,19 Kidney sections were, therefore, stained for
Ki-67, a marker of actively dividing cells. In the interstitial
compartment, Ki-67 expression was increased by 2.5-
fold to fourfold in the SO 1–, SO 2–, ASO 1–, and ASO
2–treated groups compared with the CO 2–treated group
(P ! 0.01) (Figures 6 and 7C).
Oligonucleotides also Target Other Tissues
Two hours after systemic administration, the highest con-
centrations of oligonucleotides are found in the liver and
kidneys.21 RT-qPCR analysis of hepatic tissue produced
results comparable with those obtained from the kidney.
Both SO 1 and SO 2 administration resulted in an in-
crease in Kras hepatic mRNA levels compared with the
vehicle-only–treated UUO group. Administration of ASO 1
and ASO 2 reduced Kras hepatic expression by 67% and
82%, respectively, compared with their paired, base-
matched scrambled oligonucleotides (see Supplemental
Figure S2B at http://ajp.amjpathol.org). Oligonucleotide
deposits could also be detected in other tissues, includ-
ing heart and muscle, although less than in liver and
kidney (see Supplemental Figure S2A at http://
ajp.amjpathol.org). Despite this widespread uptake of oli-
gonucleotide, wound healing did not differ, either clini-
cally or histologically, between vehicle-treated animals
and those treated with ASOs (see Supplemental Figure
S2C at http://ajp.amjpathol.org).
In H&E-stained hepatic tissue, we found mild to mod-
erate inflammation in both lobule and portal tract on ad-
ministration of oligonucleotide, with ASO 2 causing more
inflammation than ASO 1. Architecture was normal (see
Supplemental Figure S3A at http://ajp.amjpathol.org).
Similarly, mild inflammation was noted in the heart tis-
sue stained for ED-1 from oligonucleotide-treated ani-
mals, with ASO 2 being the most inflammatory oligo-
nucleotide (see Supplemental Figure S3, B and C, at
http://ajp.amjpathol.org).
Discussion
In this study, we demonstrated that a single isoform of ras
can be specifically targeted in vitro and in vivo using
ASOs. Ras is a key signaling molecule pivotal to control
of cell growth and differentiation in many cell types. Our
previous work highlighted Kras as the predominant iso-
form in renal fibroblasts. This isoform is, therefore, a de-
sirable target to maximize the effect on the kidney while
minimizing other tissue involvement. Binding of the ASO
to target mRNA results not only in steric inhibition of
translation by the ribosomal complex but also, and more
important, in the induction of RNase H, which cleaves the
3=-O-P-bond of the RNA molecule. This mechanism of
action theoretically provides 100% specificity for the tar-
get gene, an unachievable goal for most conventional
pharmacologic agents. In addition, parenterally adminis-
tered ASO accumulates principally in the kidneys, with a
kidney/plasma concentration ratio of 80:1 after 2 hours.21
Although we and other researchers have been inves-
tigating the role of Ras in renal fibrosis for some years,
Ras has become a more pertinent target recently.
RASAL1, a Ras GTPase activating protein and, hence, a
Ras inhibitor, has been found to be down-regulated in
fibroblasts from fibrotic kidneys and not in fibroblasts
from nonfibrotic kidneys as a result of hypermethylation of
its parent gene. Hypermethylation results in reduced
RASAL1 gene transcription and, hence, in Ras activa-
tion.15 This phenomenon is also present in colonic neo-
plasms, where decreased RASAL1 expression was noted
in more advanced tumors expressing wild-type Kras.22
In this study, we demonstrated that parenteral admin-
istration of ASOs targeting Kras can significantly inhibit
the onset of fibrosis in a model of UUO as measured by
PMT, PSR, collagen I deposition, and !-SMA expression.
This inhibition is achieved despite an increase in the
observed interstitial inflammation demonstrated in the
kidneys of treated animals. This inflammation is not spe-
cific to the Kras ASOs as it seems to be the same for the
scrambled control oligonucleotides. The nonstoichiomet-
ric control oligonucleotide (CO 2) caused significantly
less inflammation, suggesting that this phenomenon is
probably not sequence related but instead depends on
relative nucleotide compositions of each oligonucleotide.
We also stained the samples for FSP-1 as an assumed
marker for interstitial fibroblasts. Although expression of
FSP-1 increased with UUO, unlike !-SMA, it increased
further in scrambled oligonucleotide–treated and ASO-
treated kidneys. FSP-1 is expressed by interstitial fibro-
blasts, but it is also expressed by inflammatory cells. This
expression probably overwhelmed any reduction in fibro-
blast numbers in this study.23 Although we did not spe-
cifically characterize the nature of the inflammatory
reaction, we did demonstrate that it contained both
macrophages and actively dividing cells likely not to be
of the macrophage inflammatory lineage. Whether these
inflammatory cells or increased numbers of interstitial
fibroblasts cause increased Kras and Nras expression in
UUO is unclear. Administration of the Kras ASOs did,
however, reduce total kidney Kras expression well below
values seen in UUO alone, despite increased inflamma-
tion in the treated groups.
Although the kidneys are preferentially targeted by
small oligonucleotides, they also deposit in other tissues
throughout the body, including the liver and, to a lesser
degree, the heart and striated muscle. We noted a mod-
erate reduction in Kras expression in the livers of ASO-
treated animals and an associated mild inflammation in
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the liver and heart, suggesting a widespread oligonucle-
otide-related inflammatory reaction. This caused no sig-
nificant architectural disturbance or evidence of fibrosis.
Neither did any treated animal exhibit outward signs of ill
health, gaining weight at the same rate as untreated
animals with UUO.
In conclusion, we demonstrated that targeting Kras
with ASOs can prevent the onset of fibrosis in a rat model
of unilateral obstruction, even in the presence of signifi-
cant inflammation. New ASO design techniques promise
to produce noninflammatory ASOs, which may be used in
future studies.
Chronic inflammation is generally thought, in clinical
medicine, to inevitably lead to irreversible fibrosis. The
dissociation between inflammation and fibrosis demon-
strated herein suggests that this may not always be so. If
fibrosis can be inhibited while the initial insult resulting in
inflammation is either removed or controlled, irreversible
scarring of the kidney may be avoided. Although further
study is called for, we believe that ASOs targeting Kras
represent a first step in developing a true “antifibrotic”
therapy, one that in the future may prevent renal fibrosis.
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miR-21 and miR-214 Are Consistently Modulated
during Renal Injury in Rodent Models
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Transforming growth factor (TGF)-! is one of the
main fibrogenic cytokines that drives the pathophys-
iology of progressive renal scarring. MicroRNAs (miR-
NAs) are endogenous non-coding RNAs that post-tran-
scriptionally regulate gene expression. We examined
the role of TGF-!–induced expression of miR-21, miR-
NAs in cell culture models and miRNA expression in
relevant models of renal disease. In vitro, TGF-!
changed expression of miR-21, miR-214, and miR-145
in rat mesangial cells (CRL-2753) and miR-214, miR-
21, miR-30c, miR-200b, and miR-200c during induc-
tion of epithelial-mesenchymal transition in rat tubu-
lar epithelial cells (NRK52E). miR-214 expression was
robustly modulated in both cell types, whereas in
tubular epithelial cells miR-21 was increased andmiR-
200b and miR-200c were decreased by 58% and 48%,
respectively, in response to TGF-!. TGF-! receptor-1
was found to be a target of miR-200b/c and was down-
regulated after overexpression of miR-200c. To assess
the differential expression of these miRNAs in vivo,
we used the anti-Thy1.1 mesangial glomerulonephri-
tis model and the unilateral ureteral obstruction
model in which TGF-! plays a role and also a genetic
model of hypertension, the stroke-prone spontane-
ously hypertensive rat with and without salt loading.
The expressions of miR-214 and miR-21 were signifi-
cantly increased in all in vivo models, showing a pos-
sible miRNA signature of renal damage despite dif-
fering causes. (Am J Pathol 2011, 179:661–672; DOI:
10.1016/j.ajpath.2011.04.021)
Transforming growth factor (TGF)-! is a critically important
mediator of pathophysiological events in renal disease.1,2
Many types of glomerular diseases, including IgA nephrop-
athy and lupus nephritis are characterized by mesangial
cell proliferation,3 mesangial matrix expansion, and altera-
tions in extracellular turnover and composition. In the
chronic anti-Thy1.1 model of glomerulonephritis, prolifera-
tion of mesangial cells is followed by the production of
extracellular matrix, leading to chronic glomerulosclerosis
and eventually interstitial fibrosis. Tubulo-interstitial fibrosis
is the common end point of most progressive kidney dis-
eases and results in loss of renal function. The model of
unilateral ureteral obstruction (UUO) has been widely used
as an animal model of tubulo-interstitial disease that is char-
acterized by a mononuclear cell infiltration followed by fi-
broblast proliferation, increased extracellular matrix depo-
sition, and tubule atrophy. These common processes of
fibrosis and sclerosis are known to be driven primarily by
TGF-! along with a host of other cytokines and growth
factors. It is probable therefore that these pathologic pro-
cesses involve interrelated and complex molecular path-
ways in which microRNAs (miRNAs) may play an important
regulatory role.
In humans, decreased renal function is often a compli-
cation of essential hypertension, and hypertension is one of
the most common causes of end-stage renal disease in the
United States.4 A rat genetic model of essential hyperten-
sion the stroke-prone, spontaneously hypertensive rat
(SHRSP) also develops renal damage with age.5,6 The
damage observed is typically vascular smooth muscle hy-
perplasia and tubule atrophy and/or dilation.5 Furthermore,
in humans salt sensitivity is common in persons with essen-
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tial hypertension, and, when SHRSPs are challenged with
salt, this increases their systolic blood pressure [not ob-
served in Wistar-Kyoto (WKY) rats] and induces further re-
nal damage compared with WKY rats.7
miRNAs are endogenous non-coding RNAs that are
!22 nucleotides in length and can have structural, enzy-
matic, and regulatory functions.8 miRNAs act within the
RNA-induced silencing complex9 and can down-regulate
gene expression by binding to the 3=-untranslated region
(UTR) of the mRNA which results in either productive
translational repression or target degradation. miRNAs
are fundamental in development and are expressed in a
tissue-specific manner.10–12 However, they have now
been found to play a role in the pathophysiology of many
diverse diseases, including cancer,13,14 vascular prolif-
erative disease,15 and cardiac hypertrophy.16 It is clear
that many genes contain miRNA binding sequences
within their 3=-UTR, and a single miRNA can “hit” multiple
genes and influence many pathways.8 With respect to the
kidneys, a number of studies of miRNA expression have
been conducted.17–22 They have been shown to be fun-
damentally important in the kidney by several stud-
ies.19–21 For example, targeted knockout of DICER, a
protein important in miRNA biogenesis, selectively in
podocytes leads to severe proteinuria.2,19–22 These ani-
mals had marked abnormalities in the glomerulus, includ-
ing foot process effacement, mesangial expansion, and
glomerulosclerosis, which ultimately lead to animal
death. From those studies it appears that several miRNAs
are important for normal kidney homeostasis; miR-30a
was found to be lost in podocytes of DICER knockout
mice compared with controls20 and in mutant glomeruli
where mature miRNAs were knocked out targets of the
miR-30 family were enriched in the up-regulated genes.19
Several miRNAs have also been shown to have specific
localization within the kidney. With the use of locked nucleic
acid (LNA)—immunostaining in the normal kidney it has
been shown that miR-23b, miR-24, and miR-26a show a
pan glomerular localization20,21; miR-145 is found in mes-
angial cells20 and vascular smooth muscle cells20; miR-10a
and miR-30c are reported to be tubular specific20,21; and
miR-126 is detected in the glomerular and peritubular en-
dothelial cells.20 Furthermore, an integrated study of miR-
NAs and gene targets found several miRNAs differentially
regulated, miR-21, miR-31, miR-128, miR-147, and miR-
217, in polycystic kidney disease17; however, the role of
these differentially expressed miRNAs in polycystic kidney
disease has yet to be shown in vivo.
TGF-! has been shown to stimulate a set of
miRNAs.18,22,23 miR-192 and miR-377 are up-regulated
in mouse18,22 and human18,22 mesangial cells in vitro in
response to TGF-! and also in vivo in mouse diabetic
models.18,22 Analysis of the targets has shown that miR-
192 targets SIP118 and miR-377 targets p21-activated
kinase and superoxide dismutase,22 which results in an
increase in collagen and fibronectin, respectively. In con-
trast TGF-!–stimulated epithelial-mesenchymal transition
(EMT) results in loss of the miR-200 family,24–26 and an
increase in expression targets the E-cadherin repressors
ZEB1 and ZEB2.24–26
Because miRNAs have been shown to be essential in
kidney homeostasis, we sought to assign a specific role
for TGF-! in modulation of miRNAs in cell culture and in
vivo with respect to renal pathology. We therefore fo-
cused our analysis on a subset of miRNAs with potential
relevance in this setting (miR-21, miR-214, miR-192, miR-
26b, miR-145, miR-24, miR-30c, and miR-200b/c). We
used two in vitromodels to assess TGF-! stimulation of rat
mesangial cells and induction of EMT in rat kidney tubular
epithelial cells. We then investigated the expression of
these miRNAs in the chronic anti-Thy1.1 model of glo-
merulonephritis, the UUO model of interstitial fibrosis,
and a rat genetic model of hypertension, the SHRSP.
Materials and Methods
In Vitro Analysis of miRNA
Rat mesangial cells (CRL-2753) and rat tubular epithelial
cells (NRK52E) were cultured according to American
Type Culture Collection (ATCC; Manassas, VA) instruc-
tions. Cells were serum starved for 48 hours (0.2% fetal
calf serum) before stimulation with 10 ng/mL TGF-!(R&D
Systems, Minneapolis, MN). Total RNA was extracted
from the cells at 24, 48, 72, and 96 hours after stimulation
with the use of miRNeasy kit (Qiagen, Inc., Valencia, CA)
following the manufacturer’s instructions, treated with the
Turbo DNase (Ambion, Austin TX), to eliminate genomic
DNA contamination, and quantified with the use of the
NanoDrop ND-1000 Spectrophotometer (Nano-Drop
Technologies, Wilmington, DE).
In Vitro Analysis of EMT
NRK52E cells were plated in 6-well plates at 8" 104 cells
per well. Cells were serum starved for 48 hours (0.2%
fetal calf serum) before stimulation with 10 ng/mL TGF-!
(R&D Systems). Total RNA and protein were extracted at
24, 48, 72, and 96 hours after stimulation. RNA was
extracted and treated as before. Immunocytochemistry
was performed with "-smooth muscle actin ("-SMA;
1:500; Abcam, Cambridge, MA) and goat anti-mouse
Alexa Fluro 546 secondary antibody (Invitrogen, Paisley,
UK) with DAPI Prolong Gold mounting media (Invitrogen).
Protein was quantified, and 50 #g was fractionated on
7.5% (for E-cadherin) and 10% (for "-SMA) SDS poly-
acrylamide gels. Proteins were transferred onto nitrocel-
lulose membranes and probed for E-cadherin (1:2000;
BD Biosciences, San Jose, CA) and "-SMA (1:500; Ab-
cam) antibodies. Membranes were exposed with the use
of enhanced chemiluminescence ECL (GE Healthcare,
Chalfont St Giles, Buckingham, UK) and developed using
the X-OMAT 100 (Kodak, Rochester, NY).
TGF-! Inhibition Experiments
TGF-! inhibition experiments were performed with com-
mercially available TGF-! receptor-1 (TGF!R1; Alk5) in-
hibitors A-83-01 and AB525339 (Tocris Bioscience, Bris-
tol, UK) at a concentration of 1 #mol/L. NRK52E cells were
662 Denby et al
AJP August 2011, Vol. 179, No. 2
plated at 8 ! 104 cells per well. Cells were serum starved
for 48 hours (0.2% fetal calf serum) before adding either
inhibitor or dimethyl sulfoxide (DMSO; vehicle control) for 1
hour before stimulation with 10 ng/mL TGF-! (R&D Sys-
tems). RNA was extracted and treated as before.
Manipulation of miR-200c Levels
NRK52E cells (ATCC) were plated in 6-well plates at 1 !
105 cells per well. Cells were transfected with cytomeg-
alovirus–pri-miR-200c plasmid with the use of 2 "g of
DNA/3 "L of lipofectamine per well. Lipofectamine:DNA
complex was left on the cells for 5 hours, then supple-
mented with 20% serum containing media. Twenty-four
hours later the cells were washed with PBS, and cells
were replenished with fresh serum-free media. After 48
hours serum-starving cells were stimulated with TGF-!
(10 ng/mL) and left for 72 hours. Total RNA was ex-
tracted as described above, and miR-200c levels were
quantified.
Manipulation of miR-21 and miR-214 Levels
Lentiviral vectors were produced by triple transient trans-
fection of HEK293T cells with a packaging plasmid
(pCMV"8.74), a plasmid encoding the envelope of ve-
sicular stomatitis virus (kind gift from Adrian J. Thrasher,
London, UK), and the expression plasmid, using polyeth-
ylenimine (Sigma-Aldrich, St Louis, MO) as previously
described.27 Lentiviral titers were ascertained by Taq-
Man real-time quantitative PCR (qPCR) as previously de-
scribed.28 To overexpress the miR-21 and miR-214 the
precursor (pre)–miRNA sequences were obtained from
miRBase (http://microrna.sanger.ac.uk), codon-optimized,
and manufactured by GeneArt (Regensburg, Germany)
and subsequently cloned into the HinDIII-EcoRV sites of
pcDNA3.1 (Invitrogen). As the XhoI and BamH1 restric-
tion sites were maintained, the pre-miR sequence was
cloned directly into the pLNT/SFFV-MCS plasmid (kind
gift from Adrian J. Thrasher, London, UK) to obtain the
construct pLNT/SFFV-pre-miR.
Reverse Transcription of miRNA
After quantification of DNase-treated RNA, miRNA reverse
transcription was performed with stem-loop reverse tran-
scription primers according to the TaqMan MicroRNA As-
say protocol (Applied Biosystems, Foster City, CA). Each
reaction contained 5 ng of extracted total RNA and 50
nmol/L stem-looped reverse transcription primer, specific
for each miRNA. cDNA synthesis was performed on 1 "g of
total RNA with the use of reverse transcription reagents
(Applied Biosystems) following the manufacturer’s protocol.
miRNA and Gene Expression
Real-time qPCR was performed. The amplification step
was performed with specific Taqman miRNA probe or for
gene expression inventoried gene expression-specific
primers (Applied Biosystems) on the Applied Biosystems
7900 HT real-time PCR system following the manufactur-
er’s instructions. U87 was used as an endogenous con-
trol for the miRNA expression, and rat glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an
endogenous control for gene expression. Results are
shown as RQ # RQ max, calculated with SD.
Northern Blotting
Total RNA was extracted from cells or rat tissues with the
use of miRNeasy Mini kit (Qiagen, Dorking, Surrey, UK).
Three to 10 "g of total RNA was resolved in a 15%
tris-boric acid-EDTA and urea denaturing gel (Invitro-
gen), transferred onto Hyband-NX membrane (GE
Healthcare). After 1-ethyl-3-[3-dimethylaminopropyl]car-
bodiimide hydrochloride (EDC) cross-linking, membranes
were hybridized with 5=-DIG–labeled LNA Mercury probes
(Exiqon, Vedbaek, Denmark) at 40°C (miR-21 probe) or
55°C (miR-214 probe and U6) overnight. After post-hybrid-
ization washes, membranes were incubated with anti-
DIG-AP antibody (1:5000; Roche, Burgess Hill, UK) in 1%
blocking reagents (Roche), and signals were detected with
CDP-Star (Sigma-Aldrich) according to the manufacturer’s
instructions.
Prediction of Potential miRNA Targets
A list of targets for miR-21 and miR-214 was obtained
through searching 3=-UTR sequences of rat mRNAs for
the seeds of miRNAs. Rat mRNAs were downloaded from
the USCS Genome Browser (http://genome.ucsc.edu).
For each 3=-UTR, a number of seeds, its flanking nucle-
otides, and position were recorded.29,30 Each list of po-
tential targets was screened with specific criteria, includ-
ing high number of seeds, small distance between
seeds, intersection between the two miRNAs, and phys-
iological function of the targets.29,30
Animal Models
All protocols and surgical procedures were approved by
the local animal care committee. Animal experiments
were in accordance with the Animals Scientific Proce-
dures Act UK 1986.
Induction of Mesangial Proliferative
Glomerulonephritis
MaleWKY rats (Harlan, Wyton, UK) (7 to 12 weeks old) were
used throughout. All protocols and surgical procedures
were approved by the local animal care committee. Animals
were age matched at sacrifice to minimize age-related dif-
ferences in miRNA expression. For the induction of mesan-
gial proliferative glomerulonephritis rats were intravenously
infused with 2 mg/kg ER4. For the three-injection protocol
the ER4 was infused three times, 1 week apart. After sacri-
fice, kidneys were removed, and portions were fixed in 10%
formalin or snap frozen and stored at $80°C.
Histologic scoring was adapted from Tomita et al31
and was performed blind with 50 glomeruli and surround-
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ing tubules scored per section. Glomerular damage was
scored from 0 to 4, with 0 being 0% to 4% glomerular
lesion, mesangial matrix expansion; 1 being 5% to 24%;
2 being 25% to 49%; 3 being 50% to 74%; and 4 being
!75%. Interstitial lesions were counted as tubular dila-
tion, tubular trophy, basophilia, interstitial inflammation,
and fibrosis and were scored from 0 to 4, with 0 being no
lesion, 1 being "5%, 2 being 5% to 24%, 3 being 25% to
49%, and 4 being !50%.
Unilateral Ureteral Obstruction
Male Wistar rats weighing 200 g were used. Each rat was
initially placed in an induction chamber and exposed to
4% isoflurane and oxygen at a flow rate of 4 L/minute.
Once anesthetized, the rat was transferred to a heated
mat with continued administration of isoflurane at 2% to
2.5%. A midline incision was made with aseptic tech-
nique, and the left kidney was exposed. The left ureter
was isolated by blunt dissection, and two 6-0 silk liga-
tures were tied around it. The incision was re-sutured,
and buprenorphine was administered subcutaneously at
a dose of 30 "g/kg. As a control, a sham operation was
performed, including a laparotomy and handling of the
ureter, only it was not ligated. All rats were sacrificed on
postoperative day 16. After sacrifice, kidneys were re-
moved, and portions were fixed in 10% formalin or snap
frozen and stored at #80°C.
Genetic Rat Model of Hypertension
Inbred colonies of SHRSP and WKY rats have been de-
veloped and maintained at the University of Glasgow
since 1991, as described previously.32 For salt-loading
experiments, at 18 weeks of age, rats were given a salt
challenge (1% NaCl in drinking water) for 3 weeks. All
animals were sacrificed at 21 weeks. After sacrifice, kid-
neys were removed, snap frozen, and stored at #80°C.
Statistical Analysis
All in vitro experiments were performed in triplicate on
three separate occasions. All in vivo work was conducted
in groups of four to six. A standard Student’s t-test was
used to designate significant differences between control
and other groups.
Results
TGF-# Induces Changes in miRNA Profiles in
Renal Cells in Vitro
We first investigated the expression of miRNAs modu-
lated by TGF-# in the rat mesangial cell line CRL-2573
Figure 1. Effect of TGF-# on microRNA expression in cultured rat mesangial
cells. Rat mesangial cells (CRL-2573; RMCs) were stimulated with 10 ng/mL
rTGF-# (R&D Systems) over a 4-day time course. RNA was harvested from
the cells by miReasy kit (Qiagen), and miRNA expression was measured by
specific miRNA Taqman probes (Applied Biosystems) and normalized to
U87. RQ $ RQ max. *P " 0.05 versus unstimulated time-matched controls.
Inset is a representative Taqman amplification curve from one unstimulated
versus a TGF-# sample; N % 3.













































































































Figure 2. TGF-#–induced EMT in cultured rat tubular epithelial cells. Rat
tubular epithelial cells (NRK52E; NRK) were stimulated with 10 ng/mL
rTGF-# (R&D Systems) over a 4-day time course. A: Immunocytochemistry
for $-SMA and E-cadherin expression in unstimulated and TGF-#–stimulated
cells (5 days); original magnification, &40. B: E-cadherin gene expression.
Total RNA was extracted with the miRNeasy kit (Qiagen), and E-cadherin
expression was measured by specific rat Taqman probes (Applied Biosys-
tems) and normalized to rat GAPDH. RQ$ RQmax. *P" 0.05 and **P" 0.01
versus unstimulated time-matched controls. C: $-SMA protein expression in
cells undergoing EMT. Western blot analysis of cell lysates probed for $-SMA
and #-actin as a loading control. Images underwent densitometry. Mean
volume $ SD. **P " 0.01. D: Gene expression of collagen 1 in unstimulated
and TGF-#–stimulated cells. RQ $ RQ max. *P " 0.05, **P " 0.01, and
***P " 0.001 compared with unstimulated time-matched control cells.
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and tubular epithelial cell line NRK52E. Both were stimu-
lated with rTGF-! (10 ng/mL) and assessed for individual
miRNA levels compared with no stimulation. The re-
sponse of mesangial cells to TGF-! stimulation was to
significantly proliferate to levels similar to that seen after
incubation in growth media (see Supplemental Figure
S1A at http://ajp.amjpathol.org). We also found significant
increase in the gene expression of TGF-! and TGF!-R1
(see Supplemental Figure S1, B and C, at http://ajp.
amjpathol.org), showing that cellular levels of TGF-! were
increased after stimulation. Notably, in the mesangial cell
line miR-214 was significantly up-regulated 2 days after
stimulation (P ! 0.01) and remained elevated for the time
course with the peak expression of "16-fold increase at
4 days after stimulation when evaluated in a detailed time
course (Figure 1). miR-21 expression showed a sus-
tained significant increase "twofold from day 1 to day 3
before dropping to levels below that expressed in time-
matched control cells (Figure 1). No increase in miR-192
was observed (Figure 1), which is in contrast to previous
reports.18,22 This suggests that miR-192 may be differen-
tially regulated or expressed in rat mesangial cells as
assessed by real-time qPCR. Interestingly, miR-145 was
significantly elevated 24 hours after stimulation before
returning to unstimulated levels (Figure 1).
In tubular epithelial cells, TGF-! stimulation resulted in
EMT, characterized by loss of E-cadherin expression,
gain of "-SMA expression and increased collagen pro-
duction (Figure 2, A–D). In response to TGF-! stimulation
the NRK52E (NRK) cells also increased the expression of
both TGF-! and TGF-!R1 gene expression (see Supple-
mental Figure S2 at http://ajp.amjpathol.org). TGF-! stim-
ulation of the NRK cells resulted in miR-200b and miR-
200c being significantly down-regulated by day 4 of
TGF-! stimulation, with miR-200b and miR-200c being
reduced 58% and 48%, respectively, compared with
time-matched unstimulated controls (Figure 3). miR-192
was not significantly different over the time course (Figure
3), but miR-30c had a significant decrease in expression
24 hours after TGF-! stimulation, which remained for the
time course. However, and similar to data obtained in the
mesangial cells, miR-214 and miR-21 were significantly
up-regulated over the time course in the NRK cells (Fig-
ure 3). To further examine miR-21 and miR-214 expres-
sion we performed Northern blot analyses and found that
over the 5-day time course stimulation of NRK cells with
TGF-! resulted in increased expression of the mature
miR-21 and miR-214 (see Supplemental Figure S3 at
http://ajp.amjpathol.org). Interestingly, when the precur-
sors of the miRs are examined, there is increased expres-
sion of pre-miR-21 after stimulation of cells with TGF-!
(see Supplemental Figure S3 at http://ajp.amjpathol.org).
In contrast no pre-miR-214 could be detected, but there
was very high expression of primary (pri)–miR-214 ex-
pressed in NRK cells at all time points in both unstimu-
lated and stimulated cells (see Supplemental Figure S3 at
http://ajp.amjpathol.org).
Figure 3. miRNA expression in tubular epithelial cells undergoing EMT. Rat tubular epithelial cells (NRK52E; NRK) were stimulated with 10 ng/mL rTGF-! (R&D
Systems) over a 4-day time course. RNA was harvested from the cells by miReasy kit (Qiagen), and miRNA expression was measured by specific miRNA Taqman probes
(Applied Biosystems) and normalized to U87. Each graph represents an individual miRNA. RQ# RQ max. *P! 0.05 compared with unstimulated time-matched control cells.
MicroRNAs in Renal Disease 665
AJP August 2011, Vol. 179, No. 2
To examine whether TGF-! directly affected the ex-
pression of miR-21 and miR-214, we sought to block
TGF-! signaling with the use of TGF-!R1 signaling inhib-
itors (SB525339 and A-83-01). Both inhibitors block
downstream activation of the TGF-! signaling cascade,
but they allow binding of TGF-! to TGFRII.33 With the use
of the rat tubular epithelial cells, we serum starved the
cells for 48 hours then treated the cells with SB525339,
A-83-01, or DMSO (vehicle control) for 1 hour before
stimulating the cells with TGF-! (10 ng/mL) for 4 days. As
expected cells treated with DMSO had a significant in-
crease in miR-21 and miR-214 expressions in response
to TGF-! stimulation, which was abolished by both inhib-
itors (see Supplemental Figure S4A at http://ajp.
amjpathol.org). Similarly, the TGF-!RI inhibitors also
blocked the loss of the miR-200 family and other TGF-!–
modulated miRNAs in these cells (see Supplemental Fig-
ure S4B at http://ajp.amjpathol.org). The inhibitor A-83-01
has previously been shown to block EMT induced by
TGF-!,34 and we found that both inhibitors prevented
the loss of E-cadherin expression and increased in
expression of "-SMA and collagen 1a, observed when
the cells undergo EMT (see Supplemental Figure S4C at
http://ajp.amjpathol.org).
To examine the effects of miR-21 and miR-214 alone, we
constructed lentiviruses expressing pre-miR-21 (LNT-miR-
21) and pre-miR-214 (LNT-miR-214) to allow overexpres-
sion of each miRNA and performed experiments in culture
in the absence of TGF-!. Infection of rat tubular epithelial
cells with LNT-miR-21 resulted in an increase of mature
miR-21 expression by !3.5-fold compared with uninfected
cells or LNT-egfp–infected cells (Figure 4A). Infection with
LNT-miR-214 resulted in a significant increase of!400-fold
in the levels of mature miR-214 (Figure 4B). The effect of
overexpressing either miR-21 or miR-214 was to induce a
change in EMT-associated markers E-cadherin, "-SMA,
and collagen I, similar to that observed when these cells
undergo EMT in response to TGF-! (Figure 4C). In sum-
mary, our in vitro data show that TGF-! modulates the ex-
pression of several miRNAs in both cell types (miR-214,
miR-21, miR-30c, miR-200b, and miR 200c).
TGF!R1 Is a Target for miR-200c and Is
Modulated by Dynamic Changes in miR-200c
Levels
We examined the potential targets of miR-200b/c (be-
cause these share the same seed sequence). The 3=-
UTR sequences of rat mRNAs for the seeds of miRNAs
(nucleotides 2 to 7) that we were interested in were down-
loaded from the USCS Genome Browser and were
searched for potential targets.18,24 Interestingly, when a
search of targets of miR-200b/c was performed, many
other targets along with ZEB1 and ZEB224–26 were found
(see Supplemental Table S1 at http://ajp.amjpathol.org).
This list included TGF!R1, which has six seeds for miR-
200b/c within its 3=-UTR, one of which is a 7mer-m8
(position 746) and another a 7mer-1A (position 3755)
(see Supplemental Table S1 at http://ajp.amjpathol.org;
Figure 5A). To investigate whether the miR-200b/c mem-
bers regulate the expression of TGF!R1 we initially used
the in vitro model of TGF-!–stimulated EMT in rat tubular
epithelial cells. We used plasmid-based transfection to
overexpress miR-200c. miR-21 and miR-200b were used
as controls because TGF-! induced miR-21 expression
and reduced miR-200b expression (Figure 3). In cells
transfected with pri-miR-200c, stimulation with TGF-! re-
sulted in the same pattern, an increase in miR-21 (2.7-
fold increase) and a 64% decrease in miR-200c expres-
sion (Figure 5B). When EMT markers were examined,
overexpression of pri-miR-200c resulted in a significant
decrease in "-SMA and collagen I after stimulation with
TGF-!, which was similar to that observed before.26 Stim-
ulation with TGF-! resulted in a marked reduction in miR-
200c (75%) and a significant induction of TGF!-R1 (P "
0.05; Figure 5B). Overexpression of pri-miR-200c re-
sulted in an approximate sevenfold increase in miR-200c
expression and a marked inhibition (!48%) of TGF!R1
expression (Figure 5). Therefore, the changes in miRNA
associated with TGF-! are reflected in changes in
TGF!R1.
Figure 4. Effect of miR-21 and miR-214 overexpression on rat tubular epi-
thelial cells. NRK52E cells were infected with Lenti-(LNT) miR-21, LNT-miR-
214, or LNT-egfp at a multiplicity of infection of 5 for 24 hours. Cells were
then serum starved for 2 days and then cultured for 4 days in serum-free
media. RNA was harvested from the cells by miReasy kit (Qiagen), and
miRNA expression was measured by specific miRNA Taqman probes (Ap-
plied Biosystems) and normalized to U87. Gene expression was measured
with the use of gene-specific probes (rat) and normalized to GAPDH. A:
Expression of miR-21 by LNT-miR-21. RQ # RQ max. B: Expression of
miR-214 by LNT-miR-214. RQ # RQ max. C: Modulation of EMT-associated
genes by LNT-miR-21, LNT-miR-214, and LNT-egfp. RQ # RQ max. Un,
unifected. *P " 0.05 versus Un.
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Correlation of miRNA Modulation in Vitro in
Models of Renal Disease in Vivo
To address whether miRNAs are modulated during the de-
velopment of glomerulonephritis, we used the rat anti-
Thy1.1 model of mesangial proliferative glomerulonephritis,
which is self-limiting and has a well-characterized progres-
sion.35 We induced mesangial proliferative glomerulone-
phritis in WKY rats, and after sacrifice histologic evaluation
was performed to look at glomerular and tubular lesions. A
single administration of ER4 resulted in mild glomerular
damage (Table 1), which was resolved by 14 days (data not
shown). Kidneys from these animals had limited glomerular
lesions that featured global or segmental mesangial prolif-
eration (Table 1; Figure 6A). Multiple administration of the
ER4 protocol induced more severe histologic changes with
!50% of glomeruli affected and some evidence of tubular
damage in the form of tubular atrophy (Table 1 and Figure
6A). To quantify temporal changes in miRNA we sacrificed
a further group of animals 14 days after final administration
of ER4, which histologically appeared similar to those sac-
rificed at 7 days with the glomerular and tubular scores
remaining similar (Table 1).
We performed TaqMan analysis for miRNA expression
in animals that received three injections and sacrificed at
7 days but also in the second group which were sacri-
ficed at 14 days and compared this with age-matched
control animals (Figure 6B). miR-21 and miR-214 expres-
sion was significantly increased at 7 and 14 days com-
pared with controls (Figure 6B). No other miRs tested in
the in vitro setting showed altered expression in this path-
ological setting (Figure 6B). Because we have demon-
strated in vitro that TGF-! was stimulating expression of
miR-21 and miR-214, we sought to evaluate the levels of
Figure 5. Effect of manipulation of miR-200c on TGF!-R1 gene expression. A: Schematic diagram of 3=-UTR of rat TGF!R1 and miRNA seed sequence matches
(nucleotide 2 to 7) for miR-200b/c. B: NRK52E cells were transfected with a plasmid containing cytomegalovirus promoter-driven pri-miR-200c by lipofectamine
2000 (2 "g of DNA:3 "l of lipofectamine), serum starved for 48 hours, and then stimulated with TGF-!. Total RNA was extracted with the miRNeasy kit (Qiagen),
and miRNA expression was measured by specific miRNA Taqman probes (Applied Biosystems) and normalized to U87. TGF-!R1, #-SMA, and collagen I
expressions were measured by specific rat gene expression probes (Applied Biosystems) and normalized to GAPDH (rat). RQ" RQ max. *P# 0.05 versus control
cells and †P # 0.05 compared with control cells stimulated with TGF-!.







Control 0.25 0.25 0.5
1 $ ER4, 7 days 1 0.5 1.5
3 $ ER4, 7 days 2 2 4
3 $ ER4, 14 days 2.1 1.3 3.4
Histologic scoring of animals used in this study. Scoring was adapted
from Tomita et al.29 Scoring was performed blind (N % 4 to 6 animals per
group) with 50 glomeruli and surrounding tubules scored per section.
Glomerular damage was scored from 0 to 4, with 0 being 0% to 4%
glomerular lesion, mesangial matrix expansion; 1 being 5% to 24%; 2
being 25% to 49%; 3 being 50% to 74%; and 4 being &75%. Interstitial
lesions were counted as tubular dilation, tubular trophy, basophilia, inter-
stitial inflammation, and fibrosis and scored from 0 to 4, with 0 being no
lesion; 1 being #5%, 2 being 5% to 24%, 3 being 25% to 49%, and 4
being $50%.
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TGF-! expression in this animal model. We found that at
7 days and 14 days after injection of the third ER4 there
was a significant increase in TGF-! but no change in
TGF!RI expression (see Supplemental Figure S5 at
http://ajp.amjpathol.org).
Similarly to the chronic glomerulonephritis model,
TGF-! is the main profibrotic mediator in the UUO
model.36 To examine miRNA expression in the UUO
model, we performed a time course. Histologic evaluation
of tissue taken from animals sacrificed at 16 days after
surgery showed moderate interstitial fibrosis (Figure 7A)
and a high level of "-SMA staining in the interstitium
(Figure 7A; see also Supplemental Figure S6 at http://
ajp.amjpathol.org), suggestive of a large increase in the
number of active myofibroblasts but not the origin. Be-
cause EMT is reported to contribute to the fibroblast
population in this model,37 we examined the expression
of a panel of markers known to be indicative of the EMT
process. E-cadherin loss is an integral component of
EMT in our in vitro model; yet, the effects of pathological
insults in vivo on E-cadherin regulation and association
with EMT are less clear. Therefore, we examined E-cad-
herin gene expression and found that it was up-regulated
at this time point along with matrix metalloproteinase 2
and matrix metalloproteinase 14 (see Supplemental Fig-
ure S6 at http://ajp.amjpathol.org). We wanted to detail
how TGF-! expression in the kidney was changing in this
model, so we preformed real-time qPCR and found that
within 3 days of surgery the level of TGF-! expression
was significantly increased to !3.5-fold that of sham-
operated animals (Figure 7B). Furthermore, the level of
expression increased further when examined at 7 and 14
days after surgery. This confirmed that in the kidneys of
UUO animals the levels of TGF-! have increased (Figure
7B). On the basis of our in vitro model results, we as-
sessed the expression levels of a panel of miRNAs in
whole kidney extracts from UUO and sham-operated an-
imals at 16 days. In similarity with the anti-Thy1.1 animals
miR-21 and miR-214 were significantly up-regulated (six-
fold for miR-21 and 2.5-fold for miR-214) (Figure 7C).
miR-200b was found to be decreased in the UUO kidneys
compared with controls; in addition, several other miR-
NAs were also found to be significantly down-regulated,
miR-192, miR-329, miR-24, miR-26b, and miR-30c (Fig-
ure 7C). TGF!-R1 was also found to be up-regulated at
the gene expression level, which correlates with mem-
bers of the miR-200 family being down-regulated (see
Supplemental Figure S6 at http://ajp.amjpathol.org). To
examine what happened to miR-21 and miR-214 expres-
sion over time in this model we examined their expression
and found that miR-21 expression had doubled within 3
days and continued to increase over time (Figure 7D).
miR-214 expression was also significantly increased but
only significantly from 7 days after surgery when miR-214
expression was !2.5-fold higher than that observed in
sham-operated animals. The levels of miR-214 were then
sustained for the time course (Figure 7D). Because we
had observed previously in the in vitromodels differences
in the precursors of the miR-21 and miR-214 we per-
formed Northern blot analyses on kidney RNA extracted
from the animals 7 days after surgery (Figure 7E) that we
had also demonstrated had significantly increased
TGF-! expression (Figure 7B). For miR-21 the primary
form of miR was present in all samples but the precursor
form was only present in the UUO samples (Figure 7E).
Mature miR-21 could be detected in all samples but was
expressed higher in the UUO samples (Figure 7E). In
contrast, similar levels of pre- and pri-miR-214 were pres-
ent in both UUO and sham-operated animals. However,
the mature miR-214 levels were increased significantly
only in the UUO animals (Figure 7E).
Because the causes of these two renal diseases are
different but TGF-! plays a role, we examined the expres-
sion of miR-21 and miR-214 in the SHRSP rat to identify if
there is a common miRNA signature in the renal patho-
logical process. We assessed the expression of miR-21
and miR-214 alongside miR-30c, miR-192, and miR-145.
The expression of the miRs was assessed in 21-week
SHRSP rats with established hypertension (systolic blood
pressure " 170 mmHg)5 and compared with that ob-
served in age-matched normotensive reference strain
WKY rats (systolic blood pressure # 125 mmHg).5 Both
miR-21 (!2.25-fold increased) and miR-214 (!threefold
increased) were significantly increased when SHRSP an-
imals were compared with the reference strain (WKY)
with no change in the other miRs examined (Figure 8).
However, when young 5-week-old animals that are not
hypertensive were assessed for miR-21 and miR-214,
Figure 6. Validation of miRNA expression after induction of mesangial proliferative glomerulonephritis. Validation of miRNAs expressed in animals sacrificed 7 and 14
days after three ER4 injections 1 week apart compared with age-matched controls. A: Representative histology of normal glomeruli from control animals and the global
mesangial proliferation observed in glomeruli in kidneys from animals that received three ER4 injections. B: miRNA expression measured by specific miRNA Taqman
probes (Applied Biosystems) and normalized to U87. RQ $ RQ max. *P # 0.05 versus age-matched control animals (N % 4 to 6).
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there was no difference (data not shown), indicating that
these miRs are not altered before the onset of hyperten-
sion or renal damage. Interestingly, the expression of
these miRs was further increased in the SHRSP when
they were challenged with salt (1%), with miR-21 levels
increasing !14-fold and miR-214 levels increasing by
fourfold. Surprisingly, in the WKY rats that are not salt
sensitive and do not have any renal insufficiency, salt load-
ing significantly increased miR-21 expression by six times
compared with age-matched normal WKY rats. The salt
challenge also resulted in miR-30c and miR-192 being sig-
nificantly increased in both WKY and SHRSP rats, and miR-
145 only being increased in SHRSP. Because we found
increases in miR-21 and miR-214 in the SHRSP compared
with the WKY rats and under salt loading, we investigated
whether an increase in TGF-! is associated with this in-
crease. We therefore measured the level of mRNA for
TGF-! and TGF!RI in tissues and observed that TGF-!was
significantly increased in the SHRSP rats compared with the
WKY rats and further increased under salt loading (see
Supplemental Figure S7 at http://ajp.amjpathol.org). Further-
more, TGF!RI was also increased under salt loading, sug-
gesting an increase in TGF-! signaling (see Supplemental
Figure S7 at http://ajp.amjpathol.org).
Discussion
miRNAs have recently been shown to be dysregulated in
many diseases and are thought to contribute to the
pathophysiology of the distinct disease such as cancer
and myocardial infarction. Previously, miR-192 and miR-
377 have been highlighted as being regulated by TGF-!
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Figure 7. miRNA expression after UUO. A: His-
tologic analysis of kidneys from sham and UUO
animals for tubulo-interstitial fibrosis by Pico-
Mallory Trichrome and Picro Sirius red (viewed
under cross-polarized light) and "-SMA staining
16 days after surgery. Scale bars: 100 #m. B:
TGF-! gene expression in animals undergoing
UUO. Total kidney RNA was extracted with the
use of the miRNeasy kit (Qiagen), and TGF-!
gene expression was measured by specific rat
TGF-! gene expression probe (Applied Biosys-
tems) and normalized to GAPDH (rat). RQ" RQ
max. *P # 0.05 and **P # 0.01. C: miRNA ex-
pression in kidneys of sham or UUO animals was
measured by specific miRNA Taqman probes
(Applied Biosystems) and normalized to U87.
RQ " RQ max. *P # 0.05, **P # 0.01, and
***P# 0.001 compared with sham animals (N$ 5).
D: miR-21 and miR-214 expression in UUO ani-
mals over time. Total RNA was extracted with the
use of the miRNeasy kit (Qiagen), and miRNA
expression was measured by specific miRNA Taq-
man probes (Applied Biosystems) and normalized
to U87. RQ " RQ max. *P # 0.05 and **P # 0.01
versus age-matched control sham-operated ani-
mals (N$ 3). E:miR-21 and miR-214 expression in
kidney tissue 7 days after surgery. Northern blot
analyses were performed on total kidney RNA ex-
tracted with the use of the miRNeasy kit (Qiagen)
of tissue from UUO and sham-operated animals at
7 days after surgery and probed with 5=-DIG–la-
beled LNA Mercury probes (Exiqon) rat miRNA for
miR-21 and miR-214. U6 was used as a loading
control (Exiquon). Lane 1 indicates HeLa cells;
lane 2, RNA ladder; lanes 3 to 5, UUO RNA; lanes
6 to 8, SHAM RNA; and lanes 9 and 10, NRK52E
(NRK) control RNA.
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establish that the expression of miR-214 and miR-21 are
also regulated by TGF-!. We demonstrate in this study
that TGF-!–induced EMT in a rat tubular epithelial cell
line was blocked by small molecule inhibitors of TGF-!
signaling. Induction of miR-21 and miR-214 was also
inhibited by these agents. Furthermore, overexpression
of either miR-214 or miR-21 in the absence of TGF-!–
induced EMT-like changes in culture with associated
changes in E-cadherin, "-SMA, and collagen expression.
This underpins an important role for these two miRNAs in
TGF-! signaling-induced EMT in vitro. To underline the
importance of miR-21 and miR-214, both were signifi-
cantly increased in two models of renal disease in vivo in
which TGF-! plays a role in the pathophysiology but also
in a rat model of genetic hypertension shown to have
predominately vascular renal damage. Interestingly,
when these animals were challenged with high salt both
WKY and SHRSP animals showed an increase in miR-21,
whereas miR-214 was only increased further in the salt-
loaded SHRSP animals. Furthermore, because neither
miRNA has differential expression in non-hypertensive
5-week-old SHRSP animals, the change in these miRNAs
illustrates a role in the pathophysiology of hypertension in
this model. The effect of salt loading on WKY miR-21
expression was surprising, but together with the data
from the SHRSP on miR-21 and miR-214 it indicates that
other pathways beyond TGF-! also probably regulate
these miRNAs. Taken together this study shows that the
overexpression of both miR-21 and miR-214 represents a
common signature for renal damage unrelated to its
cause. To further support this a recent study found that
miR-214 is increased in monocytes of patients with
chronic kidney disease.38
miR-21 overexpression has been shown in mesangial
cells stimulated with glucose (to mimic diabetic nephrop-
athy) to protect the cells from proliferation by the down-
regulation of PTEN, which was verified as a target of
miR-21 in this context.39 miR-21 is frequently found up-
regulated in response to stress. In cardiac fibrosis the
source of miR-21 has been found to be cardiac fibro-
blasts.40 miR-214 has been found to be up-regulated in
epithelial ovarian carcinomas.41 Furthermore, PTEN has
also been confirmed as a target of miR-214, and in hu-
man ovarian cancer cells an increase in miR-214 induces
cell survival and cisplatin resistance via targeting the
PTEN/Akt pathway.41 miR-214 has been shown to be
activated by TWIST-1 through an E-box promoter ele-
ment42 and may be involved in the development of spe-
cific neural cell populations; therefore, because TWIST
activation is a key event in EMT, it may be through this
pathway that miR-214 expression is increased in the tu-
bular epithelial cells. However, TGF-! can also drive cells
toward apoptosis, so it is also possible that miR-214 may
mediate the switch between these two cell fates.
In mesangial cells, miR-145 expression was also mea-
sured, because it has been shown to be a mesangial cell
marker,20 and it was rapidly increased in response to
TGF-! but returned to normal levels within 24 hours of
TGF-! stimulation. miR-145 has been shown to act as a
tumor suppressor43 and to prevent proliferation of
smooth muscle cells,44 and, because mesangial cells are
specialized smooth muscle cells, the increase in miR-145
may be a protective mechanism.
miR-30c expression was lost in the UUO kidney; pre-
viously, it has been shown to be essential for normal
kidney homoeostasis and targets several genes of impor-
tance in structure and function of the kidney. It has a
tubular expression within the kidney, and whether the
loss of miR-30c was an initiating factor or as a result of the
widespread tubular damage would need to be investi-
gated further.
In similarity to other studies, stimulation of the rat tu-
bular epithelial cell line with TGF-! resulted in EMT and a
loss of the expression of the miR-200 family members
miR-200b and miR-200c. Elegant studies have previously
shown that miR-200 family overexpression prevents EMT
induced by TGF-! by binding to their targets ZEB1 and
ZEB2, which are transcriptional repressors of E-cad-
herin.24–26 Loss of the miR-200 family results in an in-
crease in ZEB1 and ZEB2 expression and loss of E-
cadherin and subsequent induction of EMT.24–26 In the
UUO animals, miR-200b was significantly down-regulat-
ed; this could be an indicator that EMT is occurring in this
model and contributing to the myofibroblast cell number.
However, E-cadherin expression was up-regulated in this
model at this time point (see Supplemental Figure S6 at
http://ajp.amjpathol.org), which has been reported be-
fore45 and is in contrast to what was observed in the in
vitromodel in which E-cadherin was down-regulated. Tar-
get analysis of miR-200b and miR-200c found that
TGF!R1 was a target for these miRNAs with six seed
matches in the rat. This study shows that TGF!R1 is a
target of the miR-200 family and suggests the miR-200
family are important regulators of TGF-! signaling, being
able to influence multiple parts of the signaling pathway.
In the UUO model in which EMT of tubular epithelial cells
has been reported to occur37 and contribute to the myo-
fibroblast population, we wanted to examine the expres-
sion of miR-200b and miR-200c. In animals 16 days after
UUO, the expression of miR-200b was significantly down-
regulated, and miR-200c was reduced. This may further
suggest that the loss of the miR-200 family is pathophysi-
ologically important in tubule-interstitial fibrosis, especially
Figure 8. miRNA expression in genetic model of hypertension, the SHRSP.
miRNA expression in kidneys of 21-week-old male WKY, SHRSP rats with
and without salt loading (1%) was measured by specific miRNA Taqman
probes (Applied Biosystems) and normalized to U87. RQ ! RQ max. *P "
0.05, **P " 0.01, and ***P " 0.001 compared with WKY expression levels;
†P " 0.05 compared with SHRSP expression levels.
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because miR-200b has been shown to have a tubular
location within the kidney.20
This study for the first time shows that miR-21 and
miR-214 may represent a miRNA signature of renal dam-
age and both these miRNAs can be regulated by TGF-!
in a cell-specific manner.
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Editorial Comment
Silencing genes in the kidney: antisense or RNA interference?
Jia-Hui Wang, Bruce M Hendry and Claire C Sharpe
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Introduction
Targeting genes in disease has long been a sought-after holy
grail, with the concept of gene therapy promising a magic
bullet for single gene mutation or deletion disorders. Re-
placing deficient or non-functional genes with the active
form has proven more difficult to achieve than originally
hoped. However, a subset of gene therapy termed ‘gene
silencing’ is being developed, which is altogether more
promising. By utilizing the unique nature of gene-sequence
specificity, complementary or antisense molecules can
be designed to ‘seek and destroy’ targetmRNAs for specific
proteins known to be pivotal in the pathogenesis of various
disease processes. Two strategies have been employed to si-
lence genes; the first involves the use of single-stranded an-
tisense oligodeoxynucleotides (ASO) and the second uses
double-stranded short-interfering RNAmolecules (siRNA)
otherwise known as RNA interference (RNAi).
Antisense oligodeoxynucleotides (ASO)
With the recent publication by Tillman et al. in the Journal
of Pharmaceutical Sciences of the first demonstration of
oral delivery of ASO in man [1] comes the possibility of
this form of gene therapy becoming part of the normal
repertoire of therapeutic options open to the physician in
the mid- to long-term future. Zamecnick and Stephenson
were the first to recognize the potential of ASO in 1978
when studying inhibition of Rous sarcoma virus replication
[2]. Since then, antisense technology has developed into a
powerful research tool and has begun to make its mark in
the world of clinical therapy.
ASO consist of a single strand of 12–22 oligodeoxynu-
cleotides which are complementary to the target mRNA se-
quence [3]. Binding of the ASO to target mRNA results in
steric inhibition of translation by the ribosomal complex but
more importantly the induction of RNase H, which cleaves
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Fig. 1. The mechanism of action of ASO versus RNA interference.
the 3′-O-P-bond of the RNA molecule (Figure 1). This
mechanism of action theoretically provides 100% speci-
ficity for the target gene, an unachievable goal for most
conventional pharmacological agents.
Since the 1970s, ASO have been used widely as research
tools used to investigate mechanisms of disease patho-
genesis in vitro, particularly in the field of nephrology.
For example, Zhang et al. used a connective tissue growth
factor (CTGF) ASO to examine the role of this molecule
during epithelial-mesenchymal transition (EMT) in proxi-
mal tubular epithelial cells [4], whilst we have employed
ASO to discern the individual functions of the isoforms
of the Ras monomeric GTPase in human renal fibroblast
proliferation [5].
The use of ASO to target the kidney in vivo has
been both challenging and highly rewarding. Unmodified,
single-stranded oligonucleotides are rapidly broken down
in serum by endogenous nucleases greatly limiting cellu-
lar uptake. To overcome this, ASO have a modification
of the phosphate backbone whereby non-bridging oxygen
molecules are replaced by sulphur molecules, greatly en-
hancing resistance to nuclease activity. These phosphoroth-
ioate ASO have a half-life in serum in the region of 10 h
(in comparison to 30–60 min of unmodified forms) and,
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following parenteral administration, have a systemic
bioavailability as high as 90% [6]. Further modifications of
the sugar–phosphate backbone of the oligonucleotides can
be made to increase their stability and RNA affinity with-
out compromising binding selectivity. Among the available
sites for modification, the furanose 2′-position has been
demonstrated to offer several advantages [7].Unfortunately,
complete 2′-O-modification of the molecule results in the
loss of its ability to activate RNase H. This has led to the
development of chimeric oligonucleotides that are formed
by combining 2′-O-modified oligonucleotides with re-
gions of 2′-deoxy phosphorothioates. The resulting second-
generation ASO both support RNase H activity and demon-
strate enhanced nuclease resistance and RNA affinity.
Following parenteral administration, these ASO distribute
to all peripheral tissues with the highest accumulation being
in the liver and kidneys, which have a concentration ratio to
plasma of 20:1 and 80:1 respectively after 2 h [8]. Within
the kidney, ASO are filtered freely by the glomerulus and
reabsorbed by proximal tubule epithelial cells [9] making
antisense technology a very attractive tool for the investi-
gation and possibly treatment of renal disease. Cheng et al.
were amongst the first to use these tools in an animal model
of renal disease. They administeredASO to intracellular ad-
hesion molecule 1 (ICAM-1) intravenously via the tail vein
in a mouse model of unilateral ureteric obstruction (UUO)
and found a decrease in inflammatory infiltration and ex-
tracellular matrix [10]. Similarly, Chen et al. demonstrated
ICAM-1ASO to be very effective in inhibiting the ICAM-1-
dependent mechanism of graft infiltration and tissue dam-
age involved in allograft rejection, ischaemic-reperfusion
injury and cyclosporin-induced nephrotoxicity [11]. Other
renal disease-associated proteins have subsequently been
targeted using parenteral ASO, such as connective tissue
growth factor (CTGF) [12,13], casein kinase II [14] and
TGF-β. Isaka et al. modified the delivery of ASO to target
interstitial fibroblasts. They developed an artificial viral
envelope (AVE) containing anionic liposomes and proteins
from the haemagglutinating virus of Japan (HVJ). The net
negative charge on the ASO/AVE complex allows for se-
lective transfection of renal interstitial fibroblasts to the ex-
clusion of proximal tubular cells. Using retrograde ureteric
administration, Isaka successfully targeted interstitial fi-
broblasts with ASO to TGF-β1, in a model of UUO. The
ASO-treated obstructed kidneys expressed less collagen I
and α-smooth muscle actin and had less interstitial fibrosis
[15,16].
Although some animal studies have shown that ASO in-
fusions may lead to complement cascade activation [17,18],
these effects appear to be both dose dependent and related to
the rate of administration. Subsequent clinical studies using
lower doses of ASO have reported minimal toxic effects.
Furthermore, subsequent generations of ASO have lower
toxicity profiles [19]. Therefore, there has been much inter-
est in pushing forward ASO for clinical therapy. Although
currently there is only one ASO licensed for clinical use,
Formivirsen (Vitravene
R©
) for AIDS-related CMV retini-
tis, numerous others are in Phase 2 of clinical development
such as ASO toApoB-100 for the treatment of hypercholes-
terolaemia, ASO to ICAM-1 in ulcerative colitis and many
others (see http://www.isispharm.com).
Short-interfering RNA
In 1990, Richard Jorgensen’s plant biology group was the
first to note the effects of administration of specific RNA
molecules on gene expression [20]. Their attempt to en-
hance the purple pigmentation in petunias by overexpres-
sion of the appropriate transcript paradoxically resulted in
the flowers losing their colouring. This phenomenon was
termed ‘cosuppression’, though the mechanism of action
was not determined until 1998. In their landmark paper,
Fire and Mello showed that sequence-specific gene knock-
down was possible by microinjection of synthetic double-
stranded RNA (dsRNA) in the nematode Caenorhabditis
elegans [21]. Furthermore, they showed that the use of
dsRNA was over 10 times more potent than either sense
or antisense RNA alone, that gene silencing was possible
on administration of only a few molecules of dsRNA and
that this effectmay be passed on to first-generation progeny.
The term ‘RNA interference’ was applied to their findings
and they were awarded the Nobel Prize for Medicine in
October 2006.
The mechanism employed by RNAi is thought to be a
defensive mechanism against the abnormal presence of
double-stranded viral RNA. It is different to that used
by ASO and has been conserved over time and is com-
mon to all eukaryotes [22]. The process involves initial
long dsRNA cleavage by the enzyme Dicer RNase III into
short RNA duplexes of 21–23 nucleotides, which are then
incorporated into a ribonucleoprotein–endonuclease com-
plex termed ‘RNA Induced Silencing Complex’ (RISC).
The siRNA is then unwound and the antisense strand di-
rects the complex to target the specific endogenous RNA
sequence. The target RNA transcript is then bound and de-
graded by the endonuclease activity of RISC (Figure 1).
There was an initial reluctance to transfer these findings to
mammalian cells since exposure to long strands of dsRNA
results in non-specific degradation of all mRNA and in-
hibition of all protein synthesis. However, Tuschl’s group
subsequently demonstrated that short-interfering RNA
(21-nt) against reporter genes in various mammalian cell
lines specifically reduced expression up to 25-fold [23].
Since this time, short-interfering RNA (siRNA) technology
has been used widely as a highly specific and powerful
tool for the in vitro study of gene function. Its specific
mechanism of action makes target site identification and
oligo design easier than for ASO as the secondary RNA
structure is not an obstacle. In vitro, the duration of knock-
down is similar to that of second-generation ASO but
the potency maybe significantly greater. Although both
siRNA and ASO are highly specific for their target genes,
siRNAmay induce ‘off target’ effects. This can occur when
non-targeted mRNA species share significant homology
(>11 bases) with either the sense or antisense strand of
the siRNA molecule. Additionally, it has been demon-
strated that partial homology (as little as 6–7 bases) be-
tween either of the siRNA strands and the 3′ untranslated
regions can cause knockdown of many genes within a cell.
This mechanism parallels that employed by micro RNA
(miRNA) molecules, which are naturally occurring, en-
dogenous gene-regulatory molecules [24,25] and its effects
can be difficult to predict.
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The major challenge for the use of siRNA, however, is
transferring the technology to the in vivo setting. Though
these molecules have a biodistribution profile similar to
ASO with preferential accumulation in the liver and kid-
ney, they do not readily cross the cell membrane due to their
large molecular mass (twice that of single-stranded ASO)
and a high negative charge. Unmodified, they have a half-
life in serum of a few seconds to a few minutes and are thus
rapidly degraded before reaching their target tissues [26]
and hence any potency advantage over ASO that they have
in vitro is lost. In addition, they can stimulate systemic
inflammatory responses by inducing interferon-mediated
pathways (though this may be related to the concurrent use
of vectors [27]) or by containing newly identified ‘danger
motifs’ that bind to certain Toll-like receptors [28]. Local
tissue delivery to organs such as the eye and lungs, avoiding
a systemic phase, has proven successful in some circum-
stances and phase 1 trials are taking place into the use of
VEGF siRNA in macular degeneration [29,30]. Systemic
delivery however remains problematic. In order to increase
siRNA delivery to less accessible tissues, researchers have
used a variety of different techniques. Hamar et al. used
hydrodynamic (large volume and high pressure) injection
to deliver siRNA to target the pro-apoptotic protein, Fas
in a murine model of acute renal ischaemia-reperfusion
injury and were able to demonstrate reduced Fas expres-
sion and reduced tubular apoptosis, atrophy and hyaline
damage [31]. Alternatively, Hwang et al. injected a short
hairpin-RNA-expressing plasmid vector targeting TGF-β1
in a single dose under low pressure, through the renal artery
in a mouse model of UUO and demonstrated that collagen
I expression in the interstitium was significantly reduced,
at least until Day 7 [32]. Similarly, Takabatake et al. in-
jected TGF-β1 siRNA via the renal artery in a rat model of
Anti-Thy-1 glomerulonephritis but required the addition of
electroporation to achieve a reduction in the expression of
TGF-β1 in glomeruli compared to the contralateral kidney
by Day 4 [33].
Although these methods have proven successful in an-
imal models, it is difficult to see how they can be trans-
lated into a clinical setting. Some groups have followed the
lessons learnt from ASO development and have made mod-
ifications, such as the addition of a cholesterol moiety or the
incorporation of 2′-O-methyl (2′OMe) uridine or guanosine
nucleosides into one strand of the siRNA duplex to extend
half-life and reduce toxicity [34]. These modifications may
yet prove successful in advancing siRNA technology into a
therapeutic setting.
Conclusion
Targeting of specific disease-causing genes using ‘anti-
sense’ mechanisms is highly attractive, particularly for the
kidney. Although, over 30 years from the original discov-
ery, there is still only one licensed ASO in clinical use,
much of the slow progress has been due to the necessary
development of pharmacological modifications to improve
ASO efficacy and safety. These next-generation molecules
are safe, highly specific and powerful medicines with the
potential for both systemic and oral delivery and many are
moving forward to the clinical setting at an accelerating
pace. RNA interference still has some way to go before
drugs utilizing this technology reach the same level of pre-
clinical and clinical applications. Though currently they ap-
pear most promising for local, non-systemic applications,
hopefully with new advances in systemic drug delivery,
problems of administration will be overcome and they will
eventually add to the growing repertoire of gene silencing
therapeutics in the future.
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